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Abstract  
Daily rhythms are an important aspect of our physiology. A central clock in the 
hypothalamus tracks light-dark cycle and coordinates the ubiquitous peripheral 
clocks. This ensures that catabolic and anabolic biochemical pathways do not 
occur simultaneously. Disassociating the light-entrainable clocks in the 
suprachiasmatic nucleus (SCN) and food-entrainable peripheral clocks has 
metabolic consequences. Evidence from animal and human studies, point to short 
sleep duration, shift work, late night eating, obesity and type two diabetes (T2DM) 
all influencing, and being influenced by the circadian timing system.  
The studies within this thesis have set out to elucidate the effect of 
disturbed metabolism using models of obesity, T2DM and delaying a 3-meal a day 
feeding schedule by five hours. The effects of obesity and T2DM were examined 
by measuring circulating a large panel of amino acids, biogenic amines and 
glycerophospholipids using targeted LC/MS metabolomics, GI hormones, PAI-1, 
glucose, triglyceride. Approximately 1/2 of the GI hormones and 1/3 of the 
metabolites from each of the classes exhibited significant 24-h cosinor rhythms. 
Where rhythms were observed, neither obesity nor T2DM influenced the peak 
time or amplitude of the rhythm. The 5-h shift in meal timing did not affect the 
timing of the SCN-driven hormone melatonin. Approximately 1/3 of the 
metabolites exhibited significant cosine rhythms before and after the meal shift, 
half of which showed a 2-h phase delay after the late meal schedule. Some 
metabolites (citrulline, proline, AC-C2 and lysoPC a (C18:2, C20:3 and C20:4)) 
exhibited significant cosinor rhythms regardless of sleep, meal timing, age, BMI or 
insulin sensitivity.  
The results demonstrate that being obese or having T2DM affected the 
circulating concentrations, but did not affect the phase or amplitude of diurnal 
rhythms. Whereas a 5 h delay in meal timing led to a phase delay of metabolite 
rhythms, without affecting the amplitude.   
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1 Literature Review  
Almost every living thing is subject to daily and seasonal environmental changes 
that influence their physiology and behaviour (Wood and Loudon, 2014). Evolution 
shows us how different species have adapted to the environmental conditions that 
maximise their access to food whilst minimising the chance of being eaten, such 
as prey animals (e.g. rodents and rabbits) that forage at night when their predators 
are asleep. In modern society, with no threats from predation, an abundance of 
food 24/7 and artificial lighting, people can be active and eat or drink at any time, 
day or night, ignoring natural behavioural cues. 
One of the consequences of shift work or travelling on across time zones 
means that meals are not eaten at their usual times. The negative metabolic 
consequences of eating late in the day (Morgan et al., 1998) and the link between 
insufficient sleep and increased body mass index (BMI), insulin resistance, type 2 
diabetes mellitus (T2DM) and cardiovascular events (Gangwisch, 2009), suggest 
the freedom to choose when we sleep and eat may not be the blessings they 
appear to be. Positive metabolic consequences of meal timing has also shown to 
impact on weight loss outcomes (Garaulet et al., 2013).  Changing the time of day 
a drug is administered can lead to increased efficacy and reduced side effects 
(Zhang et al., 2014), and there are many more examples of how circadian biology 
impacts on other scientific disciplines and everyday life.  
This review will discuss the links between the circadian system and 
metabolism and the metabolic consequences of a shift in meal timing and in health 
and diseased states (overweight/obese (OW/OB) or having T2DM) related to time 
of day.  
1.1 Circadian biology and daily oscillations 
Circadian biology is the study of the daily oscillations of multiple biological 
processes in plants and animals. Much of the research in this area has centred on 
the study of circadian rhythms. True biological circadian rhythms are 
endogenously generated oscillations, that must be capable of being synchronised 
(entrained) by external stimuli (Reppert and Weaver, 2002). Highly controlled 
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laboratory studies, such as the constant routine (CR) protocol, have disassociated 
endogenously generated rhythms from exogenous influences, such as the light-
dark cycle, to reveal an internal body clock (Duffy and Dijk, 2002a). When the 
internal body clock is disassociated from the external environment the 
endogenously controlled circadian rhythms “free-run” according to their own 
intrinsic period, expressed as tau (τ), which is slightly shorter or longer than 24 h, 
(Aschoff, 1965). In humans, the endogenously generated oscillations are typically 
slightly more than 24 hours. 
The master clock, housed in the suprachiasmatic nucleus (SCN), is a 
bilaterally symmetrical structure in the anterior hypothalamus, each side 
containing approximately 10,000 neurons. Each neuron has its own cell 
autonomous oscillator that work in concert to generate circadian rhythms 
(Mohawk et al., 2012, Takahashi et al., 2008). The master clock tracks a 24 h day 
via a transcriptional-translational feedback loop (Edery, 2000, Takahashi et al., 
2008) consisting two proteins; circadian locomotor output cycles kaput (CLOCK) 
and brain and muscle arnt-like protein 1 (BMAL1). Figure 1.1 illustrates the 
molecular components of the circadian clock. BMAL1 and CLOCK form a 
heterodimer, the positive arm drives the transcriptional expression of period (PER) 
and cryptochrome (CRY) the negative arm inhibits CLOCK:BMAL1‐induced 
transcription. The CLOCK:BMAL1 positive arm also drives the transcription of clock 
controlled genes (CCG) and Reverse‐eritroblastosis virus (REV‐ERBs. REV‐ERBs also 
inhibits BMAL1 expression (Vieira et al., 2015). The CLOCK:BMAL1 heterodimer 
oscillates approximately every 24 h (Rutter et al., 2002). BMAL1 expression is 
highest in the evening and PER1 expression is highest at the usual wake time, in 
antiphase with BMAL1. 
The master SCN clock coordinates the rhythms of peripheral clocks 
(Johnston, 2014) and sends signals, to initiate or inhibit molecular processes, to 
peripheral tissues via hormones and the autonomic nervous system (Kalsbeek et 
al., 2001, Ramsey et al., 2007).  
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Figure 1.1 Molecular components of the core circadian clock in humans. The 
CLOCK:BMAL1 heterodimer drives the transcriptional expression of PERs and CRYs, and 
once translated PER and CRY form a protein complex which inhibits CLOCK:BMAL1‐
induced transcription. This leads to a reduction in PER:CRY over time, eventually lifting 
the repression on the CLOCK:BMAL1 heterodimer; this process takes approximately 24-h. 
The CLOCK:BMAL1 positive arm also drives the transcriptional expression of CCGs and 
REV‐ERBs, and REV‐ERBs also inhibit the transcription of BMAL1.  In humans, BMAL1 
expression peaks in the evening/night time and PERs expression peaks in the morning. 
BMAL1, brain and muscle ARNT‐like 1; CLOCK, circadian locomotor output cycles protein 
kaput; PER, period homolog drosophila; CRY, cryptochrome; CCGs, clock controlled genes; 
REV‐ERB, reverse‐ erythroblastosis virus. 
 
1.1.1 Diurnal rhythms and photic signalling   
Rather than simply reacting to daily environmental changes, animals change their 
metabolism in anticipation of a regular routine, indicating a role of the circadian 
timing system in anticipatory behaviour. Daily oscillations in gene expression 
leading to metabolic changes, such as higher hormone secretions, and increased 
motor activity occur just before the beginning of the wake period in animals and 
humans (Diaz-Munoz et al., 2000, la Fleur et al., 1999). As previously mentioned, 
under free-running conditions there is a natural inter-individual variation in the 
period length of the endogenous rhythms of slightly more or less than 24 hours. 
Therefore, it is not surprising that the most influential time-cue of daily 
rhythmicity is the 24-h light-dark cycle so that a species can be connected to their 
environment through the process of entrainment. Under typical 24-h 
environmental conditions, mammals detect non-visual photic environmental 
changes through their eyes. Rods, cones and intrinsically photosensitive retinal 
CLOCK BMAL1 
E‐box 
PERs CRYs 
REV-ERBs 
+ve arm 
‐ve arm 
CCGs 
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ganglion cells (ipRGCs) in the retina sense changes in light irradiance. Photic 
information is transmitted along the retino-hypothalamic tract (RHT) to the SCN 
(Moore et al., 1995). Tracking the 24-h day is achieved because this pathway has 
a relatively high threshold to short wavelength light over long periods and 
therefore is unaffected by transient changes in light intensity over a short period, 
when for example an animal would be in a shaded area (Mohawk et al., 2012). 
1.1.2 Peripheral clocks 
All molecular clocks located outside the SCN region of the brain are referred to as 
peripheral clocks and are ubiquitous in tissues and organs throughout the body 
(Takahashi et al., 2008). Peripheral clocks, also known as cell autonomous 
oscillators, can override SCN signals in response to non-photic stimuli, such as food 
(Lamia et al., 2008). These zeitgebers are weaker than those of the light-dark cycle 
but never the less play an important role. Studies in totally blind people have been 
particularly useful in the discovery of non-photic stimuli that entrain peripheral 
clocks. Exercise has been shown to only have small phase-resetting actions 
(Mistlberger and Skene, 2005), however this may be due to the study designs and 
not delivering the bout of exercise at the most appropriate time to fully exploit 
the time resetting potential. To achieve the results, the protocols also involved 
lengthy bouts of exercise, questioning the practical applications. In one study 
exercise was performed in the early and middle waking period for 2 hours 
(incorporating 15 min exercise and 15 min rest) on a bicycle ergometer (Yamanaka 
et al., 2010). The authors also commented that whilst physical exercise 
accelerated entrainment of the sleep-wake cycle the circadian rhythms in plasma 
melatonin and rectal temperature were unaffected, suggesting only a partial 
entrainment. Another study used 1-h high intensity or 3-h low intensity workouts 
on exercise machines reported that evening exercise, before the usual sleep onset 
and dim light melatonin onset (DLMO), phase-advanced and exercise during most 
of the usual sleep period phase-delayed the circadian rhythm (Mistlberger and 
Skene, 2005). 
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Meal timing has been shown to be a more effective non-photic zeitgeber, 
although it only seems to be effective in peripheral tissues, not the SCN. Peripheral 
clocks are affected by ad libitum food quality, quantity and timing, without altering 
the biological time of the SCN (Bailey et al., 2014, Damiola et al., 2000). Cell culture 
experiments designed to express luciferase (luc) on the Per1 gene from Per1:luc 
rats (Yamazaki et al., 2000) and PER2:luc mice (Yoo et al., 2004) have shown these 
rhythms even persist in vitro without input from the SCN. Figure 1.2 shows the 
effect of exogenous signals on peripheral clocks, using the liver as an example, and 
the orchestration by the SCN (Mohawk et al., 2012). Restricted feeding rapidly 
entrains the liver, without affecting the timing of the SCN, shifting its rhythm by 
10 hours within 2 days (Stokkan et al., 2001). 
Figure 1.2 Pathways of peripheral clock entrainment. The master circadian pacemaker 
within the suprachiasmatic nuclei (SCN) relays time related information to peripheral 
oscillators through autonomic innervation, body temperature, humoral signals (such as 
glucocorticoids), and feeding-related cues. Independent of the SCN, local signalling 
pathways can also affect peripheral oscillators (Mohawk et al., 2012). 
 
In cells integral to glucose homeostasis and lipogenesis such as those in the 
liver, pancreas, skeletal muscle, intestine and adipose tissue, peripheral clocks 
influence metabolism via clock genes (Bass and Takahashi, 2010). The liver clock is 
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particularly sensitive to food and meal timing (Rutter et al., 2002) and can be reset 
by a negative energy balance (Balsalobre et al., 2000, Damiola et al., 2000). 
Rhythmic transcripts have been reported in mouse tissues such as adipose, 
pancreas and liver (Johnston, 2014). 
1.2 Energy metabolism  
Although free fatty acids (FFA) are the main fuel source for most organs (Shrayyef 
and Gerich, 2010), we require consistent levels of circulating glucose as it is the 
main energy source utilised by the brain. Because glucose homeostasis is so 
critical, most metabolic processes are centred on its storage and utilisation 
(Shrayyef and Gerich, 2010). A constant supply of glucose is supplied via 
gluconeogenic pathways in the fasting state. Carbohydrates (CHO), protein and fat 
from food are converted to energy via glucogenic pathways. Glycolysis is the 
conversion of CHO into glucose and is the main energy-producing pathway in the 
fed state. The initiation or suppression of these two metabolic pathways is tightly 
controlled to ensure glucose homeostasis (Gerich, 2000).  
Triglycerides (TAG) are the most important and abundant lipids in a human 
diet. The fatty acyl group is made up of carbon chains that range from C2 – C24 in 
length that can be saturated or unsaturated containing up to six double bonds (Mu 
and Porsgaard, 2005) Evidence suggests abnormal levels of TAG (dyslipidaemia) 
play a central role in obesity, insulin resistance and T2DM (Section 1.3). 
Fatty acids are transported across the cell membrane into the inner 
mitochondrial membrane by acylcarnitines. Gluconeogenesis is performed via β-
oxidation of long chain fatty acids (LCFA); each cycle cleaving two carbons from 
the fatty acid chain. The carbons are converted to acetyl coenzyme A (acetyl-CoA) 
for entry into the citric acid cycle to provide energy for skeletal and cardiac muscle 
(Hughes et al., 2009). 
1.2.1 Circadian metabolism 
Higher concentrations of plasma FFA and TAG in obesity and T2DM have been 
reported for many years, with plasma TAG concentrations peaking near the usual 
wake time (Morgan et al., 1998). The circadian clock gene network plays an 
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important role in mammalian energy balance (Bass and Takahashi, 2010). 
Examination of gene expression in core clock genes in animal models has provided 
evidence of the core molecular clock regulation of CHO and lipid metabolic 
pathways. The nuclear receptors Rev-erbα and peroxisome proliferator-activated 
receptors (PPARs), core components of the molecular clock, activate or repress 
the genes and couple transcriptional networks involved in CHO and lipid 
metabolism with the molecular clock (Duez and Staels, 2008). BMAL1 rhythmically 
occupies many of the DNA binding sites of genes associated with CHO and lipid 
metabolism and TAG metabolic pathways are especially enriched among BMAL1 
targets in liver; affecting lipid synthesis (Gooley and Chua, 2014).  
Hepatic de novo lipogenesis is coordinated by two closely related nuclear 
receptors (PPARδ and Rev-erbα/β) to control energy substrate homeostasis 
(Marquez et al., 2004). Phospholipids, particularly phosphatidylcholine (PC) 
(18:0/18:1) and PC aa C36:1, are receptive to the diurnal regulation of lipogenic 
gene expression by PPARδ during the night-feeding phase in mice which is 
repressed by Rev-erbα/β. 
Oscillations in glucose levels have also been attributed to endogenous 
circadian rhythms (Bailey et al., 2014, la Fleur et al., 1999, Rudic et al., 2004, Scheer 
et al., 2009, VanCauter et al., 1997). The SCN involvement in endogenous glucose 
rhythmicity in rats has been demonstrated by comparing fasted rats with rats fed 
6 identical meals equally distributed over the light-dark cycle and ad libitum fed 
rats. The 24-h glucose rhythm in all three feeding regimes in the SCN intact rats 
was absent in the SCN-lesioned rats (la Fleur et al., 1999). These rhythms can also 
be affected with an intact SCN when genetic components of the clock are 
manipulated (Ruiter et al., 2003). Glucose disposal also shows diurnal variation by 
insulin dependent and independent mechanisms (Bailey et al., 2014). In controlled 
clinical studies, glucose exhibits a circadian rhythm in humans peaking at during 
the night (Scheer et al., 2009, Shea et al., 2005). Even in healthy individuals glucose 
tolerance decreases as the day progresses (Morgan et al., 1998).  
In humans, in anticipation of increased activity, like cortisol, blood glucose, 
insulin and C-peptide concentrations rise before waking. However, in individuals 
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with insulin resistance and T2DM, who have an ineffective secondary response to 
these alterations, the hepatic glucose output causes a dramatic and potentially 
dangerous rise in circulating glucose levels; a manifestation known as the dawn 
phenomenon (Bolli et al., 1984).  
1.2.2 Desynchrony between the central and peripheral clocks 
The evolutionary advantage of anticipating environmental changes can become a 
disadvantage when the routine is acutely altered. The most common examples are 
the changes in the sleep-wake schedule in shift-workers or those crossing multiple 
time zones on long haul flights. This brings with it a change in meal time in relation 
to the sleep-wake schedule.  Why is it so important to synchronise the peripheral 
clocks and the central clock? Clocks keep time and track the day. The role of the 
peripheral clocks is to optimise metabolism to the anticipated environmental 
conditions (Section 1.1.2) and the master clock in the SCN coordinates metabolic 
processes with the light-dark cycle (Section 1.1.1) so that the opposing fasting and 
absorptive processes in organs such as the pancreas and liver occur at different 
times of the day (Section 1.14). Figure 1.3 shows the different behavioural and 
metabolic processes that occur over the 24 h day. 
 The liver clock promotes glycogen synthesis during the day and 
gluconeogenesis and glycogenolysis occur during the sleep-fasting period. Animal 
models have shown that even though it is unfavourable to eat when metabolic 
processes occur at the usual sleep time, if food is only available at this time, the 
overriding requirement is to eat (Damiola et al., 2000). If the limited food 
availability becomes routine these clocks in the periphery entrain to this new 
eating time, presumably to optimise metabolism. Meanwhile, the master clock is 
still entrained by the light-dark cycle as this is the most constant environmental 
factor, the timing of food availability could change at any time. Animal studies 
have also shown that hedonism plays a role in eating at the ‘wrong’ time of day; 
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when food is available ad libitum the palatable foods are favoured when eating in 
the rest period (la Fleur et al., 2007). 
 
 Figure 1.3 The behavioural and metabolic processes according to the time of day. 
Metabolic processes are coordinated with the light-dark cycle by the clocks in peripheral 
tissues. The liver clock promotes glycogen and cholesterol synthesis during the 
wake/feeding period and gluconeogenesis and glycogenolysis during the sleep/fasting 
period (Bass and Takahashi, 2010). 
 
The phase shift of the circadian misalignment also impacts on metabolism, 
appetite and hormone levels  (Gonnissen et al., 2012). In a highly controlled study, 
participants were mobile in a respiration chamber and fed 3 times a day in a 21-h 
day (phase delayed misalignment) and a 27-h day (phase advanced misalignment) 
circadian misalignment protocol for three days each, plasma melatonin, glucose, 
ghrelin, leptin, GLP-1 and saliva cortisol were measured. The phase advance was 
associated with significantly increased insulin response to the food. The phase 
delayed misalignment led to higher glucose concentrations and increased CHO 
oxidation and lower GLP-1 concentrations and decreased protein oxidation, the 
phase advanced misalignment increased CHO oxidation and decreased protein 
oxidation.  
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1.2.3 The effect of food and meal timing on metabolism 
Inverted feeding schedules show that behaviour and physiology (increased 
locomotor activity, body temperature, corticosterone secretion, gastrointestinal 
(GI) motility and digestive enzymes) change in anticipation of the new feeding 
regime within a few days (Damiola et al., 2000, Froy, 2007). Figure 1.4 illustrates 
the overriding effect of an imposed feeding schedule on photic signals from the 
SCN to the liver, kidney, heart and pancreas (Damiola et al., 2000, Johnston, 2014). 
Indeed, a high fat diet can lengthen the period of the circadian clock, independent 
of body weight. The diurnal rhythm of food intake was dampened due to the mice 
choosing to eat the high fat food exclusively during their normal rest (light) period 
(Kohsaka et al., 2007).  
 
Figure 1.4 Entrainment of peripheral clocks by feeding behaviour. The central clock in 
the suprachiasmatic nuclei (SCN) is entrained by the light-dark cycle. (A) Ad libitum food 
availability; the SCN synchronises peripheral clocks via the endocrine system and 
fluctuations in core body temperature. (B) Signals of low energy status from peripheral 
organs overrides signals from the SCN and wakens the animal in order to forage in the 
typical inactive phase. 
 
Experiments using gene knock-out animals confirm that daily rhythms of 
peripheral clock genes tissues are entrained by food (Stephan, 2002b). Repeating 
these findings in humans is more challenging due to the combined complexity and 
SCN 
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expense of human laboratory studies and the invasive nature of obtaining 
peripheral tissue: it is impractical to take biopsies from the liver, pancreas, spleen, 
for example. In humans adipose tissue and leucocytes have been used to 
demonstrate peripheral clock genes that display daily rhythmicity (Archer et al., 
2008, Otway, 2009). Thus, they offer the possibility to assess the human peripheral 
rhythms (Chapter 5). 
The timing, quantity and quality (macronutrient composition) of meals 
clearly affects metabolism, however the endogenous timing system also 
influences the choices we make, including appetite. Volunteers will self-select 
three regular meals a day, at the usual breakfast, lunch and dinner times, even 
when isolated from external temporal cues (Garaulet and Madrid, 2010). The 
independent effect of food timing on body weight has been demonstrated in 
dieting individuals. Those who consume their main meal before 15:00 h lose more 
weight than those eating their main meal after this time, adjusting for dietary 
composition, overall calories consumed and energy expenditure (Garaulet et al., 
2013, Jakubowicz et al., 2013). Eating a high CHO meal in the evening slows TAG 
clearance compared to the same meal served in the morning (Gibbs et al., 2014). 
1.3 Obesity, insulin resistance and T2DM  
Obesity results from a chronic imbalance between energy intake and energy 
expenditure. Excess energy is stored in adipose tissue around the body, increasing 
its mass. T2DM develops from a chronic ineffective response to insulin, typically 
presenting in adulthood, due to a combination of lifestyle factors; 
overconsumption of calories and inactivity and a genetic predisposition (Wang-
Sattler et al., 2012). Even before the symptoms of T2DM present, raised fasting C-
peptide and insulin levels are seen in obesity (Webb et al., 1982). Skeletal muscle 
is desensitised to insulin, which would normally enable entry of glucose into cells, 
causing glucose to accumulate in the circulation. The pancreas produces more 
insulin to compensate, promoting elevated insulin concentrations, reducing 
hepatic insulin tolerance and creating a relative insulin deficiency rather than 
reduced insulin per se.  
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The eventual failure of pancreatic β-cells to produce enough insulin to 
compensate for ongoing insulin resistance, resulting in disordered glucose 
metabolism is actually preceded, and caused, by elevated circulating FFA (Boden 
and Laakso, 2004). Boden and Laakso even humoured that if Minkowski, who first 
associated the pancreas with diabetes in the late 19th Century, had noticed the 
acetone smell when he discovered the sweet taste in the urine of his 
pancreatectomised dogs. It may have led to the earlier discovery of the role FFA 
play in the development and pathogenesis of T2DM (Boden and Laakso, 2004). 
Lipid induced insulin resistance may be caused by excessive lipid levels creating 
mitochondrial overload of fatty acids and inadequate TCA cycle activity which 
contribute to incomplete β-oxidation of LCFA. Which in turn leads to higher 
concentrations of their acylcarnitine by-products and inhibits the action of insulin 
(Adams et al., 2009).  
1.3.1 Diagnostic criteria for type 2 diabetes 
Glycated haemoglobin (HbA1c) is used a measure of long-term glucose control. 
Haemoglobin joins with glucose in a manner directly proportional to the levels of 
circulating glucose. Because red blood cells survive for 8-12 weeks, measuring 
HbA1c reflects the average blood glucose levels over that period. The diagnostic 
criteria for diabetes and prediabetes in mmol/l of fasting plasma glucose (FPG), 
glucose response to the oral glucose tolerance test (OGTT) of 75g of glucose after 
2-h and HbA1c, are shown in Table 1.1 (http://www.diabetes.co.uk/pre-
diabetes.html) 
Table 1.1 Diagnostic criteria for type 2 diabetes 
 Normal  Pre-diabetes  Diabetes  
FPG (mmol/l) < 6.1 6.1 - 6.9 > 7.0 
2-h OGTT (mmol/l) < 7.8 7.8 - 11.0  > 11.0 
HbA1c (mmol/mol) < 42 42 - 47 > 48 
HbA1c (%) < 6.0 6.0 - 6.4 > 6.5 
The fasting plasma glucose (FPG) test, oral glucose tolerance test (OGTT) glucose at 2 h 
after 75g OGTT in mmol/l and HbA1c in mmol/mol and %. 
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1.3.2 Links between obesity, T2DM and circadian metabolism  
The relationship between the circadian timing system and metabolic health means 
that disruption of one will affect the other, exacerbating co-morbidities (Burgueno 
et al., 2010, Schiavo-Cardozo et al., 2013). Figure 1.5 illustrates the cycle of 
circadian disruption, which may lead to increased metabolic disturbances and 
predisposition to obesity and T2DM, which then may lead to further problems 
with sleep and circadian misalignment 
Figure 1.5 Cycle of circadian disruption and disordered metabolism. Disturbed sleep and 
circadian misalignment can create metabolic disturbances such as a predisposition to 
obesity, which is a leading cause of T2DM, which can have a detrimental effect on sleep, 
completing the cycle.  
 
There are strong animal transgenic data supporting clock-metabolism links. Clock 
genes have been shown to act as candidate genes for obesity and metabolic 
syndrome. Homozygous Clock mutant mice become obese and develop metabolic 
syndrome, showing signs of hepatic steatosis, higher leptin, lipid, glucose and 
insulin levels (Turek et al., 2005). Ablation of the pancreatic clock and disruption 
of BMAL1 and CLOCK leads to hypoinsulinaemia and diabetes in mice (Marcheva 
et al., 2010). A causal relationship between Bmal1 sequence polymorphisms in 
rats has been extended to human cohort data and provides evidence that the clock 
gene BMAL1 is associated with predispositions to hypertension and T2DM with 
the metabolic syndrome (Woon et al., 2007). 
Metabolic 
disturbances
Obesity
T2DM
Restricted sleep / 
sleep deprivation
Disrupted 
clocks/ circadian 
misalignment
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A well-cited study investigating the adipocytokine mRNA expression of 
leptin, resistin and visfatin in visceral fat reported that rhythmic clock gene 
expression is influenced by disturbances in metabolism (Ando et al., 2005). Using 
female mouse knockout models of mild and severe spontaneous diabetes, they 
reported attenuated resistin and visfatin rhythmicity (using 4 x 6 hourly samples 
over 24 h). However, this study only used female mice because 24 h mRNA 
rhythmicity was not observed in male mice. Furthermore the different production 
sites in mice (macrophages) and humans (adipocytes) questions the relevance the 
relevance to human metabolism (Cao, 2014). In ob/ob mice, a mutation causing 
loss of leptin, also causes dampened rhythms in diurnal activity and dampened 
clock gene expression in liver and adipose tissue  (Gooley and Chua, 2014). Ando 
and colleagues also reported dampened clock gene expression rhythms in 
leucocytes of patients with T2DM studying a similar number of nondiabetic 
individuals (n = 6) and T2DM patients (n = 8) to the present study. However, the 
mean age of their participants were significantly different (p<0.01). The healthy 
group was more than half the age (28 ± 7 years) of the T2DM group (60 ± 10 years) 
and although they did not report a significant BMI difference, the healthy group 
was in the normal mass category (BMI 21.4 ± 2.5 kg/m2) and the T2DM group was 
OW/OB (26.3 ± 8.9 kg/m2). The lack of statistical significance could be explained 
by the 8.9 kg/m2 standard deviation (Ando et al., 2009). The same samples used in 
the present study and analysed in sections 3 and 4 of this thesis were used to 
measure circadian rhythms in clock gene expression in white adipose (Otway et 
al., 2011) and plasma leptin (Maentele et al., 2012). Daily rhythms were retained 
in white adipose tissue and leptin in obesity and T2DM compared to weight 
matched controls. 
1.4 Gastro-intestinal hormones  
Understanding the interactions and observing the diurnal rhythms of hormones 
builds a greater appreciation of the physiological significance and the complex 
nature of endocrinology, chronobiology and metabolism. Metabolic hormones 
produced by more than one tissue type and receptors on cells in different tissues, 
demonstrate the complexity of the GI system and its interdependence with other 
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systems in the body. It is well established that hormones are affected by metabolic 
states such as obesity and T2DM, and external influences such as sleep duration 
and stress (Gangwisch, 2009). Hormones send endocrine or paracrine signals in 
response to energy status and food in the GI tract to control appetite, as well as 
having systemic effects (Zhang et al., 2010). Although there are many hormones 
that integrate metabolism, the following sections only review the evidence on the 
hormones measured in the present study using a multiplex assay (Chapter 3). 
1.4.1 Insulin 
Insulin, produced in the pancreas, stimulates and facilitates the uptake of glucose 
into the liver, skeletal muscle and fat cells. Insulin release is not continuous, 
fluctuating from 100 pmol/l to more than 800 pmol/l, every 3-6 minutes. It inhibits 
glucagon release; attenuating the use of fat as an energy source and is inhibited 
by noradrenaline, leading to higher blood glucose levels during stress. Insulin is a 
potent antiproteolytic hormone. Systemic administration reduces skeletal muscle 
breakdown and increases amino acid transport into muscle leading to lower amino 
acid circulating levels (Irving et al., 2015).  
Overweight (OW) individuals have higher plasma insulin levels than those of 
normal weight independent of the effect of food (Merl et al., 2004). This study 
examined 20 normal weight and 10 OW men and women, fasted for 72 hours, with 
blood samples taken every 4 hours. Fasting plasma insulin concentrations 
displayed a daily rhythm, peaking at 08:00 h that persisted in all 3 days. Insulin and 
glucose concentrations were consistently higher in the OW participants than in 
the normal weight participants. As the participants had regular sleeping breaks 
and were allowed to walk round the ward circadian timing was not controlled and 
may have affected the observed rhythm (Merl et al., 2004). In a study in which 
sleep and activity were controlled, under CR conditions, insulin had a circadian 
rhythm, peaking in the morning, at the usual wake-up time (Shea et al., 2005). 
Insulin responds to elevated glucose levels differently throughout the day; 
postprandial insulin secretion is greater in the morning and afternoon than in the 
evening (Frape et al., 1997), resulting in better clearing of postprandial glucose 
earlier in the day. Other studies have shown insulin levels peak during the late 
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biological night / early morning (Morris et al., 2012). Other hormones work to 
oppose the action of insulin, glucagon (Section 1.4.3) being the most well-known, 
however resistin also works as an antagonist to insulin in glucose metabolism to 
further increase insulin resistance in mice (Steppan et al., 2001).  
1.4.2 C-peptide 
C-peptide (connecting peptide) joins the A and B chains of insulin, at this stage 
known as proinsulin, in the rough endoplasmic reticulum of pancreatic cells. As 
such, it is integral to and a by-product of insulin production and is released into 
the circulation at the same time and in a similar ratio. As it is not degraded as 
quickly by the liver as insulin it makes it a more useful marker of insulin release 
and is very often used for this purpose in diabetes testing (Ferrier, 2014).  
Fasting serum C-peptide concentrations are correlated with body weight 
and plasma glucose concentrations (Garciawebb et al., 1982). This positive 
correlation to BMI may be due to the increased insulin production that occurs to 
offset the effect of insulin resistance (Park et al., 1997). Merle et al. (2004) 
observed a circadian rhythm that peaked in the morning. C-peptide levels over a 
24 h period (with controlled sleep and wake times) in response to meals simulating 
daily living were consistently elevated in glucose-tolerant obese first degree 
relatives of T2DM when compared to obese non-relatives suggesting a genetic 
component to insulin resistance (Nyholm et al., 1999). In this study glucose, insulin 
and GIP levels were also significantly higher but glucagon was not, which also 
suggests early pancreatic β cell dysfunction in obese first degree relatives.  
1.4.3 Glucagon 
Glucagon is produced in the distal gut, the ileum and colon and in the small bowel 
in smaller amounts. It is secreted by the α cells of the pancreas, it has the opposite 
effect to insulin, and stimulates hepatic glucose production. It increases insulin 
sensitivity and satiety (Ferrier, 2014).  
Feeding and circadian timing both play a role in circulating glucagon 
concentrations. A daily glucagon rhythm peaking at the start of the active period 
in fasted rats with an intact SCN was lost in SCN lesioned rats (Ruiter et al., 2003). 
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However, ad libitum feeding dampened the rhythm and meal-induced glucagon 
rhythms were observed in scheduled feeding, leading to the belief that glucagon 
may contribute to energy mobilisation at the start of the active period but is then 
stimulated by food intake. 
1.4.4 Incretin hormones 
The definition of an incretin is the ability to stimulate insulin release. GIP and GLP-
1 are the only incretin hormones.  
1.4.5 Glucose-dependent insulinotropic peptide (GIP) 
GIP is mainly produced in the proximal duodenum and the jejunum. It senses 
glucose and fat in the duodenum, which then signals insulin secretion. In plasma, 
post-prandial levels peak 10-20 times baseline within 15-30 minutes (Ross and 
Dupre, 1978). GIP promotes TAG incorporation into adipocytes and GIP receptors 
have been found on rat and human adipocytes (Diakogiannaki et al., 2012).  
Insulin resistant obese individuals have higher post-prandial serum GIP 
concentrations than insulin sensitive obese individuals or controls, suggesting 
insulin sensitivity alters GIP concentrations not obesity per se (Creutzfeldt et al., 
1978). Although other evidence points to a genetic predisposition affecting 
impaired GIP concentrations in T2DM rather than solely by insulin resistance 
(Vilsboll and Holst, 2004). 
GIP rhythms observed with feeding schedules were absent in fasted rats, 
suggesting GIP concentrations correlate with the feeding schedule (Rubin et al., 
1988). In a study examining the daily rhythm of GIP and GLP-1 before and after 
bariatric surgery in morbidly obese women with and without T2DM (Mingrone et 
al., 2009), daily GIP and GLP-1 rhythms were observed. However, there was no 
reference to a period of adaptation to remove exogenous confounders and they 
were fed meals at 4 time-points. Therefore, the rhythms could have been induced 
by the light-dark cycle or the meals rather than being endogenous circadian 
rhythms. In a well-controlled study (2 x 26-h CR using hourly fortified milkshakes, 
separated by an imposed 27 h day for 27 days) plasma GIP rose in response to the 
milkshakes but did not have a circadian rhythm (Morgan et al., 1998). 
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1.4.6 Glucagon-like peptide-1 (GLP-1) 
GLP-1 is an anorexigenic amino acid pro-hormone secreted mainly in the distal 
ileum and the colon. Typical fasting plasma concentrations range from 5-10 
pmol/l, increasing 2-3 times after food (Mansour et al., 2013). GLP-1 
administration reduces food intake in healthy weight and obese individuals. It 
inhibits gastric acid secretion, slows gastric emptying and supresses glucagon 
release (Diakogiannaki et al., 2012), and has direct effects on the CNS to decrease 
food intake and increase energy expenditure (Zhang et al., 2010). GLP-1 increases 
insulin secretion in a glucose-dependent manner by binding to receptors on 
pancreatic β cells. It can increase β cell mass by stimulating proliferation and may 
indirectly decrease glucagon secretion via the paracrine effect of insulin on α cells 
(Zhang et al., 2010). 
Studies have shown that GLP-1 elimination is similar in healthy, obese and 
T2DM, however, postprandial concentrations were lower in OW and T2DM 
suggesting GLP-1 secretion is attenuated in these metabolic states (Mansour et 
al., 2013). Lower plasma GLP-1 levels observed in T2DM were the same in well-
controlled and poor-glycaemic controlled patients, suggesting T2DM per se did not 
affect GLP-1 secretion (Diakogiannaki et al., 2012). 
Mingrone et al. (2009) reported circadian rhythms of GLP-1 in morbidly 
obese T2DM patients and normal controls with acrophase times of 07:22 h and 
17:56 h, respectively. Although cosinor analysis revealed a daily rhythm, there was 
no indication the participants were synchronised before entry into the study or 
exogenous confounders were controlled during the laboratory session. Thus, the 
observed rhythm was not necessarily truly circadian and may have been due to 
endogenous and exogenous factors. Morgan et al. (1998) reported inconsistent 
postprandial levels in plasma GLP-1 with no evidence of a circadian rhythm using 
a CR protocol.  
1.4.7 Ghrelin 
Ghrelin is an orexigenic hormone produced mainly in the stomach and the 
pancreas. Fasting plasma acetylated ghrelin (AG) levels are similar in pre-diabetes 
and T2DM and lower than in normoglycaemic individuals (Sharifi et al., 2013). 
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Ghrelin seems to have two components to its metabolism, firstly, circulating 
concentrations increase when nutrient levels are low to stimulate appetite and 
secondly, rise throughout the day and peak in the middle of the night. In a 
controlled laboratory study where participants were given three meals a day, 
ghrelin concentrations rose before the meal and decreased sharply within 60 
minutes post-meal. Insulin concentrations followed a similar pattern, peaking 60 
minutes after the meal, although there was a wide inter-individual variability 
(Cummings et al., 2001). In this study, leptin was also measured and although the 
decrease in concentration was at the same time as insulin, it was not as precipitous 
as ghrelin or insulin. After the last meal at 17:30 h, ghrelin and leptin levels rose, 
both hormones reaching a peak at 01:00 h. The similar peak times of these 
hormones is intriguing as they have opposing effects on metabolism; ghrelin is a 
hunger hormone and stimulates appetite, whereas leptin is a satiety hormone.  
Ghrelin levels are positively correlated with insulin sensitivity and have 
significant inverse relationship with circulating insulin (Purnell et al., 2003). 
Moreover, insulin has been proposed as a long-term mediator of ghrelin 
regulation; as insulin concentrations rise in response to a meal, ghrelin levels 
decrease (Saad et al., 2002). Excluding the meal effect, circulating ghrelin levels 
have a similar diurnal pattern to leptin. Ghrelin levels rise throughout the day 
reaching a peak at 01:00 h with a nadir at 06:00 h (Cummings et al., 2001). Lower 
leptin and raised ghrelin levels have also been associated with short sleep and 
could explain the higher BMI observed with short sleep duration by increasing 
appetite (Taheri et al., 2004).  
There is evidence to suggest that the circadian clock plays a role in ghrelin 
regulation and that ghrelin may also be produced within the mediobasal 
hypothalamus (MBH)/subparaventricular nuclei (SPV). In a study examining 
obesity and metabolic syndrome in mice, ghrelin mRNA expression was reduced 
in the MBH in Clock mutant mice at virtually all time points of the 12L:12D cycle 
(Turek et al., 2005).   
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1.4.8 Leptin 
Leptin is an anorexigenic hormone produced in adipocytes, skeletal muscle and 
the stomach; the physiological effects from these different organs are thought to 
be the same (Zhang et al., 2010).  Gastric-derived leptin is secreted into the gut 
lumen (Buyse et al., 2001) and constitutes 25% of circulating levels. Leptin 
suppresses appetite by sending satiety signals to the brain and increases glucose 
uptake into cells in response to food (Zhang et al., 2010).  
There is a direct relationship between plasma leptin and body weight, 
thought to be due to the increased adipose tissue mass increasing leptin secretion. 
As well as higher circulating levels of leptin, dampened diurnal rhythms and 
reduced relative amplitude in obesity may contribute to leptin resistance in 
obesity (Saad et al., 1998). Fasting plasma leptin was not reported to be associated 
with T2DM (Sharifi et al., 2013). 
Leptin has a daily rhythm, which peaks around 00:00-02:00 h. Under normal 
sleep-wake conditions (23:00 – 07:00 h) leptin peaks at 02:04 h (Benedict et al., 
2012). Maentele et al. (2012) showed that leptin had a clear daily rhythm, peaking 
at 00:31 h, which was not affected by obesity or T2DM. Cummings and colleagues 
showed that leptin displayed a clear diurnal variation with a nadir at 09:00 h and 
peak at 01:00 h (Cummings et al., 2001). 
The peak time and amplitude of leptin rhythms are affected by sleep status 
(Spiegel et al., 2004). In young healthy adults, controlled for energy intake and 
expenditure, leptin levels were 19% lower in the sleep restricted group (01:00-
05:00 h) compared to those with a 12 h sleep opportunity (21:00-09:00 h). The 
dampened rhythm in the sleep debt group also peaked 2 h earlier than in the 
extended sleep group, 21:30 h ± 43 mins vs 23:30 ± 21 mins. However in another 
study, leptin concentrations did not change dramatically in response to feeding, 
only showing an 8-9% drop in circulating levels within 1 h of consuming a meal 
(Benedict et al., 2012).  
In a study examining the effect of meal timing on leptin levels in humans, 
leptin rose during the evening with an amplitude of 21%, peaking at 24:00 h, and 
nadir between 09:00 and 12:00 h (Schoeller et al., 1997). When the meals were 
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shifted by 6.5-h without changing the light or sleep cycles, the plasma leptin 
rhythm was shifted by 5-7 h. The phase shift occurred rapidly when compared with 
changes in the diurnal rhythm of cortisol, suggesting that the circadian clock does 
not solely drive diurnal leptin rhythms.  
1.4.9 Resistin 
Resistin is produced mainly in adipocytes in rodents, however, it is secreted by 
macrophages in humans making comparison between the effects of resistin in 
animal models to humans more complex (Cao, 2014). In mice it acts as a signalling 
molecule, activated by adipogenesis; higher levels observed in diet-induced 
obesity have opposing effects to insulin, and thus increase insulin resistance 
(Steppan et al., 2001).  
Epidemiological studies have linked higher circulating resistin levels with 
increased risk of T2DM (Burnett et al., 2006). Secretion of resistin by macrophages 
in humans has led to the belief that it is more closely associated with chronic 
inflammation than with obesity and T2DM per se. The higher levels of circulating 
and adipose tissue resistin in obesity may be a result of greater infiltration of 
macrophages into the adipose tissue. Although in many studies there was no 
association with adiposity, in some studies resistin levels dropped after weight loss 
but in other studies there was no change (Park and Ahima, 2013). Genetic studies 
have provided additional evidence for a role of resistin in insulin resistance and 
inflammation (Park and Ahima, 2013). Although conflicting results have been 
reported in the literature, higher baseline levels of circulating resistin have been 
observed in T2DM patients and have been significantly correlated with increased 
risk of T2DM after adjustment for other risk factors (Park and Ahima, 2013). 
Higher circulating resistin concentrations in shift workers, independent of 
age, BMI, waist-hip ratio, HOMA and cardiovascular risk have been reported and 
may provide a link between resistin and circadian misalignment (Burgueno et al., 
2010). Resistin concentrations measured over 24 h showed that circulating resistin 
levels did not display any daily variation (Aziz et al., 2011). 
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1.4.10 Visfatin  
Visfatin also named nicotinamide phosphoribosyltransferase (Nampt) and pre-β-
cell colony-enhancing factor (PBEF), is produced mainly in visceral adipose tissue 
(Dogru et al., 2007), but also in skeletal muscle and liver (Benedict et al., 2012). 
Plasma concentrations are higher after a night of sleep deprivation (Benedict et 
al., 2012). Esteghamati et al. (2011) observed no correlation between serum 
visfatin and BMI or waist circumference. By contrast, Friebe et al. (2011) reported 
higher visfatin levels in children with obesity and impaired insulin. 
Fasting morning plasma visfatin levels of newly diagnosed, non-medicated 
T2DM patients, were reported to be significantly higher than in healthy controls 
(Dogru et al., 2007). Higher fasting serum visfatin levels have been observed in 
T2DM patients than healthy controls which were also positively associated with 
the homeostatic model assessment (HOMA) insulin resistance index (Esteghamati 
et al., 2011). Up to 2000 mg metformin given to T2DM patients for 12 weeks did 
not have a significant effect on plasma visfatin levels (Erdem et al., 2008). 
Under a regular sleep-wake pattern of eight hours (23:00 – 07:00 h), visfatin 
peaks in the afternoon (15:53 h) (Benedict et al., 2012). In this study, a night of 
sleep deprivation caused the visfatin rhythm to phase advance by 2 hours, peaking 
at 13:37 h. Fasting serum visfatin levels were higher in individuals who slept more 
than 7 hours, compared to those sleeping less than 5.5 hours a night (Hayes et al., 
2011).  
1.4.11 Plasminogen activator inhibitor 1 (PAI-1) 
PAI-1, produced by endothelial cells, hepatocytes and granules of platelets, 
inhibits fibrinolysis leading to increased susceptibility to atherosclerotic plaque 
development (Shimomura et al., 1996). Higher levels of PAI-1 levels associated 
with coronary heart disease (CHD) may also be linked to insulin resistance due to 
central obesity, a well-recognised risk factor for CHD. Furthermore, the production 
of PAI-1 by adipose tissue, particularly from the omentum, the layer of peritoneum 
that surrounds abdominal organs, may be contributing to the elevated plasma PAI-
1 levels observed in insulin resistance (Shimomura et al., 1996). The link between 
higher levels of circulating PAI-1 and obesity, metabolic syndrome and T2DM is 
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also well established (Alessi and Juhan-Vague, 2006). PAI-1 levels were 20% lower 
after 16 weeks of metformin treatment in insulin treated T2DM patients, 
independent of glycaemic control, body weight and insulin dose (De Jager et al., 
2005). 
An early study reported that PAI-1 displayed diurnal rhythmicity in humans, 
with higher levels in the morning than the evening (Angleton et al., 1989). This 
study also observed significantly higher PAI-1 concentrations in atherosclerotic 
coronary artery disease patients, who had a two-fold difference compared to their 
healthy controls.  Evidence of the circadian system playing a role in PAI-1 
rhythmicity comes from a study showing that both CLOCK:BMAL1 and 
CLOCK:BMAL2 heterodimers activate the PAI-1 promoter in cultured Bovine aortic 
endothelial cells (Schoenhard et al., 2003). PAI-1 has also been reported as a clock-
controlled gene in humans, displaying a clear circadian rhythm, peaking at 06:30 
h with concentrations ranging from 1 ng/ml on the baseline day to 1.54 ng/ml 
during the 20 hour days of a forced desynchrony protocol (Scheer and Shea, 2014). 
1.4.12 Summary of hormones in obesity and type 2 diabetes 
Table 1.2 summarises the literature review in the previous sections examining the 
effect of obesity and T2DM compared to healthy weight non-diabetic individuals.  
Table 1.2 Hormones levels in obesity, T2DM, after food and rhythmicity  
hormone obesity T2DM fed state Peak time 
insulin ↑ ↑ ↑ Morning 
C-peptide ↑ ↔ or ↑ ↑ Morning 
glucagon ↑ ↑ ↓ Morning 
GIP ↔ or ↑ ↔ or ↑ ↑ No rhythm 
GLP-1 ↑ ↓ ↑ No rhythm 
ghrelin ↓ ↓ ↓ Middle of night 
leptin ↑ ↑ ↑ Middle of night 
resistin ↓ and ↑ ↔ or ↑ ↔ No rhythm 
visfatin ↔ or ↑ ↑ ↔ Afternoon 
PAI-1 ↑ ↑ ↔ Early morning 
The effect of obesity, T2DM and food on GI hormones compared to healthy weight non-
diabetic individuals and the peak time of plasma concentration, summarised from the 
previous Sections. ↑ higher, ↑ lower and ↔ no change.  
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Newgard et al (2009) reported differences between lean and obese individuals in 
a range of hormones, measured by radioimmunoassay (RIA), in the morning after 
an overnight fast. Significantly higher levels of insulin, C-peptide, glucagon, GIP 
and leptin were observed in obesity. Resistin levels were also higher however this 
difference was not significant. Ghrelin and GLP-1 levels were lower in obesity, with 
only ghrelin being statistically significantly different. 
Figure 1.6 Hormones levels affected by body mass and T2DM. The effect of obesity (blue 
arrows) and T2DM (black arrows), on GI hormones compared to healthy weight non-
diabetic individuals where ↑ = higher, ↑ = lower and ↔ = no change. The purple curve 
represents daily rhythmicity where EM = early morning, AM = morning, PM = afternoon, 
MN = middle of the night and X = no daily rhythm, summarised from the literature.  
1.5 Circulating metabolites in health and type 2 diabetes 
The following sections detail the biological significance of the most relevant 
metabolites associated with obesity and T2DM measured using targeted liquid 
chromatography (LC)/mass spectrometry (MS) metabolomics. The targeted 
metabolomics assay kits simultaneously measure over a hundred metabolites 
from amino acid, biogenic amine, acylcarnitine, glycerophospholipid and 
sphingolipid classes in the circulation, creating a metabolic snapshot of 
intermediary metabolism (Chapters 4 and 5). 
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The advantage of measuring metabolites simultaneously in a single plasma 
sample means that not only can we compare individual metabolites between 
conditions but also examine several metabolites in concert, creating metabolic 
indicators. Evidence suggests that combining metabolically related metabolites, 
by either enzyme activity or regulation, produces a lower inter-group variation and 
thus serves as a more appropriate biomarker signature than the same metabolites 
measured independently (Altmaier et al., 2008). The classes of metabolites 
measured in the present studies using the LC/MS targeted metabolomics are 
discussed in the following sections.  
1.5.1 Amino Acids 
As well as being the building blocks of proteins, amino acids play an integral part, 
as intermediates, of metabolic pathways and neurotransmitter transport. 
Mammals can make most amino acids de novo, by converting other amino acids, 
however; phenylalanine, valine, threonine, tryptophan, methionine, leucine, 
isoleucine, lysine and histidine are essential amino acids must come from the diet 
(Ferrier, 2014).  
Measuring several metabolites in concert is particularly meaningful for 
amino acids because of their interdependence in different metabolic pathways. In 
general, circulating amino acid levels are higher in insulin resistance and T2DM 
which may be due to reduced enzyme activity, such as branched chain ketoacid 
dehydrogenase (BCKD) which catalyses the irreversible catabolism of branched 
chain amino acids (BCAA) and tyrosine aminotransferase (TAT), which converts 
tyrosine to phenylalanine, rather than higher amino acid concentrations per se 
(Irving et al., 2015). Each of the following sections discusses the current evidence 
in relation to specific amino acids, obesity, insulin resistance or T2DM and meal 
timing. 
1.5.1.1 Glutamate  
All amino acids can be catabolised into glutamate. It plays a central role, as a 
nitrogen donor and acceptor, for the safe disposal of amino acids when protein 
levels are high via entry into the urea cycle. Aminotransferases transfer NH3+ group 
and oxidative deamination creates ammonia (NH4+). In the mitochondria, the 
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enzymatic reaction catalysed by carbamoyl phosphate synthase (CPS1) requires N-
acetylglutamate (Figure 1.7). Proline and glutamate are also interrelated with 
proline being a derivative of glutamate. 
 
Figure 1.7 The role of glutamate in the urea cycle. Any amino acid can be converted to 
glutamate for entry into the urea cycle for the safe disposal of excess amino acids.  
1.5.1.2 Urea cycle  
The urea cycle, also known as the ornithine cycle, converts ammonia (from excess 
amino groups) to urea in the liver to be excreted via the kidneys. The amino acids 
involved in the urea cycle are citrulline, ornithine and arginine. The function and 
regulation of the urea cycle can be assessed by comparing ratios of the amino acids 
involved in individual enzyme activity of the cycle under different conditions.  
1.5.1.3 Cit:Orn ratio 
A lower Cit:Orn ratio, indicative of decreased ornithine carbamoylphosphate 
transferase (OCT) activity, has been observed in previous studies in individuals 
with metabolic syndrome (Altmaier et al., 2008).  
1.5.1.4 Orn:Arg ratio  
The Orn:Arg ratio is an indicator of arginase activity. This is the final enzyme 
catalysed reaction of the urea cycle and is expressed as: arginine + H2O → 
ornithine + urea (Altmaier et al., 2008). Arginase activity is increased in diabetes; 
thus the ratio would be higher in diabetes.  
1.5.1.5 Glucogenic amino acids 
Together, the glucogenic amino acids, alanine, glycine and serine, are indicators 
of the balance between glycolysis, a process utilised for the conversion of glucose 
into pyruvate for energy production in the fed state, and gluconeogenesis, which 
uses the same metabolic pathway but in reverse and is responsible for the 
conversion of pyruvate into glucose, in the fasting state. Lower glycine levels 
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observed in individuals with impaired glucose tolerance (IGT) and T2DM may 
result from insulin resistance (Ferrier, 2014).  
1.5.1.6 Branched chain amino acids 
The essential amino acids isoleucine, leucine and valine form the BCAA. All the 
BCAA are essential, and therefore provided by diet. BCAA from dietary protein are 
preferentially used as a nitrogen source in muscle tissues. The same mitochondrial 
enzymes catalyse the initial steps in the degradation of these amino acids. 
Inhibited BCAA uptake in peripheral tissues of individuals with insulin resistance 
and T2DM manifest as higher circulating BCAA concentrations and indicate 
variations in short-term metabolic control between individuals (Newgard, 2012). 
  Daily rhythms in two BCAA have been reported in young healthy male 
volunteers (Davies et al., 2014). Isoleucine concentrations peaked at 22.75 h and 
valine peaked at 23.55 h although leucine did not display a significant daily rhythm. 
1.5.1.7 Amino acids, obesity and T2DM  
Amino acids have been extensively studied in diabetes research. Their roles in 
metabolic pathways associated with energy metabolism; in particular, catabolism 
of glucogenic and ketogenic amino acids (phenylalanine, threonine, tyrosine and 
tryptophan) for cellular energy when glucose levels are low makes them perfect 
candidates to measure the effects of insulin resistance. A study published as far 
back as 1969, of 10 healthy weight and 10 obese, age and sex-matched individuals, 
demonstrated higher valine, leucine, isoleucine, tyrosine and phenylalanine 
concentrations and lower glycine concentrations in the obese group. The higher 
amino acid levels also correlated directly with serum insulin concentrations (Felig 
et al., 1969).  
A study examining daily amino acid concentrations in plasma before and 
after weight loss, using 2-h sampling over 24 hours, found higher tryptophan 
concentrations in the control group compared to the obese group before weight 
loss, and lower still in the obese group after weight loss (Breum et al., 2003). 
Higher tyrosine, phenylalanine and total BCAA concentrations were observed in 
the obese group before weight loss compared to the control group. After weight 
loss, tyrosine concentrations were lower and phenylalanine and BCAA levels were 
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higher in the obese group after weight loss. There was a significant main effect of 
group and time of day, with no significant group, time interaction. Protein 
degradation is increased in numerous tissues (measured using whole body protein 
kinetics) in individuals with T2DM under hyperglycaemic conditions, mainly due to 
increased phenylalanine and tyrosine degradation (Irving et al., 2015). More detail 
of amino acids in T2DM are in Section 1.5.8. 
1.5.2 Biogenic amines 
1.5.2.1 Sarcosine  
Sarcosine, also known as N-methylglycine, is an intermediate and by-product in 
glycine synthesis and degradation. Sarcosine dehydrogenase converts sarcosine to 
glycine, and glycine-N-methyl transferase converts sarcosine from glycine.  
1.5.2.2 2-aminoadipic acid (alpha-AAA) 
Alpha-AAA is produced endogenously from tissue degradation of plasma proteins 
and is structurally similar to glutamate and aspartate. It is generated from lysine 
and can act as a substrate for enzymes downstream of tryptophan metabolism 
(Wang et al., 2013). Elevated alpha-AAA is also associated with low concentrations 
of glutathione most likely due to inflammation and oxidant oxidative stress which 
is its most likely link with T2DM (Irving et al., 2015). 
Alpha-AAA plays a role in the compensatory mechanism associated with 
glucose homeostasis in early insulin resistance by stimulating insulin secretion, 
augmenting circulating insulin in the animal model of insulin resistance induced by 
a high fat diet. Circulating alpha-AAA are 51% higher in mice fed a high fat diet 
compared to the standard chow and although present in other metabolically 
active tissues, such as adipose, muscle, liver and pancreas, the pancreas had the 
highest levels. Concentrations of alpha-AAA levels are poorly correlated with BCAA 
and although modestly correlated with lysine and kynurenine, it has been 
proposed that only alpha-AAA predicts T2DM (Wang et al., 2013). In humans, 
under low glucose conditions 30 µM alpha-AAA significantly increased insulin 
secretion. As glucose levels rose, this effect became less prominent, suggesting 
high alpha-AAA in low glycaemic or fasting conditions may induce insulin release 
(Wang et al., 2013).  
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1.5.3 Acylcarnitines 
Acylcarnitines (ACs) are fatty acid esters of L-carnitine. Carnitine can be sourced 
from the diet, mainly from meat or it can be synthesised from lysine and 
methionine (Ferrier, 2014). They are categorised according to their carbon chain 
length. Short chain ACs contain less than 6 carbons, medium chain ACs contain 12 
carbons, long chain ACs contain 21 carbons and very long chain ACs contain over 
22 carbons. As carriers of fatty acids across the mitochondrial membrane, levels 
are affected by alterations in β-oxidation such as with insulin resistance (Ferrier, 
2014).  
 
Figure 1.8 Transport of fatty acids into the mitochondria. After transportation into the 
cell, fatty acids (FA) are activated by esterification to CoA and pass through the outer 
mitochondrial membrane. CPT-1 exchanges the CoA moiety for carnitine creating 
acylcarnitine (AC). AC is transported across the inner mitochondrial membrane by 
carnitine-acylcarnitine-translocase (CAT). In the mitochondrial matrix, a reversal 
exchange takes place through the action of CPT-2 that reconverts the AC back into C0. 
Once inside the mitochondrion the fatty-CoA is a substrate for the β-oxidation machinery 
(Schooneman et al., 2013). 
 
1.5.3.1 Carnitine palmitoyltransferase I ratio 
Carnitine palmitoyltransferase I (CPT-1) ratio is the ratio of long chain 
acylcarnitines to free carnitine (AC-C16+AC-C18/AC-C0) and is indicative of CPT- 1 
activity, a rate limiting step in the uptake of long chain fatty acids into the 
mitochondria (Schooneman et al., 2013). CPT-1 transfers acylcarnitine from the 
cytosol through the outer mitochondrial membrane into the inter-membrane 
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space. Figure 1.8 shows the transport of fatty acids across the mitochondrial 
membranes using acylcarnitine as the vehicle.  
1.5.4 Acylcarnitines in T2DM  
Raised ACs and lipid concentrations in T2DM may result from excessive non-
esterified fatty acid (NEFA) availability, reduced NEFA oxidation, or both. The 
malonyl-CoA inhibition of CPT-1 slows the transfer of NEFA into the mitochondria 
(Mihalik et al., 2010). The combined effect of obesity and insulin resistance on AC 
concentrations, is demonstrated in a study that observed higher short chain AC-
(C3, C4 and C5) concentrations in T2DM compared to lean subjects and higher AC-
C3 and AC-C5 concentrations in T2DM compared to overweight subjects (Mihalik 
et al., 2010). Furthermore, the higher long chain AC concentrations in overweight 
and T2DM compared to the lean group was not evident in T2DM compared to the 
overweight subjects (Mihalik et al., 2010). Circulating AC profiles in T2DM are 
indicative of incomplete LCFA catabolism and are therefore useful biomarkers of 
insulin resistance. Higher AC-C2 and lower AC-C3 levels also correlate with HbA1c, 
appearing to be sensitive indicators of the severity of diabetes and long-term 
glycaemic control (Adams et al., 2009).  
Together, gene expression and metabolomic profiling platforms 
demonstrate the circadian-regulation of AC metabolic pathways. Cpt1A gene 
expression is regulated by the circadian clock in liver (Hughes et al., 2009). In mice 
entrained to 12 h light, 12 h dark cycle (LD 12∶12) with samples collected every 
hour in constant darkness, liver Cpt1a mRNA levels peak near the onset of the 
active phase (Hughes et al., 2009). In humans long-chain AC plasma concentrations 
peak between 05:00 h and 08:00 h under a normal sleep-wake (wake 06:30 - 22:30 
h and 22:30 - 06:30 h sleep) schedule (Ang et al., 2012). These findings suggest 
that the opposing CPT1A rhythms in mice and humans reflect the need for 
increased fatty acid oxidation at the start of the wake period. 
1.5.5 Phospholipids 
Phospholipids are present in very low concentrations in plasma. The distribution 
of small fractions of lipoprotein-free PCs, lysophoshophatydylcholines (lysoPCs) 
and Sphingomyelins (SM) from different lipoproteins has been described by Dashti 
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et al. (2011). Lipoproteins (chylomicrons, HDL, LDL, IDL and VLDL) are mainly 
synthesised in the liver and transport TAG and cholesterol between the liver and 
adipose tissue. The hydrophobic TAG and cholesteryl esters are carried internally 
surrounded by hydrophilic phospholipids, cholesterol, and apolipoproteins on the 
surface, which makes them soluble in blood (Ferrier, 2014).  
The synthetic pathways and interactions to produce different lipids are 
illustrated in Figure 1.9. Phosphatidic acid (PA) acts as a precursor of many lipids 
and can be dephosphorylated to form diacylglycerol (DAG), a substrate for TAG 
synthesis, which also forms lysoPC from PC. An alternative route via cytidine 
diphosphate diacylglycerol (CDP)-DAG (a reaction that requires serine) forms 
phosphatidylserine (PS) then PE to form PC (de Kroon et al., 2013).  
 
Figure 1.9 Lipid interactions in glycerophospholipid synthesis. Phosphatidic acid, (PA) a 
precursor of many lipids, is dephosphorylated to form diacylglycerol (DAG). DAG, a 
substrate for TAG synthesis, forms lysophospholipids (lyso PC) to form PC. Alternatively, 
PC is synthesised from PA via cytidine diphosphate diacylglycerol (CDP)-DAG, requiring 
serine, to form phosphatidylserine (PS) then by phosphatidylethanolamine (PE) (de Kroon 
et al., 2013) 
 
Plasma contains many thousands of lipid species that fall into six main 
categories including fatty acyls, glycerolipids, glycerophospholipids, sphingolipids, 
sterols, and prenols (Quehenberger et al., 2010). An in depth analysis of lipids in 
human plasma by Quehenberger et al. showed that sterols, including cholesterol 
and its esters, were the most abundant lipids on a molar basis (nmol/ml) followed 
by TAG, glycerophospholipids, free fatty acyls, sphingolipids, diacylglycerols, and 
prenols. However, glycerophospholipids formed the most by mass, mostly made 
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up of PC and phosphatidylethanolamine (PE). SM accounted for the largest 
fraction of sphingolipids. Another study examining the fatty acid composition in 
plasma reported that approximately 70% of the phospholipids in plasma 
comprised PCs, with approximately 20% made up of SM species (Hodson et al., 
2008). This study also reported that the PC content of lipoproteins, VLDL (20%) LDL 
(22%) and HDL (22%), was similar.    
Metabolic profiling under CR conditions in humans demonstrated 41 out of 
281 (15%) fatty acids were shown to exhibit circadian variation where (Dallmann 
et al., 2012). This study used 4 h time bins of pooled blood samples across 
participants who consumed hourly isocaloric snacks with continuous bed rest. 
LC/MS untargeted metabolomic profiling of the circadian nature of 
glycerophospholipids in humans using 2 hourly plasma samples over 36 h found 
several glycerophospholipid and sphingolipid species were rhythmic, however, 
there was a substantial individual variation in their timing (Kasukawa et al., 2012).  
The following sections review the current literature on the effect of obesity, 
T2DM, timed feeding and daily rhythmicity of phosphatidylcholine, 
phosphocholine plasmalogens (PC) and SM. Although lipids have been extensively 
studied in diabetes research, only a relatively small number of the total 500+ lipids 
species in plasma have been examined across time of day (Gooley and Chua, 
2014). 
1.5.5.1 Lysophosphatidylcholine acyl 
Lysophosphatidylcholine acyl (lysoPC a) is formed by hydrolytic removal of one of 
the PC fatty acids from a phosphocholine plasmalogen. The basic structure 
consists of a phosphate/choline/glycerol polar head attached to a fatty acid joined 
by an ester bond, signified by the letter a. Other names for lysoPC a are 2-
acylglycero-3-phosphocholine, 1-lyso-2-acyl-sn-glycero-3-phosphocholine, β-
lysoPC, 2-acylglycerophosphocholine, lean-1-lysolecithin and 1-lecithin. Evidence 
is emerging to indicate that metabolic disorders are associated with lower 
circulating plasma lysoPC concentrations. Lipidomic profiling has discovered lower 
circulating lysoPC in obesity in mouse models and humans (Barber et al., 2012). In 
their two-part study, Barber et al. reported reduced plasma lysoPCs with high fat-
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feeding in the rodents. In the second study, carried out to establish the relevance 
of these findings to human obesity and T2DM, they analysed plasma lysoPCs from 
lean, obese and obese T2DM individuals. Lower concentrations of lysoPC in the 
obese healthy and obese T2DM groups were observed compared to the lean 
group. Further analysis showed that plasma lysoPCs were negatively associated 
with BMI and plasma insulin concentrations. There was no relationship between 
plasma lysoPCs and glucose, HOMA and plasma lipids leading the authors to 
conclude that diet and adiposity are behind the changes in the plasma lysoPC 
profile rather than insulin resistance or T2DM. The mechanisms responsible for 
this reduction in plasma lysoPC are unknown but the authors suggested it may be 
due to an increase in breakdown or enhanced clearance from the circulation of 
lysoPC by metabolically active tissues (Barber et al., 2012). 
Obesity, independent of genetic influences, is related to distinct changes in 
the serum lipid profile. A study examining lipid profiles in obesity recruited 14 
healthy monozygotic twins, aged 24–27 years, from a large population-based 
study (Pietilainen et al., 2007): four pairs, discordant for obesity (10 to 25 kg 
weight difference) and 10 weight concordant control pairs were compared. LysoPC 
concentrations were higher or lower depending on their fatty acid composition, 
concentrations of lysoPCs were higher and concentrations of ether phospholipids 
lower in the obese co-twins irrespective of gender. LysoPCs correlated positively 
with subcutaneous obesity and negatively with insulin sensitivity, while the 
opposite was found for ether phospholipids (Pietilainen et al., 2007). 
Metabolic profiling using LC–MS under both LD and DD conditions, n = 12 
mouse samples starting at ZT0/CT0 every 4 h for 2 days reported lysoPC 
concentrations display diurnal variation. Fourteen different LysoPC species 
(C(18:1, 20:2, 20:3 and 20:4 in positive and negative mode) and C(22:4, 18:3, 
22:5,22:6  exhibited circadian variation, peaking during the biological daytime 
(Minami et al., 2009). The peak time of the circadian oscillations, was almost 
antiphasic to those in humans, which suggests circulating lysoPC levels reflect the 
metabolic requirements of diurnal humans and nocturnal animals (Minami et al., 
2009). 
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1.5.5.2 Phosphocholine plasmalogens  
Phosphocholine plasmalogens are a subgroup of glycerophospholipids. They are 
integral to the structure and function of the lipid bilayer in cell membranes. They 
also act as an energy reservoir when nutrient levels are low. Figure 1.10 shows the 
basic structure of a PC, which consists of a phosphate/choline/glycerol polar head, 
attached to 2 fatty acids joined by either ester or ether bonds.  
 Figure 1.10 The lipid bilayer and the structure of phosphatidylcholine. (A) the bilayer of 
a plasma membrane of a cell contains glycerophospholipid molecules. (B) A 
glycerophospholipid molecule is made up of two major regions: a hydrophilic head (green) 
and hydrophobic tails (purple). (C) The subregions of phosphatidylcholine shows the 
hydrophilic head composed of a choline structure (blue) and a phosphate (orange). This 
head is connected to glycerol (green) with two hydrophobic fatty acid tails (purple). (D) 
The atoms within the various sub-regions of the phosphatidylcholine (taken from Nature 
Education (2014). 
 
They are classed according to the presence of ester (a) or ether (e) bonds in 
the glycerol moiety forming diacylglycerophosphocholines (PC aa) and acyl-alkyl-
glycerophosphocholines (PC ae). A single letter, a or e, indicates a bond with only 
one fatty acid residue. The two letters (aa, ea, or ee) represent the first and the 
second position of the glycerol bound to a fatty acid residue. The fatty acid chains 
can be unsaturated (no double bond), monounsaturated (1 double bond) or 
polyunsaturated (more than 1 double bond).  PCs are the most abundant 
phospholipids in most eukaryotic cells. Many signalling cascades involve a step in 
which PC is hydrolysed to produce PA, DAG, lyso-PC and/or FFA (de Kroon et al., 
A 
B 
C D 
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2013). The targeted metabolomic platform that measures glycerophospholipids 
cannot distinguish the number of carbons on each of the fatty acid side chains on 
the PCs, therefore the nomenclature of the measured metabolites includes the 
number of carbons in both. For example PC ae C32:1 represents a PC with 32 
carbons both fatty acid side chains with a single double bond in one of them. The 
fatty acids could then both be 16 carbons in length. These two chains could also 
be different lengths, for example one chain could be 14 carbons and the other 
chain could be 18 carbons in length.     
Phospholipid biosynthesis oscillates daily in cultured fibroblasts by an 
endogenous clock mechanism that is in antiphase with Per1 expression (Marquez 
et al., 2004). Per1 expression peaks in the start of the wake period, (which in itself 
is in antiphase with Bmal1 expression) which would suggest higher levels of 
circulating phospholipids (in phase with Bmal1) occur in the evening.  
Lower plasma PC concentrations observed in inflammatory states such as 
obesity and T2DM may be due to their role in protecting mammalian cells against 
the damaging effects of reactive oxygen species (de Kroon et al., 2013). Chua et al. 
(2013) examined circadian-regulated plasma lipids in healthy males (n = 20), using 
samples collected every 4 h over 28 h. They found that 13% of the lipids exhibited 
circadian variation under constant routine conditions, mostly consisting of TAG or 
DAG, which peaked near the usual wake time. A smaller number of rhythmic PCs, 
C(32:2, 34:0, 34:1, 34:2, 36:2) and lyso-PC-a C16:0, peaked in the evening. They 
also observed substantial inter-individual variation in the peak time and strength 
of rhythms. Inter-individual agreement was only about 20%, with the timing of 
lipid rhythms varying by up to 12 hours. Only 11% of PCs exhibited circadian 
rhythms at group level, whereas 28% of PCs showed circadian variation when the 
individual rhythms were assessed. None of the sphingomyelin (SM) species were 
rhythmic at the group level, whereas 20% were rhythmic in individual subjects. 
These subjects also had inter-individual differences in blood glucose and insulin 
but not in cortisol rhythms. When the individual rhythms that were out of phase 
were averaged across subjects, they effectively cancelled each other out, resulting 
in no detectable group rhythm (Chua et al., 2013). Another study reported highly 
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variable peak times of glycerophospholipid and sphingolipid rhythms across 
subjects under a forced desynchrony (FD) protocol (Kasukawa et al., 2012). In this 
study 6 healthy individuals were kept under controlled laboratory with isocaloric 
food every 2 h while a CR1 (measurement), a 28-h sleep-wake semi-constant 
routine for 7 days (SCR) and CR2 (measurement) with hourly blood samples for 1.5 
days in CR1 and CR2 was performed. Circadian-oscillating metabolites were 
defined using the goodness of fit to a cosine of the mean peak area.  
1.5.5.3 Sphingomyelin  
Sphingomyelins (SM) are similar in structure to PC, illustrated in Figure 1.11. The 
difference between the two lipids is the sphingosine group, rather than the 
glycerol group, attached to the fatty acid side chains.  
 
 Figure 1.11 Structure of sphingomyelin compared to phosphatidylcholine. The 
structures of sphingomyelin (SM) and phospholipids (PC) are similar in the 
phosphocholine heads (purple). The differences between the two structures can be seen 
in the blue circles, where the (A) sphingosine (red) in sphingomyelin and (B) glycerol (red) 
in phosphatidylcholine groups join the phospholipid head to the fatty acids (Niemela et 
al., 2009).   
 
Very long chain fatty acid SMs had no correlation with body composition, 
whereas short and medium chain fatty acid SMs correlated positively with intra-
abdominal fat and insulin. Several other SM species, C(18∶0, 18∶1, and 20∶0), also 
correlate positively with insulin (Pietilainen et al., 2007). 
 
glycerol  
choline  
phosphate  
sphingosine A 
B 
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1.5.6 Metabolic indicators 
Metabolic indicators are groups of interrelated metabolites that have been shown 
to be more powerful predictors of T2DM than when the same metabolites are 
analysed separately (Altmaier et al., 2008; Krug et al., 2012). Examples of 
metabolic indicators are subgroups of lipids classed according to structure 
(number and position of double bonds and carbon side-chain length) (Rhee et al., 
2011, Wang-Sattler et al., 2012), BCAA (Wang et al., 2011). Ratios of metabolites 
joined in short metabolic pathways, such as Glu:Gln (Cheng et al., 2012) and 
Asp:Asn (Palmer et al., 2015) and Arg:Orn (Altmaier et al., 2008), have all been 
associated with T2DM. Typical metabolite ratios and enzyme reactions include the 
CPT-1 ratio and urea cycle intermediates. The metabolic indicators associated with 
short metabolic pathways may even help identify mechanisms behind these 
changes. Table 1.3 summarises the metabolic significance of the metabolic 
indicators measured in the targeted metabolomics kit used in the analysis of the 
samples.  
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Table 1.3 Metabolic indicators and their biological relevance 
Metabolic indicator Description Metabolic significance (indicator of) 
AAA sum of aromatic amino acids  
Essential AA sum of essential amino acids nutritional status 
BCAA sum of the BCAA short term metabolic control (muscular insulin resistance) 
Glucogenic AA sum of (Ala, Gly and Ser balance between glycolysis and gluconeogenesis 
CPT-1 ratio 
ratio of long chain AC to free carnitine 
([C16+C18]/C0) 
carnitine palmitoyl transferase I activity, rate limiting step of fatty acid 
uptake into the mitochondria 
Cit/Orn Ratio of citrulline to ornithine  
ornithine carbamoylphosphate transferase activity an intermediary step in 
the urea cycle 
Orn/Arg ratio of Orn to Arg arginase activity,the final enzyme step of the urea cycle  
ADMA /Arg 
fraction of ADMA of the unmodified Arg 
pool 
inhibition of NO synthase, associated with endothelial dysfunction and 
cardiovascular risk in general 
Kynurenine/Trp ratio of kynurenine to tryptophan rate of Trp degradation to niacin, (immunosuppression/tolerance) 
Tyr/Phe ratio of Tyr to Phe phenylalanine hydroxylase; conversion of phenylalanine to tyrosine 
Total PC ae sum of PC ae  
MUFA (PC) Total MUFA nutritional lipid composition 
MUFA (PC)/SFA (PC) ratio of MUFA to SFA fatty acid desaturase activity and nutritional lipid composition 
SFA (PC) sum of SFA nutritional lipid composition 
Total lysoPC sum of lysoPC   
Total SM sum of sphingomyelins  
Total SM-non OH sum of non-hydroxylated ceramide phosphocholines (sphingomyelins) 
Total SM-OH sum of hydroxylated ceramide phosphocholines (sphingomyelins) 
Total SM-OH / Total SM-non OH ratio of hydroxylated to non-hydroxylated ceramide phosphocholines (sphingomyelins) 
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1.5.7 Metformin 
Metformin is a biguanide insulin sensitiser drug used to treat T2DM. In a study 
examining the effect of metformin on metabolites after three months of 
treatment, it reduced functionally clustered metabolic pairs (metabolic 
indicators); Phe/Tyr, Cit/Arg and Lys/alpha-AAA (Irving et al., 2015). Tryptophan 
was the only single metabolite to have higher levels and phenylalanine, tyrosine, 
glutamate, arginine, citrulline, asparagine, lysine, alpha-AAA and lysoPCs (C16:0, 
C18:0 and C18:2) had lower levels after metformin administration. However, BCAA 
levels were not affected (Irving et al., 2015). However, in contrast another study 
administered metformin to healthy individuals and reported lower lysoPC (C16:0, 
18:0, 18:1 and 18:2) levels in plasma (Cai et al., 2009).  
1.5.8 Metabolic profiling in obesity and Type 2 Diabetes 
Evidence of a distinctive metabolic signature in obesity related to BCAA catabolism 
was investigated by Newgard et al. (2009) who examined 67 lean (57% female) 
and 74 healthy obese (70% female) participants, using single time-point samples, 
drawn after an overnight fast and assayed by MS/MS. The obese subjects were 
more insulin resistant than the lean controls, assessed by the homeostasis model 
assessment (HOMA) index and Intravenous glucose tolerance testing (IGTT). The 
HOMA index was 2.3-times higher in the obese subjects than in the lean controls 
(p < 0.0001). IGTT of a subset of 26 obese and 26 lean subjects showed that the 
insulin sensitivity index, Si, was 2.1-fold higher in lean subjects (p < 0.001); the 
obese subjects showed a trend toward higher acute insulin response to glucose 
(AIRG; p = .049), consistent with obesity-related insulin resistance. 
Isoleucine/leucine (combined) concentrations were 149 µM and 170 µM and 
valine concentrations were 235.3 µM and 271.4 µM in the lean and obese groups, 
respectively. In a principal component analysis (PCA) the BCAA showed the largest 
variance between the lean and the OW group.  
Metabolomic platforms have been used to identify potential biomarkers of 
T2DM using normoglycaemic baseline samples collected in the Framingham 
Offspring Study (1991 - 1995) and samples taken during a 12-year follow-up. 
Metabolite profiling was performed on 189 individuals who developed T2DM and 
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189 matched controls (age, BMI and fasting glucose) who did not develop T2DM 
from the same baseline examination. Isoleucine, leucine, valine, tyrosine, and 
phenylalanine had highly-significant associations with future diabetes  (Wang et 
al., 2011). The same group observed significant associations between metabolic 
risk factors (obesity, insulin resistance, high blood pressure, and dyslipidaemia) 
and higher levels of BCAA, alanine, phenylalanine and tyrosine. Particularly strong 
associations of insulin resistance with lower glutamine levels and higher glutamate 
levels have also been reported (Cheng et al., 2012). Another study investigated 
whether T2DM could be prevented in pre‐diabetic individuals with IGT (Wang-
Sattler et al., 2012). Samples collected for the Cooperative Health Research in the 
Augsburg region of (KORA) S4 cohort, analysed using the same targeted 
metabolomics kit as the studies in this thesis (Biocrates AbsoluteIDQ™ p180). A 
total 140 metabolites were quantified in 4,297 fasting serum samples. Significant 
metabolic variation was observed in the pre‐diabetic subjects, distinct from known 
diabetes risk indicators, such as HbA1c, fasting glucose and insulin concentrations. 
Glycine, lysoPC a C18:2 and AC-C2 had significantly lower levels in IGT compared 
to normal glucose tolerance. The lower glycine and LysoPC C18:2 were predictors 
of both IGT and T2DM, findings that were independently confirmed in the 
European Prospective Investigation into Cancer and Nutrition (EPIC) Potsdam 
cohort (Wang-Sattler et al., 2012).  
1.5.9 The effect of a shift in meal timing  
It is clear that when food is available at a regular time each day it acts as a zeitgeber 
(Section 1.3.1). It does not have the same capacity to entrain as the light-dark cycle 
and does not affect the molecular components or endogenous rhythms of the SCN 
(Section 1.1.1). Instead, meal timing entrains the molecular clocks in periphery. 
Most of the research investigating the effect of meal timing on endogenous 
peripheral clocks has been demonstrated by ablating the SCN or using gene 
knockout models that removes its capacity to keep time (Section 1.2.1). Animals 
with a functioning clock in the SCN that have had their feeding cycles switched 
from the active period to the rest period would not only stay awake to eat because 
they are hungry in restrictive feeding protocols. They would also stay awake for 
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the opportunity to eat high sugar, high fat palatable food when the food in the 
active phase was available ad libitum, implicating an additional hedonistic or 
‘pleasure seeking mechanism to food intake. If eating at the ‘wrong’ time of day 
becomes a regular occurrence it has been shown to shift peripheral clocks 
(particularly the liver clock) but not the timing of the master clock in the SCN. 
  There are fewer studies examining the effect of meal timing in protocols that 
shift the timing of the meals within the habitual wake period so that the sleep-
wake routine is unchanged. One such study examined the associations between 
leptin and food intake in humans (Schoeller et al., 1997). They reported that leptin 
levels rose during the evening with an amplitude of 21%, which peaked at 24:00 
h, at baseline. When meals were shifted 6.5 h without changing the light or sleep 
cycles, the plasma leptin rhythm was shifted by 5-7 h (P<0.01). The phase change 
occurred rapidly when compared with changes in the diurnal rhythm of cortisol, 
suggesting that the circadian clock does not solely drive diurnal leptin rhythms.  
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1.6 Overall aims and hypotheses 
The aims of this thesis were to investigate whether glucose, TAG and a range of 
hormones and metabolites associated with energy metabolism and inflammation 
display 24-h rhythms under controlled laboratory conditions, and whether the 
phase and/or amplitude of the rhythm was altered by weight, T2DM or meal 
timing. Furthermore it aimed to examine whether obesity, T2DM or meal timing 
also affects the 24-h concentration of the measured hormones and metabolites.  
This research project was comprised of two separate human intervention studies, 
each with separate aims: 
Chapter 3 and Chapter 4:  
Aims: To investigate the impact of OW/OB and/or T2DM compared to age-
matched controls on diurnal rhythmicity in controlled laboratory conditions that 
contained a sleep-wake schedule. As T2DM is more commonly associated with 
obesity, a further aim was to separate the effects of these two conditions. To 
elucidate the effect of T2DM, a non-T2DM OW/OB control group was incorporated 
into the study design that also served as the OW/OB study group, to which the 
lean control group was compared.  
Blood samples were collected from these 3 study groups every 2 h over 24 
h. Plasma concentrations of glucose, TAG and selected hormones (C-peptide, 
insulin, glucagon, GIP, GLP-1, ghrelin, leptin, resistin, visfatin and PAI-1) were 
measured using a multi-plex assay (Chapter 3). Plasma concentrations of a panel 
of metabolites using targeted LC/MS metabolomics were also quantified (Chapter 
4). The characteristics of the glucose, TAG, hormone and metabolite daily rhythms 
(peak time, amplitude, goodness of fit) were determined by performing cosinor 
analysis and the characteristics of these diurnal rhythms between the lean, 
OW/OB and T2DM groups compared. The 24-h concentrations of these hormones 
and metabolites were also compared in the 3 study groups (lean, OW/OB and 
T2DM group).     
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Hypotheses:  
The hypothesis that body weight and T2DM would affect the daily rhythmicity 
(peak time, amplitude) as well as the concentration of circulating metabolites 
across the 24-h day was tested. It was hypothesised that the amplitude of the 
diurnal rhythms of glucose, TAG, hormones and metabolites would dampen in 
T2DM and obesity compared to the lean group whereas the peak times would 
remain similar in the 3 study groups. The 24-h concentration of glucose and TAG 
was expected to be higher in T2DM and OW/OB compared to their control groups. 
The 24-h concentration of the majority of the hormones would be higher (except 
ghrelin would have lower 24-h concentrations) in T2DM and OW/OB compared to 
their control groups. The 24-h concentrations of the majority of the amino acids 
would be higher and the concentrations of the majority of the phospholipids 
would be lower in T2DM and OW/OB compared to their control groups. 
Chapter 5 
Aims: To investigate the impact of a 5-h delay in a 3-meal a day feeding schedule 
on metabolite circadian rhythmicity and 24-h concentration of circulating 
metabolites using targeted LC/MS metabolomics.  
Hypothesis: A 5-h delay in meal timing under fixed light/dark and sleep/wake 
cycles will phase delay metabolite circadian rhythms, whilst those under the 
control of the central pacemaker (assessed using melatonin) will remain 
unchanged and fixed to the light/dark cycle. 
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2 Materials and methods 
2.1 Diurnal rhythms in type 2 diabetes  
2.1.1 Ethical approval 
The ethics application, participant recruitment and screening was carried out by 
Dr. Daniella Otway, and details of these processes are recorded in her PhD thesis 
(Otway, 2009). A favourable ethical opinion was obtained from the Surrey 
Research Ethics Committee (08/H1109/117, submission 19th August 2008) and 
the University of Surrey Ethics Committee (EC/2008/82/FHMS/Fast-track). 
Written informed consent was given by all participants. 
2.1.2 Power calculation 
The power calculation for the present study came from the best estimate of the 
expected response, based on a study examining clock gene mRNA rhythms in male 
C57BL/6J mice by Ando et al. (2005). A difference of ≥ 1.5 SD in the peak expression 
of clock genes, Per and Dbp, and Adiponectin mRNA rhythms between the lean 
control group and the obese-diabetes groups was expected. For α ≤ 0.05 and 80% 
power with a potential drop-out rate of 10%, 9 participants per group were 
required to gain a statistically significant result (Otway, 2009). All parameters are 
shown in Table 2.1. 
Table 2.1 Calculation of sample size based on results between subjects. 
Sample size calculation parameters  Comparison between cohorts 
Type of study ANOVA 
Design Repeated measures 
Alpha – Error  0.05 
Power 80% 
SD between the means  1.5 
Mean standard deviation  1.5 
Drop-out rate 10% 
Sample size per cohort 9 
 
2.1.3 Inclusion criteria 
Male participants who were aged between 40 and 65 years, willing and able to 
give oral and written consent, with the agreement of their general practitioner 
(GP) confirming there was no medical reason they could not participate in the 
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study were recruited. Participants had to have a regular sleep-wake cycle with 
sleep duration between 6 and 8 h (self-assessed on screening),  pass the screening 
questionnaire criteria and blood analysis and agree to the rules for the pre-study 
period, for more details see Otway et al. (2011). 
2.1.4 Exclusion criteria 
Participants were excluded if the any of the following applied  
 Horne Östberg Morningness/Eveningness Questionnaire (MEQ) revealed 
an extreme morning or evening type (Horne and Östberg, 1976). 
 If they could not refrain from taking regular medication or food 
supplements known to influence either sleep, alertness and the circadian 
timing system (e.g β-blockers, barbiturates, antidepressants, 
benzodiazepines, melatonin, ritalin, modafinil, soporifics and St John's 
wort). 
 If they were taking any medication that affected metabolic function of the 
thyroid, kidney, liver or gastrointestinal function or inflammatory markers 
(e.g. aspirin, ibuprofen, antibiotics, hay fever medication, medication for 
sore throats and colds). 
 If they were taking any medication that affected endothelial markers (e.g. 
angiotensin (receptor) blockers, diuretics, beta-blockers, anti-thrombosis 
medication).  
 A history of psychiatric or neuronal disease, drug and alcohol abuse, or any 
circadian or sleep disorder, or metabolic (excluding T2DM participants), 
cardiovascular or chronic infectious / inflammatory disease. 
 If they were anaemic or had donated over 400 ml of blood in the 3 months 
preceding the study. 
 If they did not keep a regular sleep-wake cycle or travelled across more 
than 2 time zones within 1 month of the study. 
 If they did not refrain from alcohol, caffeine, heavy exercise, high fat and 
high sugar food and nicotine in the week before the laboratory study. 
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2.1.5 Participants 
Men (n = 25) aged between 40 and 65 years were recruited into three groups. Men 
with a BMI between 19 and 25 kg/m2 without any of the criteria for metabolic 
syndrome as described by the European Group for the Study of Insulin Resistance 
(EGIR) (fasting insulin ≥ 60 pmol/l) with at least 2 of the following; hyperglycaemia 
(fasting plasma glucose ≥ 6.1 mmol/l, but non-diabetic); hypertension 
(systolic/diastolic blood pressures ≥ 140/90 mmHg or treated for hypertension); 
dyslipidaemia (TAG > 2.0 mmol/l or HDL-cholesterol < 1.0 mmol/l or treated for 
dyslipidaemia); central obesity (waist circumference ≥ 94 cm in men) (Balkau and 
Charles, 1999) were assigned to the lean group. The OW/OB group comprised men 
with a BMI between 25 and 35 kg/m2 that met the criteria for insulin resistance 
defined by the EGIR. The T2DM group comprised men with a BMI between 25 and 
35 kg/m2 with diagnosis of T2DM.  
2.1.6 Demographic data  
Height, weight, waist circumference and blood pressure were measured (OMRON 
Mx3 Plus Digital Automatic Pressure Monitor, Omron Automotive Electronics) on 
the screening day.  
2.1.7 Blood tests 
Participants gave a fasting blood sample (13 ml) on the screening day. The blood 
was split into 3 tubes; 10 ml was transferred into a serum tube (Teklab), for 
analysis of HbA1c (by cation exchange chromatography (TOSOH)) and insulin at 
the Clinical Biochemistry Department at the Royal Surrey County Hospital. Plasma 
TAG and cholesterol were measured using 2 ml blood, transferred into a di-
potassium-EDTA tube (Teklab) and spun (3000 g, 10 min, 4°C) and 1 ml blood was 
transferred into a di-potassium-EDTA tube (Teklab) to measure glucose. The 
resulting plasma samples were stored at -80°C until analysis (Otway, 2009). 
Participants were excluded if any of these measurements were abnormal.  
2.1.8 The pre-study protocol 
A strict pre-study protocol was designed to limit confounding effects of irregular 
activity, sleep-wake and meal timing schedules on the participants before they 
entered the laboratory. 
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2.1.8.1 Daily routine 
Participants followed a prescribed sleep-wake routine to avoid the phase shifting 
effect of different sleep-wake times on the circadian system (Section 1.2.1). This 
included staying in bed, from 22:30 h to 06:30 h and not deviating by more than 
15 min. Naps were permitted within a three hour window in the afternoon 
(centred 12-h from the midpoint of their night-time sleep), as these naps were 
assumed not to interfere with the phase of the endogenous timing system (Buxton 
et al., 2000). Participants avoided excessive exercise, and to obtained at least 15 
min of natural outdoor light within 90 min of waking. The laboratory sessions were 
carried out between March – June 2009. Daily activity was monitored by 
actigraphy using actiwatches (Actiwatch-L, Cambridge Neurotechnology, 
Cambridge, UK), worn on the non-dominant wrist. They also called the laboratory 
voicemail when going to bed and getting up as well as keep daily sleep diary. 
2.1.8.2 Meals 
Meals were consumed within set time windows; breakfast was from 07:00 h to 
09:00 h, lunch from 12:00 h to 14:00 h and dinner from 17:30 h to 19:30 h. Three 
days preceding the laboratory session participants only ate food provided by the 
study team, consisting of ready meals with a similar macronutrient content (Light 
Choice (Tesco)), Shape fruit yoghurts (Danone), cornflakes (Kellogg's), and 
Nutrition Soft Bake snack bars (Kellogg's). Alcohol and caffeine were prohibited 
the week before the laboratory session, to avoid any influence on the endogenous 
timing system. Food diaries were completed by the participants. 
2.1.9 The laboratory session 
Participants entered the laboratory at 15:00 h, illustrated in Figure 2.1. 
 
Figure 2.1 The laboratory session protocol # denotes the time of entry (day 1 15:00 h), ʘ 
hourly milkshakes (Fortisip) during wake time, ǁ blood sampling, used for this analysis, 
|blood sampling, not included on this analysis and       lights off, 0 lux (sleep).  
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2.1.9.1 Sleep times and light conditions 
Light was approximately 500 mW/m2 (160 lux) in the direction of gaze and 1600 
mW/m2 (550 lux) on the horizontal plane during lights on (06:30 h - 22:30 h). Sleep 
occurred in complete darkness.  
2.1.9.2 Body posture 
Participants lay semi-recumbent throughout the laboratory session as body 
position may affect the parameters being measured (Deacon and Arendt, 1994). 
They were permitted to go to the toilet, during waking hours, but not within 30 
min of the next blood sample. 
2.1.9.3 Feeding 
Participants were given isocaloric Fortisip™ milkshakes (150 calories per 100 ml) 
every hour, on the half hour, during waking hours. The first milkshake was given 
at 15:30 h and the last milkshake was at 21:30 h on day 1. The first milkshake on 
day 2 was given on waking at 06:30 h and the last milkshake was at 21:30 h. 
Followed by a single final milkshake at 06:30 h on day 3. Water was provided ad 
libitum throughout the study. To maintain body mass, individual energy 
requirements in calories, based on their body weight, was estimated using the 
Schofield equation, shown in Equation 2.1 (Schofield, 1985). Basal metabolic rate 
(BMR) was used because the participants were inactive and semi-recumbent for 
most of the time during the study. 
𝐸𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑑 𝐸𝑛𝑒𝑟𝑔𝑦 𝑅𝑒𝑞𝑢𝑖𝑟𝑒𝑚𝑒𝑛𝑡 (𝑘𝑐𝑎𝑙/𝑑𝑎𝑦) = (15.1 𝑥 𝑊+692 𝑆𝐸𝐸) 
Equation 2.1 Schofield equation calculating estimated energy requirement (kcal/day) 
required by male participants. W indicates the weight of the individual in kilograms, and 
SEE is the standard error of estimation, an adjustment value within the confidence limit 
(Schofield, 1985). 
 
2.1.9.4 Blood sampling 
At 07:00 h on day 2 an indwelling cannula was inserted into the participant’s 
forearm vein and a trained nurse drew 12 ml of blood every hour until 07:00 h on 
day 3 over a total period of 25 h. The whole blood was aliquoted into tubes with 
anti-coagulation reagent (lithium heparin or di-potassium-EDTA) and spun (3000 
g, 10 min, 4°C) to produce blood plasma. Samples were stored at -80°C until the 
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analysis was performed. A maximum of 320 ml blood was taken from each 
participant during the study.  
2.2 The effect of a shift in meal timing on circulating metabolites 
2.2.1 Ethical approval 
The second intervention study examined the effect of a shift in meal timing on 
circulating metabolites in young men. Dr. Sophie Wehrens did the ethical 
application. I carried out the participant recruitment and the initial screening. The 
medical screen and the laboratory studies were carried out at the Surrey Clinical 
Research Centre (CRC). All procedures were reviewed and received a favourable 
ethical opinion from the University of Surrey Ethics Committee 
(EC/2013/42/FHMS) and the study was conducted in accordance with the principle 
of the Declaration of Helsinki. All participants gave written informed consent.  
2.2.2 Power calculation 
There was very little previous research on which to base the power calculations.  
A similar 3-meal protocol to the current study, Schoeller et al (1997) measured 
plasma leptin in humans (n = 4) in a cross-over design and found large phase 
delays. In a study measuring molecular rhythms in rat tissues with n = 12 animals 
per group, the timing of the 1st daily meal closely matched the phase of the 
peripheral clock rhythms in a 2 and 3 meal per day protocol (Wu et al., 2011). 
Therefore the current study was powered to 12 participants per group. 
2.2.3 Participant screening   
Healthy male volunteers between 18 and 30 years of age were screened for 
eligibility. BMI and fat mass were assessed using a body fat composition monitor 
(Tanita). Potential participants completed a medical history questionnaire (MHQ), 
a diet history questionnaire and five validated sleep and well-being 
questionnaires. These comprised the Horne-Östberg (HÖ) questionnaire (Horne 
and Östberg, 1976), Munich Chronotype Questionnaire (MCTQ) (Roenneberg et 
al., 2003, Roenneberg et al., 2007), Pittsburgh Sleep Quality Index (PSQI) (Buysse 
et al., 1989), Beck Depression Inventory (BDI) (Beck et al., 1961) and Epworth 
Sleepiness Scale (ESS) (Johns, 1991). 
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Medical history and written consent from the participant’s GP established 
health status. A study physician at the Surrey CRC assessed the medical history 
(including any medication) and carried out a physical examination within 6 weeks 
of the start of the laboratory session. The following procedures were performed: 
vital signs: blood pressure, heart rate, oral temperature and respiration rate, 
electrocardiogram, BMI, review of medication, alcohol breath test, urinalysis 
assessment, urinary drugs of abuse test (i.e. cannabinoids, cocaine, opiates, 
amphetamines, barbiturates, and benzodiazepines) and urinary cotinine 
(metabolite of nicotine) test. 
Fasting blood samples (approximately 12 ml) were collected to measure the 
full blood count, biochemistry and serology to test for HIV and Hepatitis B and C 
with standard reference ranges used to interpret the blood results. 
2.2.3.1 Inclusion criteria 
Participants had to be between 18 and 30 years of age, male, able and willing to 
give informed oral and written consent. They had to meet the defined criteria of 
screening questionnaires, pass a medical assessment and give consent for their GP 
to be contacted for confirmation of eligibility to participate. 
2.2.3.2 Exclusion criteria 
Participants were excluded from the study if any of the following applied 
 Had been or were taking regular medication (also non-prescribed) or food 
supplements (e.g. vitamins, minerals, fish oil, fibre supplements, 
antioxidant tablets) from which it was not possible to refrain during the 
period determined by the research team. Specifically, statins and 
medication for diabetes, antihypertensive drugs, non-steroidal anti-
inflammatory drugs, β-blockers, antihistamines, antidepressants, 
antipsychotics, benzodiazepines, barbiturates, melatonin, ritalin, 
modafinil, soporifics, hypnotics, antiepileptic drugs, decongestants or 
other drugs that affect adipose, thyroid, kidney, liver or gastrointestinal 
function and caffeine containing drugs that are known to influence the 
circadian timing system, sleep, alertness, drowsiness and metabolic 
functions. 
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 Had a history of any circadian or sleep disorder or metabolic disease as 
confirmed by the GP. 
 Had habitual irregular sleep patterns on more than 2 nights per week 
(bedtime outside 22:00-1:00 h and wake up time outside 6:00-9:00 h) or a 
slept for less than 7-h or more than 9-h on more than 2 nights per week.  
 Had any systemic, psychiatric or neurological disease or a history of drug 
or alcohol abuse (or drink more than 21 units a week).  
 If they smoked or had not abstained from smoking for more than 6 months 
or had a habitual caffeine intake of more than 300 mg/day.  
 If the alcohol breath test, cotinine or drug screen at the time of recruitment 
and on admission to the laboratory session were positive. 
 If they had donated over 400 ml of blood in the three months preceding 
the study. 
 Had abnormal blood biochemistry/haematology as deemed significant by 
the study physician 
 Exceeded the defined criteria of pre-study questionnaires as assessed at 
the screening visit (BMI < 20 or > 30 kg/m2 or fat mass < 14%, 30 ≤ HÖ ≥70, 
PSQI: > 5, BDI > 9, ESS > 9).  
 Had travelled across more than two time zones within a month before the 
start or during the study.  
 Had taken part in another study within the last 3 months or were currently 
taking part in a clinical trial or another research study.  
 Had participated in rotating or night shift work for more than 6 months 
before or during the study.  
 Did not refrain from alcohol, caffeine-containing drinks and intense 
exercise 72-h before the laboratory session. 
2.2.4 The pre-study protocol 
In order to maintain entrained circadian rhythms and to minimise sleep debt, 
participants were asked to choose a regular sleep-wake cycle (Revell et al., 2005). 
At bedtime they were instructed to remain in the dark, during their 8-h sleep 
period, trying to sleep without distraction (and not to deviate in their bed and get-
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up times by more than 10 minutes). Participants were given a 4-h window in the 
afternoon (centred 12-h away from the midpoint of their night-time sleep) in 
which they were permitted to nap if they choose to do so as these scheduled naps 
were thought not to phase shift circadian rhythms (Buxton et al., 2000). 
 To confirm this regular sleep-wake cycle, participants were asked to call 
the laboratory’s voicemail within 10 min before going to bed and after waking up. 
They were also provided with two L-actiwatches (AWL) (Cambridge 
Neurotechnology, Cambridge, UK) which recorded activity and environmental 
light levels: one was worn around the neck, as close to eye level a possible, to 
monitor light exposure and the other was worn on the non-dominant wrist to 
record activity. The participants were also asked to complete a daily sleep diary, 
which recorded bed and wake times, estimates of sleep onset latency and 
awakenings and a rating of the sleep quality on a 9-digit scale (Lockley et al., 1999). 
For the 10 days preceding, and on the morning of the laboratory session, 
participants were asked to obtain 15 min exposure to outdoor natural light 
(without wearing sunglasses) within the 90 min after waking up to strengthen the 
regularity of the circadian rhythms (Revell et al., 2005, Wehrens et al., 2012) and 
to note this in their sleep diary. This study consisted of 2 laboratory sessions. 13-
27 July 2013 and 5-19 August 2013 for the 2 sessions.   
Participants were asked to inform the research team of any changes in their 
medical condition and to only use paracetamol as a painkiller instead of non-
steroidal anti-inflammatory drugs (NSAIDs) for 3 days before and during the 
laboratory sessions. 
2.2.4.1 Meals and activity 
The week before the laboratory study, the participants had to complete a food 
and activity diary, recording the time and amount of food or drink they consumed 
and any physical activity, noting the time of the activity and recording the level of 
exertion on the Borg scale (Chen et al., 2002). They could consume < 100 mg 
caffeine, which had to be drunk in the first 3-h after waking and up to 2 units of 
alcohol per day. Meals had to be consumed within specific time windows; 
breakfast, lunch and dinner to be consumed 0.5-h, 5.5-h and 10.5-h after waking 
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up, respectively. Furthermore, participants’ food was provided 3 days before the 
laboratory session, excluding fruit and vegetables, of which they could consume 
up to 5 portions a day. The macronutrient and energy of this food matched the 
food given in the laboratory session. They were also asked to refrain from heavy 
exercise, alcohol and caffeine 3 days before the laboratory session. 
2.2.5 The laboratory session 
The laboratory sessions (Figure 2.2) were conducted at the Surrey CRC (University 
of Surrey). 
 
Figure 2.2 Laboratory protocol of the meal shift study. This figure depicts the situation 
for an individual on a self-selected 23:00-7:00 schedule.  
 
2.2.5.1 Checking compliance to the pre-study protocol 
When they first arrived at the CRC, data from the participants’ AWLs were 
downloaded to confirm compliance to the pre-study protocol. They also had 
cotinine, drugs of abuse and alcohol breath tests. 
Knowledge of time was permitted during the sleep-wake cycles, and use of 
a mobile phone was allowed. During the CR, mobile phones were removed and 
the time and internet functions were disabled on their laptops. AWLs were 
continually worn throughout the laboratory session to monitor activity. On the 
Day\Time 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 1 2 3 4 5 6
0 M M M
1 M M M
2 M M M
3 M M M
4 + + + + + + + + + +● + + + + + +● + + + + + +● + +
5 + + + +● + + + + + +● + + + + +
6 M M M
7 M M M
8 M M M
9 M M M
10 M M M
11 M M M
12 + + + + + + + + + +● + + + + + +● + + + + + +● + +
13 + + + +● + + + + + +● + + + + +
+ sandwich + milkshake hourly meals, semi-recumbent, < 8 lux, individual rooms, no knowledge of time
blood: melatonin, leptin supine, 0 lux, individual rooms
blood: melatonin, leptin & PAX leukocytes seated, allowed to move, bright room light, in lounge, knowledge of time
blood: melatonin, leptin & PMBCs seated, allowed to move, bright room light, in individual room, knowledge of time
● biopsy prior to each meal: mood, alertness & appetite
M breakfast/lunch/dinner isocaloric/ continuous glucose, skin temperature and actigraphy
macronutrient
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first evening they were then given their standardised dinner at the set time before 
bedtime. 
2.2.5.2 Diet design, meal composition and energy requirements 
Regular foods, available from the supermarket, that reflected the typical 
macronutrient intake of a free living individual, were used because the one of the 
outcomes was self-reported measures mood and satiety. The target 
macronutrient content of the meals, 55% carbohydrate, of which 15% were 
sugars, 15% protein and 30% fat, of which 11% was saturated (Whitton et al., 
2011). The meals also aimed to supply the equivalent of 5 portions of fruit and 
vegetables in a day. To maximise recruitment, all food served during the study was 
vegetarian.  
The food-energy required for each participant was calculated according to 
the Schofield equation for men aged between 18 and 29 years (Schofield, 1985), 
shown previously in Equation 2.1. During the CRs when participants were 
bedbound, BMR plus a 15% activity factor was used and during the other 
laboratory days when participants were allowed to move around, BMR plus a 20% 
activity factor was used. 
During the sleep-wake days, participants received 3 isocaloric meals which 
contained a liquid component which was adjusted to meet the energy needs of 
the individual participant. Each meal was also tailored to represent a “typical” 
breakfast, lunch and dinner. The meals given during the laboratory study differed 
between the sleep-wake cycle days and during the CRs, but was matched as well 
as possible for macronutrient composition per day. A detailed explanation of the 
diets is shown in the following sections. 
2.2.6 Days 1-3 and days 6-11 
Days 1-3 and days 6-11 of the laboratory study had the same environmental 
conditions, sleep-wake schedule and menus. Only meal timing was different 
between the two schedules. 
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2.2.6.1 Environmental conditions and sleep 
Participants remained on their self-selected sleep-wake cycle.  During wake 
periods they spent the day in the lounge in bright light, were free to move around 
and visit the bathroom and were predominantly seated. They were allowed to 
read, watch films and play computer or board games as long as these activities did 
not require physical exertion or postural change. They slept in an individual 
bedroom. 
2.2.6.2 Meals  
On days 1-3, the participants ate breakfast, lunch and dinner 0.5 h, 5.5 h and 10.5 
h after their habitual wake-up time respectively. On days 6-11 the participants ate 
the same meals with a 5-h delay; namely 5.5 h, 10.5 h and 15.5 h after wake-up, 
respectively. Participants consumed their meals in individual rooms to prevent the 
smell or sight of other food affecting their metabolism, satiety and mood. The 
energy and macronutrient composition of each meal was identical but contained 
different foods to reflect foods typically eaten at that time of day. A list of the fixed 
foods served at each meal are shown in Table 2.2. 
Table 2.2 Breakfast, lunch and dinner in the meal shift protocol  
 Energy 
kcal 
Protein 
(g) 
CHO (g) 
Sugars 
(g) 
Fat 
(g) 
sat fat 
(g) 
satsuma 28.7 0.6 6.0 6.0 0.1 0.0 
medium sliced white bread 210.0 7.5 39.2 2.8 1.8 0.6 
butter portion 51.3 0.0 0.0 0.0 5.7 3.6 
strawberry jam portion 54.6 0.1 13.6 7.2 0.0 0.0 
peanut butter 192.9 8.3 2.2 1.1 16.3 2.4 
Breakfast total 537.5 16.5 61.0 17.1 23.9 6.6 
apple and grapes snack pack 48.0 0.2 9.8 9.8 0.1 0.0 
white cheese portion 83.2 5.1 0.0 0.0 7.0 4.3 
ready salted crisps (32.5 g) 172.3 2.1 15.9 0.2 11.1 0.8 
sandwich 300.0 11.2 45.0 7.4 6.8 0.8 
Lunch total 603.5 18.6 70.8 17.4 24.9 6.0 
Quorn cottage pie 365.0 12.5 50.0 8.0 10.0 5.0 
carrots broccoli and sweetcorn 96.0 4.0 12.0 4.3 1.8 0.3 
Walkers shortbread rounds 57.1 0.6 6.5 2.1 3.2 2.0 
Tesco sherbet lemons 55.3 0.0 13.7 9.4 0.0 0.0 
Dinner total 573.4 17.1 82.2 23.8 15.0 7.3 
Daily total 1714 52 214 58 64 20 
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To minimise weight change over the study period, individual daily energy 
requirements were incorporated into the diet design. A proportion of each of the 
meals was fixed and contributed 538, 603 and 573 kcals from breakfast, lunch and 
dinner, respectively. A subtotal of 1,714 kcals, which was designed to be much less 
than any of the participants estimated energy requirements for the day so that a 
reasonable portion of the adjustable food could be served. 
An Excel spreadsheet was created that divided the participant’s estimated 
energy requirements into three (for each meal), from which the fixed meal 
component (in Table 2.2) was subtracted. The energy deficit in each meal was then 
filled from the adjustable component. This adjustable component used liquid food 
vehicles as they are more easily and accurately portion controlled. The adjustable 
breakfast component comprised cornflakes and a fortified milk containing whole 
milk, dried skimmed milk, vegetable oil, and soya protein powder. The adjustable 
lunch component was leek and potato soup fortified with dried skimmed milk, 
double cream, pea protein and corn flour. The adjustable dinner component was 
natural yoghurt fortified with mixed frozen fruit, quark, Greek yoghurt, double 
cream, vegetable oil and corn flour.  
2.2.7 37-hour constant routine - days 4-5 and days 12-13 
2.2.7.1 Facility / light conditions  
Participants were woken at their usual time on the morning of day 4, and after 
showering, were cannulated to facilitate blood sampling. The 37-hour CR, started 
at 09:00 h was designed to determine the baseline circadian phase of each 
participant. 
In accordance with the methods used in a CR protocol, the accepted 
standard for phase assessments in circadian research (Duffy and Dijk, 2002b), the 
participants remained in individual rooms for the duration of the CR in a semi-
recumbent posture in dim light (<8 lux in the direction of gaze) and received hourly 
isocaloric meals. 
A modified version (Horne and Baulk, 2004) of the Karolinska Sleepiness 
Scale (Akerstedt and Gillberg, 1990), 9-digit mood and alertness rating scales 
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(Lockley et al., 2008) and validated visual analogue appetite scales (Flint et al., 
2000) were completed before each meal. 
The participants underwent a second 37-h CR on days 12 - 13 to measure 
circadian phase, after the 5-h meal shift schedule. They were allowed to leave the 
CRC after a recovery sleep and medical discharge by a study physician. 
2.2.7.2 Meals 
During the CR, participants were given hourly isocaloric snacks which consisted of 
a small sandwich, containing quorn slices and cheese spread on crustless white 
bread, and an enriched strawberry milkshake. Participants were given 100 ml of 
water every hour throughout the study to avoid a large volume being delivered to 
the stomach, but not in the 10 min preceding a blood sample. More water could 
be requested by the participants, and this was measured by clinical staff. 
The small meals started from wake-up, and contained 1/39 of the 
participant’s estimated 48-h energy requirement. 
2.2.7.3 Blood sampling 
Qualified clinical personnel inserted an intravenous cannula into each arm before 
each CR (days 4 and 12). The cannulae were removed on days 5 and 13 after each 
31-h sampling period. Blood was collected in K2-EDTA tubes and centrifuged (1620 
g at 4°C for 10 min, within 30 minutes of collection). The plasma samples were 
kept at -20oC until analysis. The first sample was drawn at 15:00 h and every hour 
until 22:00 h the following day in both CR. However, for the current analysis, the 
second blood sample, blood drawn at 16:00 h, and every 2-h until 22:00 h the 
following day was analysed. 
2.3 Basic principles of the laboratory techniques 
The following sections detail the laboratory techniques used to analyse the 
glucose, TAG, hormones and metabolites, plus the data preparation, data 
processing and the statistical methods in both studies. 
2.3.1 Analysis of glucose and triglyceride 
The glucose and TAG diabetes study samples were thawed overnight at 4°C. They 
were decanted into ILab tubes, centrifuged at 10,621 g for 4 minutes at 4°C then 
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placed into the ILab 650 Clinical Analyser (Instrumentation Laboratory, North 
Risley, UK). The ILAB was calibrated before every experimental run using standard 
ReferrIL G (Instrumentation Laboratory). Multi-sera QCs level 2 (MSL2) and multi-
sera level 3 (MSL3) (Randox Laboratories Ltd, Crumlin, UK) were placed at the 
beginning, middle and end of each sample run to determine assay drift. 
2.3.1.1 Glucose concentration 
A colorimetric method using the glucose (oxidase) clinical chemistry kit 
(Instrumentation Laboratories) determined glucose concentration (mmol/l). The 2 
step enzymatic reaction produced red quinoneimine (Figure 2.3) and the 
absorbance of the red dye had a proportional relationship to the concentration of 
glucose in the sample. The absorbance was measured at wavelengths 510-600 nm. 
𝛽 − 𝐷 − 𝑔𝑙𝑢𝑐𝑜𝑠𝑒 + 𝑂₂ + 𝐻₂𝑂 
𝑔𝑙𝑢𝑐𝑜𝑠𝑒 𝑜𝑥𝑖𝑑𝑎𝑠𝑒 
→             𝑔𝑙𝑢𝑐𝑜𝑛𝑖𝑐 + 𝐻₂𝑂 
2𝐻₂𝑂 + 4 𝑎𝑚𝑖𝑛𝑜 𝑎𝑛𝑡𝑖𝑝𝑦𝑟𝑖𝑛𝑒 + 𝑝ℎ𝑒𝑛𝑜𝑙 
𝑝𝑒𝑟𝑜𝑥𝑖𝑑𝑎𝑠𝑒
→         𝑞𝑢𝑖𝑛𝑜𝑛𝑒𝑖𝑚𝑖𝑛𝑒 𝑑𝑦𝑒 + 4𝐻₂𝑂  
Figure 2.3 Enzyme reaction in the glucose assay.  
 
2.3.1.2 Triglyceride concentration 
A colorimetric method using the TAG clinical chemistry kit (Instrumentation 
Laboratories) determined TAG concentration (mmol/l). The 4 step enzymatic 
reaction converted TAG to the coloured red quinoneimine product (Figure 2.4), 
where the TAG concentration was proportional to the absorbance of the red dye 
component. The absorbance was measured at 510-700 nm. 
𝑇𝑟𝑖𝑔𝑙𝑦𝑐𝑒𝑟𝑖𝑑𝑒𝑠 
𝑙𝑖𝑝𝑜𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑙𝑖𝑝𝑎𝑠𝑒
→              𝑔𝑙𝑦𝑐𝑒𝑟𝑜𝑙 + 𝑓𝑎𝑡𝑡𝑦 𝑎𝑐𝑖𝑑𝑠 
𝑔𝑙𝑦𝑐𝑒𝑟𝑜𝑙 + 𝐴𝑇𝑃 
𝑔𝑙𝑦𝑐𝑒𝑟𝑜𝑙 𝑘𝑖𝑛𝑎𝑠𝑒
→            𝑔𝑙𝑦𝑐𝑒𝑟𝑜𝑙 − 3 − 𝑝ℎ𝑜𝑠𝑝ℎ𝑎𝑡𝑒 + 𝐴𝐷𝑃 
𝑔𝑙𝑦𝑐𝑒𝑟𝑜𝑙 − 3 − 𝑝ℎ𝑜𝑠𝑝ℎ𝑎𝑡𝑒 + 𝑂₂ 
𝑔𝑙𝑦𝑐𝑒𝑟𝑜𝑝ℎ𝑜𝑠𝑝ℎ𝑎𝑡𝑒 𝑜𝑥𝑖𝑑𝑎𝑠𝑒
→                     𝑑𝑖ℎ𝑦𝑑𝑟𝑜𝑥𝑦𝑎𝑐𝑒𝑡𝑜𝑛𝑒 𝑝ℎ𝑜𝑠𝑝ℎ𝑎𝑡 + 𝐻₂𝑂 
𝐻₂𝑂 + 4 − 𝑐ℎ𝑙𝑜𝑟𝑜𝑙𝑝ℎ𝑒𝑛𝑜𝑙 + 4 − 𝑎𝑚𝑖𝑛𝑜 𝑎𝑛𝑡𝑖𝑝𝑦𝑟𝑖𝑛𝑒 
𝑝𝑒𝑟𝑜𝑥𝑖𝑑𝑎𝑠𝑒
→         𝑞𝑢𝑖𝑛𝑜𝑛𝑒𝑖𝑚𝑖𝑛𝑒 𝑑𝑦𝑒 + 𝐻₂𝑂 
Figure 2.4 Enzyme reaction in the triglyceride assay.  
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2.3.2 Analysis of hormones and peptides  
The hormones C-peptide, insulin, glucagon, GIP, GLP-1, ghrelin, leptin, resistin, 
visfatin and PAI-1 were measured using the Bio-Plex Pro™ Human Diabetes Assay 
(Bio-Rad Laboratories Ltd, Hertfordshire, UK). The analysis took place over 9 
separate runs. All the samples from each subject were assayed in the same assay 
run. 
2.3.2.1 Basic principles of the BioPlex multiplex immunoassay 
The multiplex immunoassay (Bio-Rad Laboratories Ltd, Hertfordshire, UK) can 
detect up to 100 analytes simultaneously. Each analyte is assigned to 1 of the 100 
Luminex beads (Bio-Rad Laboratories Ltd, Hertfordshire, UK) available. The assay 
used for this experiment was a 10-plex assay therefore only used 10 of the 100 
beads. Each bead is identified by the coating of 2 different red and infra-red 
fluorophore dyes in varying ratios that fluoresce at unique intensities, thus there 
is no interference from other analytes within the same well as none of the bead 
signals overlap. Figure 2.5 illustrates the bead coating ratios, with the highest 
concentration of dye 2 (top left) and the highest concentration of dye 1 (bottom 
right) with varying combinations of the two dyes in-between. The 5 main steps of 
the fluorescent bead sandwich assay are shown in Figure 2.6. 
 
Figure 2.5 Graphical representation of the Luminex beads in the multiplex assay. Of the 
100 beads, the highest concentration of dye 2 in the top left hand corner and the highest 
concentration of dye 1 in the bottom right hand corner of the diagram. Beads in between 
are a unique combination of the two dyes (taken from company literature). 
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Figure 2.6 The 5 main steps of the fluorescent bead sandwich assay. The coated beads 
are conjugated with antibodies. The analyte binds to its specific antibody. SA-PE detection 
antibody binds to the analyte creating an antibody sandwich. The beads pass through 2 
lasers; one identifies the fluorescence of the bead (analyte). The other laser identifies how 
many have bound to the bead by measuring the SA-PE (taken from the manufacturers 
training information). 
 
The assay is stable for 24 h and can be re-read within 24 h if necessary. The 
premixed kit measures C-peptide, insulin, glucagon, GIP, GLP-1, ghrelin, leptin, 
resistin, visfatin and PAI-1 in plasma. 
2.3.2.2 Multiplex assay protocol 
All working solutions were provided in the kit. 50 μl of plasma was required per 
sample. The blood samples were stored K2-EDTA containing tubes at -80°C. The 
samples were taken from the -80° freezer into the -20 freezer overnight before 
thawing on the day of the analysis. 
The standards were reconstituted in 500 µl of standard diluent, vortexed for 
5 seconds and incubated on ice for 30 minutes. The coupled beads were vortexed 
for 30 seconds before adding 288 μl to 5,472 μl of Bio-Plex assay buffer, covered 
Each bead is coated with different concentrations of dye 1 and dye 2. 
The beads are conjugated with antibodies separately and additional 
binding sites are blocked. The beads are then added together. 
The detection antibody (biotin bound Streptavidin phycoerythrin (SA-
PE) is added to the wells and binds to the antibodies and analyte on 
the bead. 
The beads are suspended in buffer and drawn up into the instrument 
by a needle. They are passed through a channel so that single beads 
pass a red and a green laser. 
The red laser detects the analyte by identifying the dye coating on the 
bead. The green laser identifies the amount of the analyte by measuring 
the intensity of the phycoerythrin fluorescence bound to the bead. 
During incubation the antibodies bind to the analyte. The sample is 
washed away, leaving the analyte bound to the beads. 
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with tin foil to protect from light, and incubated for 20 minutes at room 
temperature. While the standards and beads were incubating, the samples were 
checked for haemolysis and their position on the plate was recorded. After 
incubation, the standard was diluted by adding 128 μl of reconstituted standard 
to 72 μl of standard diluent in the first tube. The 8 standards were made up by 
adding 50 μl of the previous standard to 150 μl of standard diluent x 7. The diluted 
beads were vortexed and 50 μl was added to each well of the assay plate. The 
plate was washed twice with wash buffer. Then 50 μl of the 8 standards, the blank, 
3 complete participants with n = 12 samples, were added to the plate in duplicate. 
The plate was covered with tape, protected from light by wrapping in tin foil and 
incubated on a shaker at 800 rpm for 1 h at room temperature.  
Ten minutes before the end of the incubation the detection antibodies were 
prepared by vortexing the antibodies for 5 seconds, and diluting 150 μl of 
detection antibody in 2,850 μl of detection antibody diluent. When the incubation 
of the coupled beads was complete, the plate was washed 3 times with 100 μl of 
wash buffer. The diluted detection antibodies were vortexed before adding 25 μl 
to each well of the plate. The plate was covered in plastic tape then foil and 
incubated on the shaker for 30 minutes at 800 rpm. Within 10 minutes before the 
end of the incubation the Streptavidin phycoerythrin (SA-PE) was vortexed for 5 
seconds before adding 60 μl SA-PE with 5,940 μl of the assay buffer. When the 
incubation of the detection antibodies was complete the plate was washed with 
100 μl wash buffer 3 times. The diluted SA-PE was vortexed before adding 50 μl to 
each well of the plate. The plate was covered in tape and foil and incubated on the 
shaker for 10 minutes at 800 rpm. When incubation was complete the plate was 
washed 3 times with assay buffer. The beads were re-suspended in 125 μl assay 
buffer, covered with tape and foil and shaken at 800 rpm for 30 seconds. The tape 
was removed from the plate and it was placed in the Luminex 200 to be read. 
A hand held magnetic washer is used with the magnetic beads to wash the 
plate between incubations. There is a small magnet in the washer that 
corresponds to each well of the plate. The wash buffer is added to the plate, which 
is then placed and clipped securely to the washer and left for 1 minute. The beads 
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are attracted to the magnets and stay at the bottom of the wells. After 1 minute 
the washer is turned upside down over a sink to drain off the wash buffer. The 
plate turned the upright and released from the magnetic washer. This process is 
repeated. The software used was supplied by Biorad (Bio-Plex Manager 6.1). The 
default recovery range was used which was set at 70 to 130%. 
2.3.2.3 Quality controls (QCs) 
The QCs were made up of blood taken from a healthy weight female in the fed 
state on one occasion. The whole blood was collected into tubes with K2-EDTA 
anti-coagulation reagent and spun (3000 g, 10 min, 4°C) to produce plasma. It was 
then aliquoted into volumes of 200 µl, frozen and stored at -80°C until the analysis 
was performed. The QCs were positioned before and after the first participant 
time series and at the end of all samples on each of the plates. 
2.3.2.4 Standard curve  
The BioPlex 6.1 software generates the standard curve automatically using 
Brendan Scientific's 5-Parametric Logistic Regression (5PL). The 5PL model is used 
when fitting a curve with asymmetrical data because it allows each half of the 
curve to be different. The 4PL model makes one half of the curve symmetrical to 
the other. An example of a standard curve is shown in Figure 2.7. 
 
Figure 2.7 Typical standard curve of the multiplex assay.Standard curve for C-peptide. 
The y axis shows the fluorescence (Fl) and the x axis shows the concentration (pg/ml). The 
blue S values signify the standard and the value in brackets shows the observed / expected 
concentration. Regression Type: Logistic - 5PL. Std. Curve: FI = -2.80074 + (18797.3 + 
2.80074) / ((1 + (Conc / 18932.3)^-1.74275))^0.55774. FitProb. = 0.7939, ResVar. = 0.3435. 
Where FitProb 1 is perfect fit and 0 is no fit. Standard Partial Outlier OutlierUnknown Control
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2.3.2.5 Assay specificity (% cross reactivity) 
There is a large range between the lower and the upper limit of detection (pg/ml). 
This can be seen in Table 2.2 with the sensitivity (pg/ml), the intra and the inter-
assay precision for each of the analytes in the Human Diabetes kit. 
Table 2.3 Bio-Plex assay specificity 
analyte 
working range pg/ml 
sensitivity 
pg/ml 
Precision 
LLOQ 
pg/ml 
ULOQ 
pg/ml 
LOD 
pg/ml 
Intra-assay 
%CV 
Inter-assay %CV 
C peptide 22.4 10,031 14.5 5 4 
insulin 1.7 3,541 1 3 5 
glucagon 15.7 3,500 4.9 5 6 
GIP 11.2 22,895 0.8 3 4 
GLP-1 31.3 16,000 5.3 6 3 
ghrelin 16.6 8,502 1.2 4 2 
leptin 11.5 129,107 3.1 3 4 
resistin 2.3 4,739 1.3 3 4 
visfatin 51.3 280,266 37.1 4 3 
PAI-1 8.8 47,850 2.2 5 4 
LLOQ = lower limit of quantification, ULOQ = upper limit of quantification LOD = limit of 
detection  
The mean ± SD, the minimum and maximum range observed in serum 
samples from 10 normal and 28 T2DM subjects in pg/ml, measured by the 
company is shown in Table 2.3. This also demonstrates the large inter-individual 
variation within normal and T2DM samples (Biorad company information supplied 
with the kit).  
Table 2.4 Levels of metabolic biomarkers in normal and T2DM serum samples 
Analyte 
normal (n = 10) T2DM (n = 28) 
range (pg/ml) pg/ml range (pg/ml) pg/ml 
min max mean ± SD min Max mean ± SD 
C peptide 137 1,220 475 ± 322 197 3,034 888 ±735 
insulin 1 506 108 ± 154 43 1,260 391 ± 365 
Glucagon 0 82 14 ± 26 78 457 184 ± 97 
GIP 0 163 49 ± 56 44 2,836 296 ± 517 
GLP-1 0 129 20 ± 41 71 456 211 ± 102 
ghrelin 0 58 19 ± 21 24 1,422 350 ± 313 
leptin 22 5,184 918 ± 1,778 130 42,208 4,750 ± 8,031 
resistin 555 3,652 1,816 ± 893 453 22,253 5,271 ± 5,145 
visfatin 0 1,230 228 ± 402 5 35,857 3,562 ± 6,697 
PAI-1 6,019 20,539 9,705 ± 4,343 1,842 45,173 20,786 ± 10,348 
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2.3.3 LC/MS and FIA targeted metabolomics analysis 
 Targeted metabolomics is the quantitative analysis of a large number of small 
molecule metabolites using internal standards. The samples were analysed using 
the targeted metabolomics AbsoluteIDQ p180 kit (Biocrates Life Sciences AG, 
Innsbruck, Austria). All the QCs and calibrators with isotope labelled validated 
internal standards are supplied in the kit. The analysis uses a combined flow 
injection analysis (FIA)/MS and LC/MS/MS to quantify absolute concentrations 
(μM) of 184 metabolites, grouped into metabolite classes of amino acids and 
biogenic amines by LC/MS and acylcarnitines, glycerophospholipids, sphingolipids 
and hexose by FIA in positive mode. 
The mass spectrometer used in this analysis is a triple quadrupole. It is highly 
selective (targeted), and therefore allows the instrument to be fine-tuned to 
specifically look for the metabolites in the kit (Lu et al., 2008a). The first 
confirmation is the multiple reaction monitoring (MRM). The MRM approach 
consists of three stages (Roberts et al., 2012). In the first stage of the processing, 
the ions are protonated to facilitate the identification of metabolites in positive 
mode. These are often referred to as parent or mother ions. On entering the 
quadrupoles, the first quadrupole (Q1) measures the parent weight (mass to 
charge ratio). In the second quadrupole (Q2), molecular /parent ion collides with 
an inert gas (Argon in this case) and form fragment/daughter ions and the third 
quadrupole (Q3) identifies the daughter ions and detects subtle differences in the 
fragments (the daughter ions). 
Single quadruple mass spectrometer instruments often measure amino 
acids and lipids in positive and negative mode because a single quadrupole does 
not have the MRM (protonation) capability. Measuring the samples using a triple 
quadrupole does not require the measurement in positive and negative mode 
because the majority of analytes prefer to be protonated. Measuring in both 
modes would result in less sensitivity, as the MRM does not double the processing 
time, instead it allocates half the scan window to the measurement in positive 
mode and half in negative mode. 
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 The second confirmation of the accurate detection of the metabolites is the 
internal standards provided with the kit. The chemically similar, deuterated 
internal standards have a slightly different mass/charge ratio but have the same 
retention time window. 
The p180 Kit measures free metabolites in plasma, which in general means 
all non-covalent bound metabolites. Noncovalent bonds are relatively weak 
chemical bonds that do not involve an intimate sharing of electrons. 
Macromolecule structures (proteins and lipoproteins) may be stabilised by 
multiple noncovalent bonds. Lipoprotein phospholipids are measured in this 
analysis as they are non-covalently bound to structures or compartments present 
in the sample. During the preparation of the FIA plate, the methanol step 
precipitates approximately 95% of lipids, which are caught in the filter plate. 
During the PITC (phospho-isothiocyanate) incubation, all primary amino functional 
groups are derivatised; all amino acids and biogenic amines (except creatinine). 
PITC is also known as Edman's Reagent. Only derivatised amino acids and biogenic 
amines (+ creatinine) are analysed with the p180 Kit. The Q1 mass is the mass of 
the metabolite + PITC + adduct, e.g. Ala + PITC + H+ (Biocrates). 
Plasma samples (10 µl) were extracted and derivatised (Section 2.3.3.1) and 
then analysed on a Waters Xevo TQ-S (Triple quadrupole mass spectrometer 
(MS)). TargetLynx software (Waters) was used to integrate the peaks of the LC/MS 
analysis. MetIDQ software (Biocrates Life Sciences, Innsbruck, Austria) was used 
to register the samples before analysis and validate and produce concentrations 
(μM) of both LC/MS and FIA procedures. The data were then exported to Microsoft 
Excel for further analysis. 
The samples were analysed on four 96-well plates, each plate contained at 
least one complete time series from one participant from each group with an extra 
participant from one other group (totalling 4 participants per plate). The samples 
from all four participants were randomised on the plate to minimise any effect of 
drift. One plate was measured on the MS each week and all assays were completed 
within one month. 
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2.3.3.1 Sample preparation 
All LC/MS Optima grade solvents were manufactured by Fisher Chemicals (Fisher 
Scientific Loughborough, U.K) unless otherwise specified. The plasma samples 
were removed from the -80°C freezer and defrosted on ice. The temperature of 
the centrifuge (5430 R Eppendorf, Stevenage, U.K.) was set to 4°C. The 96-well 
plate, the standards, the QCs and the calibrators were removed from the -20°C 
freezer. LC/MS Optima grade water was added to the internal standard (ISTD), QCs 
and calibration standards immediately before use. The tubes, supplied with the kit 
were vortexed and then shaken for 15 minutes at 1200 rpm. The QCs and thawed 
samples were centrifuged at 4°C for 5 minutes at 2750 g. The plate, which 
consisted of an upper filter plate and a lower collection plate taped together, was 
prepared horizontally. Firstly 10 µl of internal standard (ISTD) was added to all 
wells except the blank (well position A1). Then 10 µl zero samples (phosphate 
buffered saline (PBS)) was added to well positions A2-A4, calibration standards 1-
7 were added to well positions A5- A11, QC1 was added to well position A12, QC1 
was added to well position B1, QC2 was added to well position B2 and QC3 was 
added to well position B3. B4 wells onwards were filled with samples, with 
additional QC2s in wells C11, E8 and G5. The samples were then dried at room 
temperature under a stream of nitrogen for 30 minutes. 
 For derivatisation of the amino acids and biogenic amines a derivatisation 
pre-mix was prepared (1900 µl ethanol with 1900 µl LC/MS grade water and 1900 
µl pyridine, vortexed for 10 seconds) The pre-mix was added to 300 µl of 5% v/v 
phenylisothiocyanate (PITC) derivatisation solution. The solution was vortexed 
until it became clear. The PITC solution was used immediately and 50 µl was 
pipetted into each well. The plate was covered with the plastic lid and incubated 
for 20 minutes at room temperature. The lid was removed and the plate was dried 
again under the nitrogen evaporator for 60 minutes. The extraction solvent (300 
µl) (Biocrates) was added to each well and the plate was covered with the plastic 
lid and shaken at 450 rpm for 30 minutes. The plate was centrifuged for 2 minutes 
at 100 g to transfer the samples from the filter plate to the lower capture plate. 
50 µl from each well of the capture plate was transferred to the empty 96-well 
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plate with the label “Use for LC”. Then 450 µl of LC/MS Optima grade 40% 
methanol (MeOH) was added to each well of the LC plate and covered with the 
silicone mat. This was shaken for 2 minutes at 450 rpm before transferring to the 
autosampler on the LC/MS. The neat plate, containing the samples for the FIA run, 
was placed in the fridge at 4°C until the following day. The LC plate was prioritised 
on the LC/MS because the biogenic amines are unstable after the water has been 
added. 
 The following day the FIA running solution was prepared by mixing the 
Biocrates ‘solvent 1’ ampoule with 290 ml Optima LC/MS grade methanol in a 500 
ml Duran and shaken thoroughly. From the original neat plate 20 µl was 
transferred from each well, to the empty 96-well plate labelled “Use for FIA”. FIA 
running solvent was added to each well (380 µl), the plate was sealed with a 
silicone mat then the plate was shaken for 2 minutes at 450 rpm before it was 
placed in the autosampler on the LC/MS. 
 A method set up from a previous Biocrates assay containing the retention 
times of the metabolites, and the sample codes was imported into the LC/MS using 
TargetLynx. When the LC and FIA runs were complete the data were imported into 
MetIDQ (Biocrates). 
2.3.3.2 Measurement of the samples in MetIDQ and TargetLynx 
The acquired data from the LC/MS were loaded into TargetLynx (Waters) for 
further analysis. Files were saved as a qld. file that could be edited. 
2.3.3.3 Standard curve  
The kit contained a mixture of chemically homologous internal standards. The 7-
point serial dilution (0.1, 0.2, 1, 2, 4, 6 and 8) of calibrators generated standard 
curves for the LC analysis of amino acids and biogenic amines. An R2 value closest 
to 1 was used as a measure of accuracy of each standard curve to which the sample 
concentration was calculated. Therefore, the first stage of data preparation was 
to exclude any outliers in the standard curve and maximise the R2 value.  
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2.3.3.4 Integrating peaks 
The spectrum data from the LC/MS amino acid and biogenic amines were 
imported into TargetLynx. The first stage was to modify the settings in the method 
to automatically capture the metabolite peaks for each plate individually as this 
can vary slightly from plate to plate. After the method was amended, peaks that 
were not detected were integrated manually. 
2.3.3.5 Validating and exporting the data 
The validation process automatically assesses the quality of the calibration 
standards, QCs and internal standards. Options for export including (i) QC2 
correction, which automatically smooths intraplate and interplate variation, (ii) 
blank corrected, which considers the blanks in the FIA run and (iii) 35 metabolic 
indicators using the MetIDQ RatioExplorer (predefined ratios and sums of related 
metabolites associated with a metabolic pathway or a disease state named 
metabolic indicators). Concentration values (µM) are produced which are 
exported as an excel file. 
2.3.3.6 Quality controls (QCs) 
The QCs, comprising of human plasma, were provided with the kit. They contained 
3 concentration levels (low, medium and high) of the all metabolites measured in 
the kit and are used to verify the performance of the assay and the MS. According 
to the manufacturer’s instructions the medium QC (QC2) was repeated every 20 
samples on the assay plate. The QC2 repeats were used to calculate the intraplate 
and the interplate %CV. Figure 2.8 illustrates how the MetIDQ software 
normalised the data from more than two plates. A mean of the four QC2s on each 
plate was calculated. The mean of the QC2s on all plates was calculated. The mean 
from the plate was divided by the mean of all plates creating a correction factor. 
Each sample on the plate was then divided by this correction factor for the 
normalised value used in further analysis.  
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Plate  
1 
(μM) 
Plate 
2 
(μM) 
Plate 
3 
(μM) 
Plate 
4 
(μM) 
All 
plates 
(μM) 
QC 1 10 9 11 12  
QC 2 11.5 10 12 12  
QC 3 12 10 11 12.5  
QC 4 9 11 9.5 11.5  
mean 10.6 10.0 10.9 12.0 10.9 
Sample 495 466    
 
Figure 2.8 Normalisation of samples from multiple plates. Normalisation is carried out 
using QC2 repeats. Using the formulas A1/B = C1, where A = the plate mean, B = mean of 
all plates and C = the correction factor and S1 
normalised
 = S1/C1, where S = sample and S1 
normalised 
= normalised sample. 
2.4 Data preparation and processing 
2.4.1 Calculating the coefficient of variation 
The intra (within each plate) and inter (between the plates) coefficient of variation 
(% CV) calculates the ratio of the standard deviation (SD) to the mean (µ) QCs using 
the formula % CV = SD/µ*100 
2.4.2 Metabolite exclusion criteria 
To ensure the metabolomic data had valid observations that were consistent 
across the different plate runs, the exported data had to meet specific criteria for 
further analysis. Firstly, metabolites were excluded if the interplate CV% of QC2 
was above 30%. Metabolites were also excluded if > 25% of the samples in in the 
whole dataset were below the limit of detection (<LOD). The different groups were 
calculated separately and metabolites that were <LOD in only one group were not 
excluded as this may be a feature of the intervention. Hexose was excluded 
because the data were deemed unreliable; FIA in this analysis was run in positive 
mode and hexose (glucose) is more commonly measured using an FIA acquisition 
method in negative mode.  
A1 = mean qc2; plate 1 
B = mean qc2 all plates 
C = correction factor 
S normalised = normalised  
sample 
S = sample  
A2 = mean qc2; plate 2 
A3 = mean qc2; plate 3 
A4 = mean qc2; plate 4 
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2.4.3 Missing values and removal of outliers 
In the multiplex assay, blank cells in the exported spreadsheet may have derived 
from either a missing sample or a time-point classed as out of range by the assay 
software, because they were outside the assay limit of detection. Blank cells were 
filled because the analysis software could not cope with blank cells. If the missing 
value was in the middle of the time series, a mean of the two neighbouring values 
replaced the missing value. If the missing value was at the start or the end of the 
time series, it was replaced with a duplicate of the neighbouring value. A time 
series was removed if a participant had more than 5 missing time-points (38%) for 
any one analyte because at least 6 time points are required for cosinor analysis. 
These time points could have been sequential or intermittent. 
2.4.4 Standardising the hormones using % concentration  
To compare a daily rhythm between individuals and groups, individual time series 
were normalised. A calculation to convert each concentration into a percentage 
of its own subject mean was performed. The mean concentration over the 24 h 
for each participant and analyte was calculated. Each data-point was then divided 
by this mean and plotted as a % of the mean concentration value (Maentele et al., 
2012). 
2.4.5 Batch correction of the metabolites  
To adjust for any drift throughout the plate and assay variation between plates a 
batch correction calculation was performed. The QCs across each plate were used 
to batch correct the samples adapted from a method reported by Kamleh (2012). 
A mean of the 1st and 2nd QC 2 on the plate of each metabolite was calculated. This 
value was then used as a correction factor for the samples between the two QCs. 
Similarly, to correct for drift between the 2nd and 3rd QC 2 the mean of these was 
calculated and all the samples between these two QCs were divided by this factor. 
2.4.6 Standardisation of the metabolites using z-score 
To remove any effect of inter-individual variation in concentration, and more 
accurately compare daily rhythms between the groups, each observation was 
converted to a z-score. The formula for z-score is z= (x - µ) / δ, Where x = raw 
observation, μ = mean, δ = standard deviation.  
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2.5 Statistical analysis techniques 
2.5.1 Multivariate Analysis 
Multivariate Analysis separates out useful information from noise in the data. It is 
used to analyse the metabolomics data because the high number of 
simultaneously measured variables (metabolites) creates an extra level of 
complexity. PCA is a descriptive analysis method that numerically and graphically 
correlates the variation between observations. The simultaneous measurement of 
multiple variables, as with targeted metabolomics, is presented in a three 
dimensional matrix. These data matrices with more than 2 axes are transformed 
into scores and loadings tables and plots (Lu et al., 2008b). The scores represent 
data derived from the observations (samples) and the loadings are derived from 
the variables (metabolites) that can be used for further analysis. PCA is widely used 
to analyse data with many more variables per sample than the number of samples 
assayed (Ringner, 2008).  
In effect PCA creates more axes, known as principal components, along 
which the observations with the most variation between the conditions are 
plotted using a linear algorithm. The first PC (PC1) is calculated from within the 
matrix to provide the most variance via linear regression and is represented by t[1] 
on the PCA plot. The second PC (PC2) captures the next most variance and is 
represented by t[2] on the PCA plot and so on. The scores are displayed as co-
ordinates in a PCA plot. The eigenvalues explain the effect of each PC on the model 
(Ringner, 2008). 
The position of the co-ordinates on the plot and their relationship to each 
other carries information regarding the source of the variance. Co-ordinates close 
together represent variables that are approximately the same. Co-ordinates 
furthest away from each other on the plot and that span the axis have the most 
variance in that PC. The distance of each co-ordinate from each axis is calculated, 
with F1 relating to t[1] and F2 and relating to t[2] and so on. Each co-ordinate has a 
numerical value (vector) to indicate the position of each observation and variable 
within the matrix which can be exported for further analysis. The PCA plots can be 
colour coded to highlight similarities and differences between groups or age, for 
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example. It can also identify any outliers or differences as a result of the batch 
(samples run on different plates).  
Following from the PCA, new partial least square discriminant analysis (PLS-
DA) and orthogonal partial least square discriminant analysis (OPLS-DA) models 
can be generated. Additional information that separates the data is added as 
‘classes’ to these models regarding the different conditions being compared in the 
analysis. Thus, these models are referred to as supervised multivariate analysis (Lu 
et al., 2008a). The new scores (observations), are weighted linear combinations of 
the original variables.  
PCA and PLS are called Projection methods. PLS simultaneously summarises 
2 data tables, (X the predictor variables) and (Y the response variables) in order to 
develop a relationship between them. Each component is represented individually 
and can thus be interpreted individually. The X/Y-Overview shows R2 and Q2 for all 
variables. R2X is the amount of variation in X that is uncorrelated to Y. The 
goodness of prediction parameter (Q2X) shows the predictive power in the model. 
The parameters R2X and Q2X react differently as the model increases in complexity 
(addition of more components). As the number of PCs increase so does the R2X 
value, however, Q2X does not. Therefore, it is impossible to get a high Q2X without 
a high R2X. R2X values are between 0-1, where 0 indicates no fit and 1 signifies a 
perfectly fitting model. A low R2 indicates a large amount of noise or irrelevant 
information although the model is still usable. Q2X values of 0.5 and above are 
good and considered adequate for metabolomic data and 0.9 is excellent. R2X and 
Q2X values should not be more than 0.2 – 0.3 apart.  
R2X(cum) is the sum of variation in X that is uncorrelated to Y. R2X(cum) of 
0.769 can also be interpreted as 76.9% of the total variation in X. R2Y(cum) is the 
sum of variation in Y explained by the model. Q2(cum) is the goodness of 
prediction. A PLS-DA model is validated by leave-one-subject-out-cross-validation 
and permutation testing (n = 1,000, significance for Pperm ≤0.05). 
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2.5.2 Statistical analysis – analysis of variance  
In all ANOVA significant differences were defined as p ˂ 0.05. For both studies, the 
participant screening data were analysed using one-way ANOVA with Tukey 
multiple comparison adjustment post-hoc testing (GraphPad Prism version 6.07).  
Statistical differences between the groups and the effect of time for glucose, 
TAG and the hormones in the diabetes study were analysed using two-way ANOVA 
with Tukey multiple comparison adjustment post-hoc testing (GraphPad Prism 
version 6.07).  
2.5.3 Analysis of variance of the metabolites  
Significant group and time of day differences of metabolites were identified using 
a two-way repeated measures, multiple groups, with each repeated 
measurements for several persons at multiple time points ANOVA with the 
multiple testing correction false discovery rate (FDR) based on the Benjamini–
Hochberg procedure (R v 3.2.2; http://www.r-project.org/). The script was written 
by Dr Jeroen Pennings, RIVM, The Netherlands.  
  The FDR was used overcome type 1 errors resulting from the simultaneous 
measurement of multiple variables. Type 1 errors are the incorrect rejection of a 
true null hypothesis or conversely, accepting a false alternative hypothesis as 
correct, leading to false positive results. In this study, that would mean falsely 
increasing the effect of OW/OB or T2DM to their control groups. 
2.5.4 Fitting of a cosine curve 
The data were fitted to a 24-h cosine curve, using either an excel spreadsheet 
macro written by Dr D. Minors, University of Manchester or a Matlab script written 
by Dr Anne Skeldon (Department of Mathematics, University of Surrey). The 
cosine equation was: Y=Mesor+Amplitude*cos((2*π*X/T)+phase)+Residual 
 In the diabetes study, described in the Methods Section 2.1, the hormone 
cosinor analysis was performed on individual participants using the % of the mean 
values (described in Section 2.4.3) and the group mean data, using the Excel 
spreadsheet. The cosine fit of the metabolites was calculated using the mean z-
scored data and the Matlab script. The acrophase (peak time), amplitude and 
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goodness of fit producing a p-value that described the statistical significance of 
how well the data fit a cosine curve was derived. 
In the meal shift study described in the Methods Section 2.2, the cosine 
curves were fitted using the mean z-scored data of each CR and the raw 
concentrations. The acrophase (peak) times and the goodness of fit to a cosine 
curve (p value) and a straight line (constant and linear) was calculated.  
2.6 Calculating dim light melatonin onset 
To correct for each individual’s circadian phase, the time of their melatonin onset 
(DLMO) was calculated. The timing of the plasma melatonin is used to assess the 
circadian phase of an individual as melatonin peaks at night and the peak is related 
to the internal clock time of that individual. It is the most robust marker of 
circadian phase (Arendt, 1988).  
2.7 Pathway analysis (Quantitative Enrichment Analysis) 
Integrating metabolomic data within a biological network or pathway provides a 
more complete picture of the metabolite interactions within a biological system. 
Metabolite set enrichment analysis (MSEA) clusters functionally related 
metabolites and detects subtle but consistent changes among a group of 
metabolically related compounds. It identifies biologically meaningful patterns 
and provides a functional interpretation of a set of metabolites from public 
databases, such as Human Metabolome Database (HMDB) and Kyoto 
Encyclopedia of Genes and Genomes (KEGG). It is useful to help identify a 
biological pathway which has been altered in different conditions, such as in a 
diseased state (Xia and Wishart, 2011). 
The enrichment analysis was performed using the software package R version 
3.2.2 to generate the data with the package globaltest (MetaboAnalyst 3.0). It uses 
a generalised linear model to estimate a Q-statistic for each metabolite set, which 
describes the correlation between compound concentration profiles, X, and 
clinical outcomes, Y. The Q statistic for a metabolite set is the average of the Q 
statistics for each metabolite in the set. 
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3 Glucose, TAG and GI hormones in obesity and T2DM 
3.1 Introduction  
It is widely accepted that glucose, TAG and most GI hormone concentrations are 
higher in obesity and T2DM with the exception of ghrelin, where lower plasma 
concentrations have been observed in both these conditions (Section 1.4). Levels 
of hormones associated with glucose metabolism, such as fasting C-peptide and 
insulin have been observed in obesity, even before the symptoms of T2DM (Webb 
et al., 1982). Higher TAG concentrations in obesity and T2DM in humans have been 
reported, with plasma TAG concentrations peaking near the usual wake time 
(Morgan et al., 1998). 
Evidence from epidemiological and laboratory studies have also shown that 
some hormones and related to energy metabolism oscillate over 24 h, with some 
studies have suggesting that the natural 24-h rhythmicity is dampened in T2DM 
mouse models. Assuming that these rhythms reflect the optimum circulating 
concentrations at a given time of day in healthy individuals, any deviation in 
concentration or rhythmicity may identify biological markers for T2DM and may 
reveal novel insight into disease aetiology.  
Strong animal transgenic data support clock-metabolism links. Homozygous 
Clock mutant mice become obese and develop metabolic syndrome, with higher 
leptin, lipid, glucose and insulin levels (Turek et al., 2005). Endogenous circadian 
rhythms have been linked to plasma glucose oscillations (Bailey et al., 2014, Rudic 
et al., 2004, Scheer et al., 2009). There is some evidence from human studies that 
hormones such as leptin, ghrelin, glucagon, insulin and C-peptide exhibit a diurnal 
rhythm but there is less evidence for other hormones such as GIP, GLP-1, resistin, 
visfatin and PAI-1. Some of the hormones seem to have multiple regulatory 
mechanisms. Glucagon, insulin, ghrelin and leptin rhythms exhibited in the fasting 
state or when small meals are constantly eaten (such as in a constant routine 
protocol) are overridden when large meals are eaten. Under free-living conditions 
the diurnal rhythm of leptin and ghrelin are entrained to meal timing (Schoeller et 
al., 1997). The daily rhythms of hormones with opposing roles, such as ghrelin, 
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which acts an appetite stimulator, and the satiating hormone, leptin peak at the 
same time of day (in the middle of the night)(Bodosi et al., 2004; Cummings et al., 
2001). Reports in the literature of daily rhythms in GI hormones are sometimes 
conflicting with differences in peak time. The differences in study designs may 
explain some of these inconsistencies.  
3.2 Aims and hypotheses 
The aims of the current study were to assess whether glucose, TAG and a range of 
hormones associated with energy metabolism and inflammation display 24-h 
rhythms under controlled laboratory conditions and if so, whether the phase 
and/or amplitude was altered by OW/OB or T2DM. Furthermore, it aimed to 
assess the impact of OW/OB or T2DM on the 24-h concentration.   
To assess the effect of OW/OB and T2DM on plasma concentrations and 
diurnal rhythms of glucose, TAG and selected hormones (C-peptide, insulin, 
glucagon, GIP, GLP-1, ghrelin, leptin, resistin, visfatin and PAI-1), samples were 
collected every 2 h over 24 h in lean, OW/OB and T2DM men.  
The aim was to use cosinor analysis to characterise the glucose, TAG and 
hormone rhythms (peak time, amplitude, goodness of fit) and then compare the 
characteristics of these diurnal rhythms between the lean, OW/OB and T2DM 
groups. 
The following hypotheses were tested: 
i. Plasma concentrations of the measured glucose, TAG and the majority of the 
hormones are higher in OW/OB and T2DM than their control groups.  
ii. There would not be a phase advance or delay but the amplitude would be 
dampened in OW/OB and T2DM compared to their control groups. 
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3.3 Methods  
Detailed methods for this chapter can be found in Section 2.1. In brief, participants 
entered the laboratory the afternoon before the study day to be under strict 
conditions prior to blood sampling. Light intensity, physical activity and meals 
were highly controlled. During lights on (06:30 h – 22:30 h), the light intensity was 
~ 600 lux in the direction of gaze, participants lay semi-recumbent, toilet visits 
were not permitted during the last 30 minutes before the next blood sample. Small 
meals, comprising isocaloric milkshakes (Fortisip) every hour, to mitigate against 
any large or irregular meal effects, and water was available ad libitum. Individual 
food energy intake was set at 110% of BMR using the Schofield equation. During 
lights off, participants lay recumbent with the opportunity to sleep. Neither food 
nor toilet visits were permitted at this time. Blood samples taken every 2 h across 
a 24 h period (07:00 h day 2 to 05:00 h day 3) were used for this analysis. This 
study received ethical approval from the Surrey Research Ethics Committee and 
University of Surrey Ethics Committee. 
3.3.1 Participant screening  
The participant screening data, in Table 3.1, of the three groups (lean, n = 8, 
OW/OB, n = 10 and T2DM, n = 7), shows age, glucose, HbA1c and blood pressure 
were not statistically different between the lean and OW/OB groups. BMI (p < 
0.001) and insulin (p < 0.05) concentrations were significantly different between 
the lean and OW/OB and OW/OB and T2DM groups. The OW/OB and T2DM were 
matched for BMI. Fasting glucose (p < 0.001), HbA1c (p < 0.001) and insulin 
concentration (p < 0.005) were significantly higher in the T2DM group than the 
OW/OB group. 
There was significant difference in systolic or diastolic blood pressure between the 
lean and OW/OB groups, however only systolic blood pressure was significantly 
different (p<0.05) between the OW/OB and the T2DM groups. The questionnaire 
scores showed no significant difference between groups, except the Beck 
depression index (BDI), where the participants in the T2DM group scored 
significantly higher than the participants of the lean group (p < 0.05). 
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Table 3.1 Participant screening data 
variable  
mean ± SD  P value  
lean 
(n = 8) 
OW/OB 
(n = 10) 
T2DM 
(n = 7) 
Lean 
vs 
OW/OB 
OW/OB 
vs 
T2DM 
lean 
vs 
T2DM 
Age (years) 53.6±6 50.8±7.3 57.3±4.3 Ns Ns Ns 
BMI (kg/m2) 23.2±1.4 30.1±2.4 32±2.3 *** Ns *** 
Glucose (mmol/l) 4.2±0.7 4.8±0.7 6.7±1.4 Ns *** *** 
Insulin (pmol/l) 28.1±16.8 40.6±17.6 102.1±81 * Ns ** 
HbA1c (%) 5.4±0.4 5.4±0.5 6.9± .8 Ns *** *** 
BP Systolic (mmHg) 129.4±9.7 134.6±10.7 147.3±9.7 Ns * * 
BP Diastolic (mmHg) 84±10.2 85.9±10.4 89.6±8.5 Ns Ns Ns 
HÖ score 59±6.5 57.4±8.81 59.7± 1.3 Ns Ns Ns 
Epworth score 3±2.3 5±2.2 5.6±4.1 Ns Ns Ns 
BDI score 2±1.6 3.2±2.4 8.3±6.9 Ns Ns * 
PSQI score 3±1.5 4.4±1.8 3.7±1.8 Ns Ns Ns 
Participant screening data for the lean, OW/OB and T2DM groups. Mean values ± SD. Ns 
= not significant, * p ˂ 0.05, ** p ˂ 0.01, *** p ˂ 0.001 (one-way ANOVA, followed by 
Tukey’s multiple comparisons test (GraphPad Prism 6.07). Including Horne Östberg (HO), 
Beck Depression Index (BDI), and Pittsburgh Sleep Quality Index (PSQI) scores. 
 
3.3.2 Medication of the T2DM group 
Two participants in the T2DM group (109, 134) did not take any medication. Two 
participants were treated with statins only (136, 149) and two with statins and 
metformin (112, 131). One participant was treated with metformin only (132). 
Table 3.2 shows these medications in detail.  
Table 3.2 Medications of the participants in the T2DM group 
Subject ID Metformin Statin 
Blood 
Pressure 
medication 
Details (per day) 
109 No No No  
112 Yes Yes Yes 
Simvastatin 20 mg (before bed), 
Metformin 1,000 mg (morning and 
evening), Ramipril 10 mg (morning) 
131 Yes Yes No 
Metformin 2,000 mg, Simvastatin 
40 mg, Ventolin and 
Beclometasone inhaler 2 x 200 mg 
(x 4) Salbutamol 200 mg (x 4) 
132 Yes No No Metformin 2,000 mg (morning) 
134 No No No  
136 No Yes Yes 
Simvastatin 40 mg (evening),  
Lisinopril 5 mg (morning) 
149 No Yes No Simvastatin 40 mg   
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3.3.3 Subjects with missing samples 
Five samples from participants 100_05:00 h, 112_11:00 h, 141_05:00 h, 144_15:00 
and 166_09:00 h were missing. GLP-1 (participants 121 and 143), glucagon 
(participants 114 and 146) and visfatin (participants 114 and 146) were removed 
because there were more than 5 time-points missing therefore cosinor analysis 
could not be performed (described in Section 2.4.3).  
3.3.4 Intra- and inter-assay variation 
The intra-assay % CV, ranging from 7.2-16.0%, of the 9 assay plates are shown for 
each analyte in Table 3.3. The inter-assay % CV, ranging from 17.8 - 112%, are 
shown in Table 3.4. due to the large inter-assay variation across the 9 plates the 
data were batch corrected as described in Section 2.4.2.  
Table 3.3 Intra-assay coefficient of variation (%) across 9 plates 
 Plate number    
Hormone 1 2 3 4 5 6 7 8 9 Mean  SEM 
C peptide 17.4 8.7 17.1 7.1 14.3 26.2 6.1 10.3 16.2 13.7 ± 2.1 
insulin 17.2 4.4 20.2 7.6 7.9 9.8 6.2 9.5 18.4 11.2 ± 1.9 
glucagon 13.5 4.4 4.6 2.6 2.9 11.1 3.6 3.8 17.9 7.2 ± 1.9 
GIP 8.8 7.6 15 13.7 10.3 22.2 9.1 3.9 4.7 10.6 ± 1.9 
GLP-1 21.4 8.2 6.4 2.9 4.5 6.1 8.2 4.7 3.8 7.3 ± 1.9 
ghrelin 16 7 12.1 2.8 10.5 14.5 11.6 11.9 16.6 11.4 ± 1.5 
leptin 14.3 5.6 39.2 12.9 12.6 20.3 3.2 12.2 24.1 16 ± 3.6 
resistin 29.4 13.9 18 3.4 5.2 2.9 6.1 6.9 7.6 10.4 ± 2.9 
visfatin 5.3 11.4 12.2 7.1 7.2 15.9 10.4 4 4.9 8.7 ± 1.3 
PAI-1 8 3.3 25.2 4.7 9 15.7 6 15.2 14.6 11.3 ± 2.3 
*3 x QC2 repeats on each plate  
 
Table 3.4 Inter-assay coefficient of variation (%) of the multiplex analysis 
Hormone QC 1 QC 2 QC 3 Mean  SEM 
C peptide 22.7 32.9 27.9 27.9 ± 2.9 
insulin 44.7 37.1 38.0 39.9 ± 2.4 
glucagon 41.1 40.6 41.8 41.2 ± 0.3 
GIP 18.0 12.9 22.5 17.8 ± 2.8 
GLP-1 40.8 35.2 36.4 37.5 ± 1.7 
ghrelin 42.1 42.1 43.3 42.5 ± 0.4 
leptin 50.4 40.1 34.9 41.8 ± 4.6 
resistin 114.8 107.2 113.9 112.0 ± 2.4 
visfatin 68.7 70.9 72.9 70.8 ± 1.2 
PAI-1 47.2 51.3 43.1 47.2 ± 2.4 
*QC 1,2 and 3 are the 1st 2nd and 3rd QC2 repeat on the 9 plates  
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The mean concentration (± SEM) of the hormone QCs were; C-peptide 1,184  ± 
78.5 pg/ml, insulin 527 ± 64.4 pg/ml, glucagon 319.7 ± 67.5 pg/ml, GIP 908.6 ±38.2 
pg/ml, GLP-1 392.5 ± 50.8 pg/ml, ghrelin 1,884.9 ± 254.5 pg/ml, leptin 1,894.3 ± 
230.3 pg/ml, resistin 5,219.2 ± 1,922.5 pg/ml, visfatin 26,760.8 ± 6,737.8 pg/ml 
and PAI-1 5,152.7 ± 742.7 pg/ml.      
3.4 Results  
3.4.1 Glucose 
Only the lean group displayed a significant cosine rhythm (p<0.05) which had a 
peak time of 15.02 h. Table 3.5 shows the cosinor analysis of the concentration 
and z-score data. Figure 3.1D shows the mean ± SEM cosinor analysis of the 
relative concentration (z-score).  
Table 3.5 Diurnal glucose rhythms  
Individual cosine curve fit 
 
amp Peak 
time 
p value % rhythm 
lean 0.52 14.95 0.080 39.6  
OW/OB 0.38 15.51 0.220 26.1  
T2DM 0.71 14.89 0.335 19.6 
 
 
Group mean cosine curve fit 
lean 0.50 15.02 0.043 46.6 * 
OW/OB 0.34 16.68 0.236 25.1 
 
T2DM 0.43 13.69 0.267 23.2 
 
Significance of fit to a cosine curve * p ˂ 0.05, amp, amplitude 
 
There was no significant difference in glucose concentration between the 
OW/OB, 6.53 ± 0.15 mmol/l (mean ± SEM), and the lean group, 6.08 ± 0.6 mmol/l. 
Concentrations in the T2DM group were 7.74 ± 0.32 mmol/l (Figure 3.1B), where 
a significantly higher concentration was observed between the lean and T2DM 
groups (p<0.001) and the OW/OB and T2DM groups (p<0.001). Figure 3.1A shows 
the individual concentration profiles of each participant in the lean, OW/OB and 
T2DM groups over 24 h. Also notable was the higher SEM between the individuals 
within the T2DM group. 
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Figure 3.1 Individual and mean glucose profiles. Individual 24-h profiles (A), 24-h mean ± SEM (B), 24-h mean ± SEM over 24 h (C) plasma 
concentrations (mmol/l), and the mean ± SEM relative concentration (z-score) (D) of the lean (red), OW/OB (blue) and T2DM (black) groups. 
Some of the T2DM group were on medication; metformin (*), statins (#) and ace inhibitors (+). The light conditions (160 lux in the direction of 
gaze, hourly milkshakes 06:00 h – 21:00 h, lying semi-recumbent) are illustrated on the graph as the unshaded area. The dark conditions, (0 lux, 
fasted and recumbent from 22:30 h – 06:00 h) are illustrated on the graph as the grey shaded area. Time of day (clock time) is displayed on the x 
axis. Where a significant fit to a cosine curve was observed, and using the related colour for the group, the curve is shown and the peak time and 
significance of fit relative to a straight line * p ˂ 0.05, ** p ˂ 0.01, *** p ˂ 0.001 is shown underneath the graph. 
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3.4.2 Triglycerides 
The OW/OB and the T2DM groups displayed significant cosinor rhythms (p<0.05). 
The OW/OB (blue) group had a peak time of 15.80 h, and the T2DM (black) group 
had an earlier peak time of 14.13 h. Table 3.6 shows the significant cosinor fits to 
the TAG concentration and z-score data. The OW/OB and T2DM groups 
significantly fit a cosine, in both the mean concentration and relative 
concentration (z-score). 
The TAG concentrations were significantly higher (p<0.001) in OW/OB, 1.72 
± 0.05 mmol/l (mean ± SEM), compared to the lean group 1.15 ± 0.04 mmol/l. 
Furthermore, TAG concentrations were significantly lower (p<0.01) in the T2DM 
group, 1.43 ± 0.23 mmol/l, compared to the OW/OB group (Figure 3.2B). The 
individual profiles of each participant in the lean, OW/OB and T2DM groups are 
shown in Figure 3.2A and the mean ± SEM concentrations over 24 h are shown in 
Figure 3.2C. There was more individual variation in concentration in the OW/OB 
and the T2DM group than the lean group 
       Table 3.6 Diurnal TAG rhythms  
Individual cosine curve fit 
 
amp Peak 
time 
p value % rhythm 
lean 0.13 17.09 0.064 42.3 
 
OW/OB 0.22 16.07 0.001 77.0 *** 
T2DM 0.25 14.08 0.014 57.7 * 
 
Group mean cosine curve fit 
lean 0.47 17.42 0.066 42.0 
 
OW/OB 0.80 15.80 0.001 77.2 *** 
T2DM 0.79 14.13 0.006 64.6 ** 
Significance of fit to a cosine curve * p ˂ 0.05, ** p ˂ 0.01, *** p ˂ 0.001, amp, amplitude 
 
83 
 
Figure 3.2 Individual and mean TAG profiles. Individual 24-h profiles (A), 24-h mean ± SEM (B), 24-h mean ± SEM over 24 h (C) plasma 
concentrations (mmol/l), and the mean ± SEM relative concentration (z-score) (D) of the lean (red), OW/OB (blue) and T2DM (black) groups. 
Some of the T2DM group were on medication; metformin (*), statins (#) and ace inhibitors (+).  The light conditions (160 lux in the direction of 
gaze, hourly milkshakes 06:00 h – 21:00 h, lying semi-recumbent) are illustrated on the graph as the unshaded area. The dark conditions, (0 lux, 
fasted and recumbent from 22:30 h – 06:00 h) are illustrated on the graph as the grey shaded area. Time of day (clock time) is displayed on the x 
axis.  Where a significant fit to a cosine was observed, and using the related colour for the group, the curve is shown and the peak time and 
significance of fit relative to a straight line * p ˂ 0.05, ** p ˂ 0.01, *** p ˂ 0.001 is shown underneath the graph. 
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3.4.3 Hormones 
C-peptide, insulin, glucagon, GIP, GLP-1, ghrelin, leptin, resistin, visfatin and PAI-1 
were simultaneously measured in samples collected 2 h over 22 h. 
3.4.3.1 Daily rhythms 
C-peptide, insulin, GIP, and leptin displayed significant cosine rhythms in the lean, 
OW/OB and T2DM groups. Glucagon and ghrelin displayed significant cosinor 
rhythms in the lean group only, and GLP-1 displayed a significant cosinor rhythm 
in the T2DM group only and PAI-1 displayed a significant cosinor rhythm in the 
OW/OB group only. The 24-h profiles of the relative concentration (% of the mean) 
of all the measured hormones are shown in Figure 3.3.  
Figure 3.3 Hormones with diurnal rhythmicity. Relative concentration (% of the mean), 
shown on the y axis, of the lean (red), OW/OB (blue) and T2DM (black) participant groups. 
The light conditions (160 lux in the direction of gaze, hourly milkshakes 06:00 h – 21:00 h, 
lying semi-recumbent) are illustrated on the graph as the unshaded area. The dark 
conditions, (0 lux, fasted and recumbent from 22:30 h – 06:00 h) are illustrated on the 
graph as the grey shaded area. Time of day (clock time) is displayed on the x axis.   
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The acrophase (peak) times, in hours and minutes, and the relative 
amplitude (% of the mean) of the hormones with a significant fit to a cosine curve 
of the lean, OW/OB and T2DM groups are shown in Table 3.7. Where a significant 
cosine rhythm was exhibited, C-peptide, insulin, GIP and GLP-1 peaked in the 
afternoon, leptin and ghrelin peaked in the middle of the night. Glucagon and PAI-
1 peaked in the morning (Figure 3.4). In most cases, the peak times are similar 
between the groups when a significant cosine rhythm was exhibited in more than 
one study group, with the exception of C-peptide and insulin, which had an 
approximate 2-h delay in T2DM.  
Table 3.7 Cosinor analysis of the group mean data 
  
Lean 
(n =8) 
 
OW/OB 
(n = 10) 
  
T2DM 
(n = 7) 
  
 
acrophase 
time 
(h) 
Relative 
amplitude 
P 
value 
acrophase 
time 
(h) 
Relative 
amplitude 
P 
value 
acrophase 
time 
(h) 
Relative 
amplitude 
P 
value 
C-peptide 12.68 28.06 0.03 13.84 28.42 0.01 15.92 32.53 0.003 
insulin 11.99 38.13 0.04 13.25 28.78 0.01 16.36 39.96 <0.001 
glucagon 6.32 6.66 0.02   NS   NS 
GIP 13.93 31.04 0.03 13.84 38.04 0.003 15.22 39.75 0.004 
GLP-1   NS   NS 15.18 6.95 0.01 
ghrelin 1.56 15.71 <0.001   NS   NS 
leptin 0.63 22.03 <0.001 0.47 15.91 0.01 23.58 15.80 0.003 
resistin   NS   NS   NS 
visfatin   NS   NS   NS 
PAI-1   NS 8.81 21.20 0.03   NS 
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Figure 3.4 Peak time of hormones, glucose and TAG displaying significant diurnal 
rhythms. The analytes in the lean (red circle) OW/OB (blue square) and T2DM (black 
triangle) groups are shown on the y axis. The light conditions (160 lux in the direction of 
gaze, hourly milkshakes 06:00 h – 21:00 h, lying semi-recumbent) are illustrated on the 
graph as the unshaded area. The dark conditions, (0 lux, fasted and recumbent from 22:30 
h – 06:00 h) are illustrated on the graph as the grey shaded area. Time of day (clock time) 
is displayed on the x axis.   
 
 
3.4.3.2 Cosinor analysis of the individual participant  
The goodness of fit to a cosine curve was also used to assess the number of 
individuals within each study group displayed significant daily variation. These 
data are shown in Table 3.8. A hormone was deemed rhythmic if > 40% of the 
individuals in the group displayed a significant cosine rhythm, shown in bold in 
Table 3.8. Only GIP displayed significant cosine rhythms in > 40% of the individuals 
for all groups. C-peptide and insulin displayed significant cosine rhythms in > 40% 
of the individuals in the OW/OB and T2DM groups. Leptin displayed significant 
cosine rhythms in > 40% of the individuals in the lean and T2DM groups. Glucagon, 
ghrelin, and resistin displayed significant cosine rhythms in > 40% of the 
individuals in the lean group only.  
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Table 3.8 Number and (%) of participants with a significant daily rhythm 
  lean OW/OB T2DM 
  N = 8 
(%) 
N = 10 
(%) 
N = 7 
(%) 
C-peptide 2 (25) 6 (60) 4 (57) 
insulin 2 (25) 5 (50) 4 (57) 
GIP 5 (63) 4 (40) 3 (43) 
GLP-1 2 (25) 3 (30) 0 (0) 
glucagon 4 (50) 1 (10) 0 (0) 
ghrelin 5 (63) 2 (20) 1 (14) 
leptin 6 (75) 3 (30) 5 (71) 
resistin 5 (63) 2 (20) 1 (14) 
visfatin 3 (38) 1 (10) 0 (0) 
PAI-1 3 (38) 2 (20) 3 (43) 
 
3.4.3.3 Differences in concentration between the groups 
These data are similar to the group mean data shown in Table 3.7 with the 
exception of resistin. The concentration pg/ml (mean ± SEM) and the number of 
observations of the lean, OW/OB and the T2DM groups are shown in Table 3.9. 
The concentration of all the hormones was higher in the OW/OB group compared 
to the lean group, and with the exception of ghrelin and PAI-1, all hormones were 
higher still in the T2DM compared to the OW/OB group. Figure 3.5 illustrates the 
concentration of the hormones every 2 h over 24 h. 
Table 3.9 Hormone concentrations in the lean, OW/OB and T2DM groups 
   lean OW / OB T2DM   
 Mean 
pg/ml 
 
± SEM Mean 
pg/ml 
 
± SEM Mean 
pg/ml 
 
± SEM 
C-peptide 1306.4 ± 94.3 1649.6 ± 62.9 1807.8 ± 78.7 
insulin 486.5 ± 38.4 1047.6 ± 58.7 1480.7 ± 108.3 
glucagon 269.6 ± 7.6 433.8 ± 7.0 436.1 ± 9.9 
GIP 700.3 ± 44.2 1024.6 ± 66.7 1301.4 ± 148.3 
GLP-1 223.1 ± 14.9 325.8 ± 10.0 360.9 ± 11.8 
ghrelin 1078.2 ± 54.8 1334.7 ± 36.8 1107.7 ± 29.5 
leptin 1414.9 ± 107.8 7174.3 ± 478.1 7889.0 ± 635.6 
resistin 3097.5 ± 150.5 3626.2 ± 157.7 3858.4 ± 252.7 
visfatin 7681.2 ± 465.6 8698.1 ± 495.0 26591.9 ± 5156.9 
PAI-1 5046.2 ± 478.6 8459.3 ± 519.9 5575.7 ± 485.6 
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Figure 3.5 Mean hormone concentrations across 24 h. C-Peptide, insulin, glucagon, 
GIP, GLP-1, ghrelin, leptin, resistin, visfatin and PAI-1 over 24 h of the lean (red), OW/OB 
(blue) and T2DM (black) groups. Concentration (pg/ml ± SEM) is the displayed on the y 
axis. The light conditions (160 lux in the direction of gaze, hourly milkshakes 06:00 h – 
21:00 h, lying semi-recumbent) are illustrated on the graph as the unshaded area. The 
dark conditions, (0 lux, fasted and recumbent from 22:30 h – 06:00 h) are illustrated on 
the graph as the grey shaded area. Time of day (clock time) is displayed on the x axis.  
 
The hormones with a significant effect of time and significant differences in 
concentration between the lean and OW/OB and OW/OB and T2DM groups (2-
way repeated measures ANOVA) and the percentage difference are shown in 
Table 3.10. Glucagon and visfatin had too many missing samples in the lean group 
so were not included in the analysis. All the other hormones had significant 
differences between the lean and OW/OB groups; all of which had higher 
concentrations in the OW/OB group. The hormone with the largest difference 
between the groups was leptin, which was 80% higher in OW/OB compared to the 
lean group. Most of the hormones, C-peptide, insulin, GIP, GLP-1 ghrelin, visfatin 
and PAI-1, also had significant differences between the OW/OB and T2DM groups. 
The majority of which was significantly higher, with the exception of ghrelin and 
PAI-1 which were significantly lower in the T2DM group. 
 
 
500
1500
2500
3500
C-peptide
7 11 15 19 23 3
500
1500
2500
3500
insulin
7 11 15 19 23 3
0
200
400
600
glucagon
7 11 15 19 23 3
0
500
1000
1500
2000
GIP
7 11 15 19 23 3
0
200
400
600
GLP-1
7 11 15 19 23 3
0
500
1000
1500
2000
ghrelin
7 11 15 19 23 3
0
5000
10000
15000
leptin
7 11 15 19 23 3
0
2000
4000
6000
8000
resisitin
7 11 15 19 23 3
0
5000
10000
15000
visfatin
7 11 15 19 23 3
0
5000
10000
15000
PAI-1
7 11 15 19 23 3
C
o
n
c
e
n
tr
a
ti
o
n
 (
p
m
o
l/
L
)
Time of day (h)
C
o
n
c
e
n
tr
a
ti
o
n
 p
g
/m
l 
89 
 
Table 3.10 Hormones with significant differences between the groups 
 lean vs OW/OB (p value) OW/OB vs T2DM (p value) 
 % 
change 
group time Interaction 
% 
change 
group time Interaction 
C-peptide 20.8 ↑ 4.42E-05 9.75E-13 3.25E-01 8.8 ↑ 4.22E-02 9.13E-20 2.82E-02 
insulin 53.6 ↑ 1.60E-15 1.17E-07 8.16E-01 29.2 ↑ 1.96E-06 1.20E-07 6.06E-03 
glucagon      0.5 ↑ 8.01E-01 2.25E-01 6.14E-01 
GIP 31.7 ↑ 9.82E-06 8.03E-09 8.55E-01 21.3 ↑ 2.17E-03 1.49E-09 8.30E-01 
GLP 1 31.5 ↑ 9.37E-32 1.54E-04 2.35E-01 9.8 ↑ 1.67E-05 3.12E-04 9.19E-03 
ghrelin 19.2 ↑ 1.01E-09 2.54E-01 3.97E-01 -20.5 ↓ 3.82E-08 3.29E-01 7.20E-01 
leptin 80.3 ↑ 5.61E-48 2.24E-03 2.35E-01 9.1 ↑ 1.21E-01 2.10E-02 7.20E-01 
resistin 14.6 ↑ 1.06E-02 6.98E-01 4.56E-01 6.0 ↑ 4.02E-01 3.11E-01 2.48E-01 
visfatin      67.3 ↑ 1.57E-24 4.02E-01 1.35E-01 
PAI 1 40.3 ↑ 7.46E-06 2.63E-01 6.98E-01 -51.7 ↓ 3.70E-04 3.75E-01 6.36E-01 
* hormones shown in bold have significant differences between the groups (p <0.05) 2-
way repeated ANOVA. 
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3.5 Discussion  
The aims of the study within this chapter were to assess the impact of T2DM on 
the daily rhythmicity (peak time or the amplitude) and the concentration of 
circulating glucose, TAG and selected hormones associated with obesity and 
T2DM. As T2DM usually comes hand in hand with obesity, the first objective was 
to separate these two conditions. This was achieved with the inclusion of two non-
diabetic control groups, one lean and one OW/OB. Another important design 
feature was to age-match the three groups as age may also affect these metabolic 
markers. To assess the daily rhythms, samples taken every 2 h over 24 h were 
measured and formed the most unique aspect of the study. These findings will 
provide a unique reference to characterise T2DM over a 24-h period under normal 
sleep-wake conditions. 
3.5.1 Participant demographics 
As mentioned in the previous section, because of the confounding effect of obesity 
in the majority of individuals who have T2DM, the participants recruited into the 
T2DM group in this study were also OW/OB. This design required two control 
groups, the lean and OW/OB groups matched for markers of insulin resistance and 
glucose control (fasting glucose, insulin and HbA1c). The OW/OB group also acted 
as the control group to assess the effect of T2DM. A key separation of the OW/OB 
group from the T2DM group was the significantly different fasting glucose, insulin 
and HbA1c levels in the screening samples. Although there was no significant 
difference in BMI between the OW/OB and T2DM groups, the standard deviation 
was over 2.3 kg/m2, equating to approximately 5 kg variation within the group. 
However, it is unlikely and difficult to get much tighter groups in human studies 
and despite small numbers in the study groups and differences in glycaemic 
control some highly significant differences were observed. 
3.5.2 The postprandial response 
The protocol was designed to reflect a typical sleep-wake schedule of the 
participants, meaning that samples taken in the dark (sleep) phase also meant the 
participants were fasting (22:00 h – 06:00 h). Conversely, participants were fed 
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when samples were taken in the light (wake) phase. The effect of large meals was 
purposefully removed to avoid postprandial spikes in hormone concentrations 
and each hour small isocaloric meals containing only 6.25% of the daily energy 
intake were given. The differences in concentration over time, particularly after 
the last meal was administered (21:00 h) could have been because of 
feeding/fasting, light/dark or sleep/wake regulation. However it was most likely 
due to the lack of food than the dark or sleep.  
3.5.3 Glucose and TAG 
It was unlikely that the large inter- and intra-individual variation observed in the 
glucose profiles of some of the individuals in each of the study groups was due to 
the protocol. The participants were all under the same conditions to control 
nutritional status and physical activity from 15:00 h the day before the sampling 
period. Specifically these conditions limited physical activity (toilet visits were only 
permitted at least 30 min prior to a blood sample being drawn) and gave isocaloric 
milkshakes based on each participants BMI. The samples were not haemolysed, 
and stored at -80°C so it was unlikely they were affecting the result of the assay. It 
was unlikely to be the effect of the medication as the lean and OW/OB group were 
not medicated and the two participants in the T2DM group with spikes in the 
glucose levels were not on the same medication. Circulating glucose 
concentrations result from the balance between glucose entering the circulation 
via absorption from the gut, from ingested nutrients or output from the liver, from 
the breakdown of glycogen and clearance from the circulation into skeletal 
muscle.  Therefore the fluctuating concentrations over the 24-h period were 
affected by a combination of these factors, as discussed below.  
Oscillations in circulating glucose, attributed to endogenous circadian 
rhythms, peaking during the night, have been widely reported in the literature 
(Bailey et al., 2014, Rudic et al., 2004, Scheer et al., 2009). In the present study, 
glucose displayed a significant cosinor rhythm, which peaked in the afternoon; 
however, this was only evident in the lean group. The disruption of this rhythm in 
the OW/OB and T2DM groups could be due to insulin resistance during the wake 
period causing the accumulation of plasma glucose concentrations in the OW/OB 
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group (Bailey et al., 2014). It could also be attributed to the ineffective secondary 
response of insulin and C-peptide to the anticipatory rise in blood glucose 
concentrations before waking observed in individuals with insulin resistance and 
T2DM (Bolli et al., 1984). The peak time of the glucose rhythm in the present study, 
is in agreement with a study examining circadian rhythms of glucose in a CR 
protocol where the significant cosinor rhythms also peaked in the middle of the 
afternoon (Shea et al., 2005). There is strong evidence in the literature that the 
circadian clock regulates genes associated with glucose metabolism; e.g. mutation 
of Bmal1-/-  and Clockmut (Rudic et al., 2004) (Section 1.2.1). BMAL1 rhythmically 
occupies many of the DNA binding sites of genes associated with CHO and TAG 
metabolic pathways (Gooley and Chua, 2014) also suggesting a circadian 
component. This may in part be as a result of the close relationship between these 
clock genes and Rev-erbα and its association with PPARs which then impact on 
glucose homeostasis (Vieira et al., 2015). 
Higher circulating levels of glucose and TAG have been shown to be 
predictors of T2DM in many studies, including the Framingham offspring study 
(Wilson et al., 2007) and are related to defects in energy metabolism, particularly 
the higher glucose concentrations caused by insulin resistance (Boden and Laakso, 
2004). The significantly higher glucose concentration in the T2DM group 
compared to the lean and OW/OB groups were as expected.  
3.5.4 Hormones  
3.5.4.1 Hormone daily rhythms  
Evidence from laboratory studies in humans examining daily rhythms of the 
hormones measured in this analysis are limited, and conflicting. GI hormones are 
primarily influenced by food quantity or quality, or indeed the lack of it, and 
differences in study design, such as meal timing, may explain these discrepancies. 
However, it is generally accepted insulin, C-peptide and glucagon levels peak in 
the morning, visfatin levels peak in the afternoon and ghrelin and leptin levels 
peak in the middle of the night. GIP, GLP-1 and resistin do not display significant 
diurnal rhythmicity. PAI-1 levels peak in the early morning. However, PAI-1 is not 
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a GI hormone, it influences the endothelium and levels are not affected by 
nutritional status. 
Many endogenous and exogenous factors affect the synthesis, secretion and 
elimination of circulating hormones. There is also a large inter-individual variation 
in hormone concentrations reported in the literature. Homeostatic mechanisms 
keep some hormones, such as circulating insulin and glucose concentrations, 
within safe limits whereas other analytes fluctuate over a large concentration 
range resulting in a wide inter-individual variation. The manufacturers of the 
multiplex assay used in this study demonstrates the large inter-individual variation 
within normal and T2DM samples. This inter-individual concentration variation 
was removed when examining the diurnal rhythms by performing the cosinor 
analysis using the relative concentration (% of the mean). The results were more 
powerful when the group mean data were analysed than when a cosine curve was 
fitted to each individual within the group. This was most likely because the daily 
rhythms of each individual within each study group peaked at a similar time of day, 
strengthening the rhythm. Previous studies have shown that when the daily 
rhythms of individuals within a group do not peak at the same of day they 
essentially cancel each other out, dampening the observed rhythm (Chua et al., 
2013).  
It was notable that the glucose rhythm peaked, in the afternoon, at a similar 
time of day as C-peptide, insulin and GIP. These hormones are all closely 
associated with glucose metabolism. GIP is an incretin hormone and is secreted in 
response to nutrients in the gut to stimulate the release of insulin (Section 3.4.3.1).  
C-peptide and insulin, ex-partners of the same molecule, proinsulin, are released 
from the pancreas at the same time (Section 1.4.1). In the absence of food 
(individuals fasted over a 72-h period) plasma insulin and C-peptide rhythms 
peaked at 08:00 h (Merl et al., 2004). A forced desynchrony protocol showed that 
insulin peaked during the late biological night/early morning (Morris et al., 2012). 
Elevated insulin, C-peptide and GIP, seen in the wake period in the OW/OB and 
T2DM groups of the present study, have been observed elsewhere, albeit in a 
different protocol (Nyholm et al., 1999). The elevated postprandial hormone levels 
94 
 
in the obese first degree relatives of T2DM patients were attributed to impaired 
pancreatic β cell function in response to food, which was given to the participants 
3 times a day (Nyholm et al., 1999). 
In the present study, significant daily rhythms GIP displayed in all participant 
groups was most likely due to decreased concentrations during the dark period 
because no meals were served after 21:30 h. A similar observation was seen in rats 
where GIP concentrations correlated with the feeding schedule; GIP rhythms 
observed with feeding schedules were absent in fasted rats (Rubin et al., 1988). A 
study reporting daily GIP and GLP-1 rhythms in morbidly obese women with and 
without T2DM (Mingrone et al., 2009) conflicts with a well-controlled study using 
a forced desynchrony protocol that examined GIP and GLP-1 did not observe a 
circadian rhythm in either hormone (Morgan et al., 1998). These findings suggest 
that GIP and GLP-1 are food driven rather than circadian. 
Glucagon has opposing actions to insulin so it may be expected to have an 
opposing daily rhythm. In the present study, glucagon displayed a significant daily 
rhythm in the lean group only, peaking at the start of active/feeding period in the 
early morning, 3.5 h earlier than the peak time of insulin. The peak time of the 
glucagon rhythm in the present study has also been observed in SCN-derived daily 
rhythms in rats which peaked at the start of the active period with acute 
postprandial peaks (Ruiter et al., 2003). 
The correlation with leptin and adiposity (Sharifi et al., 2013) and the peak 
time of daily rhythms (Benedict et al., 2012, Mantele et al., 2012b, Saad et al., 
1998, Shea et al., 2005, Maentele et al., 2012) is well established  in the literature. 
In the current study leptin displayed significant cosine rhythms that peaked 
around midnight in all the study groups. These results confirmed the results from 
a previous study at the University of Surrey, which measured leptin in the same 
samples by RIA. The results of which showed that leptin had a clear diurnal rhythm 
in all groups, peaking on average at 00:31 h (Maentele et al., 2012). The study by 
Maentele et al. served to validate the multiplex assay used in the present analysis. 
The night-time leptin peak (02:04 h) has been reported elsewhere, in a study with 
a similar sleep wake-pattern (23:00–07:00 h) (Benedict et al., 2012). Furthermore, 
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a study observing this nocturnal rise in leptin levels associated wakefulness and 
food intake with lower levels of leptin and lower glucose and insulin levels were 
attributed to the effects of sleep-fasting (Shea et al., 2005).  
Similar to glucagon and leptin, ghrelin also seems to be regulated by more 
than one mechanism. It is intriguing that the diurnal rhythms of leptin and ghrelin 
both peak in the middle of the night (Bodosi et al., 2004, Cummings et al., 2001) 
although they have opposing roles on appetite; leptin is a satiety hormone and 
ghrelin acting as an appetite stimulator. Under free-living conditions, the diurnal 
rhythms of leptin and ghrelin are entrained to meal timing (Schoeller et al., 1997), 
seen as increased postprandial leptin levels and decreased postprandial ghrelin 
levels, but in the present study the masking effect of the meals was minimised 
with the inclusion of hourly isocaloric meals in the wake period. The night time 
peak (02.00 h) concords with Cummings et al. who observed a peak in ghrelin 
levels at 01:00 h (Cummings et al., 2001). There is evidence to suggest that the 
circadian clock also plays a role in ghrelin regulation within the MBH/SPV in the 
hypothalamus (Turek et al., 2005). In this study, reduced ghrelin mRNA expression 
was observed in Clock mutant mice at virtually all time points of the 12L:12D cycle. 
3.5.4.2 Differences in mean concentration  
Significant differences in hormone concentrations between the lean and the 
OW/OB groups and the OW/OB T2DM groups were observed. All of the hormone 
concentrations with significant differences between these groups were higher 
between the lean and OW/OB groups. The majority of the hormones were 
significantly different between the OW/OB and T2DM groups; C-peptide, insulin, 
GIP, GLP-1, and visfatin were significantly higher and ghrelin and PAI-1 were 
significantly lower in concentration.  
Higher insulin and C-peptide levels in obesity and T2DM were expected and 
have been reported in the literature for some time (Webb et al., 1982). The 
consistently higher insulin levels in the OW/OB compared to the lean group in the 
present study have been reported in OW fasted individuals (Merl et al., 2004). C-
peptide levels are correlated with body weight and plasma glucose concentrations 
(Garciawebb et al., 1982) which have been hypothesised to offset the effect of 
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insulin resistance (Park et al., 1997). The higher GIP levels found in the present 
study in both OW/OB (compared to lean) and T2DM (compared to OW/OB) have 
also been reported elsewhere. These differences in GIP levels are said to arise 
from increased insulin resistance rather than obesity per se (Creutzfeldt et al., 
1978).  
The inverse relationship between BMI and circulating ghrelin levels (Purnell 
et al., 2003) were also observed between the lean and OW/OB group in the 
present study. However, the authors noted this relationship was not independent 
and was also associated with HDL cholesterol. Another study observed lower 
plasma ghrelin concentrations in obesity, with fasting levels being negatively 
correlated with insulin, leptin and % body fat (Tschop et al., 2001). 
 The higher circulating leptin levels seen in overweight individuals in other 
studies (Sharifi et al., 2013, Mantele et al., 2012a, Maentele et al., 2012) were also 
observed in the present study. Leptin is secreted by adipocytes, concentrations 
are not associated with insulin sensitivity, no significant differences were expected 
or observed between obese and T2DM individuals in the present study (Sharifi et 
al., 2013). The significantly higher visfatin levels in the T2DM group compared with 
the OW/OB group in the present study maybe associated with increased insulin 
resistance. Visfatin is secreted from visceral fat and is associated with insulin 
resistance with significantly higher fasting serum visfatin levels in T2DM patients 
compared to healthy controls (Dogru et al., 2007, Esteghamati et al., 2011). 
Comparing resistin concentrations in humans and animal studies is complicated 
due to the different production sites. In rodents it is produced in adipocytes 
whereas in humans it is produced by macrophages (Cao, 2014) (Section 1.4.9). 
Obese individuals have increased infiltration of macrophages in adipose tissue 
which contributes to the higher circulating resistin levels (Park and Ahima, 2013). 
This could explain the higher resistin concentrations seen in the OW/OB group 
compared to the lean group in the present study. 
PAI-1, produced by endothelial cells and in adipose tissue (JuhanVague and 
Alessi, 1997), is a marker of inflammation (Section 1.4.11). As both obesity and 
T2DM are inflammatory conditions, the significantly higher concentrations of PAI-
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1 observed in the OW/OB group in the present study are as expected. However, 
PAI-1 levels were not elevated in our T2DM group as the literature would suggest, 
which may be due to the position of the adiposity in these two groups. Previous 
studies have shown elevated PAI-1 to be associated with increased visceral fat 
(Shimomura et al., 1996). It may also be because some of the participants in the 
T2DM group were on metformin treatment as this has been shown to lower PAI-
1 concentrations (De Jager et al., 2005). Contrary to studies that report diurnal 
rhythmicity in circulating PAI-1, the present study did not observe any significant 
daily rhythms (Angleton et al., 1989, Scheer and Shea, 2014).  
 
 
Figure 3.6 Hormones exhibiting daily rhythms and group differences. The effect of 
OW/OB (blue arrows) and T2DM (black arrows) compared to their control groups on 
hormones in the present analysis, where ↑ = higher, ↑ = lower and ↔ = no change. The 
curve signifies the hormone exhibited significant cosinor rhythmicity in the lean (red), 
OW/OB (blue) and T2DM (black) groups. Where AM = morning, PM = afternoon, MN = 
middle of the night and X = no daily rhythm. 
 
The main findings of the present study show the concentration differences 
between the OW/OB and T2DM groups and their healthy control groups support 
the hypothesis and many of the findings reported in the literature. In general the 
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results did not support the hypothesis (tested from evidence examining 
adipocytokine mRNA expression in mice (Ando et al., 2005))  that the diurnal 
rhythms of the hormones would be dampened in OW/OB and T2DM. There were 
more hormones with significant differences in concentration between the study 
groups than displayed significant daily rhythms, showing that in this analysis, being 
OW/OB or T2DM had more of an effect than time of day on the circulating levels.  
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4 Circulating metabolites in obesity and T2DM  
4.1  Introduction  
The previous chapter examined the effect of OW/OB and T2DM on hormones 
glucose and TAG. This chapter examines the metabolic profiles of the same 
samples using targeted metabolomics. Previous targeted metabolomics (Section 
2.3.3) studies, have observed differences in acylcarnitine and phospholipid (Wang 
et al., 2005), and BCAA (Newgard et al., 2009) metabolic profiles between obese 
individuals and those with T2DM. As not all obese individuals go on to develop 
T2DM, prospective studies have proved to be a useful platform to compare the 
metabolic profiles of individuals who were seemingly disease free, that go on to 
develop T2DM, compared to those that did not (Floegel et al., 2013, Rhee et al., 
2011, Wang et al., 2011, Wang-Sattler et al., 2012). Elucidating which metabolic 
changes have arisen as part of a pre-diabetic state has not only identified 
biomarkers of T2DM (Floegel et al., 2013, Guasch-Ferre et al., 2016, Wang et al., 
2011, Wang et al., 2013, Wang-Sattler et al., 2012) but it may also expose new 
areas of research.  
Most of the existing metabolic studies of T2DM are restricted to single 
time-point analysis. An emerging risk factor for cardio-metabolic disorders and 
T2DM is the disruption of daily rhythms. In animal models, local clocks within the 
pancreas, liver and other metabolic tissues are essential for the maintenance of 
whole body glucose homeostasis (Section 1.2). Transgenic mice carrying mutated 
circadian clock genes also invariably exhibit a phenotype that involves defective 
metabolism (Section 1.3.2). Links between 24-hour rhythms and metabolism in 
humans is demonstrated by the high incidence of obesity, T2DM and related 
disorders in shift workers. If different metabolites respond differently to 
endogenous and exogenous signals throughout the day, expressed as fluctuating 
concentrations, a single time point fasting sample cannot expose the full 
metabolic consequences of obesity and T2DM. 
Recent work by our group and others have reported extensive daily 
regulation of the human metabolome (Ang et al., 2012, Dallmann et al., 2012, 
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Davies et al., 2014). Daily and circadian rhythms in circulating metabolites have 
been observed in healthy individuals using a range of analytical platforms. Samples 
collected every 2 h (Davies et al., 2014, Kasukawa et al., 2012) or every 4 h (Ang et 
al., 2012, Chua et al., 2013, Dallmann et al., 2012, Krug et al., 2012), demonstrate 
time of day variation in metabolite concentration. In one of the first circadian 
studies 15% of the metabolome was rhythmic (Dallmann et al., 2012). 
The interaction between obesity, T2DM and metabolite rhythms has not yet 
been investigated. However, it is difficult to know the source or the fate of the 
circulating intermediates of metabolism, as not only are they influenced by 
exogenous factors such as previous meals but also by endogenous factors such as 
protein catabolism or β oxidation (Krug et al., 2012).  
As T2DM is often accompanied with increased weight; to more precisely 
elucidate the effects of T2DM from those of increased BMI, two control groups 
were incorporated into the current study design (Section 2.1.8). The T2DM group 
was matched for BMI and waist circumference to the OW/OB group that acted as 
the control. The same OW/OB group had a lean control group. 
Using a quantitative targeted LC/MS metabolomics approach, the effect of 
OW/OB and/or T2DM on the concentrations of circulating metabolites of middle-
aged men, compared to their age-matched counterparts was assessed. In addition, 
we aimed to characterise daily 24-h oscillations of these metabolites between the 
OW/OB or T2DM groups and their controls.  
4.2 Aims and hypotheses 
The aims of the current study were to investigate the impact of OW/OB and / or 
T2DM compared to age-matched controls under typical sleep-wake conditions. To 
assess diurnal rhythmicity blood samples were taken every 2 h over 24 h. To 
separate the effect of T2DM, from OW/OB, a non-T2DM OW/OB control group 
was incorporated into the study design that also served as the OW/OB study 
group, to which the lean control group was compared. Further aims were:   
 To measure plasma concentrations of a selection of metabolites using 
targeted metabolomics. 
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 To determine the characteristics of the metabolite daily rhythms (peak 
time, amplitude, goodness of fit) by performing cosinor analysis and then 
compare the characteristics of these diurnal rhythms between the lean, 
OW/OB and T2DM groups. 
 Compare 24-h concentrations of the T2DM group and its OW/OB  
control group and between the OW/OB and its lean control group. 
Hypotheses: The 24-h concentration of metabolites would be affected by T2DM 
and OW/OB compared to their control groups. The T2DM phenotype would have 
lower glycogenic amino acids (alanine, glycine and serine), higher levels of BCAA 
(isoleucine, leucine and valine) and both OW/OB and T2DM would have lower 
phospholipid levels compared to their controls. The amplitude of the diurnal 
rhythms would be dampened but there would be no significant difference in phase 
in OW/DM compared to their controls.        
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4.3 Methods  
Detailed explanations of the participant inclusion criteria (Section 2.1.1-2.1.6), 
study protocol (Section 2.1.7-2.1.8) and statistical analysis methods (Section 2.3.3-
2.7) for this chapter can be found in the Materials and Methods chapter. This study 
received ethical approval from the Surrey Research Ethics Committee and 
University of Surrey Ethics Committee.  
Blood samples taken every 2 h across a 25-h period (07:00 h day 2 to 07:00 
h day 3) were used for this analysis. Plasma concentrations of amino acids, 
biogenic amines, acylcarnitines and phospholipids) were measured 2-hourly over 
24 h in lean, OW/OB and T2DM middle aged men using a targeted LC/MS 
metabolomics approach (Section 2.1.8.4). 
4.3.1 Participants 
The targeted metabolomic analysis measured samples from 23 of the 25 
participants (lean, n = 8, OW/OB, n = 9 and T2DM, n = 6) in Chapter 3. Participant 
121 in the OW/OB group and participant 132 in the T2DM group were not analysed 
because over 50% of the time points were incomplete.  
4.3.2 Participant demographics 
The screening data of the participants are shown in Table 4.1. Waist circumference 
and BMI (p < 0.001) of the lean group were significantly different to the OW/OB 
and T2DM groups (one-way ANOVA, post hoc Tukey’s multiple comparisons test). 
Fasting glucose, HbA1c and insulin concentration (p < 0.01) of the T2DM 
participant group were significantly higher than the lean and OW/OB groups. All 
groups were matched for age. 
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Table 4.1 Participant screening data of the metabolomics analysis 
 
lean 
(n = 8) 
OW/OB 
(n = 9) 
T2DM 
(n = 6) 
P value 
 mean ± SD mean ± SD mean ± SD 
lean vs 
OW/OB 
lean vs 
T2DM 
OW/OB 
vs 
T2DM 
Age(years) 53.6 ± 6.0 51.0 ± 7.7 57.3 ± 4.8 
   
BMI (kg/m2) 23.2 ± 1.4 29.8 ± 2.3 32.2 ± 2.5 *** *** 
 
Waist (cm) 88.9 ± 6.5 105.1 ± 3.9 112.8 ± 8.9 *** *** 
 
Glucose (pM/l) 4.2 ± 0.7 4.9 ± 0.7 6.7 ± 1.6 
 
*** ** 
Insulin (mM/l) 28.1 ± 16.8 39.9 ± 18.5 110.5 ± 85.3 
 
** ** 
HbA1c (%) 5.4 ± 0.4 5.3 ± 0.5 6.9 ± 0.9 
 
*** *** 
Systolic (mmHg) 129.4 ± 9.7 133.8 ± 11.1 146.8 ± 10.6 
 
* 
 
Diastolic (mmHg) 84.0 ± 10.2 85.1 ± 10.7 88.8 ± 9.0 
   
Participant screening data for the lean, OW/OB and T2DM groups. Values are mean ± SD. 
Ns = not significant, * p ˂ 0.05, ** p ˂ 0.01, *** p ˂ 0.001 (one-way ANOVA). 
 
4.3.3 Data pre-processing of the metabolite study 
4.3.3.1 Missing samples  
Of the 325 samples (13 time-points x 23 participants), 15 were missing. Six were 
missing from the lean group (subject code and time of sample collection); 
100_05:00, 102_19:00, 102_07:00(2), 114_01:00, 124_7:00 and 144_15:00. Five 
were missing from the OW/OB group, of which the subject code and time of 
sample collection were 143_17:00, 143_05:00, 163_15:00, 166_09:00 and 
169_15:00 and 4 were missing in the T2DM group; 112_11:00, and subject 149 
which had 3 missing samples with time points of 09:00, 15:00 and 17:00 h. 
4.3.3.2 Excluded metabolites  
Using the exclusion criteria described in Section 2.4.1, 54 metabolites were 
excluded. Ten biogenic amines could not be integrated in MetIDQ. Six 
acylcarnitines and 4 glycerophospholipids were excluded because the interplate % 
CV of QC2 was > 30%. Twenty-four acylcarnitines, 2 biogenic amines and 6 
glycerophospholipids were excluded because > 25% of the samples in all groups 
(lean, OW/OB and T2DM calculated separately) were below the limit of detection. 
Hexose was also excluded because the FIA acquisition method was not 
appropriate. 
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4.3.3.3 Intra and inter assay variation 
The mean ± SEM intraplate % CV of the 130 metabolites, shown in the Appendix 
Table A, was 4.8 ± 0.3%. This varied according to the metabolite class, the % CV of 
the metabolite classes comprised amino acids 3.9 ± 1.4%, biogenic amines 4.7 ± 
1.2%, acylcarnitines 7.3 ± 1.2%, lysoPC a 7.3 ± 1.5%, PC aa 3.9 ± 0.4%, PC ae 3.5 ± 
0.2% and sphingolipids 6.9 ± 0.4%. 
The mean ± SEM interplate % CV of the 130 metabolites, shown in the 
Appendix Table B, was 10.2 ± 0.5%. This also varied according to the metabolite 
class, the % CV of the metabolite classes comprised amino acids 6.1 ± 0.6%, 
biogenic amines % CV of 8.2 ± 2.2%, acylcarnitines 10.3 ± 2.3%, lysoPC a 10.8 ± 
2.1%, PC aa 9.8 ± 1.0%, PC ae 11.1 ± 1.0% and sphingolipids 10.2 ± 0.5%. 
4.3.3.4 Removal of outliers 
The exported excel data sheet was examined for negative values (n = 5), generated 
because of the baseline correction in MetIDQ. Lyso PC a C24:0 (141_17:00), Lyso 
PC a C26:1 (143_07:00, 163_09:00 and 163_05:00) and Lyso PC a C28:1 
(163_11:00), were excluded. 
A PCA, described in Section 2.5.1, was constructed to highlight potential 
outliers. The observations in the scores plot in Figure 4.1 have been identified 
according to group; lean (red), OW/OB (blue) and T2DM (black). An outlier was 
observed and can be seen in Figure 4.1A, as a red coordinate in the top right corner 
of the PCA plot. Further inspection of the values confirmed this sample 
(114_01:00) was < LOD for all metabolites and was excluded. A new PCA plot was 
created without this sample, shown in Figure 4.1B. Further detail of the PCA in 
Figure 4.1B is covered in the results section (4.4.7). 
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Figure 4.1 PCA plot showing the first and second principal components. The PCA 
plot shows the first PC on the horizontal axis (t[1]) and the second PC on the vertical axis 
(t[2]). The groups can be seen as red (lean), blue (OW/OB) and black (T2DM) co-ordinates, 
where each co-ordinate represents a sample. The outlier can be seen in the top right hand 
corner of graph (A). (B) shows the PCA plot with the same data after this outlier has been 
excluded. 
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4.4 Results  
4.4.1  Quantified metabolites 
Using the targeted metabolomics method described in Section 2.3.3 and exclusion 
criteria described in sections 2.4.1, 130 metabolites were quantified (Appendix 
Table C). These comprised amino acids (n = 20), biogenic amines (n = 9), 
acylcarnitines (n = 10), lysoPC a (n = 13), PC aa (n = 30), PC ae (n = 34) and 
sphingolipids (n = 14).  
4.4.2 Cosinor analysis of mean z-score data 
A 24-h cosinor analysis (described in Section 2.5.4) using the relative concentration 
(z-score) showed that 50/130 metabolites (38.5%) had a significant cosinor rhythm 
in at least one study group. The Venn diagram in Figure 4.2 illustrates the number 
of metabolites with significant cosine rhythms in each of the participant groups. 
The full list of these metabolites is shown in Table 4.8.  
 
Figure 4.2 Number of metabolites with a significant fit to a cosine curve in each group. 
Lean (red), OW/OB (blue) and T2DM (black) groups using the group mean z-score data. 
 
Of the 50 metabolites with significant cosinor rhythms, 14 (28%) displayed a 
daily rhythm in all 3 participant groups, shown in Figure 4.3. These comprised 
citrulline, proline, sarcosine, SDMA, AC-(C2, C3, C4 and C16), lysoPC a (C18:1, 
C18:2, C20:3 and C20:4) and PC aa (C32:1 and C36:5).  
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Figure 4.3 Metabolites with daily rhythms in all the study groups. Significant cosinor 
rhythms in the lean (red), OW/OB (blue) and T2DM (black) groups. Relative concentration 
(z-score) is displayed on the y axis. The light conditions (160 lux in the direction of gaze, 
hourly milkshakes 06:00 h – 21:00 h, lying semi-recumbent) are illustrated on the graph 
as the unshaded area. The dark conditions, (0 lux, fasted and recumbent from 22:30 h – 
06:00 h) are illustrated on the graph as the grey shaded area. Time of day (clock time) is 
displayed on the x axis. 
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Eleven metabolites displayed significant cosinor rhythms in both the lean 
and OW/OB groups. Shown in Figure 4.4, these comprised alanine, glycine, 
isoleucine, tyrosine, valine, alpha-AAA, AC-C18:1, PC aa (C36:1, C36:3, C40:2) and 
PC ae C36:2. 
 
Figure 4.4 Metabolites with daily rhythms in the lean and OW/OB groups only. 
Significant cosinor rhythms in the lean (red) and OW/OB (blue) groups only. The T2DM 
(black) group is also shown. Relative concentration (z-score) is displayed on the y axis. The 
light conditions (160 lux in the direction of gaze, hourly milkshakes 06:00 h – 21:00 h, lying 
semi-recumbent) are illustrated on the graph as the unshaded area. The dark conditions, 
(0 lux, fasted and recumbent from 22:30 h – 06:00 h) are illustrated on the graph as the 
grey shaded area. Time of day (clock time) is displayed on the x axis.   
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Five metabolites displayed significant daily rhythms in both the OW/OB and 
T2DM groups, shown in Figure 4.5. These comprised AC-(C14:1 and AC-C18), 
lysoPC a (C16:0 and C18:0) and PC aa C36:2. 
Figure 4.5 Metabolites with daily rhythms in the OW/OB and T2DM groups only. 
Significant cosinor rhythms in the OW/OB (blue) and T2DM (black) groups only. The lean 
(red) group is also shown. Relative concentration (z-score) is displayed on the y axis. The 
light conditions (160 lux in the direction of gaze, hourly milkshakes 06:00 h – 21:00 h, lying 
semi-recumbent) are illustrated on the graph as the unshaded area. The dark conditions, 
(0 lux, fasted and recumbent from 22:30 h – 06:00 h) are illustrated on the graph as the 
grey shaded area. Time of day (clock time) is displayed on the x axis.  
 
Twenty metabolites displayed significant daily rhythms in only one group. In 
the lean group there were 10 metabolites (kynurenine, AC-C5, 7 x phospholipids 
and 1 sphingolipid), 9 metabolites in the OW/OB group (ornithine, threonine, AC-
C0, 3 x phospholipids and 3 x lysoPC) and one metabolite (taurine) in the T2DM 
group.  
4.4.2.1 Acrophase times 
The acrophase times of the OW/OB and the T2DM groups and their controls are 
shown in Table 4.2 in chronological order of the control group. There were 25 
metabolites with significant cosinor rhythms in both the lean and OW/OB groups 
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groups (Figures 4.6A and 4.6B). All the metabolites in OW/OB and T2DM peaked 
within 2 h of their control group (Figure 4.6C), with the exception of valine, which 
peaked at 20.57 h in the lean group and 6.29 h earlier at 14.28 h the OW/OB group.  
Table 4.2 Peak time between lean vs OW/OB and OW/OB vs T2DM groups.   
 
Acrophase 
(h) 
Phase 
Difference 
(h) 
  
Acrophase 
(h) 
Phase 
difference 
(h) 
 lean OW/OB    OW/OB T2DM  
Cit 0.92 23.53 -1.4  AC-C2 3.65 4.37 0.71 
Gly 3.13 2.27 -0.85  C14:1 5.19 3.36 -1.84 
AC-C18:1 3.99 4.5 0.52  SDMA 7.24 7.24 0.01 
AC-C2 3.99 3.65 -0.34  AC-C16 7.48 7.06 -0.42 
SDMA 6.91 7.24 0.33  AC-C18 9.05 9.32 0.27 
AC-C16 7.24 7.48 0.24  PC aa C32:1 9.81 10.64 0.82 
PC aa C32:1 10.82 9.81 -1.01  PC aa C36:5 13.94 13.98 0.04 
PC aa C36:5 13.34 13.94 0.6  AC-C3 16.56 15.77 -0.79 
Ala 14.87 16.37 1.5  Pro 17.08 18.33 1.25 
AC-C3 15.98 16.56 0.58  Sarcosine 18.21 17.94 -0.27 
Tyr 17.38 18.36 0.99  AC-C4 18.98 18.69 -0.28 
alpha-AAA 17.38 16.65 -0.72  PC aa C36:2 19.75 19.73 -0.01 
Pro 17.4 17.08 -0.32  lysoPC a C18:2 20.09 20.23 0.14 
Sarcosine 17.94 18.21 0.26  lysoPC a C16:0 20.21 21.32 1.1 
PC ae C36:2 17.94 17.9 -0.04  lysoPC a C20:3 20.41 20.78 0.37 
AC-C4 18.35 18.98 0.63  lysoPC a C20:4 20.85 21.03 0.17 
Ile 18.64 17.08 -1.56  lysoPC a C18:1 21.6 21.98 0.39 
PC aa C36:1 19.17 18.39 -0.78  lysoPC a C18:0 22.02 23.18 1.16 
lysoPC a C18:2 20.2 20.09 -0.11  Cit 23.53 24.46 0.93 
lysoPC a C20:3 20.52 20.41 -0.11          
PC aa C36:3 20.55 18.84 -1.71          
Val 20.57 14.28 -6.29          
lysoPC a C20:4 21.65 20.85 -0.8          
lysoPC a C18:1 22.42 21.6 -0.83          
PC aa C40:2 23.12 21.52 -1.6          
 
Figure 4.7 illustrates the peak times of the metabolites with significant cosinor 
rhythms (n = 14) in all participant groups, in both the lean and OW/OB (n = 11) 
groups and in both the OW/OB and T2DM groups (n = 5). Also illustrated in Figure 
4.7 was that metabolites peaked at the same time of day and that more 
metabolites peaked during the light period than the dark period. 
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Figure 4.6 Peak time of metabolites with significant diurnal rhythms. In (A) all groups, 
(B) lean (red) and OW/OB (blue) and (C) OW/OB and T2DM (black). The light conditions 
(160 lux in the direction of gaze, hourly milkshakes 06:00 h – 21:00 h, lying semi-
recumbent) are illustrated on the graph as the unshaded area. The dark conditions, (0 lux, 
fasted and recumbent from 22:30 h – 06:00 h) are illustrated on the graph as the grey 
shaded area. Time of day (clock time) is displayed on the x axis.   
 
Figure 4.7 Acrophase time according to metabolite class and study group. (A) lean (B) 
OW/OB and (C) T2DM groups of the amino acid (red), biogenic amine (blue), acylcarnitine 
(yellow), glycerophospholipid (green) and sphingomyelin (purple) classes that displayed 
significant cosine rhythms. The light conditions (160 lux in the direction of gaze, hourly 
milkshakes 06:00 h – 21:00 h, lying semi-recumbent) are illustrated on the graph as the 
unshaded area. The dark conditions, (0 lux, fasted and recumbent from 22:30 h – 06:00 
h) are illustrated on the graph as the grey shaded area. The figure illustrates metabolite 
within the same class tended to peak at the same time of day or 12 h apart from the other 
metabolites in the class. More metabolites peaked in the light period than the dark period.  
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4.4.2.2 Amplitude 
Of the 25 metabolites in the lean and OW/OB groups fitting a cosine curve, 11 had 
a higher relative amplitude (z-score) in the OW/OB group compared to the lean 
group (Table 4.3).  
Table 4.3 Amplitude of the lean vs OW/OB and the OW/OB vs T2DM groups 
 lean *n OW/OB *n 
% 
diff 
  OW/OB *n T2DM *n 
% 
diff 
Ala 0.84 3 0.68 4 -23.5        
Cit 0.94 4 0.87 3 -8.0  Cit 0.87 3 0.64 3 -35.9 
Gly 0.62 3 0.54 3 -14.8        
Ile 0.61 2 0.57 1 -7.0        
Pro 0.91 5 0.87 6 -4.6  Pro 0.87 6 0.82 4 -6.1 
Tyr 0.66 3 0.78 7 15.4        
Val 0.56 1 0.38 1 -47.4        
alpha-AAA 0.65 2 0.74 5 12.2        
Sarcosine 0.71 4 0.73 4 2.7  Sarcosine 0.73 4 0.9 6 18.9 
SDMA 0.72 2 0.38 2 -89.5  SDMA 0.38 2 0.72 2 47.2 
AC-C2 0.97 5 0.94 7 -3.2  AC-C2 0.94 7 0.91 4 -3.3 
AC-C3 0.83 5 0.83 5 0.0  AC-C3 0.83 5 0.85 3 2.4 
AC-C4 0.57 2 0.73 7 21.9  AC-C4 0.73 7 0.84 5 13.1 
       AC-C14:1 0.57 2 0.86 2 33.7 
AC-C16 0.93 5 0.83 5 -12.0  AC-C16 0.83 5 0.97 5 14.4 
AC-C18:1 0.68 3 0.47 2 -44.7  AC-C18 0.5 2 0.59 1 15.3 
       lysoPC a C16:0 0.6 1 0.61 1 1.6 
       lysoPC a C18:0 0.67 1 0.84 2 20.2 
lysoPC a C18:1 0.76 5 1 8 24.0  lysoPC a C18:1 1 8 1.04 5 3.8 
lysoPC a C18:2 1.01 5 1.14 9 11.4  lysoPC a C18:2 1.14 9 1.12 6 -1.8 
lysoPC a C20:3 0.64 5 0.97 8 34.0  lysoPC a C20:3 0.97 8 0.92 2 -5.4 
lysoPC a C20:4 0.68 5 1.04 9 34.6  lysoPC a C20:4 1.04 9 0.96 5 -8.3 
PC aa C32:1 0.94 6 0.87 5 -8.0  PC aa C32:1 0.87 5 0.86 6 -1.2 
       PC aa C36:2 0.64 3 0.65 3 1.5 
PC aa C36:1 0.45 2 0.49 0 8.2        
PC aa C36:3 0.41 4 0.52 3 21.2        
PC aa C36:5 0.69 2 0.61 2 -13.1  PC aa C36:5 0.61 2 0.64 4 4.7 
PC aa C40:2 0.62 4 0.41 1 -51.2        
PC ae C36:2 0.38 2 0.49 1 22.4        
*n = the number of participants in the other individual cosine analysis to fit a cosine curve.  
 
Thus 14 metabolites had a reduced amplitude. SDMA had the largest 
differences in amplitude between the groups. It was 89.5% lower in the OW/OB 
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group than the lean group and 47.2% higher in T2DM compared to the OW/OB 
group. Out of the 19 metabolites with significant cosine rhythms in the OW/OB 
and T2DM groups, 12 had a higher amplitude in T2DM compared to OW/OB, thus 
7 metabolites had a lower amplitude (Table 4.3). Figure 4.8 illustrates the relative 
amplitude of the metabolites classes plotted over time.  
 
Figure 4.8 Acrophase of each metabolite according to group and metabolite class. 
Metabolites in the lean, OW/OB and T2DM groups in the amino acid (red), biogenic amine 
(blue), acylcarnitine (yellow), glycerophospholipid (green) and sphingomyelin (purple) 
classes that displayed significant cosine rhythms. Relative amplitude (z-score) is displayed 
on the y axis.  The light conditions (160 lux in the direction of gaze, hourly milkshakes 
06:00 h – 21:00 h, lying semi-recumbent) are illustrated on the graph as the unshaded 
area. The dark conditions, (0 lux, fasted and recumbent from 22:30 h – 06:00 h) are 
illustrated on the graph as the grey shaded area. Time of day (clock time) is displayed on 
the x axis. 
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Figure 4.9 illustrates the change in amplitude between the metabolites with 
significant cosinor rhythms in all participant groups, between the lean and OW/OB 
groups and between the OW/OB and T2DM groups.  
 
Figure 4.9 Amplitude of metabolites with significant diurnal rhythms. (A) all groups, (B) 
lean and OW/OB and (C) OW/OB and T2DM groups 
 
4.4.3 Cosinor analysis of individual concentrations 
To assess the diurnal rhythmicity of each participant within the groups, cosine 
curves were fitted to the absolute concentrations for every metabolite from each 
participant (Section 2.5.4). If > 40% of the participants within the group 
significantly fit a cosine curve a metabolite was considered rhythmic (Davies et al., 
2014, Gunn et al., 2016). Of the 130 metabolites, 21 displayed a rhythm in at least 
one group and 9 metabolites displayed significant cosinor rhythms in all 
participant groups; proline, sarcosine, AC-(C16, C2 and C3), and lysoPC a (C18:1, 
C18:2 and C20:40) and PC aa C32:1. However, the majority of metabolites (n = 109, 
84%) did not display a significant rhythm in > 40% of the participants within each 
group and 15 metabolites did not display a significant cosine rhythm in any 
participant.  
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LysoPC a C20:3 displayed significant cosinor rhythms in the lean and OW/OB 
groups only. Alanine, tyrosine and AC-C4, displayed significant cosinor rhythms in 
the OW/OB and T2DM groups that were not present in the lean group. Citrulline 
displayed a rhythm in the lean group and T2DM groups only. PC aa (C36:3 and 
C40:2) displayed a rhythm in lean only. Alpha-AAA displayed a rhythm in OW/OB 
only and serotonin, PC aa (C36:2, C36:5) and PC ae C40:1 displayed rhythms in the 
T2DM groups only. The Venn diagram in Figure 4.10 shows number of metabolites 
that significantly fit a cosine in > 40% of the participants. 
 
 
Figure 4.10 Number of metabolites with significant diurnal rhythms.  Lean (red), OW/OB 
(blue) and T2DM (black) groups in > 40% of participants from each group. 
 
4.4.3.1 Acrophase times 
The metabolites (n = 23) and the number of participants within each group 
displaying a significant cosine rhythm are shown in Table 4.4. If a metabolite 
displayed a daily rhythm in more than one group, it peaked at approximately the 
same time of day (within 2 h) as the other groups.  
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Table 4.4 Acrophase times in the lean, OW/OB and T2DM groups 
  Lean (n = 8)  OW/OB (n = 9)  T2DM (n = 6) 
  
Mean 
acrophase  
(± SEM) 
 
Mean  
acrophase  
(± SEM) 
 
Mean 
acrophase  
(± SEM) 
 (n) (h) (n) (h) (n) (h) 
Cit 4 0.67 ± 0.45 3       3 0.01 ± 1.74 
AC-C2 5 3.78 ± 0.44 7 3.89 ± 0.49 4 4.65 ± 0.56 
AC-C16 5 7 ± 0.42 5 7.9 ± 0.85 5 7.06 ± 0.32 
PC aa C32:1 6 10.93 ± 0.23 5 9.88 ± 0.41 6 11.31 ± 0.91 
Serotonin 0       0       3 12.34 ± 2.67 
PC aa C36:5 2       2       4 14.24 ± 0.9 
AC-C3 5 15.51 ± 0.66 5 15.87 ± 0.55 3 15.82 ± 0.3 
Ala 3       4 16.33 ± 0.89 4 16.37 ± 0.8 
alpha-AAA 2       5 16.64 ± 0.54 2       
Pro 5 17.37 ± 0.75 6 16.73 ± 0.62 4 17.51 ± 0.18 
Sarcosine 4 17.77 ± 0.58 4 18.78 ± 0.58 6 17.56 ± 0.6 
PC ae C40:1 0       1       3 17.76 ± 1.76 
Tyr 3       7 18.47 ± 0.59 3 18.61 ± 0.65 
AC-C4 2       7 18.86 ± 0.81 5 18.76 ± 0.63 
PC aa C36:2 2       3       3 19.36 ± 0.5 
lysoPC a C18:2 5 20.7 ± 0.63 9 20.05 ± 0.26 6 19.97 ± 0.49 
lysoPC a C20:3 5 20.99 ± 0.98 9 20.44 ± 0.48 2       
PC aa C36:3 4 21.08 ± 1.54 3       2       
lysoPC a C20:4 5 21.24 ± 0.84 9 20.78 ± 0.38 5 20.03 ± 0.56 
lysoPC a C18:1 5 21.95 ± 0.76 9 21.6 ± 0.45 5 21.13 ± 0.5 
PC aa C40:2 4 22.37 ± 1.1 1       0       
  
 
4.4.3.2 Amplitude 
The changes in the amplitude of the metabolites with significant cosine rhythms 
between the lean and OW/OB groups are shown in Tables 4.5. Most of the changes 
in amplitude were small (<2% difference), with the exception of proline that was 
16.8% higher in OW/OB (6/9 with significant rhythms) compared to the lean (5/8 
with significant rhythms). The differences in amplitude between the OW/OB and 
T2DM are shown in Table 4.6, where again, there was less than 4% change in 
amplitude for most of the metabolites (9/10), apart from proline which was 16.3% 
lower and alanine which was 8.6% higher in T2DM compared to OW/OB.  
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Table 4.5 Differences in amplitude between the lean and OW/OB groups 
Metabolite 
lean (n = 8) OW/OB (n = 9) mean 
difference 
(%) 
n 
Mean amplitude 
± SEM (µM) 
n 
Mean amplitude 
± SEM (µM) 
lysoPC a C18:2 5 10.83 ± 1.98 9 9.15 ± 1.01 -1.68 
PC aa C32:1 6 3.55 ± 0.38 5 2.23 ± 0.37 -1.32 
C2 5 2.01 ± 0.25 7 1.49 ± 0.19 -0.51 
lysoPC a C18:1 5 3.67 ± 0.88 8 3.38 ± 0.59 -0.29 
lysoPC a C20:3 5 0.43 ± 0.03 8 0.35 ± 0.06 -0.08 
lysoPC a C20:4 5 1.13 ± 0.25 9 1.12 ± 0.16 -0.01 
C16 5 0.02 ± 0.00 5 0.02 ± 0.00 0.00 
C3 5 0.06 ± 0.01 5 0.07 ± 0.02 0.01 
Sarcosine 4 0.30 ± 0.05 4 0.51 ± 0.13 0.20 
Pro 5 68.82 ± 5.72 6 85.61 ± 12.30 16.79 
 
Table 4.6 Differences in amplitude between the OW/OB and T2DM groups 
Metabolite 
OW/OB (n = 9) 
T2DM 
(n = 6) 
mean 
difference 
(%) n 
Mean amplitude 
± SEM (µM) 
n 
Mean amplitude 
± SEM (µM) 
Pro 6 85.6 ± 12.3 4 69.4 ± 18.2 -16.2 
lysoPC a C18:2 9 9.15 ± 1.01 6 8.29 ± 1.45 -0.86 
lysoPC a C18:1 8 3.38 ± 0.59 5 3.08 ± 0.59 -0.30 
C2 7 1.49 ± 0.19 5 1.32 ± 0.11 -0.18 
Sarcosine 4 0.51 ± 0.13 6 0.47 ± 0.08 -0.03 
C3 5 0.07 ± 0.02 3 0.06 ± 0.01 -0.01 
C4 7 0.04 ± 0.01 5 0.04 ± 0.01 0.00 
C16 5 0.02 ± 0.00 5 0.02 ± 0.00 0.00 
lysoPC a C20:4 9 1.12 ± 0.16 5 1.17 ± 0.32 0.05 
PC aa C32:1 5 2.23 ± 0.37 6 3.48 ± 0.99 1.25 
Tyr 7 20.8 ± 3.97 3 24.6 ± 8.72 3.87 
Ala 4 104.5 ± 20.9 4 113.0 ± 18.3 8.6 
 
4.4.4 Comparing group mean z-score to individual cosinor rhythms 
More metabolites displayed significant cosinor rhythms using the mean z-score 
data than the individual data. The mean z-score data highlighted 50 metabolites 
with a significant fit to a cosine curve in at least one group (Section 4.4.2). Whereas 
the individual data showed 21 metabolites with significant cosinor rhythms > 40% 
of the participants in at least one group (Section 4.4.3). All the metabolites with 
significant cosine fits to the individual also fitted a cosine curve in the z-score mean 
data. There was one exception, namely serotonin which displayed a significant 
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cosine fit in > 50% of the T2DM group but did not fit a cosine curve in the mean z-
score data. Nine metabolites displayed significant cosine rhythms in all groups 
using the mean z-score data and > 40% of individuals, these comprised proline, 
sarcosine, AC-(C2, C3 and C16), PC aa C 32:1, lysoPC a (C18:1 and C18:2) and lysoPC 
a C20:4. 
 
4.4.5 Non-cosinor time of day variation  
Although many of the metabolites did not display significant cosine rhythms, time 
of day variation can be seen. Figure 4.11 illustrates the rhythmicity of all the 
metabolites according to class in the lean, OW/OB and T2DM groups.  
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Figure 4.11 24-h profiles of all metabolites according to class. All quantified metabolites 
in the lean, OW/OB and T2DM groups in the amino acid (n = 20), biogenic amine (n = 9), 
acylcarnitine (n = 10), lysoPC a (n = 13), PC aa (n = 30), PC ae (n = 34) and SM (n = 14) 
classes, where each line is a metabolite. Relative amplitude (z-score) is displayed on the y 
axis.  The light conditions (160 lux in the direction of gaze, hourly milkshakes 06:00 h – 
21:00 h, lying semi-recumbent) are illustrated on the graph as the unshaded area. The 
dark conditions, (0 lux, fasted and recumbent from 22:30 h – 06:00 h) are illustrated on 
the graph as the grey shaded area. Time of day (clock time) is displayed on the x axis. 
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4.4.6 Effect of time of day between the groups 
The 2-way ANOVA (Section 2.5.3) also measured the effect of time of day, shown 
in Table E in the Appendix. No metabolite had a significant interaction (time and 
group). In total, 80 metabolites (61.5%) had a significant effect of time of day. 
4.4.7 Principal components analysis 
Figure 4.12 shows the PCA scores plot, coloured according to lean (red), OW/OB 
(blue) and T2DM (black) groups, R2(cum) = 0.877 and Q2(cum) = 0.736. The PCA did 
not reveal any effect of group in PC1. A cosinor analysis of the scores on PC1 
showed there was no significant cosine rhythm in any group. The mean ± SEM PC1 
scores across time are shown in Figure 4.13. 
Figure 4.12 PCA scores plot of 130 quantified metabolites. Coloured according to group: 
lean (red), OW/OB (blue) and T2DM (black). R2X(cum) = 0.877 and Q2(cum) = 0.738 
 
Figure 4.13 24-h profiles of the PC 1 scores. (Mean ± SEM) of the lean (red), OW/OB (blue) 
and T2DM (black) groups of the mean ± SEM PC 1 scores of 130 metabolites are plotted 
against time. Relative amplitude (z-score) is displayed on the y axis.  The light conditions 
(160 lux in the direction of gaze, hourly milkshakes 06:00 h – 21:00 h, lying semi-
recumbent) are illustrated on the graph as the unshaded area. The dark conditions, (0 lux, 
fasted and recumbent from 22:30 h – 06:00 h) are illustrated on the graph as the grey 
shaded area. Time of day (clock time) is displayed on the x axis. 
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4.4.7.1 Supervised multivariate analysis (OPLS-DA) 
Two OPLS-DA models segregated the two classes (lean vs OW/OB and OW/OB vs 
T2DM). The p(corr) values of the metabolites are shown in Appendix Table F. Only 
p(corr) values with a standard deviation that did not cross the p[1] axis were used 
to describe differences between the groups. This was interpreted as only p(corr) 
values that were > 0.10 and < -0.10. 
4.4.7.2 Lean vs OW/OB 
The OPLS-DA scores plot (Figure 4.14) demonstrates a clear separation between 
the lean (red) and OW/OB (blue) groups. R2X(cum) of 0.636, R2Y 0.913 and the 
Q2(cum) of 0.877 with intercepts R2 = (0.0, 0.187) and Q2 = (0.0, -0.435). The p(corr) 
loadings plot, shown in Figure 4.15, demonstrates the differences between the 
metabolites of the lean vs OW/OB groups in ascending order of influence on the 
model. The most notable observation was the direction of change according to 
class; the amino acids and biogenic amines tended to have higher concentrations 
in OW/OB compared to the lean group whereas the phospholipid classes tended 
to have lower levels in OW/OB compared to the lean group.  
 
Figure 4.14 OPLS-DA scores plot of the lean vs OW/OB groups. All time points, separated 
according to group, model validated by permutation analysis of the lean (red) vs OW/OB 
(blue) groups; R2X (cum) = 0.636, R2Y (cum) = 0.913 and Q2(cum) = 0.877. On the horizontal 
axis t[1] and on the vertical axis t[2].  
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Figure 4.15 OPLS-DA loadings plot of lean vs OW/OB. Negative p(corr)[1] values represent higher metabolite concentrations and positive p(corr) 
[1] values represent lower metabolite concentrations in OW/OB compared to lean. The bars are coloured according to class; amino acids and 
biogenic amines (blue), acylcarnitines (green), PC aa (yellow), PC ae (light orange), lyso PC (dark orange) and sphingomyelin (brown). 
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4.4.7.3 OW/OB vs T2DM 
The OPLS-DA scores plot, classed according to the OW/OB (blue) vs the T2DM 
(black) groups with R2X(cum) of 0.658, R2Y(cum) 0.913 and the Q2 (cum) of 0.879 
(Figure 4.16) and R2 = (0.0, 0.202) Q2 = (0.0, -0.478) intercepts demonstrates a clear 
separation of the groups (Figure 4.16). The loadings plot of the metabolites of the 
OW/OB vs T2DM groups in ascending order of influence on the model is shown in 
Figure 4.17. The corresponding p(corr) values are shown in the Appendix Table F. 
Figure 4.16 OPLS-DA scores plot of the OW/OB vs T2DM groups.  Coloured according to 
group of the OW/OB (blue) vs T2DM (black) groups; R2X (cum) = 0.658, R2Y (cum) = 0.912 
and Q2(cum) = 0.879. On the horizontal axis t[1] and on the vertical axis t[2].  
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Figure 4.17 OPLS-DA loadings plot of OW vs T2DM. Negative p(corr)[1] values represent higher metabolite concentrations in T2DM and positive 
p(corr)[1] values represent metabolite concentrations that are higher in OW/OB.  The bars are coloured according to class; amino acids and 
biogenic amines (blue), acylcarnitines (green), PC aa (yellow), PC ae (light orange), lysoPC a (dark orange) and sphingomyelin (brown). 
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4.4.8 Differences in 24-h concentration 
There were 116 (89%) of the 130 metabolites (Figure 4.18) with significant 
differences in concentration between the groups (two-way ANOVA). The 24-h 
mean ± SEM, the minimum and maximum concentrations and the FDR of the 
quantified metabolites are shown in the Appendix Table E. Amino acids, biogenic 
amines and acylcarnitines tended to have higher concentrations and the lipids 
tended to have lower concentrations in OW/OB compared to the lean group. By 
contrast there were no similar trends observed between the OW/OB and T2DM 
groups. 
4.4.8.1 Lean vs OW/OB 
Post hoc analysis of the lean and OW/OB groups (Appendix Table E) showed that 
90 metabolites (69% of all the 130 metabolites) were significantly different. The 
majority, 70/90 (78%) had significantly lower concentrations in OW/OB, thus 
20/90 (22%) had significantly higher concentrations in OW/OB compared to the 
lean group.  
4.4.8.2 OW/OB vs T2DM 
Post hoc analysis of the OW/OB and T2DM groups (Appendix Table E) showed that 
56/130 metabolites (43%) were significantly different between the OW/OB and 
T2DM groups. Of these 56 metabolites, 34 (61%) had significantly higher 
concentrations in T2DM and 22 (39%) had significantly lower concentrations in 
T2DM compared to OW/OB. The following sections discuss the different metabolic 
classes and the group differences observed. 
 
 
 
 
 
 
  
126 
 
 
 
 
 
 
Figure 4.18 Concentration 
change between OW/OB and 
T2DM and controls Percentage 
change between the groups with 
significant differences (FDR<0.05) 
(A) lean and OW/OB (n = 90) and 
(B) OW/OB and T2DM (n = 56) 
groups in descending order. 
 
B 
B 
A 
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4.4.8.3 Metabolic indicators 
Fourteen ratios and 14 subtotals of groups of metabolites associated with 
metabolic processes or disease states were exported from Met IDQ (Section 1.5.6). 
Total- AC:AC-C0, AC-C2:AC-C0 ratios and the Fisher ratio showed a significant 
time/group interaction (FDR <0.05) and were not analysed further. Nineteen 
metabolic indicators had significant differences, shown in Table 4.7. Tyr:Phe ratio 
had a time/group interaction between the lean and OW/OB groups. There were 7 
metabolic indicators with significant differences between the lean and OW/OB 
groups that were not observed between the OW/OB and T2DM groups. These 
included AAA, BCAA, essential AA, the Cit/Orn and ADMA/Arg ratios, total SM-OH 
and total PC ae.   
Table 4.7 Metabolic indicators in the lean, OW/OB and T2DM groups  
 
Metabolic indicator 
24-h concentration 
Direction of 
change 
FDR group 
Lean 
(µM) 
OW/OB 
(µM) 
T2DM 
(µM) 
L vs 
OW 
OW/OB vs 
T2DM 
Lean vs 
OW/OB 
OW/OB v 
T2DM 
AAA 270.8 296.5 307.9 ↑ ↑ 5.03E-05 1.44E-01 
BCAA 518.2 560.8 544.9 ↑ ↓ 2.77E-04 2.90E-01 
Essential AA 1191.9 1264.3 1248.6 ↑ ↓ 4.76E-03 7.57E-01 
Glucogenic AA 760.7 758.9 821.2 ↓ ↑ 9.60E-01 1.91E-03 
Kynurenine/Trp 0.024 0.026 0.028 ↑ ↑ 4.82E-07 3.74E-06 
Tyr/Phe 0.986 1.090 1.142 ↑ ↑ 8.00E-13 4.01E-05 
CPT-1 ratio (C16+C18/C0) 0.003 0.003 0.002 ↑ ↓ 4.77E-02 6.93E-05 
Cit/Orn  0.670 0.569 0.566 ↓ ↓ 8.29E-07 9.92E-01 
Orn/Arg 0.668 0.789 0.723 ↑ ↓ 5.89E-07 4.21E-04 
ADMA/Arg 0.005 0.006 0.006 ↑ ↑ 7.48E-03 9.34E-01 
Total lysoPC 155.1 132.1 123.1 ↓ ↓ 6.88E-10 8.26E-03 
SFA (PC) 30.5 28.0 30.3 ↓ ↑ 8.80E-05 4.21E-04 
MUFA (PC) 362.2 331.9 373.4 ↓ ↑ 1.50E-04 3.93E-07 
MUFA (PC) / SFA (PC) 12.4 11.9 12.2 ↓ ↑ 5.83E-04 4.44E-03 
Total PC ae 161.8 145.1 143.7 ↓ ↓ 5.89E-07 8.76E-01 
Total SM 514.1 471.1 447.8 ↓ ↓ 1.05E-04 4.65E-02 
Total SM-non OH 427.3 393.2 372.8 ↓ ↓ 2.11E-04 3.58E-02 
Total SM-OH 86.8 77.9 75.0 ↓ ↓ 2.51E-06 1.46E-01 
Total SM-OH/Total SM-non OH 0.204 0.197 0.202 ↓ ↑ 4.73E-11 3.72E-08 
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4.4.8.4 Amino acids 
The amino acids with significantly higher concentrations in the OW/OB group 
compared to the lean group (n = 8) were glutamate (37.4%) ornithine (13.6%), 
tyrosine (13.2%), isoleucine (7.1%), tryptophan (7.1%), histidine (5.7%), valine 
(5.4%) and proline (5.2%). The amino acids with significantly lower concentrations 
(n = 4) in OW/OB compared to lean included asparagine (-13.3%), glycine (-9.6%), 
citrulline (-7.7%) and arginine (-6.1%).   
The amino acids with significantly higher concentrations in the T2DM 
compared to the OW/OB group (n = 5) were alanine (24.9%), glutamate (21.6%), 
tyrosine (11.9%) proline (9.9%) and phenylalanine (5.6%). The amino acids with 
significantly lower concentrations in the T2DM compared to the OW/OB group (n 
= 4) were histidine (15.1%), ornithine (8.9%), glutamine (6.9%) and serine (5.5%). 
The mean (± SEM) and 24-h profiles of the amino acids with the largest variation 
between lean and OW/OB groups (glutamate, asparagine) and the OW/OB and 
T2DM groups (alanine and histidine) are shown in Figure 4.19. 
Figure 4.19 Amino acids with the most difference between the groups. 24-h mean ± SEM 
and 24-h profiles ± SEM of the amino acids with the highest (glutamate) and lowest 
concentration (asparagine) in OW/OB (blue) compared to lean (red) and with the highest 
(alanine) and lowest concentrations (histidine) in T2DM (black) compared to the OW/OB 
group (two-way ANOVA). Concentrations are shown on the y axis. The light conditions 
(160 lux in the direction of gaze, hourly milkshakes 06:00 h – 21:00 h, lying semi-
recumbent) are illustrated on the graph as the unshaded area. The dark conditions, (0 lux, 
fasted and recumbent from 22:30 h – 06:00 h) are illustrated on the graph as the grey 
shaded area. Time of day (clock time) is displayed on the x axis.  
 
80
85
90
95
100
105
glutamate asparagine alanine 
C
o
n
ce
n
tr
at
io
n
 (
μ
Μ
 ±
SE
M
) 
 
Time of day (h) 
histidine 
40
60
80
100
50
55
60
65
70
300
350
400
450
500
7 15 23 7
200
300
400
500
600
7 15 23 7
40
50
60
70
80
7 15 23 7
30
50
70
90
110
130
7 15 23 7
60
80
100
120
129 
 
4.4.8.5 Branched chain amino acids 
Metabolites with a particular biological connection such as BCAA (Section 1.5.1.6) 
have been measured together. The 24-h profiles of the individual metabolites 
(isoleucine, leucine and valine) are shown and the 24-h (mean ± SEM) BCAA 
concentrations derived from the sum of isoleucine, leucine and valine, calculated 
by the MetIDQ software are shown in Figure 4.20. The combined BCAA was only 
significantly different between the lean and OW/OB group (FDR 2.77E-04). The 
FDR for the individual BCAA, isoleucine (2.06E-02), leucine (5.48E-02 (non-
significant)) and valine (2.61E-02) means that as individual metabolites, not all can 
be reported as significant, however the combined BCAA was.   
Figure 4.20 Branched chain amino acids (isoleucine, leucine and valine) concentrations. 
24-h mean ± SEM and 24-h profiles ± SEM of the BCAA of the lean (red) OW/OB (blue) and 
T2DM (black) groups.  Concentrations are shown on the y axis. The light conditions (160 
lux in the direction of gaze, hourly milkshakes 06:00 h – 21:00 h, lying semi-recumbent) 
are illustrated on the graph as the unshaded area. The dark conditions, (0 lux, fasted and 
recumbent from 22:30 h – 06:00 h) are illustrated on the graph as the grey shaded area. 
Time of day (clock time) is displayed on the x axis. 
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4.4.8.6 Glucogenic amino acids 
The glucogenic amino acids, were derived from the sum of alanine, glycine and 
serine, calculated by the MetIDQ software. The T2DM group had significantly 
higher concentrations than the OW/OB group (1.91E-03), whereas there was no 
significant difference between the lean and the OW/OB groups (FDR 9.60E-1). 
Alanine had significantly higher levels in the T2DM group compared to the OW/OB 
group (FDR 5.54E-10), serine (FDR 1.71E-02) was significantly lower in the T2DM 
group compared to OW/OB and glycine was not significantly different. In the same 
way as the BCAA (Section 4.4.8.5) analysing the glucogenic amino acids as one 
provides a significant value. Alanine and serine did not have any significant 
differences between the lean and OW/OB. Glycine was significantly lower in 
OW/OB compared to the lean group (FDR 8.46E-10). The profiles of these 
individual amino acids are shown in Figure 4.21. 
 
 
Figure 4.21 Glucogenic amino acids (alanine, glycine and serine concentrations 24-h 
mean ± SEM and 24-h profiles ± SEM of the glucogenic amino acids of the lean (red) 
OW/OB (blue) and T2DM (black) groups. Concentrations are shown on the y axis. The light 
conditions (160 lux in the direction of gaze, hourly milkshakes 06:00 h – 21:00 h, lying 
semi-recumbent) are illustrated on the graph as the unshaded area. The dark conditions, 
(0 lux, fasted and recumbent from 22:30 h – 06:00 h) are illustrated on the graph as the 
grey shaded area. Time of day (clock time) is displayed on the x axis. 
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4.4.8.7 Urea cycle metabolites  
The Orn:Arg ratio was 18% higher in OW/OB (FDR 5.89E-07) compared to the lean 
group and 8.4% lower (FDR 4.21E-04) in T2DM compared to OW/OB (Figure 4.22). 
The Cit:Orn ratio was 15% lower in OW/OB (FDR 8.29E-07) compared to the lean 
group, whereas no significant difference was observed between the OW/OB and 
T2DM group.  
Figure 4.22 Citrulline:ornithine and ornithine:arginine ratios. 24-h mean ± SEM and 24-
h profiles ± SEM of the lean (red) OW/OB (blue) and T2DM (black) groups of metabolic 
indicator ratios associated with enzyme activity of the urea cycle. Concentrations are 
shown on the y axis. The light conditions (160 lux in the direction of gaze, hourly 
milkshakes 06:00 h – 21:00 h, lying semi-recumbent) are illustrated on the graph as the 
unshaded area. The dark conditions, (0 lux, fasted and recumbent from 22:30 h – 06:00 
h) are illustrated on the graph as the grey shaded area. Time of day (clock time) is 
displayed on the x axis. 
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4.4.8.8 Biogenic amines 
The biogenic amines with significantly higher concentrations in the OW/OB 
compared to the lean group (n = 4) were kynurenine (16.2%), sarcosine (13.7%), 
creatinine (11.3%) and ADMA (9.1%), shown in Figure 4.23. None of the biogenic 
amines had significantly lower levels in OW/OB compared to the lean group. The 
biogenic amines with significantly higher concentrations in the T2DM compared 
to the OW/OB (n = 3) were sarcosine (20.6%), alpha-AAA (19.9%) and t4-OH-Pro 
(17.5%). None of the biogenic amines had significantly lower levels in T2DM 
compared to the OW/OB group.  
 
 
Figure 4.23 Biogenic amines with the largest differences in concentrations. 24-h mean ± 
SEM and 24-h profiles ± SEM of the lean (red) OW/OB (blue) and T2DM (black) groups. 
Concentration is shown on the y axis. The light conditions (160 lux in the direction of gaze, 
hourly milkshakes 06:00 h – 21:00 h, lying semi-recumbent) are illustrated on the graph 
as the unshaded area. The dark conditions, (0 lux, fasted and recumbent from 22:30 h – 
06:00 h) are illustrated on the graph as the grey shaded area. Time of day (clock time) is 
displayed on the x axis. 
 
4.4.9 Acylcarnitines 
Eight acylcarnitines were significantly higher in the OW/OB group compared to 
lean, AC-C18:1 (19.1%), AC-C5 (16.6%), AC-C16 (15.3%), AC-C18:2 (13.5%), AC-C4 
(12.8%), AC-C2 (6.4%), AC-C3 (6.4%) and AC-C0 (5.5%). None of the acylcarnitines 
had significantly lower concentrations in OW/OB compared to lean.  
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Acylcarnitines AC-C3 (19.7%) and AC-C0 (7.0%) had higher concentrations in 
the T2DM group compared to the OW/OB group. AC-C18 (13.7%), AC-C18:2 
(12.8%) and AC-C18:1 (11.8%) had lower concentrations in the T2DM group 
compared to OW/OB. The acylcarnitines with the largest difference between the 
study groups (AC-C18:1, AC-C3 and AC-C18) are shown in Figure 4.24. 
 
Figure 4.24 Acylcarnitines with the highest and the lowest concentrations. 24-h mean ± 
SEM and 24-h profiles ± SEM of the lean (red) OW/OB (blue) and T2DM (black) groups. 
Concentration is shown on the y axis. The light conditions (160 lux in the direction of gaze, 
hourly milkshakes 06:00 h – 21:00 h, lying semi-recumbent) are illustrated on the graph 
as the unshaded area. The dark conditions, (0 lux, fasted and recumbent from 22:30 h – 
06:00 h) are illustrated on the graph as the grey shaded area. Time of day (clock time) is 
displayed on the x axis. 
 
4.4.9.1 CPT-1 ratio 
The CPT-1 ratio (Section 1.5.4) was 7.1% higher (FDR 24.77E-02) in OW/OB 
compared to lean and 12.7% lower (FDR 6.93E-05) in T2DM compared to OW/OB 
(Figure 4.25). The 24-h concentration of each of these metabolites individually, 
also shown in Figure 4.25 shows free plasma carnitine (C0) concentrations were 
5.5% higher in OW/OB compared to lean (FDR 9.87E-03) and 7% higher in T2DM 
compared to OW/OB (FDR 2.55E-03). AC-C16 concentrations were 15.3% higher in 
OW/OB compared to lean (FDR 6.72E-06) and 2.2% lower in T2DM compared to 
OW/OB, although not significantly (FDR 6.63E-01). There was no significant 
difference in AC-C18 concentrations between the lean and OW/OB, however the 
T2DM group was 13.7% lower than the OW/OB group (FDR 1.81E-03). 
0.09
0.10
0.11
0.12
0.13
0.25
0.30
0.35
0.40
7 15 23 7
0.05
0.10
0.15
0.20
7 15 23 7
0.1
0.2
0.3
0.4
0.5
AC-C18:1 AC-C18AC-C3
0.022
0.024
0.026
0.028
0.030
7 15 23 7
0.01
0.02
0.03
0.04
0.05
C
o
n
ce
n
tr
a
tio
n
 (

M
)
Time of day (h)
134 
 
 
 
Figure 4.25 CPT-1 ratio. 24-h mean ± SEM and 24-h profiles ± SEM of the lean (red) 
OW/OB (blue) and T2DM (black) groups. Concentration is shown on the y axis. The light 
conditions (160 lux in the direction of gaze, hourly milkshakes 06:00 h – 21:00 h, lying 
semi-recumbent) are illustrated on the graph as the unshaded area. The dark conditions, 
(0 lux, fasted and recumbent from 22:30 h – 06:00 h) are illustrated on the graph as the 
grey shaded area. Time of day (clock time) is displayed on the x axis. 
 
4.4.10 Phospholipids 
There were 58 phospholipids with significantly lower concentrations in the 
OW/OB group compared to the lean group, which included 9 lysoPC (6.7-27.4%), 
20 PC aa (6.3-28.4%) and 29 PC ae (5.2-29.1%). The majority of which were highly 
significant (n = 25 FDR <1.0E-10, n = 10 FDR <1.0E-08, n = 10 FDR <1.0E-06). The 
24-h mean and 24-h profile of the glycerophospholipids with the lowest 
concentrations in OW/OB compared to lean, namely lysoPC 20:3 and PC ae C34:3 
are shown in Figure 4.26. None of the phospholipids had significantly higher 
concentrations in OW/OB compared to lean. 
The phospholipids with significantly higher concentrations in the T2DM 
compared to the OW/OB group (n = 22) included 19 PC aa (6.5-50.1% higher), FDR 
1.71E-02-3.36E-22) and 3 PC ae (7.1-14.5%, FDR 2.09E-02 – 1.57E-06) PC aa C32:1 
had the biggest difference between the groups, with a 50.1% higher 
concentration. The phospholipids with significantly lower concentrations in the 
T2DM compared to the OW/OB group (n = 13) included 2 x PC aa and 6 x PC ae, 
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ranging from 5.8 – 19.6% lower (FDR 2.60E-02–3.06E-04) and 5 lysoPC a ranging 
from 7.9 – 20.5% lower (FDR 5.53E-03–2.30E-13).  
Figure 4.26 Phospholipids with the highest and lowest difference in concentration. 24-
h mean ± SEM and 24-h profiles ± SEM of the lean (red) OW/OB (blue) and T2DM (black) 
groups. Concentration is shown on the y axis. The light conditions (160 lux in the direction 
of gaze, hourly milkshakes 06:00 h – 21:00 h, lying semi-recumbent) are illustrated on the 
graph as the unshaded area. The dark conditions, (0 lux, fasted and recumbent from 22:30 
h – 06:00 h) are illustrated on the graph as the grey shaded area. Time of day (clock time) 
is displayed on the x axis. 
 
4.4.11 Sphingomyelins 
Eight sphingomyelins had significantly lower concentrations in the OW/OB group 
compared to the lean group, comprising 3 SM OH (8.8-10% lower) and 5 SM (8.4-
13.9%). The 24-h mean and 24-h profiles of the sphingomyelins with the lowest 
concentrations in OW/OB compared to lean, SM C26:1, is shown in Figure 4.27. 
There were no sphingomyelins with significantly higher concentrations in the 
OW/OB group than in the lean group. 
SM C20:2 (8.3%) and SM C26:1 (7.9%) and had significantly higher 
concentrations and SM C16:0 (8.6%) and SM (OH) C16:1 (7.0%) had significantly 
lower concentrations in the T2DM group compared to the OW/OB group.  
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Figure 4.27 SM with the highest concentrations. 24-h mean ± SEM and 24-h profiles ± 
SEM of the lean (red) OW/OB (blue) and T2DM (black) groups. Concentration is shown on 
the y axis. The light conditions (160 lux in the direction of gaze, hourly milkshakes 06:00 h 
– 21:00 h, lying semi-recumbent) are illustrated on the graph as the unshaded area. The 
dark conditions, (0 lux, fasted and recumbent from 22:30 h – 06:00 h) are illustrated on 
the graph as the grey shaded area. Time of day (clock time) is displayed on the x axis. 
 
4.4.12 Metabolite Set Enrichment Analysis 
The clustering of functionally related metabolites by metabolite enrichment 
analysis (MSEA) (MetaboAnalyst 3.0) (Section 2.7) did not identify any meaningful 
patterns between the lean and OW/OB groups or between the OW/OB and the 
T2DM groups. The top ten functionally related metabolic pathways between the 
lean and the OW/OB groups are shown in Table 4.8 and Figure 4.28 and the 
OW/OB and the T2DM groups are shown in Table 4.9 and Figure 4.29 
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Table 4.8 Pathway analysis of lean vs OW/OB 24-h concentrations  
 Total 
Cmpd 
Hits 
Statistic 
Q 
Expected 
Q 
Raw 
p 
Holm 
p 
FDR 
tyrosine metabolism 38 1 19.6 6.25 0.075 1.00 0.667 
catecholamine 
biosynthesis 
5 1 19.6 6.25 0.075 1.00 0.667 
phenylalanine and tyrosine 
metabolism 
13 2 13.2 6.25 0.120 1.00 0.667 
propanoate metabolism 18 1 10.0 6.25 0.216 1.00 0.667 
tryptophan metabolism 34 2 8.18 6.25 0.265 1.00 0.667 
excitatory neural signalling 
through 5-htr 4 and 
serotonin 
5 1 8.10 6.25 0.268 1.00 0.667 
valine, leucine and 
isoleucine degradation 
36 2 7.94 6.25 0.269 1.00 0.667 
aspartate metabolism 12 2 8.16 6.25 0.272 1.00 0.667 
histidine metabolism 11 1 6.67 6.25 0.317 1.00 0.667 
 
 
 
Figure 4.28 Quantitative Enrichment Analysis (QEA) of the lean vs OW/OB groups. 
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Table 4.9 Pathway analysis of OW/OB vs T2DM 24-h concentrations 
Metabolic pathway 
Total 
Cmpd 
Hits 
Statistic 
Q 
Expected 
Q 
Raw 
 p 
Holm 
p 
FDR 
histidine metabolism 11 1 29.7 7.14 0.036 1 0.671 
pyrimidine metabolism 36 1 17.3 7.14 0.123 1 0.671 
purine metabolism 45 1 17.3 7.14 0.123 1 0.671 
glutamate metabolism 18 1 17.3 7.14 0.123 1 0.671 
urea cycle 20 4 15.2 7.14 0.136 1 0.671 
ammonia recycling 18 5 13.6 7.14 0.155 1 0.671 
protein biosynthesis 19 12 11.4 7.14 0.166 1 0.671 
tyrosine metabolism 38 1 10.3 7.14 0.243 1 0.671 
catecholamine biosynthesis 5 1 10.3 7.14 0.243 1 0.671 
arginine and proline 
metabolism 
26 4 29.7 7.14 0.036 1 0.671 
 
 
 
Figure 4.29 Quantitative Enrichment Analysis (QEA) of the OW/OB vs T2DM groups.
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4.5 Discussion 
The aims within this chapter were to assess whether being OW/OB or T2DM 
affected 24-h cosinor rhythms of circulating metabolites, and to identify 
metabolites with significant differences in concentration between the OW/OB and 
lean control group and between T2DM and their OW/OB control group. The 
results demonstrate that being OW/OB, with or without T2DM affected the 
concentration and rhythmicity of some of these metabolites.  
The most unique aspect of this study was the 2-h sampling over a 24-h period 
in OW/OB and T2DM men. The highly controlled conditions of the laboratory were 
designed to reflect a typical sleep-wake, light-dark, feeding-fasting schedule. The 
administration of hourly isocaloric drinks during the light period provided the 
opportunity for the metabolome to be assessed while controlling for the effect of 
large meals. Moreover, large fluctuations in activity/exercise were minimised but 
was not strictly controlled. Another important design feature was using the same 
sex (male) so not to add the effect of fluctuating hormones that occurs over a 
monthly cycle in females and matching age and BMI (using two control groups), 
which is not always included in other study designs.  
As discussed in Section 2.3.3 the targeted metabolomic analysis measured 
non-covalent bound metabolites, which includes lipoproteins. In this analysis, 
there was no way of knowing from which circulating lipoproteins (for example 
HDL, LDL or VLDL fractions), or their associated metabolic pathways, the measured 
metabolites were derived.  
The adult male T2DM signature, namely higher short chain AC-(C0, C3) and 
higher amino acid levels observed in OW/OB and T2DM compared to the lean 
controls in the present study may demonstrate the role age plays in T2DM. This 
was also seen in a study examining the differences in the typical T2DM metabolic 
signature (higher short-chain acylcarnitine and amino acid concentrations) 
between adults and adolescents (Mihalik et al., 2012).  The adolescents with T2DM 
had lower amino acid and short and medium chain AC-(C2, C6), combined with 
higher long chain AC-(C14:0-C18:2) compared to obese controls. The T2DM 
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metabolic signature is generally considered an indicator of dysregulated fatty acid 
metabolism, and as such, these discordant observations suggest an early adaptive 
metabolic plasticity in adolescence, which becomes dysfunctional with continued 
obesity and ageing.  
Significant changes in the relative concentration metabolites have been associated 
with age in a study comparing 20-35, 36-50 and 51-65 years age groups (Lawton 
et al., 2008) The plasma levels of serine, alanine, glutamine, glycine, glutamate, 
histidine, isoleucine, valine, leucine and lysine were significantly higher in the 
oldest age group compared with the youngest. Sex affected these concentrations 
but to a lesser degree. If not controlled for, both of these confounders (sex and 
age) could therefore be mistaken for the effects of insulin resistance. 
The higher number of metabolites with significant differences between the 
lean and OW/OB groups than between the OW/OB and T2DM groups may point 
to the deleterious effects on amino acid metabolism had already occurred with 
increased weight (Section 1.5.7). This could also have been due to the smaller 
number of participants in the T2DM group (n= 6) compared to the lean (n = 8) and 
OW/OB (n = 9) groups. The power calculation for the original study required n = 9 
per study group (Section 2.1.2). 
4.5.1 Compared with other protocols 
In the present study, a targeted LC/MS metabolomics approach was applied. Some 
metabolic profiling studies reported in the literature have used an untargeted 
approach. Concordant results between these two techniques, using the same 
samples, have been reported in the literature (Davies et al., 2014), although 
inconsistencies have also been observed. One such study compared three 
different analytical platforms, targeted metabolomics (Biocrates Life Sciences), 
the same company and platform used in the present analysis, a non-targeted 
approach, combining gas (GC) and liquid phase chromatography (LC); 
UHPLC/MS/MS2 (Metabolon) and a nuclear magnetic resonance (NMR) 
spectroscopy approach, (Chenomx) (Suhre et al., 2010). The different platforms 
measured the effect of T2DM gave different percentage change, p and q values, 
even when using the same 100 samples. This discord is most likely due to the 
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different sample preparation methods and fractionation patterns employed by the 
platform manufacturers. 
The blood derivative used when studying metabolomics also influences the 
result. Most studies use plasma to measure LC-MS metabolomics. Although 
reproducibility is better in plasma, some metabolites read > 20% higher in serum, 
useful when measuring low concentrations. However, this needs to be considered 
when comparing concentrations between studies (Yu et al., 2011). As the 
metabolites are measured simultaneously their measured concentrations would 
be relative to each other, therefore a metabolic signature from one analysis 
technique would be comparable to the signature from a different technique.  
4.5.2 Rhythmicity - effect of time of day  
Many of the published metabolomic studies have drawn on epidemiological data 
using single time-point samples. Metabolic profiling at multiple time-points has 
generally used samples at 4-h time-points to identify diurnal rhythmicity. The 
present study measured the daily rhythmicity with more precision (at 2-h time-
points over a 24-h period). 
As expected, and also seen in the hormone analysis in Chapter 3, more 
metabolites showed a significant effect of time of day in the 2-way ANOVA than 
displayed significant cosinor rhythms, as fitting a sine wave is very specific. It was 
also observed that more significant cosinor rhythms were observed using the 
mean z-score data than when cosine curves were fitted to each individual’s z-
score. This finding again may be expected because only the individuals with 
significant fits to a cosine curve were considered in the individual cosinor analysis, 
whereas all the participants were included in the mean z-score data fits. However, 
using the mean of several participants or using pooled blood samples that do not 
peak at the same time of day or are antiphasic within a group dampens individual 
rhythms as they cancel each other out (Gooley and Chua, 2014). In the present 
study, the significant individual cosine rhythms peaked within 2-h of the mean z-
score cosinor rhythms, suggesting that the individual rhythms did not oppose each 
other or dampen the rhythms of the other individuals within the group. In fact, 
more cosinor rhythms were observed when all of the participants in each group 
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were included in the analysis. Nine metabolites displayed significant cosine 
rhythms in all the study groups (mean z-score and > 40% of individuals). These 
comprised proline, sarcosine, AC-(C2, C3 and C16), PC aa C 32:1, lysoPC a (C18:1 
and C18:2) and lysoPC a C20:4, indicating that these metabolites have the most 
robust rhythms. These metabolites are discussed more fully later in the chapter. 
There was a general decrease in the concentration of the metabolites in all 
groups over the dark/fasting period, which may lead one to assume the metabolite 
levels are related to changes in energy metabolism during fasting. This may be the 
case but there is also evidence to suggest that some of these metabolites are 
under circadian clock control. Hepatic de novo lipogenesis is coordinated by two 
closely related nuclear receptors (PPARδ and Rev-erbα/β) to control energy 
substrate homeostasis (Section 1.2.1). Phospholipids, particularly PC (18:0/18:1) 
(PC aa C36:1), are receptive to the diurnal regulation of lipogenic gene expression 
by PPARδ during the night-feeding phase in mice which is repressed by Rev-erbα/β 
(Liu et al., 2013). Furthermore, administering PC (18:0/18:1) reduced TAG and FFA 
levels as well as improving glucose tolerance test results and daytime restricted 
feeding reversed the patterns of gene expression implicating deviations in diurnal 
hepatic PPARδ-PC(18:0/18:1) signalling in metabolic disorders such as obesity. In 
the present study PC aa C 36:1 exhibited significant cosine rhythms in the lean and 
OW/OB groups only. More evidence of the clock control of phospholipid 
biosynthesis has been observed in cultured fibroblasts which display daily 
rhythmicity generated by a circadian clock mechanism involving Per1 expression 
(Marquez et al., 2004). 
4.5.3 Cosine rhythms 
Some of the samples from the lean individuals in the present study were also 
measured in an untargeted metabolomics pilot study by Ang et al. (2012). In this 
study, time of day variation was also assessed using the goodness of fit of the 
group mean z-score to a cosine curve. This study, however, used 6 time points 
(07:00, 10:00, 16:00, 22:00, 04:00, and 07:00 h), rather than the 13 time points 
used in the present study. Nine metabolites displayed a significant daily rhythm in 
the lean group of both studies; namely proline and tyrosine, acylcarnitines AC-(C2, 
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C3, C4, C16 and C18:1), LysoPC a C18:2 and LysoPC a C20:3 which all peaked at the 
same time of day in both studies. There were other metabolites displaying 
significant daily rhythms (alanine, arginine, valine, LysoPC a C16:0 and LysoPC a 
18:1) in the present study, not seen in the Ang study, most likely due to the higher 
number of sampling points increasing the resolution of the cosine curve.  
If a significant diurnal rhythm was observed in more than one study group, 
(Table 4.12) the metabolite rhythms peaked at the same time of day, with most 
peaking in the afternoon or evening, similar to the peak times observed in the 
hormone analysis in Chapter 3. Another study from the University of Surrey 
(Davies et al., 2014) examined the effect of sleep deprivation on circulating 
metabolites in young healthy male volunteers. They observed significant 24-h 
cosine rhythms in the amino acids glutamate, ornithine, proline, isoleucine and 
valine, regardless of sleep status or meals, with levels peaking between 21:00 and 
01:30 h. In contrast, neither glutamate nor ornithine displayed significant cosinor 
rhythms in the present study. Proline, isoleucine and valine displayed significant 
cosinor rhythms but the peak times were earlier, between 17:30 and 21:00 h. 
Other metabolites in the study by Davies et al. (2014) reported significant daily 
rhythms on day 1 (the normal sleep/wake) in kynurenine, SDMA, taurine, 
sarcosine and alpha-AAA peaking at 11:30 h, 13:00 h, 16:00 h, 22:00 h and 23:00 
h, respectively. Whereas in the present study significant cosinor rhythms in 
kynurenine, SDMA, sarcosine and alpha-AAA peaked approximately 5 h earlier at 
07:00 h, 07:00 h, 18:00 h and 17:30 h in the present study, taurine did not display 
a significant cosinor rhythm. The acylcarnitines also peaked earlier and the lyso PC 
a peaked later in the present study. Although the participants in both studies had 
similar sleep-wake times, the participants in the sleep deprivation study were 
younger and had three regular meals rather than the hourly meals in the present 
study. The different meal schedules may thus account for these different peak 
times in the two studies.  
4.5.4 Differences between the study groups 
The multivariate analysis, PCA and OPLS-DA, identified the metabolites with the 
greatest difference in concentration between the T2DM and OW/OB groups and 
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their healthy controls. The variance between the groups observed in the 
multivariate OPLS-DA were confirmed by the ANOVA, with the same metabolites 
appearing in both analysis methods in the same rank order. Although not 
necessarily biologically relevant, it was notable that almost twice as many 
metabolites had significant differences between the lean and OW/OB group (n = 
90) than the OW/OB and T2DM (n = 56). 
In the present study, the 24-h concentrations were used to compare 
differences between the groups, which is more representative of the changes in 
concentration over the whole day. The 24-h concentrations may not necessarily 
be comparable to the single time-point, fasting, samples analysed in most cohort 
studies. Much of the work regarding the effect of T2DM on the metabolome has 
related to the discovery of biomarkers for T2DM risk using case control and cohort 
data (Newgard et al., 2009, Suhre et al., 2010, Wang et al., 2005). Not all of the 
studies identified the same metabolites, but there were commonalities; higher 
BCAA, glutamate, tyrosine, alanine, carnitine and phenylalanine concentrations 
being associated with increased risk of T2DM and higher glycine and glutamine 
concentrations being associated with decreased risk of T2DM (Guasch-Ferre et al., 
2016). Lower glycerophospholipid concentrations in obesity and T2DM and even 
newly discovered biomarkers of T2DM risk such as alpha-AAA (Wang et al., 2013) 
and t4-OH-Pro (Wang-Sattler et al., 2012) have also been observed. The 
associations between amino acids and obesity are well established in the 
literature. Felig et al (1969) reported higher valine, leucine, isoleucine, tyrosine 
and phenylalanine levels and lower glycine levels in obesity, concordant with the 
present study, with the exception of leucine where no significant differences were 
observed between any of the groups in the present study.  
Intervention studies employing oral glucose tolerance tests (OGTT) have 
detected altered amino acids (Zhou et al., 2013), acylcarnitines (Mihalik et al., 
2010) and lipid levels in T2DM (Mihalik et al., 2012, Yi et al., 2008, Zhou et al., 
2013). Previous studies thus suggest that a T2DM metabolic phenotype could 
resemble lower glycogenic amino acids (alanine, glycine and serine), higher levels 
of BCAA (isoleucine, leucine and valine) and a higher Arg:Orn ratio (Altmaier et al., 
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2008). In the present study tyrosine, proline, carnitine and AC-C3 had significantly 
higher levels in the OW/OB group that were even higher in T2DM. Although the 
elevated BCAA concentrations, seen as a T2DM signature in the literature, were 
significantly higher in the OW/OB group compared to the lean group and they 
were higher in the T2DM group compared to the OW/OB group, this difference 
was not statistically significant. The statistical significance between only the lean 
and OW/OB groups may be because the individuals in the OW/OB group were 
already in a pre-diabetic state therefore T2DM did not affect BCAA metabolism to 
the same degree as weight. Or that the T2DM diagnosis had less impact because 
the medication in 4/6 of the T2DM group may be having an effect although in the 
literature BCAA concentrations were not affected by metformin (Irving et al., 
2015). It may also have been because of the smaller size of the T2DM group, with 
only 6 participants compared to the 9 in the OW/OB group. Other metabolites 
with elevated levels in the OW/OB group were tryptophan, kynurenine, and 
acylcarnitines. Of course there is no way of knowing whether these OW/OB 
individuals would go on to develop T2DM but these metabolites have also been 
associated with T2DM (Mihalik et al., 2010). 
Newgard et al. observed higher BCAA concentrations in OW individuals 
compared to lean controls concordant with the present study. Their obese 
subjects were more insulin resistant than the lean subjects (Newgard et al., 2009), 
suggesting these changes may be due to insulin resistance rather than increased 
adiposity per se. In the present study, however, the lean and OW/OB group were 
matched for markers of insulin resistance. Short chain AC, AC-C3 and AC-C5 had 
significantly higher levels in the OW/OB group compared to the lean group with 
only AC-C3 having concentrations that were significantly higher in the T2DM group 
compared to the OW/OB group. These acylcarnitines have been linked to BCAA 
metabolism as leucine and isoleucine can be converted to AC-C5 and isoleucine 
and valine can be converted to AC-C3 (Menni et al., 2013). In BCAT2 gene knockout 
mice the first steps of BCAA conversion to AC-C3 and AC-C5 are blocked leading to 
higher BCAA concentrations, with no detrimental effect on glucose control, or 
insulin sensitivity and are even resistant to diet induced obesity. This suggests it is 
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the breakdown of BCAA rather than the higher concentrations per se that are 
associated with T2DM (She et al., 2007). 
Many of the associations between metabolic risk factors (obesity, insulin 
resistance, high blood pressure, dyslipidaemia) centre on differences in amino acid 
concentrations in different metabolic states. Elevated BCAA, alanine, glutamate, 
phenylalanine, tyrosine and lower glutamine concentrations reported by Cheng et 
al. (2012) were also observed in both the OW/OB and T2DM groups compared to 
their control groups in the present study. 
Most of the amino acids associated with the urea cycle were significantly 
lower in OW/OB and T2DM compared to their controls, with the exception of 
ornithine in the OW/OB group. Figure 4.30 illustrates the amino acids in the TCA 
and the urea cycles with significantly higher concentrations (as a positive number) 
or significantly lower concentrations (as a negative number) in OW/OB compared 
to lean (blue) and T2DM compared to OW/OB (black). The amino acid (alanine), 
associated with the TCA cycle, had higher levels in the T2DM and OW/OB groups 
compared to their control groups. Glutamate had higher concentrations in OW/OB 
and T2DM compared to their controls, while the amino acids associated with the 
urea cycle (citrulline and arginine) were lower in T2DM and OW/OB compared to 
their control groups with the exception of ornithine which had higher significantly 
concentrations in OW/OB compared to the lean group. As all amino acids are 
converted to glutamate to enter the urea cycle this could contribute to the higher 
circulating levels of other amino acids, such as the higher BCAA levels observed in 
the OW/OB and T2DM study groups of the present study (Section 4.4.8.5) and in 
the literature (Section 1.5.1.6). 
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Figure 4.30 Amino acids in the urea and TCA cycle. Percentage difference in OW/OB compared to lean (blue) and T2DM compared to OW/OB 
(black) amino acids related to the urea and TCA cycles.  
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The significantly higher alpha-AAA concentrations in T2DM but not in the 
OW/OB group compared to their controls indicates the association is with T2DM 
only and not increased body mass. Our finding supports a previous prospective 
study showing that individuals in the top quartile of alpha-AAA concentrations had 
the strongest association with future diabetes over the 12-year follow-up period 
(Wang et al., 2013) The higher alpha-AAA concentrations were also associated 
with insulin resistance and β cell function (Wang et al., 2013) which would support 
the link with T2DM. 
Long chain acylcarnitines accumulate in the circulation under conditions of 
ineffective β oxidation of fatty acids in the mitochondria. Thus Long chain 
acylcarnitines levels provide a good marker for insulin resistance (Chua et al., 
2013).  
Differences in AC concentrations in T2DM are well documented. Evidence 
from previous studies, in particular higher plasma long chain AC in obesity and 
T2DM, suggest more fatty acids can enter mitochondria (Section 1.5.3). Observing 
higher concentrations of long chain AC in the T2DM group during the day when 
the participants were awake and being fed was most likely due to reduced CPT-1 
activity associated with T2DM, possibly slowing the entry of LC-AC into the 
mitochondria for ẞ-oxidation in the fed state. Our data were consistent with 
Mihalik et al who observed higher concentrations of short chain AC (C3, C4 and 
C5) in T2DM subjects. In T2DM, many shorter species AC accumulate, suggesting 
that they have a generalised complex oxidation defect (Adams et al., 2009). 
Consistent with Mihalik et al. (2010),  in the present study the medium and long 
chain acylcarnitines (AC-C5–C18) levels were significantly higher in the OW/OB 
group but AC-(C18, C18:1 and C18:2) levels were significantly lower in the T2DM 
group, possibly a result of the medication in the T2DM group. Although, of the 
short chain acylcarnitines (AC-(C0, C2, C3, and C4)) with significantly higher 
concentrations in the OW/OB group, AC-C0 and AC-3 were higher still in the T2DM 
group. ACs, AC-(C2, C3 and C4), also displayed significant daily rhythms in all 
groups. These metabolites peaked at 04:00 h, 16:00 h and 18:00 h, respectively. 
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Using the same targeted metabolomics kit (AbsoluteIDQ™ p180) as the 
present study, Wang et al. found lower lysoPC C18:2 and glycine, and higher AC-
C2 concentrations were predictors of T2DM (Wang-Sattler et al., 2012). They also 
found that combining these three metabolites, as a metabolic indicator, created 
an even more robust candidate as an early T2DM biomarker (Wang-Sattler et al., 
2012). Metabolic indicators are groups of interrelated metabolites that have been 
shown to be more powerful predictors of T2DM than when the same metabolites 
are analysed separately (Altmaier et al., 2008; Krug et al., 2012). Examples of 
metabolic indicators are subgroups of lipids classed according to structure 
(number and position of double bonds and carbon side-chain length) (Rhee et al., 
2011; Wang-Sattler et al., 2012), BCAA (Wang et al., 2011). Ratios of metabolites 
joined in short metabolic pathways, such as Glu:Gln (Cheng et al., 2012) and 
Asp:Asn (Palmer et al., 2015) and Arg:Orn (Altmaier et al., 2008), have all been 
associated with T2DM. In the present study significant differences between the 
lean and OW/OB groups of the individual amino acids that form BCAA (Section 
4.4.8.7) and the glucogenic amino acids between the OW/OB and T2DM groups 
(Section 4.4.8.8) were not all significant but when analysed collectively, as 
metabolic indicators, this difference was significant. 
It is notable that all the lipid species levels were lower in OW/OB compared 
to the lean group. Between the OW/OB and the T2DM groups levels of 22 
glycerophospholipids were elevated in T2DM. by contrast, lysoPC levels were 
lower in T2DM, which was also observed in another study of obese healthy and 
obese T2DM groups compared to lean individuals (Barber et al., 2012). Higher PC 
aa 36:1 levels have also been associated with T2DM risk in cohort studies (Floegel 
et al., 2013). Most of the lipid classes had significantly lower levels in the OW/OB 
group compared to the lean group, whereas there was no consistent pattern in 
T2DM compared OW/OB. PC aa C32:1 had the largest difference between the 
OW/OB and T2DM groups, which was 50% higher in the T2DM group. Lower total 
PC aa, total SFA and monounsaturated fatty acids (MUFA) levels were observed in 
OW/OB. However, MUFA levels were higher in T2DM whereas no difference was 
seen in the other subclasses. Guasch et al. also noted that a meta-analysis could 
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not be performed on the lipid class as there was not enough consistency between 
the metabolomics studies (Guasch-Ferre et al., 2016). 
In summary, the cosinor analysis exposed significant daily rhythms in over a 
third of the metabolites in at least one study group, some displaying a daily rhythm 
in all study groups, with some metabolites losing and some gaining cosinor 
rhythmicity with increased body mass and T2DM. The concentrations of 
approximately a third of the metabolites were affected by both OW/OB and T2DM 
and 12% were affected by T2DM only. The metabolites with significant cosinor 
rhythms and group differences are shown in Figure 4.31.  
Figure 4.31 Metabolites with significant daily rhythms and group differences. Venn 
diagram of the metabolites with significant daily rhythms and the peak time of 
metabolites with daily rhythms in more than one study groups. The arrows illustrate the 
metabolites, which also showed significant differences in the 24-h concentration between 
the T2DM and OW/OB groups and their controls. ↑↑ = higher concentrations in both 
OW/OB and T2DM, ↓↓ = lower concentrations in both OW/OB and T2DM, ↑↓ = higher 
concentrations in OW/OB and lower concentrations in T2DM, ↓↑ = lower concentrations 
in OW/OB and higher concentrations in T2DM. ↑ = higher concentrations in T2DM and 
↓ = lower concentrations in T2DM compared to OW/OB only. 
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5 Circulating metabolites after a 5-h shift in meals 
5.1 Introduction  
It is clear from the previous chapters that the circadian system and metabolism 
are intrinsically linked (Section 1.2.1). Desynchrony between the endogenous 
timing system in the SCN and the peripheral clocks that are involved in the control 
of metabolism creates an internal desynchrony that may result in metabolic 
disturbances such as increased incidence of obesity and T2DM risk (Section 1.3.2). 
Desynchrony can occur with acute changes in externally imposed cycles such as 
people who cross time zones or shift workers, (e.g. they may be awake and eat at 
night when the body is programmed to sleep and fast), leading to feelings of jet 
lag and disturbances in metabolism (Arendt, 2009, Knutsson and Boggild, 2000).  
Light is the primary zeitgeber (Section 1.1), the weaker, non-photic 
zeitgebers, exercise and food, need more research (Section 1.1.2). Much of the 
evidence to support the hypothesis that timed feeding can influence endogenous 
rhythms comes from animal studies. Meal timing has been shown to act as a weak 
zeitgeber on the circadian system (Damiola et al., 2000, Stephan, 2002b). The food 
anticipatory activity observed when food was only available for a limited period of 
time, not seen it in ad libitum fed rodents, persisted for a few days, even when the 
rodents were deprived of food (Mistlberger, 2009, Stephan, 2002a). Other 
restricted feeding protocols have demonstrated the impact of food timing on 
physiology. In restricted feeding schedules leptin, TAG, FFA, ketone bodies and 
corticosterone levels are linked to meal time compared to ad libitum feeding, 
indicating entrainment of metabolism by food in these rodent models (Diaz-
Munoz et al., 2000, Escobar et al., 1998, Martinez-Merlos et al., 2004). Timed 
feeding affects peripheral clocks in rodents (Pezuk et al., 2010, Stokkan et al., 
2001). There is also evidence that clock genes, BMAL and CLOCK, play a role in the 
regulation of glucose homeostasis (Rudic et al., 2004).  
Only a few studies have investigated the effects of timed feeding in humans 
(Section 1.2.3). A CHO rich evening meal led to an acute increase and subsequent 
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phase delay in core body temperature (CBT) and heart rate rhythms compared to 
a morning meal (Kräuchi et al., 2002).  
The animal and human data indicate that timed feeding shifts the clocks in 
peripheral tissues (Section 1.2.1) but not the central SCN clock suggesting there 
may be separate light and food entrainable oscillators (FEO). The study in this 
chapter examines the metabolic effects when a typical daily eating routine of 
three meals (breakfast, lunch and dinner) was delayed by 5-h. The protocol 
enabled the comparison of 5-h delay in ‘normal’ meal times without a shift in the 
light-dark or sleep-wake cycle.  
5.1.1 Aims and objectives 
The objective of this study was to examine whether a 5-h delay in a typical 3-meal 
schedule could phase shift peripheral circadian rhythms in humans without 
changing their sleep-wake and light-dark cycle.  
The hypothesis being tested was that the timed feeding protocol would shift 
the phase of peripheral clock rhythms without altering the phase of SCN driven 
rhythms such as melatonin or cortisol. We expected that the food-entrainable 
rhythms would gradually delay to synchronise with the new feeding times whereas 
the light-entrainable SCN-driven rhythms would remain synchronised to the light-
dark cycle.  
5.2 Materials and methods 
The screening (Section 2.2.2) and laboratory (Section 2.2.4) protocols are 
described in the Materials and Methods Section. Samples from this study have 
also been measured elsewhere and form another PhD thesis. These measures 
include plasma melatonin, cortisol, insulin, glucose, NEFA and TAG and gene 
expression in whole blood (BMAL1, REVERB-β, Glucocorticoid receptor and PER3), 
as well as gene expression in adipose tissue (PER2 and PER3) and subjective 
measures of appetite and sleepiness. 
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5.2.1 Participant demographics 
The participant demographics are shown in Table 5.1. Self-reported race 
classification showed most of the group (n = 8) were white European, one 
participant was African and one participant was mixed white/black Caribbean.   
Table 5.1 Participant demographic and screening data 
Subject 
    
body weekda
y 
(meal time) weekend (meal time) 
ID Age 
(years) 
Height 
(m) 
Weight 
(kg) 
BMI 
kg/m2 
Fat 
% 
b/fast 
(h) 
lunch 
(h) 
dinner 
(h) 
b/fast 
(h) 
lunch 
(h) 
dinner 
(h) 
1 21 1.8 87.7 26.5 14.1 8.5 12.0 19.0 11.0 13.0 19.0 
2 28 1.8 91.0 28.1 28.5 10.0 13.5 18.0 11.0 14.5 19.5 
3 20 1.7 68.9 23.8 17.9 9.5 13.0 21.0 10.5 13.0 21.0 
5 30 1.8 65.2 20.3 6.6 7.5 13.0 19.0 9.5 13.0 19.0 
6 20 1.8 66.9 20.0 1.3 8.0 12.5  8.5 12.5  
4 27 1.9 84.6 22.9 16.5 8.0 13.0 19.0 10.0 15.0 20.0 
7 22 1.8 68.3 22.3 14.5 8.8 12.0 19.0 9.5 12.5 19.0 
8 23 1.8 72.2 22.0 17.5 8.3 15.5 20.5 9.3 1.0 20.5 
9 19 1.9 79.6 22.0 8.6 8.3 13.0  10.0 13.0  
10 19 1.8 71.8 22.9 15.9 8.3 12.0 20.0 10.3 12.0 23.0 
mean 22.9 1.8 75.6 23.1 15.0 8.5 13.0 19.4 10.0 12.0 20.1 
SD 4.0 0.1 9.4 2.5 6.1 0.7 1.0 1.0 0.79 4.0 1.4 
 * Times are 24h, decimal format 
 
5.2.2 DLMO correction 
Each participant was corrected for their internal body clock time using 25% of the 
melatonin peak time (DLMO) as a marker (Section 2.6). Melatonin was measured 
hourly and started at 16:00 h and continued throughout both CR. The assay was 
conducted by RIA by Dr Benita Middleton using the tritium (3H) based assay, 
described elsewhere (Middleton, 2013). The plasma melatonin limit of detection 
was 2.1 pg/ml +/- 1.5 and the maximum measured sample was 101.8 pg/ml. The 
low QC mean = 8.1 pg/ml CV = 12.8%; medium QC = 32.7 pg/ml CV = 8.7%; high 
QC = 88.3 pg/ml CV = 8.1%; extra high QC = 123.8 pg/ml CV = 10.6%. Table 5.2 
shows the 25% DLMO times for each participant and the mean ± SEM in each CR.  
A two-tailed t test (Graphpad, Prism) showed there was no significant 
difference between the CR 1 and CR2 (p = 0.37). The plasma melatonin profiles 
identified the peak concentration time, from which the 25% DLMO value is 
calculated. The exact times of the 25% melatonin onset were binned to coincide 
with the nearest 2-h time-point in the sampling schedule. As the first sample was 
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drawn at 16:00 h clock time, if the 25% DLMO of a participant was 21.98 h, thus 
the new ‘0’ time-point, the first 16:00 h sample time-point would now be -5.98 h. 
This -5.98 h value was rounded the nearest 2-h sampling time-point; -6 h relative 
to melatonin onset. For the 22 time-points measured in each CR, the binned time-
points were -8, -6, -4, -2, 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 and 22 h. As the 25% 
DLMO times ranged from 22:00 h to 01:00 h (Table 5.2) not all participants had a 
sample at every first or last time-point. Participants 1, 2 and 7 did not have a first 
time-point, participant 3 did not have a last time-point in CR 1 and participants 1 
and 4 did not have a first time-point and participant 8 did not have a last time-
point in CR 2. 
Table 5.2. Dim light melatonin onset times 
Participant CR1 CR2 
1 21.98 21.96 
2 22.22 22.72 
3 25.06 24.25 
4 22.86 22.43 
5 22.95 23.12 
6 23.58 23.50 
7 22.26 22.83 
8 24.23 24.76 
9 23.28 23.32 
10 22.63 23.92 
Mean  23.11 23.28 
± SEM 0.31 0.27 
* Times are 24h, decimal format, DLMO was calculated as 25% of the melatonin peak. 
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5.3 Results  
5.3.1 Metabolic profiling using targeted metabolomics 
Using the targeted metabolomics method and exclusion criteria described in 
Sections 2.6 and 2.7.5, 127 metabolites were quantified (Table 5.3). These 
comprised amino acids (n = 20), biogenic amines (n = 7), acylcarnitines (n = 9), 
glycerophospholipids (n = 80), of which there were 12 lysoPC a, 33 PC aa and 35 
PC ae, and sphingolipids (n = 11).  
5.3.1.1 Circadian variation 
Oscillations in metabolite concentration across time in each of the CRs were 
identified using the goodness of fit to a cosine curve compared to a straight line 
(constant or linear); the linear model assessed the monotonic increase or decrease 
in concentration. The cosinor analysis is described fully in the following Sections 
(5.3.1.2 – 5.3.1.9). Circadian variation across time was analysed in a 2-way ANOVA 
that considered the combined effect of both CR. The ANOVA identified 42 (33%) 
metabolites that varied significantly over the 32-h period. These comprised 8 
amino acids, 1 biogenic amine, 3 acylcarnitines, 8 lyso PC a, 16 PC aa and 6 PC ae. 
None of the SM showed significant circadian variation over time.  
5.3.1.2 Circadian rhythmicity 
The mean z-score was used to calculate the goodness fit to a cosine curve. P< 0.05 
was used as a measure of significance.   
To remove the confounding effect of differences in concentration between 
individuals or CRs the data were z-scored before a mean of each CR was fitted to 
4 models. The significance of fit to a 24-h cosine curve, straight line (constant and 
linear fit) and a combination of a 24-h cosine curve and linear fit were compared 
to a constant, from which the relative amplitude and peak time of the cosine and 
combined models and the slope of the linear fit were calculated.  
Out of the 127 quantified metabolites, 81 (64%) had a significant fit to at 
least one of the cosine models in at least one CR. Of these 81, 65 (52% of the 
quantified metabolites), displayed significant circadian rhythms (significantly fit a 
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cosine or the combined model) in CR1 and 55 (43% of the quantified metabolites), 
displayed a significant circadian rhythm in CR2. Significant circadian rhythms were 
observed in 39 (31% of the quantified metabolites) in both CR1 and CR2. Table 5.3 
shows all the quantified metabolites, the model type the metabolite displayed a 
significant fit, with preference to a cosinor, then combined and lastly linear where 
more than one fit was significant. The amplitude and peak time of the cosine or 
combined model and the slope of the linear model, where a positive value 
represents an increase across the CR and a negative value represents a decrease 
in relative concentration for CR1 and CR2 are also shown.  
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Table 5.3 Metabolites with a cosine fit, a linear fit or a combination of cosine and linear fit 
* Red text signifies cosine in both CR, blue text signifies cosine in one CR and black text signifies no cosine fit in either CR. 
 CR1 CR2 
change 
(h) 
% change 
Metabolite p value best fit 
peak 
time 
amplitude slope p value best fit 
peak 
time 
amplitude slope 
peak 
time 
amplitude 
Ala 2.01E-02 combined 11.26 0.27 0.03 1.57E-02 cosine 11.90 0.60  0.65 119 
Arg 4.43E-02 cosine 1.69 0.39   No fit      
Asn 3.07E-02 cosine 3.99 0.35   No fit      
Cit 8.07E-03 cosine 1.27 0.39  1.13E-02 cosine 2.65 0.46  1.37 17 
Gln 1.64E-02 combined 14.48 0.17 0.02  No fit      
Glu  No fit    1.80E-02 linear   0.02   
Gly 2.22E-05 combined 7.64 0.34 0.04 1.99E-02 combined 9.90 0.20 0.03 2.25 -42 
His  No fit     No fit      
Ile 3.40E-02 cosine 3.69 0.35  1.08E-02 cosine 5.76 0.45  2.07 29 
Leu 3.51E-02 combined 3.20 0.26 0.02  No fit      
Lys  No fit     No fit      
Met  No fit     No fit      
Orn 4.22E-03 combined 8.71 0.27 0.03 3.79E-02 combined 11.38 0.14 0.03 2.68 -49 
Phe 2.50E-02 cosine 0.64 0.26   No fit      
Pro 7.68E-06 combined 10.13 0.13 0.05 1.62E-02 combined 11.64 0.19 0.04 1.51 53 
Ser 3.65E-02 cosine 6.04 0.40  4.84E-02 combined 8.92 0.30 0.02 2.89 -25 
Thr 1.28E-04 combined 6.83 0.34 0.05 2.63E-03 combined 8.78 0.43 0.04 1.96 26 
Trp 1.12E-05 cosine 2.00 0.70  6.51E-04 cosine 2.28 0.69  0.28 -2 
Tyr 1.84E-06 cosine 5.48 0.70  1.94E-03 cosine 6.10 0.64  0.62 -8 
Val 4.16E-02 cosine 6.53 0.24  4.55E-02 combined 6.17 0.23 0.03 -0.36 -2 
ADMA 4.77E-02 linear   -0.02  No fit      
alpha-AAA  No fit     No fit      
Kynurenine  No fit     No fit      
Met-SO  No fit     No fit      
t4-OH-Pro  No fit     No fit      
Taurine  No fit     No fit      
SDMA  No fit     No fit      
AC-C0  No fit     No fit      
158 
 
AC-C2 1.04E-03 combined 12.96 0.10 -0.03 1.05E-02 combined 12.14 0.14 -0.03 -0.82 45 
AC-C3  No fit     No fit      
AC-C4  No fit     No fit      
AC-C5  No fit    3.36E-02 cosine 14.16 0.30    
AC-C14:1 3.26E-02 combined 15.28 0.18 -0.03 6.11E-03 combined -5.89 0.24 -0.03 2.83 30 
AC-C16 2.76E-03 combined -7.78 0.21 -0.04  No fit      
AC-C18:1 1.18E-06 combined -6.13 0.15 -0.06  No fit      
AC-C18:2  No fit     No fit      
lysoPC a C16:0 3.50E-02 combined -0.04 0.23 0.02  No fit      
lysoPC a C16:1  No fit     No fit      
lysoPC a C17:0 1.13E-02 combined -0.67 0.23 0.02  No fit      
lysoPC a C18:0 4.95E-04 combined -0.14 0.28 0.04 1.24E-02 combined -2.67 0.16 0.03 -2.53 -42 
lysoPC a C18:1 1.83E-02 combined -0.40 0.31 0.02  No fit      
lysoPC a C18:2 5.88E-05 combined -1.01 0.21 0.05 2.76E-03 combined -2.27 0.22 0.04 -1.26 1 
lysoPC a C20:3 3.82E-03 cosine -2.08 0.41  3.65E-02 cosine -2.30 0.40  -0.22 -4 
lysoPC a C20:4 1.73E-03 cosine -1.34 0.47  8.08E-03 cosine -1.70 0.43  -0.37 -9 
lysoPC a C24:0 1.86E-02 cosine -7.77 0.38  2.57E-02 cosine -4.94 0.36  2.83 -5 
lysoPC a C26:1  No fit    1.12E-02 combined -3.88 0.30 0.03   
lysoPC a C28:0 2.28E-03 cosine 15.72 0.44  4.64E-03 combined -4.71 0.20 0.03 3.57 -54 
lysoPC a C28:1  No fit    2.33E-03 combined -4.87 0.28 0.03   
PC aa C24:0 1.57E-02 cosine -7.91 0.35  5.14E-03 combined -4.66 0.22 0.03 3.25 -39 
PC aa C28:1  No fit    4.38E-02 combined -6.56 0.23 0.01   
PC aa C30:0 5.62E-05 combined -5.67 0.17 0.04 4.44E-02 cosine 12.72 0.40  -5.61 133 
PC aa C32:0  No fit     No fit      
PC aa C32:1  No fit    2.00E-02 cosine 13.26 0.35    
PC aa C32:3 2.94E-05 combined 12.20 0.29 0.05 2.40E-03 combined 10.74 0.23 0.04 -1.46 -21 
PC aa C34:1 1.21E-03 combined -7.85 0.08 -0.03  No fit      
PC aa C34:2  No fit     No fit      
PC aa C34:3 1.00E-03 combined 11.34 0.20 0.03 3.66E-03 combined 12.77 0.28 0.03 1.43 44 
PC aa C34:4 7.54E-08 combined 13.08 0.25 0.06 9.92E-04 combined 13.00 0.35 0.04 -0.07 39 
PC aa C36:0 3.35E-02 combined 15.42 0.23 0.02  No fit      
PC aa C36:1 3.92E-02 linear   -0.01  No fit      
PC aa C36:2 8.74E-05 combined 6.83 0.25 0.03 4.07E-02 combined 12.54 0.27 0.02 5.71 11 
PC aa C36:3  No fit     No fit      
PC aa C36:4 1.65E-02 combined 5.35 0.10 -0.02  No fit      
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PC aa C36:5  No fit     No fit      
PC aa C36:6 1.98E-04 combined 15.69 0.31 0.04 8.54E-03 combined 14.47 0.31 0.02 -1.22 0 
PC aa C38:0  No fit     No fit      
PC aa C38:3 4.16E-02 linear   -0.01  No fit      
PC aa C38:4 6.50E-04 combined 1.91 0.16 -0.03 2.85E-02 linear   -0.02  -100 
PC aa C38:5 2.14E-03 combined -0.10 0.17 -0.02  No fit      
PC aa C38:6 1.87E-05 combined 1.36 0.13 -0.04 4.33E-02 combined 15.93 0.12 -0.03 14.57 -5 
PC aa C40:1 4.89E-02 cosine 15.80 0.33   No fit      
PC aa C40:3 3.23E-02 cosine 15.95 0.29  1.23E-02 combined -4.95 0.21 0.02 3.10 -25 
PC aa C40:4 4.50E-02 linear   -0.01  No fit      
PC aa C40:5 5.95E-04 combined -1.29 0.13 -0.03  No fit      
PC aa C40:6 2.89E-05 combined -0.20 0.12 -0.04  No fit      
PC aa C42:0 4.66E-02 cosine -6.73 0.22  3.27E-02 cosine -6.21 0.35  0.52 62 
PC aa C42:1  No fit    3.08E-02 cosine -6.28 0.36    
PC aa C42:2 3.74E-03 cosine -7.93 0.40  2.31E-02 cosine -5.75 0.32  2.19 -21 
PC aa C42:4 1.96E-02 cosine 15.57 0.39  3.19E-02 combined -4.35 0.24 0.02 4.09 -40 
PC aa C42:5  No fit     No fit      
PC aa C42:6  No fit     No fit      
PC ae C30:0  No fit    1.30E-02 combined 14.86 0.13 0.02   
PC ae C30:2  No fit     No fit      
PC ae C32:1 1.17E-02 linear   -0.02  No fit      
PC ae C32:2  No fit     No fit      
PC ae C34:0  No fit     No fit      
PC ae C34:1 6.68E-03 combined -7.57 0.12 -0.02  No fit      
PC ae C34:2  No fit    4.63E-02 linear   0.02   
PC ae C34:3  No fit     No fit      
PC ae C36:0  No fit    4.82E-02 cosine 14.58 0.35    
PC ae C36:1  No fit     No fit      
PC ae C36:2 3.37E-02 combined 9.38 0.10 0.02  No fit      
PC ae C36:3  No fit     No fit      
PC ae C36:4  No fit     No fit      
PC ae C36:5 4.76E-02 linear   -0.01 3.31E-02 combined -7.41 0.27 -0.02   
PC ae C38:0  No fit     No fit      
PC ae C38:2 2.57E-03 combined 15.04 0.27 0.03 6.28E-04 combined -5.74 0.15 0.03 3.22 -45 
PC ae C38:3  No fit     No fit      
160 
 
PC ae C38:4 3.08E-03 combined -4.65 0.15 -0.02  No fit      
PC ae C38:5 1.66E-02 combined 2.76 0.06 -0.02  No fit      
PC ae C38:6 5.20E-03 combined -3.18 0.09 -0.03 4.50E-02 combined -7.39 0.21 -0.02 -4.21 131 
PC ae C40:1 7.05E-03 cosine -7.97 0.33   No fit      
PC ae C40:2 1.90E-02 cosine -7.30 0.34  1.32E-02 combined -6.51 0.26 0.02 0.78 -24 
PC ae C40:3 2.12E-02 cosine -7.81 0.31  1.19E-02 combined -5.28 0.25 0.02 2.53 -19 
PC ae C40:4  No fit     No fit      
PC ae C40:5  No fit     No fit      
PC ae C40:6 3.26E-02 combined 12.63 0.01 -0.02  No fit      
PC ae C42:1 9.24E-03 cosine 15.86 0.37  1.51E-02 combined -5.43 0.29 0.02 2.71 -23 
PC ae C42:2 7.53E-03 cosine 15.88 0.36   No fit      
PC ae C42:3  No fit     No fit      
PC ae C42:4  No fit    4.40E-02 cosine -6.55 0.25    
PC ae C42:5  No fit     No fit      
PC ae C44:3 5.34E-03 cosine -7.96 0.40  2.83E-02 cosine -6.70 0.36  1.27 -11 
PC ae C44:4  No fit     No fit      
PC ae C44:5  No fit     No fit      
PC ae C44:6 4.16E-02 linear   -0.01  No fit      
SM C16:0  No fit    4.48E-02 cosine -5.56 0.29    
SM C16:1  No fit     No fit      
SM C18:0  No fit    4.93E-02 cosine -6.10 0.26    
SM C18:1 1.41E-02 combined -1.66 0.19 -0.02 4.06E-03 cosine -5.82 0.32  -4.16 67 
SM C20:2 3.58E-03 combined -5.88 0.17 0.03  No fit      
SM C24:0 4.98E-02 combined -4.22 0.18 -0.02 3.25E-03 cosine -7.02 0.38  -2.80 106 
SM C24:1  No fit     No fit      
SM (OH) C14:1  No fit    1.02E-02 cosine -6.53 0.34    
SM (OH) C16:1  No fit    1.81E-03 cosine -5.97 0.28    
SM (OH) C22:1  No fit    4.90E-02 cosine -7.63 0.29    
SM (OH) C22:2  No fit    1.49E-03 cosine -7.94 0.26    
* Red text signifies cosine in both CR, blue text signifies cosine in one CR and black text signifies no cosine fit in either CR. 
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5.3.1.3 Circadian rhythmicity in both constant routines 
 Of the 39 metabolites displaying a significant circadian rhythm in both CR, 10 
metabolites fit the cosine models compared to a constant, comprising citrulline, 
isoleucine, tryptophan and tyrosine, 3 x lyso PC a, 2 x PC aa and 1 x PC ae. Figure 
5.1 shows the amino acids, in order of significance and the most significant 
phospholipids displaying a circadian rhythm in both CR (Table 5.3). The 0.0 h 
circadian time (relative to melatonin) on the x axis of the following graphs was at 
approximately 23:00 h clock time.   
Figure 5.1 Metabolites with circadian rhythms in both constant routines. Mean ±SEM 
relative concentration (z-score) plotted on the y axis against time (h) relative to 25% 
DLMO on the x axis of CR1 (black circles) and CR2 (red squares). 
 
5.3.1.4 Circadian rhythmicity with changing relative concentration  
There were 29 metabolites with significant circadian rhythms combined with a 
linear change in relative concentration over both CR.  If the relative concentration 
of a metabolite increased or decreased over the course of CR1, it increased or 
decreased in the same direction in CR2, and with a similar gradient. Most of the 
metabolites (n = 21) increased over the 32-h period. Figure 5.2 illustrates 
metabolites that increased (top panel) and decreased (bottom panel) the most in 
CR1 and CR2.  
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Figure 5.2 Metabolites with linear circadian rhythms in both CR. Mean ±SEM relative 
concentration (z-score) plotted on the y axis against time (h) relative to 25% DLMO on the 
x axis of CR1 (black circles) and CR2 (red squares). 
 
5.3.1.5 Phase shift between constant routines 
Out of the 39 metabolites with significant cosinor rhythms, 15 had peak times with 
> 2 h phase delay in CR2. These comprised serine + 2.9 h, ornithine + 2.7 h, glycine 
+ 2.3 h, isoleucine + 2.1 h, AC-C14:2 + 2.8 h, 2 x lysoPC a (C28:0 + 3.6 h and C24:0 
+ 2.8 h), 6 x PC aa (C38:6 + 14.6 h, C36:2 + 5.7 h, C42:4 + 4.1 h, C24:0 + 3.3 h, C40:3 
+ 3.1 h and C42:2 + 2.2 h) and 3 x PC ae (C38:2 + 3.2 h, C42:1 + 2.7 h and C40:3 2.5 
h) (Table 5.3). Five metabolites had peak times > 2 h phase advance in CR2; namely 
lysoPC a C18:0 - 2.5 h, PC aa C30:0 - 5.6 h, PC ae C 38.6 - 4.2 h and 2 x SM (C18:1 - 
4.2 h and C24:0 - 2.8 h). Figure 5.3 summarises the peak circadian time of all 
metabolites with significant circadian rhythms according to metabolite class. 
Figure 5.3 also illustrates that metabolites within a class peaked at approximately 
at the same time, for example, amino acids peaked at night and 
glycerophospholipids peaked in the early and late evening.  
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Figure 5.3 Phase shift of metabolite rhythms in CR1 and CR2. Separated according to 
metabolite class of CR1 (black circles) and CR2 (red squares). Time relative to melatonin 
(25% DLMO) is shown on the x axis.  
 
5.3.1.6 Amplitude change 
Sixteen of the 39 metabolites displaying significant circadian rhythmicity had 
higher relative amplitudes in CR2; PC aa C30:0 + 133%, PC ae C38:6 + 131%, alanine 
+ 119%, SM C24:0 + 106%, SM C18:1 + 67%, PC aa C42:0 + 62%, proline (53%), AC-
C2 45% PC aa C34:3 + 44%, PC aa C34:4 + 39%, AC-C14:1 30%, isoleucine 29%, 
threonine 26%, citrulline 17%, PC aa C36:2 11% and lysoPC a C18:2 1% (Table 5.3). 
Twenty-two metabolites had a lower relative amplitude in CR2; lysoPC a C28:0 had 
the largest difference (54%) followed by ornithine (49%), PC ae C38:2 (45%), 
lysoPC a C18:0 (42%), glycine (42%) and PC aa C42:4 - 40%, PC aa C24:0 - 39%, PC 
aa C40:3 - 25%, serine - 25%, PC ae C40:2 - 24%, PC ae C42:1 - 23%, PC aa C42:2 - 
21%, PC aa C32:3 - 21%, PC ae C40:3 - 19%, PC ae C44:3 - 11%, lysoPC a C24:0 - 9%, 
tyrosine -8%, lysoPC a C24:0 - 5%, PC aa C38:6 - 5%, lysoPC a C20:3 - 4%, valine and 
tyrosine – 2%. The relative amplitude of PC aa C36:6 did not change. The relative 
amplitude of the metabolites separated according to metabolite class, are 
illustrated in Figure 5.4.  
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Figure 5.4 Relative amplitude of metabolites in CR1 and CR2. Separated according to 
metabolite class.  
 
5.3.1.7 Metabolites with circadian rhythmicity in only one CR  
Twenty-six metabolites displayed significant circadian rhythms in CR1 only and 16 
metabolites displayed significant circadian rhythms in CR2 only. Figure 5.5 shows 
3 metabolites that had circadian rhythms in CR1 only.  
 
Figure 5.5 Metabolites with a circadian rhythm in CR1. Mean ±SEM relative 
concentration (z-score) plotted on the y axis against time (h) relative to 25% DLMO on the 
x axis of CR1 (black circles) and CR2 (red squares). 
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5.3.1.8 Metabolites without circadian rhythmicity 
Forty-seven metabolites (37%) did not display significant circadian rhythms in 
either CR. These comprised asparagine, glutamate, histidine, lysine and 
methionine, 7 biogenic amines (ADMA, alpha-AAA, kynurenine, Met-SO, SDMA, 
t4-OH-Pro and taurine), 4 acylcarnitines (AC(C0, C3, C4 and C18:2)), lysoPC a C16:1, 
27 glycerophospholipids and 2 sphingomyelins (Table 5.3). Selected amino acids, 
and one metabolite from each class that did not fit any of the models are shown 
in Figure 5.6. 
Figure 5.6 Metabolites with no significant cosinor fit in both constant routines. Mean 
±SEM relative concentration (z-score) plotted on the y axis against time (h) relative to 25% 
DLMO on the x axis of CR1 (black circles) and CR2 (red squares). 
 
5.3.1.9 Metabolic indicators with significant circadian rhythms 
Table 5.4 shows the metabolic indicators (Section 1.5.6) in chronological order of 
the peak time CR1. The circadian rhythms of BCAA peaked in the early morning, 
Orn:Arg peaked in the middle of the day and  Cit:Orn peaked in the middle of the 
night. All of which phase advanced in CR2 by 2-h.  
 
 
 
 
 
-1.0
-0.5
0.0
0.5
1.0
histidine
-8 -4 0 4 8 12 16 20
-1.0
-0.5
0.0
0.5
1.0
-8 -4 0 4 8 12 16 20
alpha-AAA
-1.0
-0.5
0.0
0.5
1.0
lysoPC a C16:1
-8 -4 0 4 8 12 16 20
-1.0
-0.5
0.0
0.5
1.0
PC aa C36:5
-8 -4 0 4 8 12 16 20
-1.0
-0.5
0.0
0.5
1.0
SM C24:1
-8 -4 0 4 8 12 16 20
-1.0
-0.5
0.0
0.5
1.0
AC-C18:2
-8 -4 0 4 8 12 16 20
Time (h) relative to melatonin (25% DLMO) 
R
el
at
iv
e 
co
n
ce
n
tr
at
io
n
 (
z-
sc
o
re
) 
166 
 
Table 5.4 Metabolic indicators with significant circadian rhythms 
  CR1    CR2   
  Amp 
z-score 
Peak time 
(h) 
  Amp  
z-score 
peak time 
(h) 
Difference 
(h) 
AAA 2.31E-05 0.53 3.34  9.19E-03 0.52 3.67 0.32 
BCAA 9.08E-03 0.28 4.03  4.12E-02 0.33 6.14 2.11 
Tyr/Phe 7.19E-08 0.88 6.78  2.93E-05 0.96 6.71 -0.07 
Orn/Arg 5.80E-05 0.75 11.46  9.61E-04 0.41 13.34 1.88 
Kynurenine/Trp 1.44E-03 0.61 13.22  1.05E-04 0.88 12.07 -1.15 
SDMA/Arg 3.42E-03 0.35 15.11  7.23E-03 0.39 17.40 2.30 
Cit/Orn 5.00E-05 0.52 23.04  2.31E-03 0.66 1.42 2.38 
Total lysoPC 2.48E-03 0.29 23.50  2.89E-02 0.25 21.85 -1.65 
Essential AA 1.50E-02 0.26       
ADMA/Arg     6.84E-02 0.18 19.27  
Cit/Arg     9.18E-03 0.34 0.94  
Glucogenic AA     5.85E-02 0.46 11.03  
Total DMA/Arg     3.51E-02 0.22 18.70  
Total SM     3.57E-02 0.30 17.23  
Total SM-non OH     5.53E-02 0.29 17.45  
Total SM-OH     3.13E-03 0.30 16.34  
Peak time is relative to melatonin (25% DLMO). 0.00 h ≈ 23.00 h  
5.3.1.10 Assessment of non-cosinor rhythms 
 As well as the 24-h cosinor rhythms seen in the previous sections, the metabolites 
had similar ultradian oscillations to the other metabolites in their class. Figure 5.7 
shows the mean metabolite profiles, of the 10 participants in CR1 and CR2, in each 
metabolite class. The differences in the feeding schedule preceding the CRs are 
shown on the graphs. The black vertical dashed lines represent the time the meal 
was served in the previous feeding schedule (B=breakfast, L=lunch and D=dinner). 
The vertical red dotted line represents a meal that was served in the feeding 
schedule before the other CR only. The grey shaded area represents the time the 
feeding schedules differed before the CR; as the 3 meals contained the same 
calories and macronutrients the meal times outside this shaded are considered 
the same. Before CR1, in the early feeding schedule, the last meal (dinner) was at 
approximately 17:30 h. Before CR2, in the late feeding schedule, the last meal 
(dinner) was at approximately 22:30 h (participants’ meals were staggered to 
correspond to their wake-up time), in Figure 5.7. Although the blood samples were 
taken in the CR, and during the CR small meals were given every hour, differences 
between the metabolite oscillations in each CR can be seen, with CR2 appearing 
to be less rhythmic.  
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Figure 5.7 CR1 and CR2 profiles according to metabolite class. Each line represents a 
metabolite mean z-score plotted against time of day (h). The vertical gridlines lines 
represent mean mealtimes in the previous feeding schedule; breakfast (B) in CR1 ≈ 7.5 h 
and in CR2 ≈ 12.5 h, lunch (L) in CR1 ≈ 12.5 h and in CR2 ≈ 17.5 h, dinner (D) in CR1 ≈ 17.5 
h and in CR2 ≈ 22.5 h. The vertical black dashed lines represent the time the meal was 
served in the previous feeding schedule. The vertical red dotted line represents a meal 
that was not served in the feeding schedule. The shaded area shows dinner to lunch time 
the following day as these times of day the energy intake differed in the days preceding 
the CR.  
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5.3.2 Unsupervised multivariate analysis (PCA) 
The unsupervised multivariate PCA followed by the OPLS-DA, described in Section 
2.2.6, (SIMCA-P v11.0) was applied to the 127 quantified metabolites. The PCA 
scores plot of all the data, coloured according to plate 1 (red), 2 (blue), 3 (black) 
and 4 (yellow), where each co-ordinate represents a sample, shows there was a 
slight effect of plate (Figure 5.8). The PCA did not reveal any obvious effect of CR 
in PC1 and PC2 (Figure 5.9). The amount of variance in the x matrix explained by 
PC1, expressed by R2 (cum) was 0.925 and the estimate of the predictive ability of 
the model, expressed by Q2 (cum) was 0.856.  
Figure 5.8 PCA of all samples coloured according to plate.  Plate 1 (red), 2 (blue), 3 (black) 
and 4 (yellow), where each co-ordinate represents a sample. R2X(cum) = 0.925 and 
Q2(cum) = 0.856 
 
Figure 5.9 PCA scores plot of 127 metabolites coloured according to CR. 1 (red) and 2 
(black) where each co-ordinate represents a sample. R2X(cum) = 0.925 and Q2(cum) = 
0.856. 
 
-15
-10
-5
0
5
10
15
-20 -18 -16 -14 -12 -10 -8 -6 -4 -2 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32
t[
2
]
t[1]
FAB all metabolites for all analysis.M1 (PCA-X)
t[Comp. 1]/t[Comp. 2]
Colored according to Obs ID (Plate)
R2X[1] = 0.41538            R2X[2] = 0.168931          
Ellipse: Hotelling T2 (0.95) 
1
2
3
4
SIMCA-P+ 12 - 2016-07-14 20:11:32 (UTC+0) 
-10
-5
0
5
10
-20 -18 -16 -14 -12 -10 -8 -6 -4 -2 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32
t[
2
]
t[1]
FAB 2 DLMO for Simca.M1 (PCA-X)
t[Comp. 1]/t[Comp. 2]
Colored according to Obs ID (group)
R2X[1] = 0.434829            R2X[2] = 0.167204            
Ellipse: Hotelling T2 (0.95) 
CR 1
CR 2
SIMCA-P+ 12 - 2016-08-17 22:14:57 (UTC+0) 
169 
 
5.3.3 Supervised multivariate analysis (OPLS-DA) 
The OPLS-DA demonstrated a clear separation between CR 1 (red) and CR2 (black), 
shown in the OPLS-DA scores plot (Figure 5.10); R2X(cum) of 0.821, R2Y(cum) 0.868 
and the Q2(cum) of 0.795.  The model was validated by permutation analysis 
intercepts R2 = (0.0, 0.276) Q2 = (0.0, -0.674). The p(corr) loadings plot, shown in 
Figure 5.11, shows the variance in the metabolite concentrations between the two 
CR in ascending order of influence on the model. The p(corr) values from the 
loadings plot are shown in the Table 5.5 and Table 5.6. 
Figure 5.10 OPLS-DA separated according to constant routine. Component 1 coloured 
according to condition; CR1 (black circles) and CR2 (red squares); R2X (cum) = 0.821, R2Y 
(cum) = 0.868 and Q2(cum) = 0.795. 
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Figure 5.11 OPLS-DA loadings plot of CR 1 vs CR2. Positive p(corr)[1] values represent higher metabolite concentrations and negative p(corr) [1] 
values represent lower metabolite concentrations in CR1 compared to CR2. The bars are coloured according to metabolite class; amino acids and 
biogenic amines (blue), acylcarnitines (green), PC aa (yellow), PC ae (light orange), lyso PC (dark orange) and sphingomyelin (brown). 
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Table 5.5 Metabolites with higher concentrations in CR1 vs CR2 in OPLS-DA 
metabolite p(corr) metabolite p(corr) metabolite p(corr) metabolite p(corr) 
SM C18:1 0.391 PC ae C32:2 0.236 SM C16:1 0.188 PC aa C42:0 0.150 
PC aa C36:0 0.325 PC ae C40:2 0.236 PC ae C38:6 0.187 SM(OH)C22:2 0.136 
PC ae C36:5 0.312 PC ae C40:5 0.235 lysoPC a C28:0 0.186 PC ae C38:0 0.135 
SM C16:0 0.307 PC ae C40:4 0.230 lysoPC a C24:0 0.186 PC ae C36:0 0.131 
SM C18:0 0.291 PC aa C42:1 0.224 SM C24:1 0.185 SM(OH)C14:1 0.130 
PC ae C36:4 0.271 PC ae C40:1 0.220 PC aa C42:5 0.181 PC ae C34:3 0.128 
PC ae C42:2 0.269 PC ae C30:2 0.217 PC ae C44:3 0.174 PC ae C38:2 0.122 
PC aa C38:0 0.265 SM(OH)C22:1 0.217 PC aa C32:0 0.173 Tyr 0.115 
PC ae C42:1 0.257 PC ae C36:1 0.216 AC-C16 0.172 PC ae C44:4 0.111 
PC ae C42:3 0.254 AC-C14:1 0.215 PC aa C40:1 0.169 PC ae C38:5 0.102 
PC aa C42:2 0.252 PC aa C40:3 0.210 PC ae C42:4 0.165 PC aa C34:1 0.099 
PC ae C40:3 0.248 PC ae C38:4 0.209 PC aa C40:4 0.164 PC aa C28:1 0.092 
SM(OH)C16:1 0.241 Thr 0.200 AC-C18:1 0.158 PC aa C36:4 0.092 
PC ae C38:3 0.241 lysoPC a C26:1 0.194 lysoPC a C28:1 0.157 PC ae C30:0 0.090 
PC aa C24:0 0.241 PC ae C32:1 0.192 SM C24:0 0.155 Ser 0.071 
PC aa C42:4 0.236  
 
 
 
 
 
 
Table 5.6 Metabolites with lower concentrations in CR1 vs CR2 in OPLS-DA 
metabolite p(corr) metabolite p(corr) metabolite p(corr) 
PC aa C34:4 -0.251 PC aa C32:1 -0.170 PC aa C40:6 -0.094 
PC aa C30:0 -0.200 lysoPC a C20:3 -0.135 PC aa C36:6 -0.097 
lysoPC a C17:0 -0.188 PC aa C38:5 -0.118 Arg -0.088 
 
5.3.4 Metabolite concentrations between the constant routines 
Differences between CR1 and CR2 were analysed by 2-way ANOVA (R v 3.2.2, 
Section 2.12), with factors circadian time and condition, corrected for multiple 
testing. The false discovery rate (FDR) < 0.05, showed 61 of the 127 (48%) 
metabolites had significant differences between the two CR conditions. Of these 
61 metabolites, 55 (90%) had significantly lower mean concentrations in CR2 
compared to CR1. These comprised 1 amino acid, 3 x AC, 4 x lysoPC a, 14 x PC aa, 
23 x PC ae and 10 x SM (Table 5.5). One amino acid, 2 x lysoPC a and 3 x PC aa had 
significantly higher concentrations in CR2 compared to CR1. Details regarding the 
specific metabolites are described in the following subsections. The 24-h mean ± 
SEM, the minimum and maximum metabolite concentrations and the FDR of the 
quantified metabolites are shown in the Table 5.6.  
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Differences between CR1 and CR1 were analysed by two-way ANOVA (R v 
3.2.2), (Section 2.12), with factors circadian time and condition, corrected for 
multiple testing. The false discovery rate (FDR) < 0.05, showed 61 of the 127 (48%) 
metabolites had significant differences between the two CRs. Of these 61 
metabolites, 55 (90%) had significantly lower mean concentrations in CR2 
compared to CR1. Of the quantified metabolites, this included 1/20 amino acids 
(5%), 3/7 AC (43%), 4/12 lysoPC a (33%), 14/33 PC aa (42%), 23/35 PC ae (66%) 
and 10/11 SM (91%). One amino acid, 2 lysoPC a and 3 PC aa had significantly 
lower concentrations. Details regarding the specific metabolites are in the 
following sections. The 24-h mean ± SEM, the minimum and maximum 
concentrations and the FDR of the quantified metabolites are shown in the Table 
5.7. 
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Table 5.7 Mean, minimum and maximum values for each constant routine 
   CR1     CR2       
 mean ± SEM min max mean ± SEM min max  group time  
Ala 398.4 ± 6.87 208.9 741.7 396.7 ± 6.05 193.1 747.6  9.18E-01 5.30E-04  
Arg 95.8 ± 1.72 46.0 181.4 99.1 ± 1.54 52.0 157.0  1.70E-01 8.71E-02  
Asn 55.1 ± 1.16 36.3 105.9 55.4 ± 1.15 33.2 100.6  8.96E-01 9.15E-03  
Cit 40.8 ± 1.27 14.5 77.1 39.8 ± 1.24 18.5 76.3  6.16E-01 6.86E-02  
Gln 577.2 ± 17.43 302.8 1371.1 609.5 ± 18.27 341.8 1487.7  1.03E-01 6.14E-01  
Glu 146.6 ± 4.55 59.7 281.6 143.7 ± 4.69 59.0 290.7  6.14E-01 9.49E-01  
Gly 311.5 ± 7.81 160.0 750.3 323.8 ± 7.71 176.1 651.5  1.55E-01 5.58E-02  
His 98.7 ± 1.86 62.6 182.9 99.8 ± 1.62 61.2 180.7  8.33E-01 8.92E-01  
Ile 86.3 ± 2.15 47.1 189.0 87.0 ± 1.97 46.3 165.1  8.92E-01 3.90E-02  
Leu 131.9 ± 4.71 13.2 379.6 125.5 ± 4.12 10.1 326.9  4.09E-01 5.43E-01  
Lys 284.7 ± 10.54 106.3 619.3 291.0 ± 11.44 110.4 744.6  7.07E-01 8.45E-01  
Met 24.3 ± 0.53 13.6 49.5 24.8 ± 0.47 12.0 43.7  7.71E-01 4.70E-02  
Orn 66.0 ± 1.74 32.7 140.0 68.7 ± 1.63 35.0 125.3  1.81E-01 2.64E-01  
Phe 64.8 ± 1.75 30.9 131.9 63.9 ± 1.69 34.5 128.8  7.81E-01 7.71E-01  
Pro 279.8 ± 6.04 141.9 497.2 292.0 ± 6.17 133.7 513.1  4.02E-02 1.70E-05  
Ser 140.8 ± 3.77 81.3 342.3 135.6 ± 3.33 79.3 274.8  3.35E-01 3.94E-01  
Thr 162.4 ± 3.26 101.1 310.3 150.4 ± 2.90 92.0 298.3  1.14E-03 6.61E-04  
Trp 74.5 ± 1.38 34.0 129.1 75.5 ± 1.26 43.9 133.7  7.90E-01 3.19E-07  
Tyr 62.9 ± 1.28 38.5 138.6 60.2 ± 1.14 33.0 114.4  6.94E-02 1.89E-08  
Val 234.2 ± 3.54 148.3 379.4 230.3 ± 3.46 133.1 354.2  5.21E-01 8.85E-02  
ADMA 0.778 ± 0.05 0.017 2.23 0.850 ± 0.05 0.156 2.32  8.37E-02 9.79E-01  
alpha-AAA 2.13 ± 0.21 0.052 9.98 1.96 ± 0.18 0.009 8.33  4.77E-01 9.59E-01  
Kynurenine 2.19 ± 0.07 0.503 4.25 2.14 ± 0.07 0.696 5.03  6.73E-01 3.96E-02  
Met-SO 3.93 ± 0.15 0.908 11.20 3.76 ± 0.15 0.736 10.2  4.72E-01 5.36E-01  
t4-OH-Pro 8.02 ± 0.21 4.49 17.60 8.05 ± 0.21 3.88 19.4  9.36E-01 3.94E-01  
Taurine 42.7 ± 0.86 25.5 82.3 43.3 ± 0.64 28.5 70.5  7.71E-01 5.21E-01  
SDMA 0.49 ± 0.01 0.259 0.87 0.482 ± 0.01 0.213 0.868  5.37E-01 1.51E-01  
AC-C0 73.2 ± 4.92 23.6 341.6 74.926 ± 4.98 24.2 279.4  8.68E-01 2.22E-01  
AC-C2 6.34 ± 0.46 1.54 25.8 6.00 ± 0.40 1.78 26.7  4.89E-01 8.86E-02  
AC-C3 0.517 ± 0.03 0.150 2.01 0.523 ± 0.03 0.186 1.63  8.99E-01 8.17E-01  
AC-C4 0.308 ± 0.02 0.077 1.16 0.329 ± 0.02 0.067 1.23  4.06E-01 7.78E-01  
AC-C5 0.288 ± 0.02 0.067 1.06 0.268 ± 0.02 0.063 0.947  2.82E-01 7.07E-01  
AC-C14:1 0.035 ± 0.00 0.016 0.076 0.030 ± 0.00 0.014 0.106  9.79E-06 2.69E-02  
AC-C16 0.054 ± 0.00 0.025 0.131 0.047 ± 0.00 0.021 0.105  2.38E-05 3.46E-03  
AC-C18:1 0.060 ± 0.00 0.029 0.174 0.053 ± 0.00 0.029 0.123  1.74E-04 5.24E-05  
AC-C18:2 0.027 ± 0.00 0.014 0.061 0.026 ± 0.00 0.013 0.058  4.88E-01 8.16E-01  
lysoPC a C16:0 107.6 ± 1.76 66.2 185.8 106.7 ± 1.72 56.5 176.1  8.73E-01 2.61E-01  
lysoPC a C16:1 2.84 ± 0.07 1.06 5.34 2.91 ± 0.07 1.32 5.04  5.44E-01 8.24E-01  
lysoPC a C17:0 2.35 ± 0.04 1.46 4.56 2.55 ± 0.04 1.34 4.22  1.64E-04 1.51E-01  
lysoPC a C18:0 28.9 ± 0.44 18.4 48.7 29.8 ± 0.42 16.7 43.5  1.83E-01 5.51E-04  
lysoPC a C18:1 24.4 ± 0.39 12.4 43.3 24.8 ± 0.38 14.2 38.7  6.93E-01 1.26E-01  
lysoPC a C18:2 56.5 ± 1.03 30.5 103.9 56.8 ± 0.98 31.3 94.3  9.00E-01 3.05E-05  
   CR1     CR2       
 mean ± SEM min max mean ± SEM min max  group time  
lysoPC a C20:3 3.11 ± 0.08 1.28 6.29 3.34 ± 0.07 1.62 5.96  3.73E-03 6.24E-04  
lysoPC a C20:4 7.75 ± 0.14 4.82 14.5 7.71 ± 0.13 4.39 14.6  8.96E-01 1.85E-04  
lysoPC a C24:0 0.372 ± 0.01 0.115 0.901 0.316 ± 0.01 0.130 0.812  5.89E-05 3.58E-02  
lysoPC a C26:1 0.197 ± 0.01 0.058 0.560 0.165 ± 0.01 0.053 0.584  2.48E-05 1.64E-04  
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lysoPC a C28:0 0.572 ± 0.03 0.123 2.22 0.461 ± 0.03 0.099 1.69  6.81E-06 1.82E-03  
lysoPC a C28:1 0.610 ± 0.02 0.219 1.81 0.522 ± 0.02 0.158 1.51  1.28E-05 1.29E-04  
PC aa C24:0 0.287 ± 0.01 0.074 0.926 0.216 ± 0.01 0.063 0.703  1.89E-08 1.28E-02  
PC aa C28:1 2.25 ± 0.06 1.13 4.36 2.12 ± 0.05 0.974 3.68  2.94E-03 5.21E-01  
PC aa C30:0 2.41 ± 0.05 1.31 4.19 2.65 ± 0.06 1.30 5.01  6.39E-06 1.21E-04  
PC aa C32:0 11.7 ± 0.18 7.51 20.6 11.0 ± 0.17 6.90 18.30  6.73E-03 8.96E-01  
PC aa C32:1 7.14 ± 0.22 0.981 14.2 8.05 ± 0.29 1.58 17.3  5.28E-06 7.71E-01  
PC aa C32:3 0.459 ± 0.01 0.252 0.973 0.453 ± 0.01 0.197 0.764  7.71E-01 3.74E-12  
PC aa C34:1 183.8 ± 3.70 87.4 354.3 174.5 ± 3.86 88.9 320.3  1.91E-02 4.02E-02  
PC aa C34:2 336.2 ± 4.42 197.4 509.7 331.0 ± 4.30 224.2 544.5  6.26E-01 9.22E-01  
PC aa C34:3 16.0 ± 0.32 7.60 28.6 15.9 ± 0.34 7.53 26.2  9.36E-01 1.96E-04  
PC aa C34:4 1.47 ± 0.04 0.665 3.41 1.71 ± 0.04 0.817 3.36  7.52E-11 4.41E-13  
PC aa C36:0 6.22 ± 0.17 2.39 13.50 5.03 ± 0.15 2.29 11.4  1.21E-12 5.59E-04  
PC aa C36:1 41.0 ± 0.76 23.6 76.8 40.3 ± 0.77 22.2 76.6  7.00E-01 8.17E-01  
PC aa C36:2 238.8 ± 3.85 136.2 395.6 235.4 ± 3.57 136 379.7  7.03E-01 1.66E-02  
PC aa C36:3 132.0 ± 2.76 56.2 254.9 132.5 ± 2.54 69.8 219.4  9.22E-01 8.96E-01  
PC aa C36:4 171.0 ± 2.68 112.0 322.9 164.6 ± 2.55 98.7 297.7  1.16E-01 8.73E-01  
PC aa C36:5 14.8 ± 0.30 7.67 24.8 15.2 ± 0.30 8.94 27.4  3.35E-01 8.04E-01  
PC aa C36:6 0.860 ± 0.02 0.394 1.83 0.899 ± 0.02 0.436 1.58  8.40E-02 2.10E-07  
PC aa C38:0 3.11 ± 0.07 1.72 6.23 2.72 ± 0.06 1.55 5.62  6.69E-08 1.91E-02  
PC aa C38:3 43.1 ± 1.03 21.6 90.8 45.0 ± 0.99 22.7 95.6  8.10E-02 8.25E-01  
PC aa C38:4 84.7 ± 1.43 56.4 150.2 84.1 ± 1.34 48.5 157.3  8.92E-01 6.27E-02  
PC aa C38:5 39.8 ± 0.74 24.1 68.7 41.4 ± 0.68 26.9 72.7  1.24E-01 4.72E-01  
PC aa C38:6 57.2 ± 1.35 33.3 126.4 55.4 ± 1.22 29.2 132.4  3.58E-01 3.11E-02  
PC aa C40:1 0.775 ± 0.02 0.350 1.85 0.683 ± 0.02 0.332 1.97  2.59E-05 1.16E-02  
PC aa C40:3 1.49 ± 0.04 0.793 3.28 1.30 ± 0.04 0.516 3.64  1.62E-06 2.69E-02  
PC aa C40:4 4.00 ± 0.06 2.70 6.63 3.74 ± 0.06 2.06 5.72  6.80E-04 4.57E-01  
PC aa C40:5 7.57 ± 0.17 3.71 14.9 7.79 ± 0.18 3.62 14.1  3.75E-01 5.34E-01  
PC aa C40:6 18.8 ± 0.45 9.80 42.6 19.6 ± 0.44 11.5 45.4  2.04E-01 3.95E-01  
PC aa C42:0 0.732 ± 0.01 0.39 1.40 0.682 ± 0.02 0.283 1.3  2.14E-03 8.97E-02  
PC aa C42:1 0.497 ± 0.01 0.268 0.972 0.435 ± 0.01 0.196 0.883  5.87E-07 1.91E-02  
PC aa C42:2 0.613 ± 0.02 0.271 1.20 0.522 ± 0.01 0.2 1.24  1.89E-08 1.21E-02  
PC aa C42:4 0.662 ± 0.01 0.318 1.21 0.586 ± 0.01 0.255 1.04  1.35E-06 1.39E-02  
PC aa C42:5 0.548 ± 0.01 0.330 1.11 0.500 ± 0.01 0.237 0.978  7.08E-05 1.39E-01  
PC aa C42:6 0.559 ± 0.01 0.275 1.02 0.542 ± 0.01 0.249 0.848  3.37E-01 4.86E-01  
PC ae C30:0 0.357 ± 0.01 0.200 0.750 0.342 ± 0.01 0.164 0.63  8.11E-02 1.51E-01  
PC ae C30:2 0.207 ± 0.01 0.077 0.613 0.169 ± 0.01 0.049 0.475  6.69E-08 1.52E-02  
PC ae C32:1 1.94 ± 0.03 1.25 3.70 1.79 ± 0.03 1.08 3.37  3.22E-04 4.15E-01  
PC ae C32:2 0.587 ± 0.01 0.307 1.08 0.528 ± 0.01 0.309 1.11  1.93E-06 2.27E-01  
   CR1     CR2       
 mean ± SEM min max mean ± SEM min max  group time  
PC ae C34:0 1.23 ± 0.03 0.727 2.62 1.21 ± 0.03 0.503 2.55  5.56E-01 8.92E-01  
PC ae C34:1 8.14 ± 0.14 3.87 14.10 8.10 ± 0.14 4.54 13.1  8.96E-01 3.83E-01  
PC ae C34:2 8.46 ± 0.14 4.40 14.60 8.28 ± 0.13 5.04 12.8  4.88E-01 8.67E-01  
PC ae C34:3 5.35 ± 0.08 3.34 8.92 5.11 ± 0.08 3.35 8.14  4.88E-02 7.78E-01  
PC ae C36:0 0.800 ± 0.02 0.18 1.60 0.746 ± 0.02 0.184 2.07  2.51E-02 1.92E-01  
PC ae C36:1 19.8 ± 0.31 11.8 31.3 18.1 ± 0.34 7.73 32.4  2.36E-06 1.58E-01  
PC ae C36:2 15.9 ± 0.28 9.54 26.0 15.7 ± 0.29 7.87 27.7  5.90E-01 8.04E-01  
PC ae C36:3 5.52 ± 0.10 2.94 10.6 5.53 ± 0.10 2.96 9.07  9.49E-01 8.96E-01  
PC ae C36:4 9.86 ± 0.16 6.00 18.3 8.85 ± 0.14 5.09 16.6  3.70E-07 8.73E-01  
PC ae C36:5 7.90 ± 0.15 4.46 15.3 6.87 ± 0.11 4.17 13.8  4.34E-10 8.46E-01  
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PC ae C38:0 2.51 ± 0.04 1.50 5.00 2.36 ± 0.04 1.39 4.47  2.95E-03 3.94E-01  
PC ae C38:2 4.27 ± 0.11 1.09 9.52 4.00 ± 0.12 1.09 11.2  8.37E-02 1.08E-03  
PC ae C38:3 14.8 ± 0.22 8.74 23.2 13.5 ± 0.24 5.63 24.3  2.50E-06 8.86E-02  
PC ae C38:4 11.8 ± 0.18 7.26 20.6 10.9 ± 0.17 6.25 20.8  4.80E-05 4.38E-01  
PC ae C38:5 12.6 ± 0.19 9.01 22.7 12.1 ± 0.19 7.87 23.0  1.08E-01 8.48E-01  
PC ae C38:6 4.25 ± 0.08 2.66 8.37 3.92 ± 0.07 2.13 8.42  4.39E-04 6.93E-01  
PC ae C40:1 1.91 ± 0.04 0.990 3.49 1.70 ± 0.03 0.956 3.55  5.56E-06 1.05E-01  
PC ae C40:2 3.33 ± 0.07 1.66 6.50 2.92 ± 0.08 1.43 6.67  5.05E-09 3.90E-02  
PC ae C40:3 6.41 ± 0.10 3.80 10.40 5.74 ± 0.11 1.96 11.1  2.74E-07 8.34E-02  
PC ae C40:4 4.86 ± 0.07 3.02 7.90 4.43 ± 0.08 1.88 8.58  2.36E-06 1.60E-01  
PC ae C40:5 7.55 ± 0.11 4.47 13.8 6.91 ± 0.10 3.01 11.9  8.84E-06 8.71E-01  
PC ae C40:6 4.07 ± 0.07 2.65 8.29 3.97 ± 0.07 2.34 8.41  3.94E-01 6.07E-01  
PC ae C42:1 0.958 ± 0.03 0.486 2.00 0.807 ± 0.02 0.379 1.97  3.88E-09 7.81E-03  
PC ae C42:2 1.04 ± 0.02 0.590 2.04 0.885 ± 0.02 0.377 2.04  3.88E-09 3.12E-02  
PC ae C42:3 1.42 ± 0.03 0.872 2.58 1.26 ± 0.03 0.484 2.62  2.74E-07 6.27E-02  
PC ae C42:4 1.46 ± 0.03 0.841 2.65 1.35 ± 0.03 0.499 2.54  3.32E-04 5.56E-01  
PC ae C42:5 3.10 ± 0.05 1.98 5.35 3.02 ± 0.05 1.33 5.52  3.37E-01 8.04E-01  
PC ae C44:3 0.326 ± 0.01 0.165 0.642 0.291 ± 0.01 0.102 0.818  3.44E-05 1.06E-03  
PC ae C44:4 0.503 ± 0.01 0.253 0.885 0.472 ± 0.01 0.168 0.928  1.19E-02 6.01E-01  
PC ae C44:5 1.69 ± 0.04 0.826 3.32 1.73 ± 0.05 0.582 4.0  5.21E-01 8.96E-01  
PC ae C44:6 1.20 ± 0.02 0.604 2.25 1.19 ± 0.02 0.589 2.5  9.36E-01 8.96E-01  
SM C16:0 148.3 ± 2.28 94.3 248.4 131.9 ± 2.19 66.7 223.9  3.28E-09 5.41E-01  
SM C16:1 19.4 ± 0.36 9.46 32.8 17.7 ± 0.34 9.69 28.3  2.36E-06 3.52E-01  
SM C18:0 28.8 ± 0.56 17.2 52.3 25.1 ± 0.51 11.9 40.6  3.86E-11 4.06E-01  
SM C18:1 11.8 ± 0.22 6.88 20.3 9.79 ± 0.20 5.02 18.0  1.59E-18 4.53E-01  
SM C20:2 0.552 ± 0.02 0.197 1.04 0.52 ± 0.02 0.080 1.27  1.51E-01 6.65E-01  
SM C24:0 35.4 ± 0.77 20.0 69.0 32.6 ± 0.75 16.0 62.5  2.18E-04 1.51E-01  
SM C24:1 152.3 ± 3.09 86.0 283.6 139.0 ± 3.08 64 260.9  7.25E-05 3.83E-01  
SM (OH) C14:1 6.94 ± 0.17 3.45 14.6 6.43 ± 0.16 2.98 12.1  3.50E-04 8.67E-01  
SM (OH) C16:1 4.29 ± 0.08 2.38 7.64 3.83 ± 0.08 1.72 6.8  1.66E-07 9.34E-01  
SM (OH) C22:1 32.0 ± 0.86 17.2 70.2 27.9 ± 0.76 11.8 66.6  2.88E-08 3.94E-01  
SM (OH) C22:2 37.4 ± 0.89 20.8 75.7 34.6 ± 0.83 15.4 65.4  2.30E-03 8.96E-01  
* Bold text = significant group or time differences (FDR < 0.05) between CR1 and CR2 
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5.3.4.1 Amino acids and biogenic amines 
Threonine, with a significantly lower mean concentration (FDR = 1.14E-03), and 
proline, with a significantly higher mean concentration (FDR = 4.02E-02) in CR2, 
shown in Figure 5.12, were the only amino acids with significant differences 
between the CRs. Notably, the biogenic amines did not show any significant 
differences between the CRs.  
Figure 5.12 Amino acids with significant differences between constant routines.  Mean 
±SEM relative concentration (z-score) plotted on the y axis against time (h) relative to 25% 
DLMO on the x axis of CR1 (black circles) and CR2 (red squares). 
 
5.3.4.2 Acylcarnitines 
All of the three AC with significant differences between the CRs, shown in Figure 
5.13; AC-C14:1 (FDR = 9.79E-06), AC-C16 (FDR = 2.38E-05), and AC-C18:1 (FDR =  
1.74E-04), were significantly lower in CR2.  
Figure 5.13 Acylcarnitines with significant differences between constant routines.Mean 
±SEM relative concentration (z-score) plotted on the y axis against time (h) relative to 25% 
DLMO on the x axis of CR1 (black circles) and CR2 (red squares). 
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5.3.4.3 Glycerophospholipids  
Of the 12 quantified lysoPC a, 6 were significantly different between the CRs. Four 
of these had significantly lower concentrations in CR2 (lysoPC a C24:0, C26:1, 
C28:0 and C28:1) and lysoPC a C17:0 and C20:3 had significantly higher 
concentrations in CR2.  Of the 33 quantified PC aa, 17 were significantly different 
between the CR, 14 of which had significantly lower concentrations in CR2. PC aa 
(C30:0, C32:0 and C34:4) had significantly higher concentrations in CR2. Of the 35 
quantified PC ae, 23 were significantly different between the CRs, all of which had 
lower mean concentrations in CR2. The 4 most significant lyso PC a, PC aa and PC 
ae are shown in Figure 5.14.  
Figure 5.14 Glycerophospholipids with significant differences between constant 
routines. Mean ±SEM relative concentration (z-score) plotted on the y axis against time 
(h) relative to 25% DLMO on the x axis of CR1 (black circles) and CR2 (red squares). 
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5.3.4.4 Sphingomyelins  
Of the 11 quantified SM, 10 had significantly different mean concentrations 
between the CR, all of which were lower in CR2.  The 4 most significant SMs (SM 
(C18:1, C18:0 and C16:0) and SM (OH) C22:1) are shown in Figure 5.15.  
 
Figure 5.15 Sphingomyelins with significant differences between constant routines. 
Mean ±SEM relative concentration (z-score) plotted on the y axis against time (h) relative 
to 25% DLMO on the x axis of CR1 (black circles) and CR2 (red squares). 
 
5.3.4.5 Ultradian variation of metabolites in CR1 and CR2 
Many of the metabolites displayed ultradian variation over the day. A heat map 
combined with hierarchical clustering (Euclidean distance and Ward linkage) of the 
61 metabolites with significant differences between CR1 and CR2 is shown in 
Figure 5.16. As well as showing metabolite concentrations were in general lower 
in CR2, differences across time between the two CRs can also be observed. The 
longer chain PC were higher in concentration toward the end of CR1 (after 10 h 
relative to 25% DLMO time-point 10), thus also showing metabolite 
concentrations were lower at the beginning of CR2 (before 10 h relative to 25% 
time-point 10).  
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Figure 5.16 Metabolites with significant differences between constant routines. 
Heat map combined with hierarchical clustering of the 61 metabolites showing 
significant changes between constant routines. (Euclidean distance and Ward linkage) 
Metabolites were measured across a 32 h period (16:00 - 22:00 h) in both the CRs. Colour 
values are based on the relative value compared to the average value of each metabolite 
of the 61 metabolites with significant differences between the CRs. Higher levels of 
metabolites are shown in red, lower levels are shown in blue.  
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5.4 Discussion  
The study in this chapter examined circulating metabolite circadian rhythms when 
a daily eating routine of three isocaloric meals, breakfast, lunch and dinner at 
approximately 07:30 h, 12:30 h and 17:30 h, are postponed by 5 h. During the two 
37-h CRs undertaken after each eating schedule, hourly isocaloric meals, matched 
to individual energy requirements, were given and blood samples were drawn 
every 2 h for metabolomic analysis. The results demonstrate that the 5-h meal 
shift phase delayed 20 of the 39 metabolites (51%) exhibiting significant circadian 
rhythms, by more than 2-h. In addition, most of the metabolite rhythms had a 
lower amplitude (n = 23, 59%). 
An extensive screening protocol which excluded participants with extremely 
early and late sleep and wake times (Section 2.2.2) and the strict pre-laboratory 
protocol (Section 2.2.3) adapted the participants to the sleep-wake and the early 
meal schedule (food and timing) before they entered the laboratory and 
minimised any acute effects of changing these potential confounders. All the 
meals given to the participants were designed to minimise any confounding effect 
of macronutrient composition or energy distribution and reflect the average 
macronutrient ratios of free-living individuals; namely 55% CHO, 30% fat and 15% 
protein. The three meals in the laboratory were isocaloric because the calorie 
distribution of daily meals has also been shown to affect body weight and markers 
of insulin resistance (Jakubowicz et al., 2013). OW/OB women with metabolic 
syndrome consumed 1,400 kcal a day, distributed as either as a 700 kcal, 500 kcal, 
and 200 kcal or 200 kcal, 500 kcal and 700 kcal breakfast, lunch and dinner for 12 
weeks. Not only did the higher calorie breakfast group lose more weight than the 
group that consumed majority of their calories at dinner, their fasting glucose, 
insulin, and HOMA-IR was lower, as well as lower glucose and insulin levels in 
response to an oral glucose tolerance test. Furthermore, in the group with the 
higher calorie breakfast, TAG levels were 33.6% lower, whereas in the higher 
calorie dinner they were 14.6% higher. Moreover, eating any food late in the day 
has detrimental effects on glucose response regardless of the glycaemic index  
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(Gibbs et al., 2014). Healthy volunteers were fed low (37) and high glycaemic index 
(73) meals, matched for energy, available carbohydrate, protein and fat, at 08:00 
h and 20:00 h and reported higher glycaemic responses in the evening. A high CHO 
(75%) meal can also phase shift core body temperature and heart rate in humans 
(Kräuchi et al., 2002). Moreover, a high fat diet (Kohsaka et al., 2007) and a 
negative energy balance has been shown to reset the liver clock in mice (Damiola 
et al., 2000). Much of the work examining peripheral clocks and food has come 
from animal studies measuring clock genes. As has been discussed in the literature 
review (Section 1.2.1) and in the previous chapter (Section 4.5.1) genetic 
manipulation of core clock genes has metabolic consequences. 
The time relative to melatonin onset (25% DLMO) was calculated for every 
individual for each CR to correct the metabolite data for different circadian phases. 
There was no significant difference in melatonin onset between CR1 and CR2 
(Section 5.3.2) which demonstrates there was no change in the individuals’ 
circadian phase over the study period. 
In the present study the oscillations of most of the metabolites within each 
class peaked at similar times of day (Figure 5.7), not always observed in other 
studies. A well-controlled metabolomic analysis of human plasma to assess 
circadian regulation using targeted lipidomics reported 13% of the lipids showed 
circadian variation in a CR protocol (Chua et al., 2013) (using a non-parametric 
algorithm). However, they reported only 20% intersubject agreement, with the 
peak time of some individuals 12-h apart for some of the lipids. Some of the 
variability could be due to the sampling time of 4-h which decreased the 
resolution. This variability, however, was not observed in the SCN driven rhythms; 
body temperature, cortisol and melatonin being similar between individuals. The 
authors reported that the variability was unlikely due to the food as all the 
participants were fed hourly in the laboratory and there was no difference in the 
breakfast, lunch and dinner that they ate the week before. Most of the 
metabolites examined were TAG (which tended to peak in the morning). A small 
number of PC peaked in the evening, similar to the present study, we observed 
peak times in the afternoon up to midnight in most of the glycerophospholipids.  
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5.4.1 Metabolite rhythms 
Over half (64%) of the quantified metabolites displayed a significant circadian 
rhythm in at least one CR, in agreement with other published work in mice 
(Minami et al., 2009) and in humans (Chua et al., 2013, Dallmann et al., 2012) 
check these are right. In each of these studies, not all the same metabolites were 
quantified but of the common metabolites, Dallmann et al. also reported a large 
proportion of the rhythmic metabolites to be fatty acids. In the present study, 
64/80 (80%) quantified lipids displayed a significant circadian rhythm in at least 
one of the CR. Dallmann et al. also reported circadian rhythms in acylcarnitines 
and only one amino acid; namely glutamate. In the present study, approximately 
50% of the acylcarnitines exhibited a significant circadian rhythm. A more notable 
difference in the present study were the clear rhythms observed in the amino 
acids, 11 of which (9% of the 127 quantified metabolites) displayed a significant 
circadian rhythm in both CR. The increased number of metabolites with significant 
circadian rhythmicity in the present study may be due in part to the number of 
time points used to fit the cosine curve in each of the constant routines. In 
addition, Dallmann et al. analysed 4-h pooled samples whereas in the present used 
a 2-h sampling schedule in 10 individuals. Davies et al. (2014), describing 
metabolite rhythms in an entrained sleep-wake protocol, also found that the 
majority of the lipids were rhythmic. Rhythmic lysoPC peaked in the early morning 
in mice, whereas in the present study the rhythmic lysoPC mainly peaked at night. 
These time differences may reflect the lipid substrate requirements in respect of 
the sleep-wake cycle in diurnal versus nocturnal species as the rhythmic amino 
acids common to the studies peaked at midnight in the mice (01:00 – 04:00 h) and 
mainly during the day in the present study (Kasukawa et al., 2012).  
Twenty-six metabolites had significant circadian rhythms in CR1 that were 
not present in CR2 and conversely 16 metabolites had significant circadian 
rhythms in CR2 not present in CR1. Of the metabolites that exhibited significant 
circadian rhythms in both CR (n = 39), metabolites in the same class tended to 
peak at the same time of day (Figure 5.3). Amino acids peaked in the early morning 
or during the day, with the exception of citrulline and tryptophan (and isoleucine 
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in CR1) which peaked during the night. The significantly elevated citrulline levels 
at night could in part be attributed to increased activity of the citrulline-nitric oxide 
cycle. Nitric oxide is associated with many biological processes including 
neurotransmission, memory, and blood pressure regulation (Ayers et al., 1996). 
The only two acylcarnitines with significant circadian rhythms in both CRs 
peaked in the afternoon. These findings suggest increased fatty acid β-oxidation 
at this time. The glycerophospholipids with significant cosinor rhythms in both 
CRs, generally peaked after the acylcarnitines; there was a trend for the longer the 
length of the lysoPC a, the earlier the peak time and the longer the carbon side-
chain of PC aa the later the peak time, whereas there was no trend in the PC ae 
peak times (Figure 5.3). Dallmann et al. also reported most of the lipid levels 
peaked around subjective “lunchtime” and were greatly reduced at other times of 
the day, even though food intake was constant (Dallmann et al., 2012).  
The cosinor analysis only compared the peak time and amplitude of a 
metabolite with a 24 h period that peaks only once, similar to melatonin and 
cortisol. However, the metabolite profiles in both CRs appear to have multiple 
(ultradian) peaks that may be related to the feeding schedule before the CR. Thus 
just comparing the peak time and amplitude of one peak may not truly reflect the 
shift in metabolite rhythms. Measuring the ultradian oscillations that occur more 
than once a day (Hughes et al., 2009), identified non-24 h rhythms in gene 
transcription in mouse liver of 8 and 12 h. Thus to characterise the metabolite 
rhythms and whether they have shifted in the present analysis, it may be more 
appropriate to compare the peak time and amplitude of the multiple peaks 
observed between the two CRs. This analysis may help to expose a ‘memory’ of 
the previous meal schedule and potential food anticipatory mechanism.  
5.4.2 Metabolite concentrations 
Of the 127 quantified metabolites, the concentration of just under half, 48%, 
changed significantly between CR1 and CR2; the majority had significantly lower 
levels in CR2. The most notable finding was that the glycerophospholipid (4/12 
lysoPC a (33%), 14/33 PC aa (42%), 23/35 PC ae (66%) and 10/11 SM (91%)) classes 
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drove this change. Lower phospholipid concentrations have been associated with 
insulin resistance in cohort studies (Section 1.5.8) and could possibly be the 
reason, although it is unclear from the literature whether this change would occur 
after just a few days of late eating. Just under half (43%) of the acylcarnitine class 
also had significantly lower levels in CR2 whilst most of the amino acids or biogenic 
amines were not significantly affected by the 5-h meal shift. The exceptions were 
threonine, an essential amino acid, and precursor of glycine, which significantly 
was significantly lower levels, and proline a non-essential precursor of glutamate, 
which had significantly higher concentrations in CR2 compared to CR1. As all 
participants received the same daily macronutrients and food-energy preceding 
both CRs, and the only difference was the timing of the 3-meal food schedule, then 
the significantly lower glycerophospholipid concentrations are most likely be due 
to the 5-h delay in meal timing. Before the first CR the last meal the participants 
ate was at approximately 17:30 h and the last meal they ate before CR2 was at 
approximately 22:30 h. The first small meal of the CR was served at approximately 
07:30 h, 14 h after the last meal of the feeding schedule before CR1 and 9 h after 
the last meal before CR2. This 5-h fasting time difference is unlikely to have 
contributed to these lower lipid concentrations since all the participants had been 
eating small meals every hour over the previous 7.5 h, therefore the participants 
were all in the absorptive state when the first blood sample was drawn at 
approximately 16:00 h. It may be that the effect eating meals 5 h later disrupted 
the metabolic pathways, as previously seen in hormones such as ghrelin, leptin 
insulin and GLP-1 (Gonnissen et al., 2012) and hepatic TAG accumulation 
(Adamovich et al., 2015). 
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6 Discussion  
It is clear from the results of the studies within this thesis that dynamic changes in 
circulating metabolite concentration occurs in blood throughout the day. 
Exploiting the uniqueness of the data, the studies within this thesis set out to 
elucidate the effect of disordered metabolism, using models of obesity, T2DM and 
shifting a 3-meal a day feeding schedule by 5 h on the hormone and metabolite 
profiles, in two separate studies using 2-hourly sampling and well controlled 
laboratory studies. The similar exclusion criteria and pre-study protocols in both 
studies meant that the participants also had similar sleep-wake schedules and 
meal times that were controlled before they entered the laboratory.  
In the first study, the participants had the opportunity to sleep between 
22:30 h and 06:30 h and in the second study the participants were awake 
throughout the sampling period in the CR protocol. Other differences between the 
two protocols were the feeding schedule and nutrient vehicle; namely milkshakes 
versus sandwiches. Moreover, the participants in the first study were older (mean 
± SD, 53.6 ± 6 years) than the participants in the second study (mean ± SD, 22.9 ± 
4 years).  If only the lean group of the diabetes study was to be considered, the 
BMI of the participants was similar in both studies, in the first study the BMI (mean 
± SD) was 23.2 ± 1.4 kg/m2 and in the second study it was 23.1 ± 2.5 kg/m2.  
6.1 Glucose, TAG and hormones 
Glucose, TAG and a set of GI hormones were measured in the diabetes study. The 
results of the diabetes study demonstrate that despite the small number of 
participants in each study group and the hetero-medicated T2DM group, 
significant differences in hormone and metabolite concentration between the 
lean and OW/OB and the OW/OB and T2DM were observed. In general, being 
OW/OB or having T2DM was associated with higher glucose, TAG and metabolic 
hormone concentrations (Section 3.6). The most notable observation in the 
diabetes study was the clear diurnal rhythms and similar peak times, in the 
afternoon, of glucose (Section 3.6.1), TAG (Section 3.6.2) and the hormones 
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involved in glucose homeostasis (Section 3.6.3.1), namely C-peptide, insulin and 
GIP.  
The average 24-h mean metabolite concentrations were affected more than 
the rhythmicity as a result of being OW/OB or having T2DM. The higher TAG levels 
observed may have been due to the action of insulin that activates lipoprotein 
lipase (LPL), a key regulatory enzyme governing circulating TAG uptake into cells 
(Morgan et al., 2003). LPL activity has been demonstrated to exhibit diurnal 
variation. 
6.2 Metabolite profiles 
The same LC/MS targeted metabolomics assay was used to analyse circulating 
plasma metabolites in both studies. Thus comparing the results from the two 
different protocols, with different sleep-wake schedules, foods and ages provides 
an opportunity firstly to identify the metabolites that exhibit significant cosine 
rhythms irrespective of the sleep-wake / light-dark cycle, age, glucose tolerance 
or meal timing. Indeed some metabolites displayed significant cosinor rhythms in 
all study groups of both studies. Secondly, examining the metabolites that 
exhibited significant cosine rhythms in both CRs of the meal shift study and the 
lean group only of the diabetes study may, help to identify whether the 
metabolites are influenced by age or glucose tolerance. Thirdly, identifying the 
metabolites that exhibit significant cosine rhythms in the lean study group of the 
diabetes study and in the first CR (CR1) of the meal shift study identifies the 
metabolites that were affected by the sleep-wake / light-dark cycle, feeding and / 
or age from metabolites that are circadian driven. 
Comparing the results of the diabetes study in chapter 4 and the meal shift 
study in chapter 5, 123 metabolites were quantified in both studies, 32 (26%) of 
which did not exhibit significant cosinor rhythms in either study. These monotonic 
metabolites were glutamate, histidine, lysine, methionine, ADMA, t4-OH-Pro, AC-
C18:2 and 25 phospholipids. Glutamate is a notable metabolite do not exhibit a 
cosine rhythm in any condition, possibly because of its role as the amino acid 
substrate that other amino acids are converted to before entry into the urea cycle 
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(Section 1.5.1.1). However, other mechanisms may also impact on glutamate 
levels, as urea cycle activity decreases in the rest period (Fujisawa et al., 2016) so 
lower plasma levels may have been expected during sleep. 
Six metabolites exhibited significant cosinor rhythms regardless of sleep, 
meal timing, age, BMI or insulin sensitivity, as all study groups (lean, OW/OB and 
T2DM) of the diabetes study and both CRs of the meal shift study exhibited 
significant cosine rhythms. These comprised, citrulline, proline, AC-C2 and lysoPC 
a (C18:2, C20:3 and C20:4) and notably all these metabolites peaked in the late 
evening, early morning.  A recent study examining the diurnal rhythms in the 
hepatic tissue of medaka (similar to a zebra fish) under 12:12 L:D conditions with 
a light period from 08:00 – 20:00 h reported that citrulline rhythms, peaked close 
to midnight (Fujisawa et al., 2016). Under diurnal conditions in the diabetes study 
citrulline also had a peak time of midnight in all the study groups and in CR1 of the 
meal shift study that occurred and 1.5 - 2 h later in CR2 in the meal shift study. 
Furthermore, the Cit:Orn ratio, indicative of ornithine carbamoylphosphate 
transferase activity, was lower during the day and higher at night in the medaka 
and the diabetes studies, indicating reduced night time urea cycle activity. This 
was also evident in the meal shift study, with the Cit:Orn ratio peaking 2-h later in 
CR2 than in CR1 (Table 5.4). The Orn:Arg ratio, indicative of arginase activity, also 
associated with urea cycle activity peaked in the morning. As the urea cycle 
removes potentially harmful excess amino acids from the circulation it is expected 
that the urea cycle activity is lower when most of the circulating amino acids are 
lower and during the night when metabolism reduces. The 2-h delay in the 
citrulline peak in CR2 may suggest a phase shift in the mechanism involved in the 
urea cycle. Further evidence of reduced night-time metabolic activity is 
demonstrated in lower night-time levels of most of the amino acids in the medaka 
study; also observed in the diabetes study (Figure 4.6) and the meal shift study 
(Figure 5.3). The mechanisms behind the retained proline rhythms are difficult to 
pinpoint due to the complex interactions between the amino acids. Amino acids 
can be synthesised de novo from other amino acids depending on the cellular 
requirements (Wu, 2009). It could be due to proline’s importance as one of the 
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functional amino acids (which also include arginine, cysteine, glutamine, leucine 
and tryptophan), in particular immune functions (Wu, 2009) or the role of proline 
in collagen synthesis (Ferrier, 2014) which predominantly occurs at night 
(Hassager et al., 1992). 
Higher acylcarnitine levels at night / inactive phase have been attributed to 
hepatic PPARα mRNA expression, which also peaks at night (Oishi et al., 2005). 
PPARα regulates a range of target genes involved in cellular lipid catabolism and 
storage and facilitates β oxidation, although in the present studies AC-C2 peaked 
in the afternoon. AC-C2 also exhibited a significant cosinor rhythm in the first 24 h 
peaking at the same time of day as the present studies, but not after a night of 
sleep deprivation (Davies et al., 2014) which indicates some relationship with 
sleep status. The peak time of the LysoPC rhythms, also occurred at night in the 
present studies. Similar findings have been observed in mouse plasma that 
showed oscillations that were almost antiphasic to those in humans, suggesting 
these circulating levels reflect the metabolic requirements of diurnal humans and 
nocturnal animals (Minami et al., 2009). Phospholipid levels are also influenced by 
the oscillations in Per1 expression (Marquez et al., 2004). In CLOCK mutant 
fibroblasts PER1 and phospholipid labelling were monotonic; demonstrating that 
phospholipid biosynthesis oscillates by an endogenous clock mechanism (Marquez 
et al., 2004).  
The amino acids (n = 5) with significant cosinor rhythms in both CRs of the 
meal shift study but only in the lean and OW/OB groups of the diabetes study 
comprised alanine, glycine, isoleucine, tyrosine and valine. Thus it could be said 
that these cosinor rhythms have been dampened in the T2DM group. With the 
exception of glycine, which has significantly lower levels in both OW/OB and T2DM 
compared to their control groups; the other 4 amino acids had significantly higher 
levels compared to their control groups in the diabetes study. The meal shift study 
did not significantly affect the concentrations of any of these amino acids, 
suggesting the higher concentrations throughout the day may be a result of insulin 
resistance.  
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Of the 91 phospholipids measured, only the PC aa species (n = 3) retained 
their cosinor rhythm in the meal shift study and in the lean group of the diabetes 
study. The OW/OB study group had significantly lower concentrations than the 
lean group whereas the T2DM group had significantly higher concentrations 
compared to the OW/OB group. Only PC aa 34:4 had significantly higher 
concentrations in CR2 than in CR1 of the meal shift study. Lower circulating 
phospholipids have been associated with insulin resistance in several cohort 
studies (Section 1.5.8) which in the present studies seems to be influenced by 
increased weight but not by a shift in meal time.  
Many more metabolites (n = 16) exhibited significant cosine rhythms in both 
CRs of the meal shift study that were not evident in any study group of the 
diabetes study, suggesting the entrained sleep-wake feeding-fasting protocol of 
the diabetes study actually masked or dampened the cosine rhythm of these 
metabolites. These metabolites comprised serine and tryptophan, 12 
phospholipids and 2 sphingomyelins and are thus likely circadian controlled 
metabolites. In the meal shift study tryptophan peaked at 2.00 h. Tryptophan has 
been shown to exhibit circadian rhythms in mice (Minami et al., 2009) and humans 
(Kasukawa et al., 2012) peaking at opposite times of day, the equivalent of  ≈1.00 
h  in humans, reflecting the similarity in phase of the central clock in nocturnal and 
diurnal animals. Further investigation of these possible clock controlled 
mechanisms are warranted.  
There were 7 metabolites that had a significant circadian rhythm in the meal 
shift study in CR1 but not in CR2 that also displayed a significant diurnal rhythm in 
all study groups in the diabetes study. These comprised AC-(C16:0 and C18:1), 
lysoPC a C18:1, PC aa C36:0, PC ae (C34:1 and C36:2) and SM C20:2. These 
metabolite rhythms could have been influenced by the 5-h meal shift or the sleep-
wake schedule, age or food vehicle. From these data it is not possible to distinguish 
between these factors.    
There were more metabolites with significant differences in mean 
concentration between the study groups than metabolites that displayed 
significant daily rhythms, showing that being OW/OB or T2DM had more of an 
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effect than time of day on metabolite concentrations in the diabetes study. All the 
metabolites exhibiting cosine rhythms peaked at the same time of day irrespective 
of being lean, OW/OB or T2DM. By contrast, in the meal shift study, most of the 
metabolites with significant cosine rhythms peaked more than 2-h later in CR2 
compared to CR1.  
As can be seen in both studies, the metabolites also appear to display 
ultradian rhythms. Figures 4.11 and 5.7 illustrate some sort of “memory” of the 
previous feeding schedule even when small isocaloric meals are being consumed 
during the CR. More work needs to be done in humans examining these potential 
food anticipatory mechanisms and the role of the liver clock, as unlike in animal 
experiments, liver tissue biopsies are not possible in human volunteers.  
6.2.1 Potential mechanisms 
Combining metabolomic data with data from other omics analysis platforms such 
as transcriptomics and proteomics may also shed light on any mechanisms that 
result in the delayed rhythms observed in CR2 of the meal shift study. In a review 
of the circadian control of lipids Adamovich et al. (2015) noted that high 
amplitudes at the transcript level were more pronounced than the metabolite 
oscillations in plasma, which were in turn more pronounced than the amplitude of 
metabolites oscillations in the liver. The differences in amplitude may reflect the 
multiple regulatory pathways leading to circulating levels. Indeed, the same 
samples measured in the meal shift study have also been used to measure plasma 
melatonin, from which it was established that there was no change in the SCN 
circadian phase (measured by melatonin) of the participants between the two CRs. 
From unpublished data using the same samples, cortisol, insulin, glucose, NEFA, 
TAG and gene expression (in whole blood to examine the metabolite rhythms 
related to the positive arm of the clock (BMAL1), the negative arm of the clock 
(PER3) or the auxiliary loop (REVERB-β)) were measured, as well as gene 
expression in white adipose tissue (PER2 and PER3). The results of this analysis 
showed the plasma glucose had a 5-h phase delay in CR2, whereas neither BMAL1 
nor PER3 in whole blood had significant differences in the cosine rhythms between 
CR1 and CR2 (Christou et al., unpublished). In adipose tissue, however, PER2 and 
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PER3 cosine rhythms exhibited phase delays of just less than 1 h. Where a phase 
shift was observed in the metabolites in the meal shift study there was on average 
a 2-h delay (Section 5.3.1.5). These different times of phase shift are reflective of 
phase shifting observed in other studies (Section 1.2.1). If the circulating 
metabolites are related to a shift in the liver clock, they may shift quicker than 
those in adipose tissue, explaining the 1-h delay in adipose tissue and the 2-h delay 
in plasma. A series of studies in mice have demonstrated that Per2 modulates Cpt1 
a (Section 1.5.3.1) to facilitate β oxidation to produce the necessary β-OHB 
(Chavan et al., 2016). However, Per2 expression in the liver alone is not sufficient 
to stimulate Cpt1 a expression. 
The entrainment to food timing may arise as a response to fasting. Liver-
derived ketone bodies have recently been reported to play an important signalling 
role in the food entrainable oscillator (Chaix and Panda, 2016), specifically β-
hydroxybutyrate (β-OHB). β-OHB is the first ketone synthesised from fatty acid 
oxidation in the liver in response to fasting. It can pass the blood-brain barrier and 
is used as a vital energy source for the brain. An important feature of these 
experiments in animals is the low nutrient levels from fasting that stimulates β-
OHB, which in turn seems to induce Per2 expression. How would this phenomenon 
relate to the meal shift study? In respect to the 3-meal schedule when they 
became accustomed to eating the meals at specific times, the breakfast would be 
in the fasting state as the participants had not eaten since the previous evening. 
The lunch and dinner were 5-h after the previous meal, and as the absorptive state 
lasts between 2-4 h (Ferrier, 2014) it was more than likely that the participants 
were in the fasted state before these two meals also. Thus it may be that β-OHB 
was acting as a signalling metabolite in humans, further investigation into this 
mechanism may be warranted.  
The significant daily rhythms and the possible food anticipatory ultradian 
rhythms observed in the studies in this thesis demonstrate that, not only does 
time of day matter, but also that what we eat and when on previous days has 
implications on our current metabolism. It also confirms that to create more 
robust laboratory studies to unmask any potential time of day confounders, not 
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only should food be controlled during the study but also before the study starts. 
Furthermore, if only a single time point sample can be taken, rather than 
comparing morning fasting samples when metabolism has not been challenged, 
using an ‘optimal’ time of day, when the metabolome is at its most varied would 
serve as more appropriate sampling times (Krug et al., 2012).  
The studies within this thesis tested the hypothesis that being OW/OB 
and/or with T2DM or a 5-h shift in meal timing would affect the 24-h cosine 
rhythms and concentration of a selection of circulating hormones and 
metabolites. Evidence from the studies within this thesis point to food and meal 
timing being the main driver in the fluctuations of circulating of hormone and 
metabolite levels, demonstrated in the meal shift study where more significant 
differences were observed in the rhythmicity of the metabolites between the CRs 
than the concentration. Furthermore, being OW/OB and/or with T2DM influenced 
the concentration of the hormones rather than the rhythmicity as more significant 
differences were observed between the concentration than the cosine rhythms. 
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6.3 Limitations and further work 
There are some limitations common to both the interventions in this thesis as the 
study conditions and the pre-laboratory protocols are similar and standard 
practice in chronobiology studies. In highly controlled laboratory studies, activity 
needs to be controlled as inter-individual variation in the participant activity levels 
or differences in activity throughout the study may influence the outcome 
measures. Therefore the most consistent way to control activity is to restrict it so 
that all the participants are tested under the same conditions. However, remaining 
semi-recumbent for the duration of the study could have caused some analytes to 
accumulate. Imposed inactivity has been shown to reduce lipoprotein lipase 
activity, reducing TAG uptake (Wilmot et al., 2012). Furthermore light or moderate 
activity lowers postprandial glucose and insulin levels in OW/OB adults (Dunstan 
et al., 2012).  
The small meals administered in the diabetes study were made up of 
fortified milkshakes similar to those given in hospitals and may be metabolised 
differently than solid food. The milkshakes meet the nutritional needs of the 
participants whilst minimising a meal effect and have been used to easy deliver 
small isocaloric meals in many circadian biology studies in the past. However, free-
living individuals eat solid food. Studies comparing the effect of liquid versus solid 
foods have shown that there are differences in perceived sweetness, creaminess 
and fat content between the two food vehicles (Drewnowski et al., 1989). The act 
of chewing solid food also provides an internal satiety signal not triggered by 
swallowing the liquid or pureed versions. Early pancreatic exocrine and endocrine 
responses to oral viscous or solid stimuli being greater than those to liquids also 
suggest a different metabolic responses to these different food vehicles (DiMeglio 
and Mattes, 2000) which could impact on the outcomes of the study. Using the 
small meal approach and feeding participants hourly but with solid food rather 
than the milkshakes, a method included in the protocol of the meal shift in Chapter 
5, is then closer to the type of food eaten by free-living individuals.   
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The higher number of metabolites with significant differences between the 
lean and OW/OB group than between the OW/OB group and the T2DM groups in 
the diabetes study could have been due to increased size of the lean and OW/OB 
groups compared to the T2DM group. Conversely, fewer significantly different 
metabolites between the OW/OB group and the T2DM group may have been 
because it was smaller (n = 6) or that it was mixed in regard to the medication 
(Section 3.3.2). Reports in the literature point to metformin affecting amino acid 
concentrations (Section1.5.7) and statins in particular affecting lipid levels. The 
power calculation for this study, discussed in Section 2.1.2 shows that n=9 
participants were required per study group. Therefore the group size and 
medication of the T2DM group were major limitations. 
In the meal shift study, all the participants took part in the early meals 
session before the meal-shift session which may have created an order effect. The 
participants were only in the laboratory for 3 days (on the early meal schedule) 
before the first CR. Although the participants were prescribed a 10-day at-home 
protocol which controlled the sleep-wake schedule and meal timing, with the last 
three days highly controlled, as they ate the food supplied to them, they may not 
have been 100% compliant. Whereas when they were in the laboratory before the 
second CR they were more strictly monitored. The precise feeding and sleep 
schedule and just being less active in the laboratory could have influenced the 
results. The 29 metabolites that best fit the linear model (significant monotonic 
increase or decrease) or combined model (Section 5.3.1.1) over the 32-h sampling 
period may be evidence that these metabolites were influenced by the protocol 
as there was an accumulation or decrease in the concentration. 
It is common to prescribe a 3-meal controlled eating schedule for 
participants before a study. However, the ultradian rhythms seen in the 
metabolites in both studies may point to a ‘memory’ of the eating pattern the day 
before the testing period. Therefore, future studies could control this pre-study 
period by more accurately reflecting the meal pattern of the testing period. For 
example, if small meals were being given every hour then these same hourly meals 
ought to be given to the participants before they enter the laboratory.  
195 
 
A future study could determine how both meal timing and size or the 
macronutrient content of meal affects the human circadian system.  In the meal 
shift study, the deliberate equal distribution of macronutrients and energy 
between the three meals was designed to expose any effect of time only. 
Manipulating the macronutrient content of the meals, for example designing a 
diet with high CHO or fat may produce a greater metabolic response. Evidence 
suggests that high fat meals phase shift peripheral clocks in mice (Kohsaka et al., 
2007), lower circulating lysoPC (Barber et al., 2012) and raise alpha-AAA levels 
(Wang et al., 2013) but there are no metabolomic data examining the impact of 
high fat feeding over 24-h in humans. Studies in humans have examined the 
impact of a high calorie breakfast or dinner on body weight and glucose 
metabolism, but no studies that have investigated the impact of a proportionally 
larger breakfast, lunch or dinner on circulating metabolites. Using the results from 
the meal shift study and comparing with data from studies that have manipulated 
the energy or macronutrient distribution of meals could then establish which diet 
manipulation affects the concentration or rhythmicity of circulating metabolites.  
Much of the work examining entrainment of peripheral clocks has come 
from animal studies using organ tissues such as the liver. As we cannot biopsy the 
liver or pancreas in humans, we need more robust non-invasive markers such as 
the liver-derived ketone bodies in particular β-OHB  which have recently been 
reported to play an important signalling role in the food entrainable oscillator 
(Chaix and Panda, 2016).  
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Table a intraplate % cv of qc 2 of the four plates and the mean % cv of all plates  
Plate   1    2    3    4    Mean  
Metabolite Mean ± Sem % cv Mean ± Sem % cv Mean ± Sem % cv Mean ± Sem % cv Mean ± Sem % cv 
Ala 712.08 ± 13.6 3.8 732.78 ± 9.2 2.5 697.45 ± 16.0 4.6 679.83 ± 7.6 2.2 679.83 ± 15.3 1.1 
Arg 207.85 ± 3.9 3.7 202.78 ± 2.7 2.6 189.78 ± 3.7 3.9 201.48 ± 8.9 8.9 201.48 ± 17.9 4.4 
Asn 143.65 ± 3.6 5.0 150.95 ± 2.3 3.1 137.50 ± 3.6 5.2 193.35 ± 57.4 59.4 193.35 ± 114.9 29.7 
Cit 143.20 ± 2.8 4.0 158.18 ± 2.9 3.7 144.90 ± 6.5 8.9 152.38 ± 3.2 4.2 152.38 ± 6.3 2.1 
Gln 765.68 ± 19.9 5.2 731.33 ± 18.6 5.1 674.18 ± 17.6 5.2 694.43 ± 10.8 3.1 694.43 ± 21.6 1.6 
Glu 353.70 ± 9.9 5.6 350.23 ± 8.2 4.7 330.10 ± 8.3 5.0 406.25 ± 12.9 6.3 406.25 ± 25.7 3.2 
Gly 855.88 ± 19.5 4.5 810.60 ± 9.3 2.3 766.75 ± 17.5 4.6 917.03 ± 68.5 14.9 917.03 ± 137.0 7.5 
His 176.58 ± 8.1 9.2 180.25 ± 2.9 3.2 162.58 ± 2.9 3.5 158.38 ± 3.4 4.3 158.38 ± 6.8 2.1 
Ile 180.55 ± 7.2 8.0 177.75 ± 2.3 2.6 166.93 ± 4.4 5.2 166.28 ± 1.9 2.3 166.28 ± 3.8 1.2 
Leu 184.08 ± 7.6 8.2 191.65 ± 3.3 3.4 176.00 ± 5.3 6.1 188.25 ± 3.3 3.5 188.25 ± 6.5 1.7 
Lys 461.23 ± 16.0 6.9 429.15 ± 13.0 6.1 418.43 ± 10.8 5.1 395.58 ± 15.2 7.7 395.58 ± 30.5 3.9 
Met 161.58 ± 7.1 8.8 156.40 ± 5.5 7.0 148.78 ± 4.0 5.3 152.83 ± 2.5 3.3 152.83 ± 5.0 1.6 
Orn 177.28 ± 7.3 8.3 172.65 ± 6.0 7.0 151.53 ± 3.7 4.8 160.53 ± 4.4 5.5 160.53 ± 8.9 2.8 
Phe 169.03 ± 13.8 16.4 158.58 ± 2.2 2.8 158.68 ± 7.9 9.9 154.85 ± 5.0 6.4 154.85 ± 9.9 3.2 
Pro 415.13 ± 23.6 11.4 345.70 ± 3.4 2.0 442.50 ± 12.7 5.7 352.30 ± 4.6 2.6 352.30 ± 9.2 1.3 
Ser 184.13 ± 7.6 8.3 176.08 ± 1.9 2.2 168.10 ± 5.1 6.1 171.65 ± 3.1 3.6 171.65 ± 6.2 1.8 
Thr 186.98 ± 5.0 5.3 190.63 ± 2.0 2.1 176.10 ± 4.3 4.8 175.20 ± 1.4 1.6 175.20 ± 2.8 0.8 
Trp 171.48 ± 9.2 10.7 171.53 ± 2.7 3.1 173.70 ± 6.2 7.2 164.60 ± 3.8 4.7 164.60 ± 7.7 2.3 
Tyr 188.73 ± 5.9 6.2 180.83 ± 4.2 4.6 174.65 ± 3.7 4.2 182.30 ± 2.9 3.2 182.30 ± 5.8 1.6 
Val 250.00 ± 17.1 13.7 263.55 ± 1.2 0.9 251.10 ± 5.9 4.7 272.20 ± 9.9 7.2 272.20 ± 19.7 3.6 
Adma 6.08 ± 0.4 14.8 6.40 ± 0.6 19.5 7.98 ± 0.0 1.2 5.55 ± 0.4 12.9 5.55 ± 0.7 6.4 
Alpha-aaa 22.20 ± 1.4 12.8 18.98 ± 0.6 5.9 20.10 ± 0.6 5.7 20.00 ± 0.3 2.6 20.00 ± 0.5 1.3 
Creatinine 344.45 ± 47.5 27.6 345.85 ± 4.5 2.6 247.53 ± 22.5 18.2 354.53 ± 20.9 11.8 354.53 ± 41.8 5.9 
Kynurenine 30.78 ± 0.7 4.4 29.53 ± 0.3 1.8 28.03 ± 0.7 4.7 28.35 ± 0.6 4.2 28.35 ± 1.2 2.1 
Sarcosine 27.05 ± 1.1 7.9 28.15 ± 0.5 3.4 26.30 ± 0.8 5.7 26.88 ± 0.3 2.1 26.88 ± 0.6 1.0 
Sdma 2.85 ± 0.1 8.4 2.83 ± 0.1 7.8 2.60 ± 0.0 0.0 2.95 ± 0.2 14.8 2.95 ± 0.4 7.4 
Serotonin 2.85 ± 0.1 6.7 3.00 ± 0.1 4.7 2.83 ± 0.0 3.4 2.78 ± 0.0 1.8 2.78 ± 0.0 0.9 
T4-oh-pro 11.63 ± 1.6 28.1 11.03 ± 1.0 17.5 11.13 ± 0.4 6.4 9.10 ± 1.0 22.5 9.10 ± 2.1 11.3 
Taurine 108.85 ± 6.2 11.3 87.53 ± 1.7 3.8 97.30 ± 3.6 7.5 117.83 ± 6.6 11.3 117.83 ± 13.3 5.6 
Ac-c0 60.98 ± 3.5 11.5 65.36 ± 1.2 3.6 64.41 ± 1.8 5.7 60.35 ± 2.9 9.5 62.78 ± 2.5 2.0 
Ac-c2 13.74 ± 0.6 8.3 14.81 ± 0.5 6.5 14.36 ± 0.5 7.2 13.59 ± 0.4 5.3 13.59 ± 0.7 2.6 
Ac-c3 4.04 ± 0.1 6.1 3.76 ± 0.1 6.8 3.70 ± 0.2 10.9 3.08 ± 0.4 23.3 3.08 ± 0.7 11.7 
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Plate   1    2    3    4    Mean  
Metabolite Mean ± Sem % cv Mean ± Sem % cv Mean ± Sem % cv Mean ± Sem % cv Mean ± Sem % cv 
Ac-c4 4.30 ± 0.1 6.2 4.46 ± 0.1 3.0 5.13 ± 0.4 16.7 4.03 ± 0.4 18.8 4.03 ± 0.8 9.4 
Ac-c5 4.54 ± 0.2 10.2 4.95 ± 0.1 2.6 5.63 ± 0.6 21.7 4.33 ± 0.3 12.2 4.33 ± 0.5 6.1 
Ac-c14:1 0.04 ± 0.0 13.7 0.05 ± 0.0 8.7 0.05 ± 0.0 7.0 0.07 ± 0.0 27.5 0.07 ± 0.0 13.7 
Ac-c16 4.30 ± 0.2 10.5 4.33 ± 0.1 2.5 4.32 ± 0.1 2.5 4.47 ± 0.3 11.4 4.47 ± 0.5 5.7 
Ac-c18 2.06 ± 0.1 7.0 2.04 ± 0.0 3.5 2.07 ± 0.1 9.2 1.94 ± 0.1 13.1 1.94 ± 0.3 6.5 
Ac-c18:1 0.06 ± 0.0 11.4 0.06 ± 0.0 11.3 0.07 ± 0.0 8.5 0.07 ± 0.0 10.6 0.07 ± 0.0 5.3 
Ac-c18:2 0.02 ± 0.0 9.9 0.02 ± 0.0 8.2 0.02 ± 0.0 7.1 0.02 ± 0.0 20.4 0.02 ± 0.0 10.2 
Lysopc a c16:0 97.05 ± 5.5 11.4 109.76 ± 3.2 5.8 99.30 ± 4.9 9.8 94.83 ± 2.3 4.8 94.83 ± 4.6 2.4 
Lysopc a c16:1 2.14 ± 0.1 13.9 2.40 ± 0.0 3.7 2.37 ± 0.1 8.5 2.08 ± 0.1 11.6 2.08 ± 0.2 5.8 
Lysopc a c17:0 1.56 ± 0.1 12.1 1.70 ± 0.1 6.6 1.51 ± 0.1 9.5 1.38 ± 0.1 9.7 1.38 ± 0.1 4.9 
Lysopc a c18:0 60.07 ± 3.8 12.5 61.39 ± 2.2 7.2 47.35 ± 2.1 8.8 51.07 ± 2.2 8.5 51.07 ± 4.3 4.2 
Lysopc a c18:1 13.26 ± 0.8 11.8 14.22 ± 0.3 4.7 12.57 ± 0.4 5.8 12.21 ± 0.5 9.0 12.21 ± 1.1 4.5 
Lysopc a c18:2 15.56 ± 0.9 11.4 17.46 ± 0.4 4.3 16.30 ± 0.7 8.0 15.06 ± 0.6 7.9 15.06 ± 1.2 4.0 
Lysopc a c20:3 1.13 ± 0.1 11.6 1.25 ± 0.0 3.9 1.09 ± 0.0 8.4 1.05 ± 0.0 7.8 1.05 ± 0.1 3.9 
Lysopc a c20:4 4.92 ± 0.3 12.6 5.45 ± 0.1 4.4 4.79 ± 0.2 8.3 4.59 ± 0.2 6.9 4.59 ± 0.3 3.5 
Lysopc a c24:0 0.16 ± 0.0 10.3 0.15 ± 0.0 9.2 0.12 ± 0.0 11.3 0.13 ± 0.0 20.0 0.13 ± 0.0 10.0 
Lysopc a c26:0 0.17 ± 0.0 27.3 0.16 ± 0.0 9.7 0.13 ± 0.0 31.3 0.12 ± 0.0 25.8 0.12 ± 0.0 12.9 
Lysopc a c26:1 0.08 ± 0.0 37.9 0.07 ± 0.0 16.7 0.03 ± 0.0 17.9 0.05 ± 0.0 39.7 0.05 ± 0.0 19.8 
Lysopc a c28:0 0.14 ± 0.0 11.4 0.12 ± 0.0 7.6 0.11 ± 0.0 9.6 0.10 ± 0.0 10.3 0.10 ± 0.0 5.1 
Lysopc a c28:1 0.23 ± 0.0 1.7 0.19 ± 0.0 15.5 0.13 ± 0.0 6.2 0.14 ± 0.0 27.8 0.14 ± 0.0 13.9 
Pc aa c28:1 1.61 ± 0.1 10.6 1.09 ± 0.0 6.5 0.93 ± 0.0 5.4 1.06 ± 0.0 6.4 1.06 ± 0.1 3.2 
Pc aa c32:0 8.67 ± 0.4 9.8 7.70 ± 0.2 4.1 7.73 ± 0.3 7.4 8.25 ± 0.2 4.9 8.25 ± 0.4 2.4 
Pc aa c32:1 5.66 ± 0.2 8.6 3.94 ± 0.1 7.1 3.59 ± 0.3 15.5 4.21 ± 0.1 2.6 4.21 ± 0.1 1.3 
Pc aa c32:3 0.40 ± 0.0 7.5 0.33 ± 0.0 3.0 0.32 ± 0.0 11.3 0.33 ± 0.0 2.7 0.33 ± 0.0 1.3 
Pc aa c34:1 139.60 ± 7.0 10.0 140.42 ± 1.2 1.7 144.29 ± 3.4 4.7 143.75 ± 5.1 7.1 143.75 ± 10.2 3.5 
Pc aa c34:2 220.05 ± 16.4 14.9 209.00 ± 4.7 4.5 227.38 ± 9.0 7.9 242.43 ± 5.2 4.3 242.43 ± 10.4 2.1 
Pc aa c34:3 8.88 ± 0.4 9.0 8.87 ± 0.0 0.7 8.96 ± 0.3 6.0 9.21 ± 0.2 4.3 9.21 ± 0.4 2.2 
Pc aa c34:4 1.11 ± 0.1 11.6 1.04 ± 0.0 2.4 1.00 ± 0.0 6.2 1.05 ± 0.0 7.6 1.05 ± 0.1 3.8 
Pc aa c36:0 3.92 ± 0.2 12.2 3.71 ± 0.1 4.8 4.26 ± 0.1 4.6 4.20 ± 0.2 9.7 4.20 ± 0.4 4.8 
Pc aa c36:1 34.61 ± 2.5 14.6 33.63 ± 0.6 3.7 37.06 ± 1.2 6.6 37.55 ± 1.4 7.7 37.55 ± 2.9 3.9 
Pc aa c36:2 152.10 ± 9.0 11.8 128.31 ± 3.5 5.4 117.92 ± 2.8 4.8 135.23 ± 4.8 7.0 135.23 ± 9.5 3.5 
Pc aa c36:3 79.33 ± 4.2 10.7 78.60 ± 1.0 2.7 80.65 ± 2.2 5.5 82.75 ± 2.3 5.5 82.75 ± 4.6 2.8 
Pc aa c36:4 140.65 ± 7.3 10.3 127.51 ± 2.0 3.1 119.65 ± 2.9 4.9 131.35 ± 4.3 6.5 131.35 ± 8.5 3.2 
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Plate   1    2    3    4    Mean  
Metabolite Mean ± Sem % cv Mean ± Sem % cv Mean ± Sem % cv Mean ± Sem % cv Mean ± Sem % cv 
Pc aa c36:5 14.91 ± 0.8 11.0 15.15 ± 0.2 2.4 15.55 ± 0.4 4.8 15.74 ± 0.5 6.2 15.74 ± 1.0 3.1 
Pc aa c36:6 0.52 ± 0.0 13.0 0.48 ± 0.0 2.0 0.43 ± 0.0 6.6 0.46 ± 0.0 8.1 0.46 ± 0.0 4.1 
Pc aa c38:0 2.29 ± 0.1 8.1 2.71 ± 0.0 1.6 3.12 ± 0.1 5.9 2.82 ± 0.1 6.4 2.82 ± 0.2 3.2 
Pc aa c38:3 33.15 ± 2.3 13.8 32.80 ± 0.5 3.0 33.68 ± 1.0 5.7 34.74 ± 1.0 5.8 34.74 ± 2.0 2.9 
Pc aa c38:4 80.82 ± 4.2 10.4 69.13 ± 1.8 5.3 63.79 ± 1.4 4.4 70.94 ± 3.1 8.7 70.94 ± 6.2 4.4 
Pc aa c38:5 39.04 ± 1.7 8.7 39.36 ± 0.2 0.8 39.94 ± 0.9 4.5 41.19 ± 1.4 6.8 41.19 ± 2.8 3.4 
Pc aa c38:6 57.58 ± 3.2 11.1 50.81 ± 0.3 1.3 47.12 ± 1.4 6.1 53.01 ± 1.6 5.9 53.01 ± 3.1 2.9 
Pc aa c40:2 0.21 ± 0.0 15.7 0.18 ± 0.0 9.9 0.18 ± 0.0 8.5 0.18 ± 0.0 23.4 0.18 ± 0.0 11.7 
Pc aa c40:3 0.46 ± 0.0 11.4 0.54 ± 0.0 11.0 0.58 ± 0.0 6.6 0.56 ± 0.0 9.2 0.56 ± 0.1 4.6 
Pc aa c40:4 2.85 ± 0.1 6.0 2.54 ± 0.0 1.5 2.34 ± 0.1 8.6 2.52 ± 0.1 7.8 2.52 ± 0.2 3.9 
Pc aa c40:5 8.57 ± 0.6 13.9 8.65 ± 0.1 2.7 8.80 ± 0.3 6.0 9.10 ± 0.4 9.9 9.10 ± 0.9 4.9 
Pc aa c40:6 20.66 ± 1.2 11.8 18.20 ± 0.4 3.9 16.42 ± 0.5 5.8 18.42 ± 0.7 7.1 18.42 ± 1.3 3.6 
Pc aa c42:0 0.44 ± 0.0 15.9 0.48 ± 0.0 4.0 0.56 ± 0.0 5.4 0.46 ± 0.0 20.1 0.46 ± 0.1 10.1 
Pc aa c42:1 0.25 ± 0.0 10.2 0.29 ± 0.0 2.2 0.36 ± 0.0 6.0 0.33 ± 0.0 2.8 0.33 ± 0.0 1.4 
Pc aa c42:2 0.18 ± 0.0 5.1 0.19 ± 0.0 4.3 0.22 ± 0.0 2.5 0.20 ± 0.0 9.2 0.20 ± 0.0 4.6 
Pc aa c42:4 0.15 ± 0.0 16.5 0.14 ± 0.0 9.3 0.15 ± 0.0 9.3 0.13 ± 0.0 12.3 0.13 ± 0.0 6.2 
Pc aa c42:5 0.23 ± 0.0 10.2 0.24 ± 0.0 5.2 0.22 ± 0.0 7.2 0.25 ± 0.0 6.7 0.25 ± 0.0 3.4 
Pc ae c30:0 0.21 ± 0.0 12.2 0.19 ± 0.0 3.4 0.17 ± 0.0 9.4 0.19 ± 0.0 9.5 0.19 ± 0.0 4.7 
Pc ae c30:2 0.08 ± 0.0 10.0 0.06 ± 0.0 5.1 0.05 ± 0.0 22.1 0.06 ± 0.0 8.5 0.06 ± 0.0 4.3 
Pc ae c32:1 1.43 ± 0.1 9.0 1.17 ± 0.1 9.2 0.85 ± 0.0 9.2 1.15 ± 0.1 12.8 1.15 ± 0.1 6.4 
Pc ae c32:2 0.47 ± 0.0 8.1 0.45 ± 0.0 3.7 0.47 ± 0.0 8.0 0.46 ± 0.0 4.7 0.46 ± 0.0 2.4 
Pc ae c34:0 1.11 ± 0.1 11.8 1.21 ± 0.0 1.9 1.46 ± 0.0 4.3 1.35 ± 0.0 5.7 1.35 ± 0.1 2.8 
Pc ae c34:1 5.04 ± 0.2 9.0 4.87 ± 0.2 7.1 4.96 ± 0.1 5.6 4.96 ± 0.1 4.8 4.96 ± 0.2 2.4 
Pc ae c34:2 7.66 ± 0.4 9.8 7.69 ± 0.1 3.5 8.39 ± 0.3 6.7 8.21 ± 0.2 5.8 8.21 ± 0.5 2.9 
Pc ae c34:3 5.77 ± 0.3 11.1 5.43 ± 0.1 3.7 5.22 ± 0.2 7.7 5.46 ± 0.1 3.9 5.46 ± 0.2 1.9 
Pc ae c36:0 0.72 ± 0.1 16.5 0.73 ± 0.0 4.2 0.87 ± 0.0 10.7 0.83 ± 0.1 13.3 0.83 ± 0.1 6.7 
Pc ae c36:1 9.30 ± 0.6 12.0 9.95 ± 0.3 6.8 12.38 ± 0.3 4.2 10.68 ± 0.1 1.5 10.68 ± 0.2 0.8 
Pc ae c36:2 8.69 ± 0.5 12.1 10.02 ± 0.2 3.9 10.81 ± 0.3 5.6 10.49 ± 0.3 5.4 10.49 ± 0.6 2.7 
Pc ae c36:3 4.78 ± 0.3 13.3 4.69 ± 0.1 6.0 4.43 ± 0.1 5.2 4.64 ± 0.1 4.9 4.64 ± 0.2 2.4 
Pc ae c36:4 12.94 ± 0.7 10.1 13.17 ± 0.3 4.9 12.96 ± 0.5 7.0 12.75 ± 0.3 5.1 12.75 ± 0.6 2.5 
Pc ae c36:5 10.02 ± 0.6 12.3 9.35 ± 0.3 5.5 8.49 ± 0.2 5.7 9.20 ± 0.2 4.6 9.20 ± 0.4 2.3 
Pc ae c38:0 1.66 ± 0.1 14.9 2.14 ± 0.0 2.3 2.66 ± 0.1 5.9 2.15 ± 0.1 6.1 2.15 ± 0.1 3.0 
Pc ae c38:3 4.88 ± 0.2 8.3 5.60 ± 0.1 4.6 7.02 ± 0.3 8.1 6.09 ± 0.2 7.3 6.09 ± 0.4 3.6 
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Plate   1    2    3    4    Mean  
Metabolite Mean ± Sem % cv Mean ± Sem % cv Mean ± Sem % cv Mean ± Sem % cv Mean ± Sem % cv 
Pc ae c38:4 9.23 ± 0.5 11.0 9.62 ± 0.3 6.3 9.79 ± 0.3 6.6 9.64 ± 0.3 5.5 9.64 ± 0.5 2.7 
Pc ae c38:5 11.21 ± 0.3 5.6 10.69 ± 0.3 5.5 9.37 ± 0.4 8.4 10.34 ± 0.3 5.6 10.34 ± 0.6 2.8 
Pc ae c38:6 5.82 ± 0.3 9.7 5.75 ± 0.1 3.9 5.52 ± 0.1 4.5 5.73 ± 0.2 7.2 5.73 ± 0.4 3.6 
Pc ae c40:1 0.93 ± 0.0 8.7 1.20 ± 0.0 4.8 1.47 ± 0.0 4.5 1.18 ± 0.1 10.7 1.18 ± 0.1 5.3 
Pc ae c40:2 1.44 ± 0.1 11.2 1.48 ± 0.0 5.3 1.60 ± 0.1 8.6 1.53 ± 0.1 7.1 1.53 ± 0.1 3.5 
Pc ae c40:3 1.88 ± 0.1 5.9 2.10 ± 0.1 6.2 2.71 ± 0.0 3.7 2.29 ± 0.1 9.5 2.29 ± 0.2 4.8 
Pc ae c40:4 1.84 ± 0.1 6.1 2.02 ± 0.0 3.8 2.07 ± 0.0 4.4 1.99 ± 0.1 5.3 1.99 ± 0.1 2.7 
Pc ae c40:5 3.32 ± 0.2 12.7 3.82 ± 0.1 4.1 4.25 ± 0.1 6.2 3.88 ± 0.1 7.1 3.88 ± 0.3 3.5 
Pc ae c40:6 3.34 ± 0.2 14.2 3.39 ± 0.1 8.6 3.41 ± 0.1 5.9 3.41 ± 0.1 4.8 3.41 ± 0.2 2.4 
Pc ae c42:1 0.33 ± 0.0 4.7 0.39 ± 0.0 9.7 0.53 ± 0.0 12.3 0.40 ± 0.0 12.7 0.40 ± 0.1 6.3 
Pc ae c42:2 0.43 ± 0.0 10.5 0.48 ± 0.0 5.4 0.61 ± 0.0 8.4 0.53 ± 0.0 6.7 0.53 ± 0.0 3.3 
Pc ae c42:3 0.54 ± 0.0 10.2 0.63 ± 0.0 2.8 0.68 ± 0.0 7.1 0.66 ± 0.0 5.3 0.66 ± 0.0 2.6 
Pc ae c42:4 0.62 ± 0.0 9.8 0.60 ± 0.0 7.6 0.60 ± 0.0 15.3 0.56 ± 0.0 6.7 0.56 ± 0.0 3.4 
Pc ae c42:5 1.45 ± 0.1 14.1 1.60 ± 0.1 6.3 1.72 ± 0.0 3.9 1.61 ± 0.1 8.2 1.61 ± 0.1 4.1 
Pc ae c44:3 0.09 ± 0.0 16.6 0.11 ± 0.0 6.5 0.15 ± 0.0 13.9 0.12 ± 0.0 10.4 0.12 ± 0.0 5.2 
Pc ae c44:4 0.24 ± 0.0 9.8 0.26 ± 0.0 2.4 0.27 ± 0.0 4.2 0.24 ± 0.0 8.5 0.24 ± 0.0 4.2 
Pc ae c44:5 0.69 ± 0.0 13.1 0.67 ± 0.0 5.7 0.55 ± 0.0 9.0 0.63 ± 0.0 7.6 0.63 ± 0.0 3.8 
Pc ae c44:6 0.77 ± 0.0 13.0 0.68 ± 0.0 2.1 0.64 ± 0.0 5.4 0.68 ± 0.0 6.9 0.68 ± 0.0 3.5 
Sm (oh) c14:1 5.07 ± 0.3 10.5 4.93 ± 0.1 3.8 4.52 ± 0.2 7.1 5.04 ± 0.3 11.6 5.04 ± 0.6 5.8 
Sm (oh) c16:1 3.53 ± 0.3 16.1 3.43 ± 0.1 5.0 2.96 ± 0.1 6.7 3.37 ± 0.2 14.1 3.37 ± 0.5 7.0 
Sm (oh) c22:1 28.59 ± 2.1 14.8 28.82 ± 1.1 7.3 21.57 ± 1.0 9.5 26.11 ± 2.0 15.0 26.11 ± 3.9 7.5 
Sm (oh) c22:2 26.66 ± 2.3 17.5 28.54 ± 0.8 5.3 23.59 ± 1.0 8.8 27.16 ± 2.1 15.1 27.16 ± 4.1 7.6 
Sm (oh) c24:1 1.15 ± 0.2 26.5 1.09 ± 0.1 10.9 0.80 ± 0.0 10.1 1.01 ± 0.1 19.7 1.01 ± 0.2 9.8 
Sm c16:0 113.48 ± 6.9 12.2 113.47 ± 3.4 6.0 101.95 ± 3.1 6.2 111.35 ± 6.2 11.1 111.35 ± 12.4 5.5 
Sm c16:1 18.36 ± 1.3 14.6 19.66 ± 0.5 5.3 18.03 ± 0.6 7.1 18.56 ± 1.0 10.9 18.56 ± 2.0 5.5 
Sm c18:0 29.58 ± 1.3 8.7 28.90 ± 1.0 7.0 21.98 ± 0.8 7.6 27.21 ± 1.3 9.7 27.21 ± 2.7 4.9 
Sm c18:1 14.76 ± 0.7 9.9 15.12 ± 0.4 5.5 12.54 ± 0.5 8.5 14.76 ± 0.9 12.8 14.76 ± 1.9 6.4 
Sm c20:2 0.68 ± 0.0 13.7 0.96 ± 0.0 4.9 0.98 ± 0.0 9.7 0.88 ± 0.1 16.9 0.88 ± 0.1 8.4 
Sm c24:0 25.63 ± 1.9 15.1 24.88 ± 1.1 8.7 16.58 ± 0.3 4.1 22.96 ± 1.8 15.8 22.96 ± 3.6 7.9 
Sm c24:1 109.24 ± 8.3 15.1 120.63 ± 4.9 8.2 98.37 ± 2.9 5.9 111.51 ± 7.8 13.9 111.51 ± 15.5 7.0 
Sm c26:0 0.17 ± 0.0 7.1 0.21 ± 0.0 8.8 0.18 ± 0.0 16.9 0.19 ± 0.0 10.5 0.19 ± 0.0 5.3 
Sm c26:1 0.30 ± 0.0 21.4 0.28 ± 0.0 7.6 0.22 ± 0.0 4.6 0.25 ± 0.0 16.6 0.25 ± 0.0 8.3 
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Table b. Interplate % cv of the second replicate of qc 2 
Plate 1 2 3 4 N Mean Sem % cv 
Ala 698.00 726.90 701.20 678.60 4 701.18 19.8 2.8 
Arg 212.30 208.40 191.20 196.10 4 202.00 10.0 4.9 
Asn 135.60 151.30 141.50 138.80 4 141.80 6.8 4.8 
Cit 135.30 163.60 140.00 157.50 4 149.10 13.6 9.1 
Gln 780.10 779.60 679.30 695.30 4 733.58 53.8 7.3 
Glu 340.00 366.10 349.10 408.40 4 365.90 30.3 8.3 
Gly 849.80 834.40 789.90 832.30 4 826.60 25.7 3.1 
His 186.30 183.70 166.20 167.60 4 175.95 10.5 6.0 
Ile 183.20 183.80 164.30 171.00 4 175.58 9.6 5.4 
Leu 192.40 199.70 182.80 186.60 4 190.38 7.4 3.9 
Lys 465.60 467.30 430.50 416.30 4 444.93 25.5 5.7 
Met 168.70 155.10 153.90 159.20 4 159.23 6.7 4.2 
Orn 188.70 190.10 152.00 172.60 4 175.85 17.8 10.1 
Phe 195.60 162.30 161.40 168.00 4 171.83 16.1 9.4 
Pro 447.10 354.40 456.80 360.50 4 404.70 54.8 13.5 
Ser 196.20 178.70 177.40 180.60 4 183.23 8.7 4.8 
Thr 179.80 190.50 179.60 172.70 4 180.65 7.3 4.1 
Trp 180.30 177.10 174.50 167.90 4 174.95 5.3 3.0 
Tyr 192.20 179.10 179.00 188.80 4 184.78 6.8 3.7 
Val 287.10 264.90 247.70 301.10 4 275.20 23.6 8.6 
Adma 6.90 6.90 8.10 5.60 4 6.88 1.0 14.9 
Alpha-aaa 21.90 20.50 20.30 20.60 4 20.83 0.7 3.5 
Creatinine 406.20 334.50 277.70 322.20 4 335.15 53.3 15.9 
Kynurenine 30.70 28.80 29.00 30.00 4 29.63 0.9 3.0 
Sarcosine 24.90 27.00 27.80 26.50 4 26.55 1.2 4.6 
Sdma 2.60 2.70 2.60 2.60 4 2.63 0.1 1.9 
Serotonin 2.60 2.90 2.90 2.80 4 2.80 0.1 5.1 
T4-oh-pro 11.50 10.20 11.40 10.50 4 10.90 0.6 5.9 
Taurine 92.70 88.20 101.80 131.40 4 103.53 19.4 18.8 
Lysopc a c16:0 103.56 113.05 103.56 100.56 4 105.19 5.4 5.2 
Ac-c0 65.56 66.60 68.02 62.68 4 65.71 2.3 3.4 
Ac-c2 14.69 16.12 15.11 13.98 4 14.98 0.9 6.0 
Ac-c3 4.19 3.44 4.02 3.51 4 3.79 0.4 9.7 
Ac-c4 4.48 4.48 5.55 4.47 4 4.74 0.5 11.3 
Ac-c5 4.86 4.92 7.44 4.88 4 5.52 1.3 23.2 
Ac-c14:1 0.05 0.05 0.05 0.07 4 0.05 0.0 21.6 
Ac-c16 4.52 4.33 4.30 4.22 4 4.34 0.1 2.9 
Ac-c18 2.24 2.10 2.07 2.16 4 2.15 0.1 3.5 
Ac-c18:1 0.07 0.06 0.07 0.07 4 0.07 0.0 7.4 
Ac-c18:2 0.03 0.02 0.02 0.03 4 0.02 0.0 13.6 
Lysopc a c16:1 2.43 2.47 2.50 2.30 4 2.43 0.1 3.7 
Lysopc a c17:0 1.75 1.79 1.53 1.45 4 1.63 0.2 10.4 
Lysopc a c18:0 67.20 64.96 48.78 56.59 4 59.38 8.4 14.2 
Lysopc a c18:1 14.59 14.58 12.81 13.75 4 13.93 0.8 6.1 
Lysopc a c18:2 17.17 17.68 17.13 16.68 4 17.17 0.4 2.4 
Lysopc a c20:3 1.21 1.25 1.17 1.16 4 1.19 0.0 3.7 
Lysopc a c20:4 5.46 5.54 5.10 4.99 4 5.27 0.3 5.1 
Lysopc a c24:0 0.15 0.17 0.13 0.13 4 0.15 0.0 13.8 
Lysopc a c26:0 0.11 0.17 0.14 0.13 4 0.14 0.0 19.1 
Lysopc a c26:1 0.04 0.06 0.04 0.04 4 0.04 0.0 25.0 
Lysopc a c28:0 0.13 0.12 0.11 0.10 4 0.11 0.0 9.9 
Lysopc a c28:1 0.22 0.20 0.13 0.16 4 0.18 0.0 22.4 
Pc aa c28:1 1.67 1.07 0.97 1.03 4 1.19 0.3 27.4 
Pc aa c32:0 9.35 7.95 7.68 7.97 4 8.24 0.8 9.1 
Pc aa c32:1 6.00 3.83 4.31 4.22 4 4.59 1.0 21.0 
Pc aa c32:3 0.41 0.32 0.33 0.32 4 0.34 0.0 12.3 
Plate 1 2 3 4 N Mean Sem % cv 
Pc aa c34:1 147.54 142.09 145.61 137.77 4 143.25 4.3 3.0 
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Pc aa c34:2 224.52 218.36 227.66 245.51 4 229.01 11.7 5.1 
Pc aa c34:3 9.51 8.85 9.18 9.15 4 9.17 0.3 2.9 
Pc aa c34:4 1.21 1.01 1.00 1.13 4 1.09 0.1 9.4 
Pc aa c36:0 3.61 3.51 3.99 4.05 4 3.79 0.3 7.1 
Pc aa c36:1 38.34 34.75 36.83 40.55 4 37.62 2.4 6.5 
Pc aa c36:2 162.45 130.75 119.59 139.33 4 138.03 18.2 13.2 
Pc aa c36:3 80.12 77.48 82.06 88.08 4 81.93 4.5 5.5 
Pc aa c36:4 141.42 126.52 119.56 135.72 4 130.80 9.7 7.4 
Pc aa c36:5 16.33 15.10 15.75 16.42 4 15.90 0.6 3.9 
Pc aa c36:6 0.56 0.49 0.42 0.46 4 0.48 0.1 12.6 
Pc aa c38:0 2.36 2.66 3.13 3.03 4 2.79 0.4 12.8 
Pc aa c38:3 34.80 32.80 34.70 36.79 4 34.77 1.6 4.7 
Pc aa c38:4 87.23 68.97 64.96 75.94 4 74.28 9.8 13.1 
Pc aa c38:5 40.78 39.24 40.60 45.30 4 41.48 2.6 6.4 
Pc aa c38:6 59.36 50.87 48.17 55.95 4 53.58 5.0 9.4 
Pc aa c40:2 0.20 0.21 0.19 0.24 4 0.21 0.0 10.9 
Pc aa c40:3 0.48 0.51 0.57 0.60 4 0.54 0.1 10.3 
Pc aa c40:4 2.93 2.54 2.34 2.59 4 2.60 0.2 9.4 
Pc aa c40:5 9.15 8.70 8.90 10.05 4 9.20 0.6 6.5 
Pc aa c40:6 22.50 18.22 15.99 19.09 4 18.95 2.7 14.3 
Pc aa c42:0 0.42 0.48 0.54 0.57 4 0.50 0.1 13.0 
Pc aa c42:1 0.25 0.29 0.38 0.34 4 0.31 0.1 18.9 
Pc aa c42:2 0.18 0.19 0.23 0.20 4 0.20 0.0 9.8 
Pc aa c42:4 0.14 0.15 0.16 0.15 4 0.15 0.0 4.5 
Pc aa c42:5 0.25 0.24 0.24 0.26 4 0.25 0.0 3.8 
Pc ae c30:0 0.21 0.20 0.18 0.21 4 0.20 0.0 6.2 
Pc ae c30:2 0.08 0.07 0.05 0.06 4 0.06 0.0 13.7 
Pc ae c32:1 1.45 1.15 0.91 1.20 4 1.18 0.2 18.5 
Pc ae c32:2 0.45 0.43 0.46 0.45 4 0.45 0.0 2.5 
Pc ae c34:0 1.26 1.24 1.44 1.44 4 1.35 0.1 8.2 
Pc ae c34:1 5.19 4.65 4.95 5.29 4 5.02 0.3 5.7 
Pc ae c34:2 8.38 7.35 8.45 8.80 4 8.25 0.6 7.6 
Pc ae c34:3 6.27 5.17 5.35 5.70 4 5.62 0.5 8.7 
Pc ae c36:0 0.69 0.75 0.94 0.96 4 0.83 0.1 16.1 
Pc ae c36:1 9.98 9.25 12.32 10.93 4 10.62 1.3 12.5 
Pc ae c36:2 8.48 9.65 11.00 11.15 4 10.07 1.3 12.5 
Pc ae c36:3 4.82 4.30 4.49 4.84 4 4.61 0.3 5.7 
Pc ae c36:4 13.81 12.69 13.06 13.65 4 13.30 0.5 3.9 
Pc ae c36:5 10.86 9.01 8.43 9.44 4 9.44 1.0 11.0 
Pc ae c38:0 1.81 2.15 2.72 2.18 4 2.22 0.4 16.9 
Pc ae c38:3 5.08 5.43 6.76 6.70 4 5.99 0.9 14.4 
Pc ae c38:4 9.63 9.17 9.38 10.23 4 9.60 0.5 4.8 
Pc ae c38:5 12.03 10.08 8.66 10.93 4 10.42 1.4 13.6 
Pc ae c38:6 6.26 5.53 5.57 6.14 4 5.87 0.4 6.4 
Pc ae c40:1 0.83 1.22 1.51 1.33 4 1.22 0.3 23.5 
Pc ae c40:2 1.50 1.38 1.54 1.68 4 1.53 0.1 8.2 
Pc ae c40:3 1.94 1.99 2.58 2.32 4 2.21 0.3 13.7 
Pc ae c40:4 1.88 2.11 2.10 2.13 4 2.05 0.1 5.8 
Pc ae c40:5 3.50 3.59 4.01 4.25 4 3.84 0.4 9.3 
Pc ae c40:6 3.78 2.99 3.50 3.62 4 3.47 0.3 9.9 
Pc ae c42:1 0.32 0.39 0.62 0.46 4 0.45 0.1 28.9 
Pc ae c42:2 0.42 0.45 0.54 0.58 4 0.50 0.1 15.0 
Pc ae c42:3 0.53 0.61 0.66 0.68 4 0.62 0.1 10.6 
Pc ae c42:4 0.66 0.55 0.55 0.59 4 0.59 0.1 8.7 
Pc ae c42:5 1.54 1.45 1.63 1.76 4 1.60 0.1 8.3 
Pc ae c44:3 0.11 0.10 0.13 0.12 4 0.11 0.0 11.8 
Pc ae c44:4 0.23 0.25 0.26 0.25 4 0.25 0.0 4.4 
Plate 1 2 3 4 N Mean Sem % cv 
Pc ae c44:5 0.79 0.67 0.50 0.68 4 0.66 0.1 18.1 
Pc ae c44:6 0.83 0.66 0.66 0.73 4 0.72 0.1 11.1 
Sm (oh) c14:1 5.09 5.18 4.35 5.41 4 5.01 0.5 9.1 
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Sm (oh) c16:1 3.95 3.60 2.91 3.59 4 3.51 0.4 12.4 
Sm (oh) c22:1 31.32 30.79 20.51 26.12 4 27.19 5.0 18.5 
Sm (oh) c22:2 31.51 30.41 23.87 28.59 4 28.59 3.4 11.8 
Sm (oh) c24:1 1.49 1.20 0.83 0.94 4 1.11 0.3 26.4 
Sm c16:0 119.96 121.91 99.98 110.73 4 113.14 10.0 8.9 
Sm c16:1 18.52 20.89 17.62 18.73 4 18.94 1.4 7.3 
Sm c18:0 30.36 31.04 20.81 26.46 4 27.17 4.7 17.3 
Sm c18:1 15.45 15.93 12.17 16.43 4 14.99 1.9 12.8 
Sm c20:2 0.67 1.02 0.97 0.80 4 0.87 0.2 18.6 
Sm c24:0 29.42 26.78 16.14 24.57 4 24.23 5.7 23.7 
Sm c24:1 129.78 130.88 100.90 106.60 4 117.04 15.5 13.3 
Sm c26:0 0.16 0.20 0.17 0.21 4 0.19 0.0 11.9 
Sm c26:1 0.31 0.32 0.22 0.21 4 0.26 0.1 21.3 
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Table c. List of the 130 metabolites measured with the biocrates kit  
Amino acids (20) Full name Glycerophospholipids (77)  Sphingolipids (14) 
Ala Alanine 
Lysophosphatidylcholine 
acyl (13) 
Pc aa c42:0 Sm (oh) c14:1 
Arg Arginine Lysopc a c16:0 Pc aa c42:1 Sm (oh) c16:1 
Asn Asparagine Lysopc a c16:1 Pc aa c42:2 Sm (oh) c22:1 
Cit Citrulline Lysopc a c17:0 Pc aa c42:4 Sm (oh) c22:2 
Gln Glutamine Lysopc a c18:0 Pc aa c42:5 Sm (oh) c24:1 
Glu Glutamate Lysopc a c18:1  Sm c16:0 
Gly Glycine Lysopc a c18:2 
Phosphatidylcholine 
acyl-alkyl 
Sm c16:1 
His Histidine Lysopc a c20:3 Pc ae c30:0 Sm c18:0 
Ile Isoleucine Lysopc a c20:4 Pc ae c30:2 Sm c18:1 
Leu Leucine Lysopc a c24:0 Pc ae c32:1 Sm c20:2 
Lys Lysine Lysopc a c26:0 Pc ae c32:2 Sm c24:0 
Met Methionine Lysopc a c26:1 Pc ae c34:0 Sm c24:1 
Orn Ornithine Lysopc a c28:0 Pc ae c34:1 Sm c26:0 
Phe Phenylalanine Lysopc a c28:1 Pc ae c34:2 Sm c26:1 
Pro Proline  Pc ae c34:3  
Ser Serine Phosphatidylcholine diacyl Pc ae c36:0  
Thr Threonine Pc aa c28:1 Pc ae c36:1  
Trp Tryptophan Pc aa c32:0 Pc ae c36:2  
Tyr Tyrosine Pc aa c32:1 Pc ae c36:3  
Val Valine Pc aa c32:3 Pc ae c36:4  
Biogenic amines (9)  Pc aa c34:1 Pc ae c36:5  
Adma 
Asymmetric 
dimethylarginine 
Pc aa c34:2 Pc ae c38:0  
Alpha-aaa Alpha-aminoadipic acid Pc aa c34:3 Pc ae c38:3  
Creatinine  Pc aa c34:4 Pc ae c38:4  
Kynurenine  Pc aa c36:0 Pc ae c38:5  
Sarcosine  Pc aa c36:1 Pc ae c38:6  
Sdma 
Symmetrical 
dimethylarginine 
Pc aa c36:2 Pc ae c40:1  
Serotonin  Pc aa c36:3 Pc ae c40:2  
T4-oh-pro Trans-4-hydroxyproline Pc aa c36:4 Pc ae c40:3  
Taurine  Pc aa c36:5 Pc ae c40:4  
Acylcarnitines (10)  Pc aa c36:6 Pc ae c40:5  
Ac-c0 Carnitine Pc aa c38:0 Pc ae c40:6  
Ac-c2 Acetylcarnitine  Pc aa c38:3 Pc ae c42:1  
Ac-c3 Propionylcarnitine  Pc aa c38:4 Pc ae c42:2  
Ac-c4 Butyrylcarnitine Pc aa c38:5 Pc ae c42:3  
Ac-c5 Valerylcarnitine Pc aa c38:6 Pc ae c42:4  
Ac-c14:1 Tetradecenoylcarnitine Pc aa c40:2 Pc ae c42:5  
Ac-c16 Hexadecanoylcarnitine Pc aa c40:3 Pc ae c44:3  
Ac-c18 Octadecanoylcarnitine Pc aa c40:4 Pc ae c44:4  
Ac-c18:1 Octadecenoylcarnitine Pc aa c40:5 Pc ae c44:5  
Ac-c18:2 Octadecadienylcarnitine Pc aa c40:6 Pc ae c44:6  
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Table d. Excluded metabolites (including the cause) from the biocrates analysis 
 Metabolite 
Stage of 
exclusion 
Interplate cv 
˃30%   (%) 
<lod (%) <0 (%) 
L Ow T2dm All groups All groups 
1 Ac-orn Metidq 3.6 100.0 86.6 95.9 93.7 0.0 
2 C4-oh-pro Metidq 3.0 88.9 80.4 97.3 87.7 0.0 
3 Carnosine Metidq 5.9 100.0 100.0 100.0 100.0 0.0 
4 Dopa Metidq 6.4 0.0 0.9 1.4 0.7 22.1 
5 Dopamine Metidq 5.9 17.2 15.2 16.2 16.1 71.9 
6 Histamine Metidq 2.7 18.2 26.8 23.0 22.8 34.0 
7 Nitro-tyr Metidq 5.9 100.0 100.0 100.0 100.0 49.5 
8 Pea Metidq 10.9 98.0 33.9 12.2 50.5 0.0 
9 Spermidine Metidq 4.1 0.0 0.0 0.0 0.0 7.7 
10 Spermine Metidq 7.7 64.6 0.0 0.0 22.5 18.2 
1 Ac-c16-oh %cv 59.1 7.1 8.0 32.4 14.0 1.1 
2 Ac-c16:1-oh %cv 32.6 97.0 99.1 98.6 98.2 3.2 
3 Ac-c3-dc (c4-oh) %cv 45.8 0.0 54.5 66.2 38.6 0.0 
4 Ac-c3:1 %cv 39.9 99.0 99.1 98.6 98.9 47.4 
5 Ac-c5-m-dc %cv 71.3 98.0 97.3 100.0 98.2 46.7 
6 Ac-c5-oh (c3-dc-m) %cv 37.8 78.8 98.2 100.0 91.9 0.0 
1 Asp %cv 7.4 44.4 58.0 0.0 38.2 0.0 
1 Pc aa c30:0 %cv 35.3 0.0 0.0 0.0 0.0 0.0 
2 Pc aa c42:6 %cv 33.7 0 0.0 0.0 0.0 0.0 
3 Pc ae c38:1 %cv 146.6 87.9 79.5 82.4 83.2 60.4 
4 Pc ae c38:2 %cv 92.0 0 0.9 0.0 0.4 62.8 
1 Ac-c10 < lod 5.2 85.9 87.5 73.0 83.2 0.0 
2 Ac-c10:1 < lod 15.1 99.0 100.0 100.0 99.6 13.0 
3 Ac-c10:2 < lod 27.0 91.9 98.2 93.2 94.7 0.0 
4 Ac-c12 < lod 3.5 99.0 99.1 98.6 98.9 0.0 
5 Ac-c12-dc < lod 9.8 99.0 99.1 100.0 99.3 64.6 
6 Ac-c12:1 < lod 12.6 99.0 100.0 100.0 99.6 46.7 
7 Ac-c14 < lod 4.7 99.0 99.1 100.0 99.3 0.0 
8 Ac-c14:1-oh < lod 11.8 88.9 100.0 98.6 95.8 1.1 
9 Ac-c14:2 < lod 12.4 35.4 57.1 58.1 49.8 0.0 
10 Ac-c14:2-oh < lod 7.9 65.7 62.5 91.9 71.2 13.0 
11 Ac-c16:1 < lod 17.4 44.4 59.8 68.9 56.8 0.0 
12 Ac-c16:2 < lod 20.5 96.0 99.1 98.6 97.9 10.9 
13 Ac-c16:2-oh < lod 25.2 100.0 99.1 100.0 99.6 9.1 
14 Ac-c18:1-oh < lod 11.1 99.0 99.1 100.0 99.3 10.9 
15 Ac-c3-oh < lod Nv 92.9 99.1 87.8 94.0 22.1 
16 Ac-c4:1 < lod 19.2 92.9 99.1 100.0 97.2 22.8 
17 Ac-c5-dc (c6-oh) < lod 16.9 19.2 84.8 86.5 62.5 0.0 
18 Ac-c5:1 < lod 13.4 99.0 98.2 100.0 98.9 3.5 
19 Ac-c5:1-dc < lod 17.9 84.8 97.3 100.0 93.7 11.9 
20 Ac-c6 (c4:1-dc) < lod 9.1 86.9 95.5 90.5 91.2 0.0 
21 Ac-c6:1 < lod 19.6 94.9 98.2 100.0 97.5 12.3 
22 Ac-c7-dc < lod 15.5 49.5 84.8 78.4 70.9 0.0 
23 Ac-c8 < lod 3.2 93.9 98.2 83.8 93.0 0.0 
24 Ac-c9 < lod 19.3 6.1 71.4 32.4 38.6 0.0 
1 Met-so < lod 5.4 46.5 27.7 73.0 46.0 0.0 
2 Putrescine < lod 4.9 81.8 58.9 54.1 65.6 0.0 
1 Lysopc a c14:0 < lod 6.0 100.0 100.0 100.0 100.0 0.0 
1 Pc aa c24:0 < lod 9.1 18.2 74.1 62.2 51.6 0.0 
2 Pc aa c26:0 < lod 5.3 99.0 99.1 82.4 94.7 0.0 
3 Pc aa c40:1 < lod 5.6 98.0 89.3 62.2 85.3 0.0 
4 Pc ae c30:1 < lod Nv 68.7 82.1 47.3 68.4 97.9 
5 Pc ae c42:0 < lod 17.2 100 94.6 98.6 97.5 0.0 
6 H1   7.3 0 0.0 0.0 0.0 0.4 
    Total  10 41 45 45 44 30 
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Table e. Mean (± sem), minimum and maximum concentrations (μm) of the 130 metabolites 
 
Metabolite 
Lean (n = 8) Ow (n = 9) T2md (n = 6)  % change 
Concentration (µm) Concentration (µm) Concentration (µm)      
Mean  ± sem 
(µm) 
Min 
(mean) 
Max 
(mean) 
Mean  ± sem 
(µm) 
Min 
(mean) 
Max 
(mean) 
Mean  ± sem 
(µm) 
Min 
(mean) 
Max 
(mean) 
Fdr 
All 
groups 
L vs 
ow 
Fdr 
L vs 
ow 
Ow vs 
t2dm 
Fdr 
Ow vs 
t2dm 
Ala 367.9 ± 21.52 168.19 640.01 376.8 ± 17.42 180.73 831.85 470.7 ± 23.80 151.43 768.80 1.13e-15 2.4 5.95e-01 24.9 5.54e-10 
Arg 105.5 ± 5.36 62.88 154.68 99.1 ± 4.87 63.86 172.62 97.6 ± 7.89 44.88 146.79 6.64e-04 -6.1 3.12e-03 -1.5 7.62e-01 
Asn 63.8 ± 5.90 25.32 130.57 55.3 ± 2.03 24.80 127.60 57.9 ± 2.51 22.49 102.44 1.79e-06 -13.3 2.07e-06 4.6 2.92e-01 
Cit 45.4 ± 4.69 16.26 95.13 41.9 ± 1.98 18.61 146.18 39.2 ± 5.25 13.22 95.25 7.69e-04 -7.7 2.85e-02 -6.4 2.43e-01 
Gln 720.5 ± 22.65 559.73 1189.66 698.6 ± 20.38 464.29 1201.14 650.6 ± 23.38 283.42 850.91 1.93e-07 -3.0 1.04e-01 -6.9 4.12e-04 
Glu 53.1 ± 3.73 22.27 101.66 73.0 ± 7.01 22.17 271.47 88.8 ± 10.74 32.99 177.76 1.00e-19 37.4 3.03e-09 21.6 3.33e-04 
Gly 223.4 ± 16.33 137.00 337.05 202.1 ± 10.58 133.07 333.72 200.4 ± 16.35 104.88 303.74 2.37e-11 -9.6 8.46e-10 -0.9 8.76e-01 
His 96.5 ± 2.60 77.17 145.68 102.1 ± 5.07 76.17 194.69 86.7 ± 3.59 41.08 118.37 3.08e-15 5.7 3.33e-03 -15.1 1.76e-13 
Ile 93.1 ± 3.35 55.77 161.36 99.7 ± 4.82 52.48 202.71 103.5 ± 3.11 41.62 165.64 6.87e-04 7.1 2.06e-02 3.8 3.09e-01 
Leu 158.4 ± 4.02 109.91 250.58 168.2 ± 9.15 82.41 360.83 169.6 ± 7.65 69.09 282.08 2.91e-02 6.2 5.48e-02 0.8 9.50e-01 
Lys 292.3 ± 9.02 197.01 427.93 298.6 ± 14.75 173.67 521.80 313.3 ± 13.00 98.41 459.69 1.23e-02 2.1 4.75e-01 4.9 8.83e-02 
Met 33.6 ± 0.89 20.72 47.29 34.6 ± 0.78 23.84 66.46 36.4 ± 1.80 15.30 60.18 4.62e-03 3.1 2.97e-01 5.2 8.54e-02 
Orn 67.8 ± 4.05 44.13 127.86 77.0 ± 7.23 42.55 205.12 70.1 ± 5.35 34.43 113.86 1.02e-06 13.6 1.11e-06 -8.9 3.36e-03 
Phe 90.9 ± 4.14 59.89 140.69 92.7 ± 2.92 63.01 145.81 97.9 ± 4.57 53.60 143.63 6.03e-04 2.0 4.12e-01 5.6 1.46e-02 
Pro 310.6 ± 16.79 157.55 480.71 326.9 ± 12.87 184.78 600.22 359.4 ± 20.29 242.19 588.83 3.66e-10 5.2 2.92e-02 9.9 6.65e-05 
Ser 119.8 ± 4.21 93.10 207.70 118.3 ± 6.28 80.48 213.72 111.8 ± 5.80 49.70 160.49 3.10e-03 -1.3 6.63e-01 -5.5 1.71e-02 
Thr 136.4 ± 5.72 68.94 207.15 142.4 ± 5.88 70.60 382.32 138.6 ± 8.22 64.89 240.79 3.79e-01 4.4  -2.7  
Trp 74.6 ± 3.49 46.61 106.39 79.9 ± 5.38 47.53 154.78 83.7 ± 6.08 44.75 148.73 3.93e-06 7.1 2.54e-03 4.8 1.13e-01 
Tyr 87.5 ± 3.51 61.82 136.36 99.1 ± 4.92 62.59 206.76 110.9 ± 9.84 44.49 216.07 1.78e-20 13.2 4.14e-08 11.9 7.13e-06 
Val 207.9 ± 5.86 101.27 310.05 219.1 ± 7.06 100.90 392.51 225.4 ± 5.51 156.21 305.72 1.50e-03 5.4 2.61e-02 2.9 3.49e-01 
Adma 0.563 ± 0.03 0.32 0.94 0.614 ± 0.03 0.32 1.61 0.568 ± 0.03 0.31 0.94 8.51e-03 9.1 1.04e-02 -7.5 6.52e-02 
Alpha-aaa 1.21 ± 0.10 0.29 2.12 1.25 ± 0.09 0.54 2.26 1.50 ± 0.11 0.75 2.42 8.46e-23 3.6 1.56e-01 19.9 1.96e-16 
Creatinine 69.0 ± 3.19 21.92 118.81 76.9 ± 4.28 28.17 151.96 72.9 ± 6.65 20.25 140.46 2.38e-02 11.3 8.85e-03 -5.2 3.69e-01 
Kynurenine 1.86 ± 0.16 0.80 3.29 2.16 ± 0.21 1.01 4.37 2.29 ± 0.12 0.73 3.29 5.49e-13 16.2 1.65e-08 5.6 9.92e-02 
Sarcosine 1.57 ± 0.14 0.71 3.27 1.79 ± 0.09 0.71 5.92 2.16 ± 0.10 1.42 3.43 5.54e-18 13.7 7.05e-04 20.6 3.96e-07 
Sdma 0.542 ± 0.03 0.21 1.00 0.530 ± 0.02 0.21 1.43 0.509 ± 0.03 0.20 0.80 2.03e-01 -2.2  -3.9  
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Serotonin 0.209 ± 0.02 0.00 1.11 0.179 ± 0.01 0.00 0.93 0.165 ± 0.03 0.00 0.40 2.43e-01 -14.2  -7.8  
T4-oh-pro 4.91 ± 0.19 3.59 6.90 4.96 ± 0.15 3.58 7.48 5.82 ± 0.60 3.84 9.35 1.99e-21 1.0 7.28e-01 17.5 7.47e-16 
Taurine 61.7 ± 3.66 27.33 204.66 59.7 ± 3.23 25.43 195.92 61.9 ± 4.63 27.70 207.53 9.12e-01 -3.2  3.6  
Ac-c0 41.0 ± 2.91 22.26 57.00 43.3 ± 4.81 21.47 84.91 46.3 ± 4.38 19.68 69.56 1.42e-08 5.5 9.87e-03 7.0 2.55e-03 
Ac-c2 4.828 ± 0.29 2.23 11.17 5.14 ± 0.42 1.89 10.89 5.254 ± 0.42 2.55 9.46 1.16e-02 6.4 4.75e-02 2.2 6.37e-01 
Ac-c3 0.266 ± 0.02 0.13 0.43 0.283 ± 0.03 0.11 0.57 0.339 ± 0.03 0.17 0.60 7.11e-16 6.4 2.11e-02 19.7 5.76e-08 
Ac-c4 0.173 ± 0.01 0.06 0.28 0.196 ± 0.01 0.11 0.40 0.204 ± 0.02 0.12 0.39 6.03e-11 12.8 9.43e-07 4.4 1.71e-01 
Ac-c5 0.148 ± 0.01 0.08 0.28 0.173 ± 0.01 0.08 0.37 0.161 ± 0.01 0.09 0.29 1.56e-06 16.6 2.03e-06 -6.8 5.88e-02 
Ac-c14:1 0.061 ± 0.00 0.03 0.12 0.058 ± 0.00 0.02 0.09 0.056 ± 0.01 0.02 0.11 8.13e-02 -4.3  -3.3  
Ac-c16 0.071 ± 0.01 0.03 0.16 0.082 ± 0.01 0.04 0.18 0.080 ± 0.01 0.03 0.15 3.65e-06 15.3 6.72e-06 -2.2 6.63e-01 
Ac-c18 0.028 ± 0.00 0.01 0.09 0.028 ± 0.00 0.01 0.07 0.024 ± 0.00 0.01 0.05 3.51e-03 1.3 8.37e-01 -13.7 1.81e-03 
Ac-c18:1 0.102 ± 0.01 0.04 0.26 0.122 ± 0.01 0.06 0.26 0.107 ± 0.01 0.05 0.21 2.52e-07 19.1 6.14e-07 -11.8 6.21e-04 
Ac-c18:2 0.033 ± 0.00 0.01 0.07 0.037 ± 0.00 0.02 0.10 0.032 ± 0.00 0.01 0.06 1.28e-05 13.5 1.61e-04 -12.8 3.19e-04 
Lysopc a c16:0 72.7 ± 2.54 47.75 106.65 67.9 ± 4.98 35.93 133.75 62.5 ± 10.45 25.51 137.34 9.16e-08 -6.7 4.64e-03 -7.9 5.76e-03 
Lysopc a c16:1 2.47 ± 0.08 1.64 4.84 2.32 ± 0.27 0.84 5.10 2.30 ± 0.31 0.96 4.71 1.37e-02 -6.2 1.53e-02 -0.5 9.89e-01 
Lysopc a c17:0 1.30 ± 0.06 0.86 2.32 1.11 ± 0.12 0.52 2.56 0.88 ± 0.14 0.23 1.84 2.57e-31 -14.2 1.01e-09 -20.5 2.51e-13 
Lysopc a c18:0 16.5 ± 0.60 11.24 29.34 14.1 ± 1.11 7.89 28.29 12.9 ± 2.84 5.51 31.45 4.10e-18 -14.5 1.04e-09 -8.8 1.90e-03 
Lysopc a c18:1 17.3 ± 0.65 10.63 27.25 14.1 ± 1.00 6.61 31.62 12.6 ± 1.49 5.40 23.16 8.51e-27 -18.4 5.49e-15 -10.2 2.88e-04 
Lysopc a c18:2 32.4 ± 1.29 17.40 56.55 24.7 ± 1.59 10.07 59.66 21.4 ± 2.44 6.12 43.46 4.00e-37 -24.0 1.80e-21 -13.2 7.14e-06 
Lysopc a c20:3 1.89 ± 0.15 0.80 4.01 1.37 ± 0.13 0.56 3.12 1.46 ± 0.28 0.54 3.57 4.24e-26 -27.4 1.34e-22 5.9 1.32e-01 
Lysopc a c20:4 4.84 ± 0.16 3.02 8.22 4.37 ± 0.45 2.03 9.64 4.64 ± 0.56 2.24 9.63 4.88e-04 -9.6 1.53e-04 6.1 6.73e-02 
Lysopc a c24:0 0.090 ± 0.00 0.04 0.19 0.085 ± 0.00 0.04 0.16 0.086 ± 0.00 0.05 0.16 3.73e-01 -5.9  1.1  
Lysopc a c26:0 0.157 ± 0.01 0.06 0.32 0.143 ± 0.01 0.07 0.36 0.141 ± 0.01 0.06 0.31 5.28e-02 -9.1  -1.1  
Lysopc a c26:1 0.070 ± 0.00 0.03 0.11 0.066 ± 0.00 0.04 0.14 0.070 ± 0.00 0.03 0.13 2.79e-01 -6.2  6.3  
Lysopc a c28:0 0.125 ± 0.01 0.05 0.25 0.104 ± 0.01 0.04 0.23 0.095 ± 0.01 0.04 0.24 8.17e-09 -16.4 2.17e-05 -9.1 1.15e-01 
Lysopc a c28:1 0.262 ± 0.02 0.16 0.56 0.241 ± 0.03 0.10 0.49 0.227 ± 0.02 0.10 0.40 2.23e-06 -8.0 3.12e-03 -5.8 6.51e-02 
Pc aa c28:1 1.78 ± 0.08 1.22 3.34 1.77 ± 0.15 0.83 3.01 1.76 ± 0.24 0.87 3.76 9.64e-01 -0.6  -0.5  
Pc aa c32:0 11.7 ± 0.66 7.08 17.56 10.9 ± 0.74 7.27 19.74 12.7 ± 1.81 6.46 23.25 3.44e-10 -6.3 3.98e-03 16.1 5.54e-10 
Pc aa c32:1 10.3 ± 1.09 2.06 23.22 10.3 ± 2.64 1.75 37.61 15.4 ± 3.32 4.96 39.43 6.77e-32 -0.4 9.15e-01 50.1 5.13e-22 
Pc aa c32:3 0.323 ± 0.01 0.14 0.47 0.321 ± 0.04 0.18 0.72 0.341 ± 0.05 0.14 0.62 1.30e-02 -0.6 8.33e-01 6.5 1.78e-02 
Pc aa c34:1 258.7 ± 13.10 173.71 487.22 241.6 ± 21.60 141.56 472.76 269.4 ± 39.71 161.07 511.80 1.16e-05 -6.6 3.98e-03 11.5 4.90e-06 
Pc aa c34:2 289.3 ± 11.45 196.42 497.73 285.0 ± 15.54 188.05 536.39 286.5 ± 31.26 174.17 550.26 9.49e-01 -1.5  0.5  
Pc aa c34:3 16.3 ± 0.99 10.40 24.59 14.3 ± 1.64 6.89 31.77 15.6 ± 2.90 7.41 34.49 2.09e-09 -12.4 1.14e-09 9.3 1.01e-03 
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Pc aa c34:4 1.08 ± 0.09 0.52 1.78 1.05 ± 0.17 0.38 2.56 1.37 ± 0.19 0.67 2.66 5.62e-30 -3.4 1.89e-01 31.1 5.13e-22 
Pc aa c36:0 4.10 ± 0.60 1.41 9.88 3.81 ± 0.42 1.45 8.91 4.04 ± 0.47 1.57 7.81 4.37e-02 -7.0 2.19e-02 6.1 1.01e-01 
Pc aa c36:1 58.5 ± 3.94 38.68 89.90 49.6 ± 4.55 23.03 103.74 58.4 ± 10.85 32.89 136.61 2.73e-16 -15.3 3.01e-14 17.7 5.54e-10 
Pc aa c36:2 202.8 ± 11.58 135.56 325.49 185.1 ± 13.82 110.73 350.43 193.5 ± 35.57 98.75 430.37 7.98e-05 -8.7 3.40e-05 4.5 1.10e-01 
Pc aa c36:3 150.0 ± 9.45 83.10 234.34 132.6 ± 9.75 72.62 247.71 143.8 ± 28.02 70.50 331.28 7.07e-09 -11.6 3.03e-09 8.5 1.21e-03 
Pc aa c36:4 162.8 ± 5.31 120.99 214.05 163.1 ± 14.88 97.81 306.67 201.2 ± 17.97 129.91 335.83 5.75e-26 0.2 9.20e-01 23.4 5.07e-18 
Pc aa c36:5 29.2 ± 6.55 9.51 93.21 20.9 ± 3.45 6.95 48.73 29.1 ± 3.16 15.08 52.18 4.54e-39 -28.4 1.48e-33 39.3 1.52e-25 
Pc aa c36:6 0.604 ± 0.09 0.19 1.59 0.520 ± 0.08 0.15 1.04 0.632 ± 0.07 0.38 1.20 3.12e-14 -13.8 4.78e-09 21.6 5.92e-12 
Pc aa c38:0 3.316 ± 0.43 1.81 6.71 3.228 ± 0.32 1.78 7.33 3.100 ± 0.28 1.97 5.48 1.97e-02 -2.6 3.41e-01 -4.0 1.78e-01 
Pc aa c38:3 51.8 ± 3.63 34.92 76.42 46.3 ± 4.12 21.64 84.15 56.3 ± 12.05 29.76 137.24 7.36e-18 -10.5 6.02e-08 21.6 6.24e-15 
Pc aa c38:4 79.7 ± 3.26 53.28 102.99 78.5 ± 7.92 44.29 147.86 99.9 ± 10.99 65.84 183.74 6.58e-30 -1.5 6.11e-01 27.4 1.01e-21 
Pc aa c38:5 61.6 ± 4.24 37.90 100.20 52.0 ± 5.13 25.16 93.68 59.3 ± 7.16 38.76 116.39 4.00e-17 -15.6 3.01e-16 14.0 5.22e-08 
Pc aa c38:6 72.8 ± 8.18 41.86 141.76 74.6 ± 7.14 37.20 148.85 77.2 ± 9.28 49.09 153.02 4.34e-02 2.5 3.79e-01 3.5 2.52e-01 
Pc aa c40:2 0.197 ± 0.02 0.02 0.41 0.162 ± 0.01 0.04 0.38 0.130 ± 0.01 0.02 0.31 1.93e-13 -17.9 8.11e-06 -19.6 3.33e-04 
Pc aa c40:3 0.720 ± 0.03 0.37 1.02 0.587 ± 0.03 0.36 0.92 0.653 ± 0.11 0.25 1.43 4.09e-16 -18.4 2.60e-16 11.1 1.31e-04 
Pc aa c40:4 2.74 ± 0.17 1.73 3.84 2.16 ± 0.18 1.23 4.06 2.67 ± 0.71 1.37 7.53 1.22e-26 -21.3 1.75e-24 23.6 5.93e-16 
Pc aa c40:5 11.9 ± 0.71 5.37 15.75 10.0 ± 0.99 3.93 18.83 10.9 ± 2.16 6.47 26.01 4.19e-17 -16.7 2.60e-16 9.8 2.88e-04 
Pc aa c40:6 23.1 ± 2.47 13.97 44.46 24.1 ± 3.01 9.85 54.46 26.1 ± 2.27 15.70 40.96 1.95e-07 4.4 7.13e-02 8.2 1.23e-03 
Pc aa c42:0 0.762 ± 0.12 0.32 1.59 0.632 ± 0.05 0.31 1.23 0.593 ± 0.06 0.28 0.92 7.82e-26 -17.0 1.64e-16 -6.2 1.38e-02 
Pc aa c42:1 0.379 ± 0.05 0.20 0.77 0.322 ± 0.02 0.15 0.58 0.333 ± 0.03 0.17 0.61 4.22e-13 -14.9 6.43e-12 3.3 3.13e-01 
Pc aa c42:2 0.235 ± 0.03 0.12 0.46 0.202 ± 0.02 0.11 0.43 0.200 ± 0.02 0.10 0.37 4.00e-10 -14.0 2.90e-08 -1.4 8.65e-01 
Pc aa c42:4 0.156 ± 0.00 0.11 0.23 0.140 ± 0.01 0.07 0.25 0.140 ± 0.01 0.07 0.22 6.45e-05 -10.1 7.13e-05 0.3 9.89e-01 
Pc aa c42:5 0.343 ± 0.02 0.22 0.56 0.290 ± 0.03 0.13 0.55 0.320 ± 0.03 0.19 0.54 4.39e-13 -15.2 1.78e-13 10.1 2.88e-04 
Pc ae c30:0 0.252 ± 0.01 0.09 0.43 0.212 ± 0.03 0.09 0.48 0.216 ± 0.04 0.08 0.43 6.04e-13 -15.7 7.12e-11 1.9 6.88e-01 
Pc ae c30:2 0.075 ± 0.00 0.05 0.14 0.074 ± 0.01 0.00 0.13 0.079 ± 0.01 0.04 0.19 1.21e-01 -0.5  6.1  
Pc ae c32:1 1.99 ± 0.16 1.16 3.64 1.68 ± 0.17 0.62 3.82 1.81 ± 0.37 0.71 4.07 7.35e-12 -15.4 1.64e-11 7.7 9.60e-03 
Pc ae c32:2 0.662 ± 0.05 0.33 1.10 0.588 ± 0.05 0.36 1.18 0.569 ± 0.06 0.26 0.98 1.73e-11 -11.1 9.97e-08 -3.3 3.13e-01 
Pc ae c34:0 1.93 ± 0.07 0.85 2.96 1.82 ± 0.25 0.80 4.22 1.95 ± 0.32 0.70 3.94 1.23e-02 -5.6 2.94e-02 7.1 2.16e-02 
Pc ae c34:1 9.21 ± 0.38 6.45 14.54 8.43 ± 1.02 5.17 19.30 8.60 ± 1.20 3.81 16.28 1.19e-04 -8.5 9.34e-05 2.0 6.43e-01 
Pc ae c34:2 10.6 ± 0.57 6.72 17.12 8.81 ± 0.78 6.06 18.98 8.37 ± 1.49 3.06 17.00 2.16e-23 -17.0 2.99e-15 -5.0 8.51e-02 
Pc ae c34:3 5.41 ± 0.43 3.05 10.35 3.83 ± 0.26 2.28 7.49 3.80 ± 0.71 1.36 8.35 5.92e-52 -29.1 1.05e-38 -0.9 8.97e-01 
Pc ae c36:0 1.16 ± 0.08 0.59 1.88 0.974 ± 0.10 0.38 1.92 1.12 ± 0.16 0.52 2.15 3.03e-12 -16.3 1.69e-11 14.5 1.85e-06 
Pc ae c36:1 16.8 ± 0.91 10.77 27.51 15.0 ± 1.71 8.53 33.05 15.3 ± 1.97 6.37 29.08 1.27e-07 -11.0 3.67e-07 1.9 6.88e-01 
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Pc ae c36:2 17.3 ± 0.99 11.44 27.93 15.1 ± 1.52 9.47 34.82 13.6 ± 2.35 5.92 28.61 1.33e-20 -12.9 9.35e-10 -9.6 2.66e-04 
Pc ae c36:3 5.83 ± 0.26 3.79 8.91 4.71 ± 0.33 3.28 9.41 4.65 ± 0.93 1.76 10.25 1.12e-25 -19.1 1.56e-18 -1.4 7.91e-01 
Pc ae c36:4 12.7 ± 0.54 9.17 20.89 12.2 ± 0.91 6.84 23.74 12.3 ± 1.40 5.44 20.49 1.93e-01 -3.8  0.9  
Pc ae c36:5 8.89 ± 0.46 5.31 13.46 8.06 ± 0.54 5.38 15.46 7.95 ± 0.79 4.37 13.35 3.42e-08 -9.4 2.18e-06 -1.3 7.76e-01 
Pc ae c38:0 3.37 ± 0.37 1.69 7.46 2.92 ± 0.35 1.18 5.39 2.90 ± 0.35 1.64 5.30 3.08e-12 -13.4 3.61e-10 -0.6 9.79e-01 
Pc ae c38:3 7.81 ± 0.47 4.03 11.47 6.83 ± 0.65 3.29 13.02 6.95 ± 1.21 2.86 15.56 1.22e-10 -12.6 8.84e-10 1.8 6.78e-01 
Pc ae c38:4 12.0 ± 0.54 8.11 18.79 11.7 ± 1.06 7.15 24.52 12.0 ± 1.44 5.68 21.84 3.60e-01 -2.8  2.7  
Pc ae c38:5 11.9 ± 0.58 7.42 17.47 11.4 ± 0.65 7.85 19.79 11.1 ± 0.99 6.71 17.47 1.07e-02 -3.9 9.71e-02 -2.8 3.69e-01 
Pc ae c38:6 6.15 ± 0.63 3.66 11.39 5.83 ± 0.45 3.53 10.53 5.49 ± 0.52 3.19 9.31 4.02e-06 -5.2 1.92e-02 -5.8 2.70e-02 
Pc ae c40:1 1.66 ± 0.12 0.87 2.86 1.39 ± 0.10 0.75 2.58 1.38 ± 0.20 0.63 2.81 1.18e-14 -16.0 7.68e-12 -0.7 9.86e-01 
Pc ae c40:2 2.33 ± 0.20 1.55 4.13 2.21 ± 0.25 0.99 4.68 2.20 ± 0.18 1.30 3.30 1.62e-02 -5.4 2.51e-02 -0.3 9.89e-01 
Pc ae c40:3 1.80 ± 0.05 1.15 2.68 1.50 ± 0.10 0.92 2.90 1.54 ± 0.18 0.71 2.96 8.31e-19 -16.8 2.11e-16 2.6 4.29e-01 
Pc ae c40:4 2.21 ± 0.11 1.64 3.64 1.96 ± 0.11 1.27 3.57 1.96 ± 0.25 0.97 3.70 1.57e-09 -11.5 2.90e-08 0.1 9.89e-01 
Pc ae c40:5 4.51 ± 0.19 3.43 6.83 4.04 ± 0.26 2.56 7.95 3.86 ± 0.41 1.93 6.83 2.03e-12 -10.4 1.48e-07 -4.6 8.83e-02 
Pc ae c40:6 4.70 ± 0.42 2.64 7.90 4.51 ± 0.39 2.50 8.27 4.15 ± 0.40 2.07 7.13 3.29e-07 -3.9 9.18e-02 -8.1 7.47e-04 
Pc ae c42:1 0.450 ± 0.02 0.27 0.65 0.367 ± 0.02 0.20 0.75 0.374 ± 0.05 0.21 0.82 3.18e-17 -18.4 9.38e-15 2.0 7.08e-01 
Pc ae c42:2 0.756 ± 0.04 0.45 1.15 0.604 ± 0.05 0.35 1.08 0.605 ± 0.10 0.35 1.37 5.82e-26 -20.1 6.25e-21 0.3 9.89e-01 
Pc ae c42:3 0.907 ± 0.10 0.42 2.03 0.757 ± 0.05 0.42 1.28 0.746 ± 0.11 0.41 1.44 4.10e-18 -16.6 6.87e-14 -1.5 7.76e-01 
Pc ae c42:4 0.813 ± 0.07 0.41 1.76 0.667 ± 0.03 0.36 1.27 0.641 ± 0.10 0.22 1.23 9.72e-18 -18.0 3.97e-12 -3.9 2.98e-01 
Pc ae c42:5 1.93 ± 0.14 1.32 3.24 1.75 ± 0.09 1.07 2.89 1.64 ± 0.16 0.95 2.78 8.47e-12 -9.2 1.05e-05 -6.7 5.37e-03 
Pc ae c44:3 0.103 ± 0.01 0.04 0.17 0.085 ± 0.00 0.04 0.14 0.086 ± 0.01 0.04 0.16 2.09e-09 -17.4 3.56e-08 0.5 9.89e-01 
Pc ae c44:4 0.414 ± 0.03 0.22 0.77 0.357 ± 0.02 0.18 0.52 0.325 ± 0.04 0.18 0.62 4.56e-18 -13.7 4.48e-09 -9.0 6.39e-04 
Pc ae c44:5 1.29 ± 0.13 0.79 2.70 1.20 ± 0.06 0.75 2.11 1.10 ± 0.13 0.62 1.99 4.82e-09 -6.8 3.86e-03 -8.5 1.17e-03 
Pc ae c44:6 1.04 ± 0.13 0.57 2.14 0.87 ± 0.05 0.45 1.54 0.88 ± 0.11 0.48 1.50 7.68e-18 -16.2 2.32e-14 1.1 8.59e-01 
Sm (oh) c14:1 7.51 ± 0.35 5.03 11.53 7.43 ± 0.52 4.56 11.84 7.09 ± 0.99 3.32 15.17 1.93e-02 -1.1 7.00e-01 -4.5 6.26e-02 
Sm (oh) c16:1 4.43 ± 0.19 3.01 6.85 4.25 ± 0.31 2.56 7.76 3.95 ± 0.39 1.79 6.63 7.61e-06 -4.2 7.26e-02 -7.0 7.45e-03 
Sm (oh) c22:1 32.6 ± 1.35 22.73 53.63 29.4 ± 2.03 18.40 51.83 29.8 ± 3.09 15.90 47.12 1.96e-06 -10.0 6.17e-06 1.4 7.98e-01 
Sm (oh) c22:2 41.0 ± 1.71 28.62 76.27 35.8 ± 2.78 22.24 66.39 35.0 ± 3.45 16.60 55.54 2.71e-12 -12.8 4.20e-09 -2.2 5.56e-01 
Sm (oh) c24:1 1.43 ± 0.07 0.70 2.38 1.31 ± 0.09 0.82 2.36 1.36 ± 0.13 0.54 2.36 1.12e-03 -8.8 4.84e-04 3.6 3.49e-01 
Sm c16:0 153.9 ± 6.99 109.82 244.43 139.6 ± 6.37 98.36 244.75 127.6 ± 14.56 62.32 208.74 2.56e-14 -9.3 4.93e-06 -8.6 3.33e-04 
Sm c16:1 22.7 ± 0.98 15.43 32.36 22.1 ± 1.46 13.73 42.03 21.3 ± 3.39 11.26 48.65 3.66e-02 -2.7 3.18e-01 -3.4 2.87e-01 
Sm c18:0 31.7 ± 0.99 23.13 49.40 30.5 ± 1.77 18.84 52.68 30.3 ± 1.68 17.17 45.78 1.14e-01 -3.7  -0.8  
Sm c18:1 15.1 ± 0.48 10.98 29.04 14.3 ± 1.01 8.27 27.62 13.9 ± 1.38 8.27 25.15 5.07e-03 -4.8 5.72e-02 -3.0 3.69e-01 
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Sm c20:2 0.839 ± 0.03 0.50 1.19 0.859 ± 0.09 0.44 1.60 0.931 ± 0.11 0.34 1.62 5.70e-05 2.4 4.62e-01 8.3 2.42e-03 
Sm c24:0 29.4 ± 0.56 17.27 45.11 26.8 ± 0.89 17.94 42.29 26.7 ± 3.61 13.90 49.37 3.61e-05 -8.7 1.53e-04 -0.3 9.89e-01 
Sm c24:1 172.8 ± 5.48 123.71 314.81 158.4 ± 7.67 101.24 267.19 161.0 ± 18.89 80.96 270.38 1.54e-04 -8.4 1.35e-04 1.6 7.24e-01 
Sm c26:0 0.294 ± 0.02 0.17 0.49 0.255 ± 0.01 0.15 0.48 0.258 ± 0.02 0.15 0.44 4.00e-08 -13.3 4.12e-07 1.4 8.65e-01 
Sm c26:1 0.476 ± 0.05 0.24 0.91 0.410 ± 0.03 0.17 0.85 0.442 ± 0.03 0.25 0.74 2.10e-07 -13.9 3.00e-07 7.9 1.95e-02 
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Table f. P(corr) values for oplsda; lean vs ow and ow vs t2dm 
Opls-da m3 (lean vs ow) Opls-da m7 ow vs t2dm  
Metabolite P(corr)[1] Metabolite P(corr)[1] 
Glu -0.36 Ala -0.40 
Tyr -0.29 Pc aa c36:5 -0.39 
Ac-c5 -0.27 Pc aa c38:4 -0.39 
Ac-c18:1 -0.27 T4-oh-pro -0.38 
Orn -0.26 Alpha-aaa -0.38 
Ac-c4 -0.25 Pc aa c36:4 -0.37 
Kynurenine -0.24 Sarcosine -0.34 
C18:2 -0.21 Pc aa c34:4 -0.30 
His -0.21 Ac-c3 -0.30 
Ac-c16 -0.19 Pc aa c32:1 -0.29 
Val -0.18 Pro -0.26 
Ile -0.18 Pc aa c36:6 -0.25 
Sarcosine -0.18 Tyr -0.24 
Leu -0.16 Glu -0.23 
Adma -0.16 Pc aa c32:0 -0.23 
Creatinine -0.16 Pc aa c38:3 -0.22 
Trp -0.13 Pc aa c40:4 -0.20 
Pro -0.13 Phe -0.20 
Met -0.11 Pc aa c38:5 -0.20 
Ac-c3 -0.10 Pc aa c36:1 -0.20 
Ac-c0 -0.10 Pc ae c36:0 -0.18 
Ac-c2 -0.09 Sm c26:1 -0.18 
Lys -0.08 Pc aa c42:5 -0.17 
Alpha-aaa -0.08 Met -0.17 
Phe -0.08 Pc aa c40:3 -0.16 
Thr -0.07 Lys -0.16 
Pc aa c40:6 -0.07 Pc aa c34:1 -0.16 
Sm c20:2 -0.05 Lysopc a c26:1 -0.15 
Pc aa c38:6 -0.04 Kynurenine -0.14 
Ac-c18 -0.04 Pc aa c40:6 -0.13 
Ala -0.04 Ile -0.13 
T4-oh-pro -0.03 Sm c20:2 -0.13 
Pc aa c36:4 -0.01 Val -0.12 
Pc aa c28:1 -0.01 Trp -0.11 
Ser 0.01 Pc aa c40:5 -0.11 
Pc aa c38:4 0.01 Ac-c4 -0.10 
Sm (oh) c14:1 0.01 Pc aa c36:0 -0.10 
Pc ae c30:2 0.01 Asn -0.10 
Pc aa c34:2 0.03 Pc aa c34:3 -0.10 
Pc aa c38:0 0.04 Pc aa c36:3 -0.10 
Pc aa c32:1 0.04 Pc aa c32:3 -0.10 
Pc aa c32:3 0.04 Pc ae c30:2 -0.08 
Taurine 0.05 Lysopc a c20:4 -0.08 
Pc ae c38:4 0.05 Pc ae c32:1 -0.08 
Pc aa c34:4 0.06 Pc ae c34:0 -0.08 
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Sm c16:1 0.06 Ac-c0 -0.08 
Sdma 0.06 Sm (oh) c24:1 -0.07 
Ac-c14:1 0.07 Pc aa c42:1 -0.07 
Pc ae c40:6 0.07 Pc aa c38:6 -0.07 
Pc ae c36:4 0.09 Taurine -0.06 
Sm c18:0 0.09 Sm c26:0 -0.06 
Sm (oh) c16:1 0.09 Pc aa c36:2 -0.06 
Lysopc a c26:1 0.09 Lysopc a c24:0 -0.04 
Lysopc a c24:0 0.09 Leu -0.04 
Gln 0.09 Pc ae c38:4 -0.04 
Serotonin 0.10 Lysopc a c20:3 -0.04 
Pc ae c38:6 0.10 Ac-c2 -0.04 
Pc aa c36:0 0.10 Sm (oh) c22:1 -0.04 
Pc ae c38:5 0.11 Sm c24:1 -0.04 
Pc ae c40:2 0.11 Pc ae c40:3 -0.04 
Pc ae c34:0 0.11 Pc ae c42:1 -0.03 
Lysopc a c16:1 0.12 Pc ae c30:0 -0.03 
Cit 0.12 Pc ae c34:1 -0.03 
Arg 0.12 Pc ae c44:6 -0.02 
Sm c18:1 0.12 Pc ae c36:1 -0.02 
Pc ae c44:5 0.13 Pc aa c42:4 -0.02 
Lysopc a c28:1 0.14 Sm c18:0 -0.02 
Lysopc a c26:0 0.15 Pc ae c44:3 -0.01 
Lysopc a c16:0 0.15 Pc ae c36:4 -0.01 
Pc aa c34:1 0.16 Pc ae c38:3 -0.01 
Lysopc a c20:4 0.16 Pc aa c34:2 -0.01 
Pc aa c32:0 0.17 Sm c24:0 -0.01 
Pc ae c34:1 0.18 Pc aa c28:1 0.00 
Pc aa c36:6 0.18 Pc ae c42:2 0.00 
Sm (oh) c24:1 0.19 Pc ae c40:2 0.00 
Pc aa c36:2 0.20 Lysopc a c26:0 0.00 
Pc aa c38:3 0.22 Arg 0.00 
Pc ae c36:1 0.22 Pc ae c40:4 0.01 
Pc ae c38:0 0.22 Pc ae c38:0 0.01 
Pc ae c42:5 0.22 Pc ae c40:1 0.01 
Pc ae c36:5 0.22 Ac-c16 0.02 
Gly 0.23 Gly 0.02 
Sm c24:1 0.23 Pc aa c42:2 0.02 
Sm (oh) c22:1 0.23 Pc ae c42:3 0.03 
Pc aa c34:3 0.24 Sm (oh) c22:2 0.03 
Sm c24:0 0.24 Pc ae c34:3 0.03 
Pc aa c42:1 0.24 Lysopc a c16:1 0.03 
Sm c26:1 0.24 Pc ae c36:5 0.03 
Sm c16:0 0.25 Pc ae c36:3 0.03 
Pc aa c42:2 0.25 Sm c18:1 0.04 
Pc aa c42:0 0.25 Pc ae c38:5 0.05 
Pc ae c36:2 0.25 Ac-c14:1 0.06 
Pc ae c32:2 0.25 Serotonin 0.06 
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Lysopc a c17:0 0.26 Pc aa c38:0 0.06 
Pc aa c40:2 0.26 Sm c16:1 0.06 
Pc aa c36:3 0.26 Thr 0.06 
Pc ae c38:3 0.26 Sm (oh) c14:1 0.07 
Lysopc a c28:0 0.27 Pc ae c32:2 0.07 
Pc aa c42:4 0.27 Pc ae c42:4 0.08 
Asn 0.27 Pc ae c34:2 0.09 
Pc ae c40:5 0.27 Lysopc a c28:1 0.09 
Sm (oh) c22:2 0.28 Ser 0.10 
Pc ae c44:6 0.29 Sdma 0.10 
Pc ae c40:4 0.29 Lysopc a c28:0 0.11 
Lysopc a c18:0 0.30 Pc ae c38:6 0.11 
Pc ae c32:1 0.30 Cit 0.11 
Sm c26:0 0.30 Pc ae c40:5 0.11 
Pc ae c30:0 0.31 Sm (oh) c16:1 0.12 
Pc aa c36:5 0.31 Pc aa c42:0 0.12 
Pc aa c42:5 0.32 Creatinine 0.13 
Pc ae c44:4 0.32 Ac-c5 0.13 
Pc aa c38:5 0.32 Lysopc a c18:0 0.14 
Pc aa c36:1 0.32 Pc ae c40:6 0.14 
Pc ae c40:1 0.33 Orn 0.15 
Pc ae c36:0 0.33 Lysopc a c16:0 0.15 
Pc ae c42:3 0.34 Pc ae c36:2 0.15 
Pc aa c40:5 0.35 Pc ae c42:5 0.17 
Pc ae c34:2 0.37 Sm c16:0 0.17 
Pc ae c42:4 0.37 Adma 0.17 
Lysopc a c18:1 0.38 Pc ae c44:5 0.18 
Pc ae c44:3 0.41 Ac-c18:2 0.18 
Lysopc a c18:2 0.42 Ac-c18 0.18 
Pc ae c42:1 0.44 Ac-c18:1 0.18 
Pc aa c40:4 0.46 Lysopc a c18:1 0.19 
Lysopc a c20:3 0.46 Lysopc a c18:2 0.19 
Pc ae c36:3 0.47 Pc ae c44:4 0.22 
Pc ae c40:3 0.47 Gln 0.23 
Pc ae c42:2 0.50 Pc aa c40:2 0.29 
Pc aa c40:3 0.53 Lysopc a c17:0 0.31 
Pc ae c34:3 0.59 His 0.40 
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Table g. Metabolites with a significant cosine fit (mean z score and individuals in the groups) 
Metabolite 
All groups     
(n= 23) 
L (8) mean z score 
Ind 
(conc) 
Ow (9) mean z score 
Ind 
(conc) 
T2dm (6) mean z score 
Ind 
(conc) 
(time) 
Fdr 
P 
value 
Peak 
time 
Amp  P value 
Peak 
time 
Amp  
P 
value 
Peak 
time 
Amp  
Ala 5.37e-06 0.017 14.87 0.84 3 0.001 16.37 0.68 4 
   
4 
Cit 5.37e-06 0.000 24.92 0.94 4 0.000 23.53 0.87 3 0.005 24.46 0.64 3 
Gly 5.37e-06 0.020 27.13 0.62 3 0.020 26.27 0.54 3 
   
2 
Ile 5.37e-06 0.009 18.64 0.61 2 0.025 17.08 0.57 1 
   
1 
Orn 5.37e-06 
   
1 0.011 14.59 0.50 1 
   
0 
Pro 5.37e-06 0.003 17.40 0.91 5 0.001 17.08 0.87 6 0.012 18.33 0.82 4 
Thr 2.99e-02 
   
0 0.040 21.09 0.35 3 
   
1 
Tyr 5.37e-06 0.039 17.38 0.66 3 0.003 18.36 0.78 7 
   
3 
Val 1.37e-02 0.006 20.57 0.56 1 0.033 14.28 0.38 1 
   
0 
Alpha-aaa 5.37e-06 0.012 17.38 0.65 2 0.002 16.65 0.74 5 
   
2 
Kynurenine 5.37e-06 0.041 7.39 0.62 2 
   
1 
   
0 
Sarcosine 5.37e-06 0.005 17.94 0.71 4 0.000 18.21 0.73 4 0.007 17.94 0.90 6 
Sdma 1.27e-03 0.003 6.91 0.72 2 0.003 7.24 0.38 2 0.041 7.24 0.72 2 
Taurine 4.35e-01 
   
0 
   
0 0.014 11.32 0.63 2 
Ac-c0 2.26e-03    0 0.009 15.61 0.49 2    1 
Ac-c2 5.37e-06 0.005 27.99 0.97 5 0.003 27.65 0.94 7 0.006 28.37 0.91 4 
Ac-c3 5.37e-06 0.013 15.98 0.83 5 0.003 16.56 0.83 5 0.006 15.77 0.85 3 
Ac-c4 5.37e-06 0.046 18.35 0.57 2 0.001 18.98 0.73 7 0.009 18.69 0.84 5 
Ac-c5 5.37e-06 0.043 15.31 0.49 1    3    1 
Ac-c14:1 5.37e-06    0 0.001 29.19 0.57 2 0.001 27.36 0.86 2 
Ac-c16 5.37e-06 0.001 7.24 0.93 5 0.000 7.48 0.83 5 0.001 7.06 0.97 5 
Ac-c18 5.37e-06    2 0.040 9.05 0.50 2 0.037 9.32 0.59 1 
Ac-c18:1 5.37e-06 0.023 27.99 0.68 3 0.028 28.50 0.47 2    1 
Lysopc a c16:0 5.37e-06 
   
2 0.002 20.21 0.60 1 0.047 21.32 0.61 1 
Lysopc a c16:1 5.37e-06 
   
1 0.024 20.69 0.46 0 
   
1 
Lysopc a c17:0 5.37e-06 
   
1 0.003 20.77 0.62 0 
   
1 
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Lysopc a c18:0 5.37e-06 
   
1 0.001 22.02 0.67 1 0.005 23.18 0.84 2 
Lysopc a c18:1 5.37e-06 0.000 22.42 0.76 5 0.000 21.60 1.00 8 0.000 21.98 1.04 5 
Lysopc a c18:2 5.37e-06 0.000 20.20 1.01 5 0.000 20.09 1.14 9 0.000 20.23 1.12 6 
Lysopc a c20:3 5.37e-06 0.001 20.52 0.64 5 0.000 20.41 0.97 8 0.001 20.78 0.92 2 
Lysopc a c20:4 5.37e-06 0.001 21.65 0.68 5 0.000 20.85 1.04 9 0.000 21.03 0.96 5 
Lysopc a c26:0 5.37e-06 
   
1 0.018 10.78 0.49 1 
   
2 
Pc aa c32:1 5.37e-06 0.003 10.82 0.94 6 0.001 9.81 0.87 5 0.003 10.64 0.86 6 
Pc aa c34:4 5.37e-06 0.009 10.33 0.75 2 
   
0 
   
0 
Pc aa c36:0 1.69e-02 0.009 12.06 0.44 1 
   
1 
   
1 
Pc aa c36:1 5.37e-06 0.012 19.17 0.45 2 0.006 18.39 0.49 0 
   
2 
Pc aa c36:2 5.37e-06 
   
2 0.001 19.75 0.64 3 0.029 19.73 0.65 3 
Pc aa c36:3 5.37e-06 0.036 20.55 0.41 4 0.004 18.84 0.52 3 
   
2 
Pc aa c36:4 5.37e-06 
   
1 0.014 15.67 0.46 1 
   
1 
Pc aa c36:5 5.37e-06 0.017 13.34 0.69 2 0.005 13.94 0.61 2 0.041 13.98 0.64 4 
Pc aa c36:6 5.37e-06 0.008 11.56 0.72 2 
   
2 
   
1 
Pc aa c40:2 5.37e-06 0.022 23.12 0.62 4 0.016 21.52 0.41 1 
   
0 
Pc aa c42:2 1.52e-01 0.040 22.62 0.42 2 
   
0 
   
0 
Pc ae c30:0 5.37e-06 0.050 12.05 0.57 2 
   
1 
   
0 
Pc ae c34:0 5.37e-06 0.043 12.56 0.58 3 
   
1 
   
1 
Pc ae c34:1 5.37e-06 0.017 11.47 0.55 1 
   
0 
   
1 
Pc ae c36:2 5.37e-06 0.040 17.94 0.38 2 0.014 17.90 0.49 1 
   
2 
Pc ae c40:1 5.37e-06 
   
0 0.025 20.45 0.40 1 
   
3 
Pc ae c44:3 1.53e-01 
   
1 0.028 15.97 0.25 1 
   
0 
Sm c20:2 4.74e-02 0.020 12.10 0.53 2 
   
0 
   
0 
 
